Note: Descriptions are shown in the official language in which they were submitted.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE
THEREOF
RELATED APPLICATIONS
[001] This application claims the benefit of U.S. Provisional Application No.
62/328,255, filed April 27, 2016, which is incorporated herein by reference in
its entirety.
BACKGROUND
Technical Field
[002] This disclosure relates to inhibitors of one or more proteins in the Wnt
pathway,
including inhibitors of one or more Wnt proteins, and compositions comprising
the same. More
particularly, it concerns the use of an isoquinoline compound or salts or
analogs thereof, in the
treatment of disorders characterized by the activation of Wnt pathway
signaling (e.g., cancer,
abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or
cartilage diseases, and
osteoarthritis), the modulation of cellular events mediated by Wnt pathway
signaling, as well as
genetic diseases and neurological conditions/disorders/diseases due to
mutations or dysregulation
of the Wnt pathway and/or of one or more of Wnt signaling components. Also
provided are methods
for treating Wnt-related disease states.
Background
[003] The Wnt growth factor family includes more than 10 genes identified
in the
mouse and at least 19 genes identified in the human. Members of the Wnt family
of signaling
molecules mediate many short-and long-range patterning processes during
invertebrate and
vertebrate development. The Wnt signaling pathway is known for its role in the
inductive
interactions that regulate growth and differentiation, and it also plays roles
in the homeostatic
maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic 0-
catenin, which
stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin
Dl. In addition,
misregulation of Wnt signaling can cause developmental defects and is
implicated in the genesis
of several human cancers. The Wnt pathway has also been implicated in the
maintenance of stem
or progenitor cells in a growing list of adult tissues including skin, blood,
gut, prostate, muscle, and
the nervous system.
1
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
SUMMARY
[004] The present disclosure provides methods and reagents, involving
contacting a
cell with an agent, such as an isoquinoline compound, in a sufficient amount
to antagonize a Wnt
activity, e.g., to reverse or control an aberrant growth state or correct a
genetic disorder due to
mutations in Wnt signaling components.
[005] Some embodiments disclosed herein include Wnt inhibitors containing
an
isoquinoline core. Other embodiments disclosed herein include pharmaceutical
compositions and
methods of treatment using these compounds.
[006] One embodiment disclosed herein includes a compound having the
structure
of Formula I:
R4 R5
123
N
R2 N 0
R1
as well as prodrugs and pharmaceutically acceptable salts thereof.
[007] In some embodiments of Formula (I):
RI, R2, R4, and R5 are independently selected from the group consisting of H,
halide,
unsubstituted ¨(C1_3 haloalkyl), and unsubstituted ¨(C1_3 alkyl);
R3 is a 5-membered heteroaryl optionally substituted with 1-4 R45;
R6 is selected from the group consisting of ¨aryl substituted with 1-5 R36 and
a 6-membered
heteroaryl optionally substituted with 1-6 R37;
each R36 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(0)N(R47)2, ¨(C1-4 alkylene)pheterocycly1 optionally substituted with
1-10 R43, and ¨(C1-
4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each
¨(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
each R37 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(0)N(R47)2, ¨(C1-4 alkylene)pheterocycly1 optionally substituted with
1-10 R43, and ¨(C1-
4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each
¨(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
2
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each R38 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R39 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R4 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R41 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R42 is independently selected from the group consisting of unsubstituted
¨(C1_5 alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), unsubstituted
¨(C1_5 haloalkyl), ¨(C1-4
alkylene)paryl optionally substituted with 1-10 R46, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-12 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
each R43 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R44 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R45 is independently selected from the group consisting of unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
3
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
a1ky1ene)pheterocyc1y1 optionally substituted with 1-10 R38, and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently, optionally
substituted with one or
more substituents as defined anywhere herein;
alternatively, two adjacent R45 taken together form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
each R46 is independently selected from the group consisting of halide,
unsubstituted ¨(C1_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R47 is independently selected from the group consisting of unsubstituted
¨(C1_5 alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5 haloalkyl);
each X is selected from the group consisting of 0, S, and NH; and
each p is independently 0 or 1.
[008] In another embodiment of Formula
(I):
R1, R2, R4, and R5 are independently selected from the group consisting of H,
halide,
unsubstituted ¨(C1_3 haloalkyl), and unsubstituted ¨(C1_3 alkyl);
R3 is selected from the group consisting of:
R7 R" R15 R" R21
/ R" R19
N
NR 4. NT.....8
I I tR13 .. ________________________ I I ¨R2C/
jy..?_R24
R. R7ip R" Rn
i R9 R13 / R17 R23 R25
,
R7_,y R32 Nir
N,Y --Y
N \
flif--Rn 11_1? _________________ R" 11-1!/1--Rn I N
N., 1 /N- /R31
/ R34.1.--<
Rn R35
, and = , ,
wherein each of R7-R35 is, independently, a substituent as defined anywhere
herein or a
single bond connecting R3 to the isoquinoline ring; wherein only one of R7-R1
(when present) is a
bond, only one of R11-R14 (when present) is a bond, only one of R15-R17 (when
present) is a bond,
only one of R18-R2 (when present) is a bond, only one of R21-R23 (when
present) is a bond, only
one of R24-R26 (when present) is a bond, only one of R27-R29 (when present) is
a bond, only one of
R30-R31 (when present) is a bond, only one of R32-R33 (when present) is a
bond, and only one of
R34-R35 (when present) is a bond; for purposes of clarification, any one of
the nitrogen atoms
attached to R7, RH, R15, R'8,
or R21 can serve as the point of attachment of R3 to the isoquinoline
ring; likewise, any one of the carbon atoms attached to Ir, R9, Rim, R12, Rj3,
R14, R16, R17, R19, R20,
4
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, K-=-=34,
or R35 can serve as the point of attachment
of R3 to the isoquinoline ring; so that:
when the nitrogen atom to which R7 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R7 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R8 is attached serves as the point of attachment
of R3 to the
isoquinoline ring, then R8 is a single bond connecting R3 to the isoquinoline
ring;
when the carbon atom to which R9 is attached serves as the point of attachment
of R3 to the
isoquinoline ring, then R9 is a single bond connecting R3 to the isoquinoline
ring;
when the carbon atom to which RI is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then RI is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R" is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R" is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R12 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R12 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R13 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R13 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R14 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R14 is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R15 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R15 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R16 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R16 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R17 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R17 is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R18 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R18 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R19 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R19 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R2 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R2 is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R21 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R21 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R22 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R22 is a single bond connecting R3 to the
isoquinoline ring;
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
when the carbon atom to which R23 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R23 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R24 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R24 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R25 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R25 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R26 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R26 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R27 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R27 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R28 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R28 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R29 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R29 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R3 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R3 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R31 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R3' is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R32 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R32 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R33 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R33 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R34 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R34 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R" is attached serves as the point of attachment
of R3 to
the isoquinoline ring, then R35 is a single bond connecting R3 to the
isoquinoline ring;
R6 is selected from the group consisting of ¨aryl substituted with 1-5 R" and
a 6-membered
heteroaryl optionally substituted with 1-6 R37;
R7 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R", and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein ¨(C1_4 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
6
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R8, R9, and R1 are independently selected from the group consisting of a
single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, one of R7 and R8, R8 and R9, or R9 and R1 are taken together
to form a ring
which is selected from the group consisting of ¨heterocyclyl optionally
substituted with 1-10 R4
and ¨carbocyclyl optionally substituted with 1-12 R41;
R" is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R38, and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein ¨(C1_4 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
R12, R13, and K-14
are independently selected from the group consisting of a single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, one of R" and R12, R12 and ¨13,
or R14 and R11 are taken together to form a
ring which is selected from the group consisting of ¨heterocyclyl optionally
substituted with 1-10
R4 and ¨carbocyclyl optionally substituted with 1-12 R41;
R15 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R38, and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein ¨(C1_4 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
RI and R17 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, one of R15 and RI or RI and R17 are taken together to form a
ring which is
selected from the group consisting of ¨heterocyclyl optionally substituted
with 1-10 R4 and ¨
carbocyclyl optionally substituted with 1-12 R41;
7
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
IV is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R38, and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein ¨(C1_4 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
R19 and R2 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, one of R18 and R19 or R18 and R2 are taken together to form a
heterocyclyl
optionally substituted with 1-10 R40;
R21 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R38, and ¨carbocyclyl
optionally substituted
with 1-12 R39; wherein ¨(C1_4 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
R22 and R23 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 le,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, R22 and R23 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R24, R25, and R26 are independently selected from the group consisting of a
single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, one of R24 and R25 or R25 and R26 are taken together to form a
ring which is
selected from the group consisting of ¨heterocyclyl optionally substituted
with 1-10 R4 and ¨
carbocyclyl optionally substituted with 1-12 R41;
8
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R27, R28, and R29 are independently selected from the group consisting of a
single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 le,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, R27 and R28 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R" and R31 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, R" and R31 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R32 and R" are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 le,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
R34 and R" are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and ¨carbocyclyl optionally substituted with 1-12 R39; wherein each ¨(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
alternatively, R34 and R" are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
each R" is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(0)N(R47)2, ¨(C1-4 alkylene)pheterocycly1 optionally substituted with
1-10 R43, and ¨(C1-
4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each
¨(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
9
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each R37 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(0)N(R47)2, ¨(C1-4 alkylene)pheterocycly1 optionally substituted with
1-10 R43, and ¨(C1-
4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each
¨(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein;
each R38 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R39 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R4 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R41 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R42 is independently selected from the group consisting of unsubstituted
¨(C1_5 alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), unsubstituted
¨(C1_5 haloalkyl), ¨(C1-4
alkylene)paryl optionally substituted with 1-10 R46, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-12 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
each R43 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each R44 is selected from the group consisting of halide, unsubstituted ¨(C1_5
alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), unsubstituted
¨(C1_5 haloalkyl), and ¨
CN;
each R46 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R47 is independently selected from the group consisting of unsubstituted
¨(C1_5 alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5 haloalkyl);
each X is selected from the group consisting of 0, S, and NH;
each Y is selected from the group consisting of 0 and S; and
each p is independently 0 or 1.
[009] In another embodiment of Formula (I):
RI, R2, R4, and R5 are independently selected from the group consisting of H,
halide, amino,
unsubstituted ¨(C1_3 haloalkyl), and unsubstituted ¨(C1_3 alkyl);
R3 is a 5-membered heteroaryl optionally substituted with 1-4 R45;
II" is selected from the group consisting of ¨phenyl substituted with 1-5 R36,
¨(C1-3
alkylene)ppyridinyl optionally substituted with 1-6 R37, and a 6-10 membered
heteroaryl optionally
substituted with 1-6 R37; wherein the carbonyl of Formula I is attached to an
aromatic ring of the
heteroaryl; wherein ¨(C1_3 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
each R3' is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42,¨C(=0)N(R47)2, ¨(C1_4 alkylene)pN(R50)2, ¨(C1_4 alkylene)pheterocycly1
optionally
substituted with 1-10 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
each R37 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(=0)N(R47)2, ¨(C1_4 alkylene)pN(R50)2, ¨(C1_4 alkylene)pheterocycly1
optionally
substituted with 1-10 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
each R38 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
11
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
¨CN, and ¨(C1_4 a1ky1ene)pcarbocyc1y1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R39 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R4 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R41 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R42 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨(C1_4 alkylene)N(R48)2, ¨(C1_4 alkylene)paryl optionally substituted with 1-
10 R46, ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-12 R43, and ¨(C1_4
alkylene)pcarbocycly1
optionally substituted with 1-12 R44; wherein each ¨(C1_4 alkylene) is,
independently, optionally
substituted with one or more substituents as defined anywhere herein;
each R43 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, ¨OH, ¨C(=0)R51, ¨N(R50)2, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-
12 R44; wherein each ¨(C1_4 alkylene) is, independently, optionally
substituted with one or more
substituents as defined anywhere herein;
each R44 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R45 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨(C1_4 alkylene)pN(R48)2, ¨(C1-4 alkylene)p0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 R38, and ¨carbocyclyl optionally substituted
with 1-12 R39; wherein
12
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each ¨(C1_4 alkylene) is, independently, optionally substituted with one or
more substituents as
defined anywhere herein;
alternatively, two adjacent R45 taken together form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
each R46 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R47 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R48 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R49 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R5 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨(C1_4 alkylene)N(R48)2; wherein ¨(C1_4 alkylene) is optionally
substituted with one or more
substituents as defined anywhere herein;
each R51 is a heteroaryl optionally substituted with 1-6 R52;
each R52 is a ¨heterocyclyl optionally substituted with 1-10 R46;
each X is selected from the group consisting of 0, S, and NR48; and
each p is independently 0 or 1.
[010] In another embodiment of Formula (I):
RI, R2, R4, and R5 are independently selected from the group consisting of H,
halide, amino,
unsubstituted ¨(C1_3 haloalkyl), and unsubstituted ¨(C1_3 alkyl);
R3 is selected from the group consisting of:
13
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R7 R11 R15 R18 R21
/ Ru i / R1Nr_..5 Ni /
NR ..¨ . N-1....8
11 I tR12 R16 I I -R2(/ I / R24
itii!1-/ / it ,N
R10 R2.21-< R26/----
/ R9 Ri3 / Ri7 R23 R29
R2_....._8 y R3 ____..2 y
N \
q-R27 q _________ R38 ii -R33
"/11i R341?
/ R28 / R31 R35
and = , ,
wherein each of R7-R35 is, independently, a substituent as defined anywhere
herein or a
single bond connecting R3 to the isoquinoline ring; wherein only one of R7-R1
(when present) is a
bond, only one of R"-R'4 (when present) is a bond, only one of 12_15-R17 (when
present) is a bond,
only one of R"-R2 (when present) is a bond, only one of R21-R23 (when
present) is a bond, only
one of R24-R26 (when present) is a bond, only one of R27-R29 (when present) is
a bond, only one of
R30-R31 (when present) is a bond, only one of R32-R33 (when present) is a
bond, and only one of
R34-R35 (when present) is a bond; for purposes of clarification, any one of
the nitrogen atoms
attached to R7, RH, R15, R'8,
or R21 can serve as the point of attachment of R3 to the isoquinoline
ring; likewise, any one of the carbon atoms attached to 128, R9, R10, R12,
R13, R14, R16, R17, R19, R20,
R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, or R35 can
serve as the point of attachment
of R3 to the isoquinoline ring; so that:
when the nitrogen atom to which R7 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R7 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R8 is attached serves as the point of attachment
of R3 to the
isoquinoline ring, then R8 is a single bond connecting R3 to the isoquinoline
ring;
when the carbon atom to which R9 is attached serves as the point of attachment
of R3 to the
isoquinoline ring, then R9 is a single bond connecting R3 to the isoquinoline
ring;
when the carbon atom to which RI is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then RI is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R" is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R" is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R12 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R12 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R13 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R13 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R14 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R14 is a single bond connecting R3 to the
isoquinoline ring;
14
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
when the nitrogen atom to which R'5 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R'5 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which IV' is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R'' is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R'7 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R'7 is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R" is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R" is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R'9 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R'9 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R2 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R2 is a single bond connecting R3 to the
isoquinoline ring;
when the nitrogen atom to which R2' is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R2' is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R22 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R22 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R23 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R23 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R24 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R24 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R25 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R25 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R2' is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R2' is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R27 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R27 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R28 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R28 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R29 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R29 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R" is attached serves as the point of attachment
of R3 to
the isoquinoline ring, then R3 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R3' is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R3' is a single bond connecting R3 to the
isoquinoline ring;
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
when the carbon atom to which R32 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R32 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R33 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R33 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R34 is attached serves as the point of
attachment of R3 to
the isoquinoline ring, then R34 is a single bond connecting R3 to the
isoquinoline ring;
when the carbon atom to which R" is attached serves as the point of attachment
of R3 to
the isoquinoline ring, then R" is a single bond connecting R3 to the
isoquinoline ring;
R6 is selected from the group consisting of ¨phenyl substituted with 1-5 R36,
¨(C1-3
alkylene)ppyridinyl optionally substituted with 1-6 R37, and a 6-10 membered
heteroaryl optionally
substituted with 1-6 R37; wherein the carbonyl of Formula I is attached to an
aromatic ring of the
heteroaryl; wherein ¨(C1_3 alkylene) is optionally substituted with one or
more substituents as
defined anywhere herein;
R7 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)N(R48)2, ¨(C1_4 alkylene)0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-10 R38, and ¨carbocyclyl optionally substituted with 1-12
R39; wherein ¨(C1-4
alkylene) is optionally substituted with one or more substituents as defined
anywhere herein;
R8, R9, and R1 are independently selected from the group consisting of a
single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)N(R48)2, ¨(C1_4
alkylene)0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, one of R7 and R8, R8 and R9, or R9 and R1 are taken together
to form a ring
which is selected from the group consisting of ¨heterocyclyl optionally
substituted with 1-10 R4
and ¨carbocyclyl optionally substituted with 1-12 R41;
R11 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)N(R48)2, ¨(C1_4 alkylene)0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-10 R38, and ¨carbocyclyl optionally substituted with 1-12
R39; wherein ¨(C1-4
alkylene) is optionally substituted with one or more substituents as defined
anywhere herein;
R12, R13, and K-14
are independently selected from the group consisting of a single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
16
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 a1ky1ene)pN(R48)2, ¨(C1_4
a1ky1ene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 a1ky1ene)pheterocyc1y1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, one of R" and R12, R12 and R'3,
or R14 and R11 are taken together to form a
ring which is selected from the group consisting of ¨heterocyclyl optionally
substituted with 1-10
R4 and ¨carbocyclyl optionally substituted with 1-12 R41;
R15 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)N(R48)2, ¨(C1_4 alkylene)0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-10 R38, and ¨carbocyclyl optionally substituted with 1-12
R39; wherein ¨(C1-4
alkylene) is optionally substituted with one or more substituents as defined
anywhere herein;
R16 and R17 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)N(R48)2, ¨(C1_4
alkylene)0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, one of R15 and R16 or R16 and R17 are taken together to form a
ring which is
selected from the group consisting of ¨heterocyclyl optionally substituted
with 1-10 R4 and ¨
carbocyclyl optionally substituted with 1-12 R41;
R18 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)N(R48)2, ¨(C1_4 alkylene)0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-10 R38, and ¨carbocyclyl optionally substituted with 1-12
R39; wherein ¨(C1-4
alkylene) is optionally substituted with one or more substituents as defined
anywhere herein;
R19 and R2 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)N(R48)2, ¨(C1_4
alkylene)0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, one of R18 and R19 or R18 and R2 are taken together to form a
heterocyclyl
optionally substituted with 1-10 R40;
17
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R21 is selected from the group consisting of a single bond, H, unsubstituted
¨(C1_9 alkyl),
unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl), unsubstituted
¨(C1_9 haloalkyl), ¨(C1-4
alkylene)N(R48)2, ¨(C1_4 alkylene)0R49, ¨C(=0)N(R48)2, ¨(C1_4
alkylene)pheterocycly1 optionally
substituted with 1-10 R38, and ¨carbocyclyl optionally substituted with 1-12
R39; wherein ¨(C1-4
alkylene) is optionally substituted with one or more substituents as defined
anywhere herein;
R22 and R23 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)pN(R48)2, ¨(C1_4
alkylene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, R22 and R23 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R24, R25, and
K are
independently selected from the group consisting of a single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)pN(R48)2, ¨(C1_4
alkylene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, one of R24 and R25 or R25 and R26 are taken together to form a
ring which is
selected from the group consisting of ¨heterocyclyl optionally substituted
with 1-10 R4 and ¨
carbocyclyl optionally substituted with 1-12 R41;
R27, R28, and R29 are independently selected from the group consisting of a
single bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)pN(R48)2, ¨(C1_4
alkylene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, R27 and R28 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R3 and R31 are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
18
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 a1ky1ene)pN(R48)2, ¨(C1_4
a1ky1ene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 a1ky1ene)pheterocyc1y1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, R3 and R31 are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
R32 and R" are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)pN(R48)2, ¨(C1_4
alkylene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
R34 and R" are independently selected from the group consisting of a single
bond, H,
halide, unsubstituted ¨(C1_9 alkyl), unsubstituted ¨(C2_9 alkenyl),
unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl), ¨(C1-4 alkylene)pN(R48)2, ¨(C1_4
alkylene)p0R49, ¨C(=0)N(R48)2, ¨
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and
¨carbocyclyl optionally
substituted with 1-12 R39; wherein each ¨(C1_4 alkylene) is, independently,
optionally substituted
with one or more substituents as defined anywhere herein;
alternatively, R34 and R" are taken together to form a ring which is selected
from the group
consisting of ¨heterocyclyl optionally substituted with 1-10 R4 and
¨carbocyclyl optionally
substituted with 1-12 R41;
each R3' is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(=0)N(R47)2, ¨(C1_4 alkylene)pN(R50)2, ¨(C1_4 alkylene)pheterocycly1
optionally
substituted with 1-10 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
each R37 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
9 alkyl), unsubstituted ¨(C2_9 alkenyl), unsubstituted ¨(C2_9 alkynyl),
unsubstituted ¨(C1_9 haloalkyl),
¨XR42, ¨C(=0)N(R47)2, ¨(C1_4 alkylene)pN(R50)2, ¨(C1_4 alkylene)pheterocycly1
optionally
substituted with 1-10 R43, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-12 R44;
wherein each ¨(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein;
19
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each R38 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R39 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R4 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, and ¨(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44;
wherein each ¨(C1-4
alkylene) is, independently, optionally substituted with one or more
substituents as defined
anywhere herein;
each R41 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨CN;
each R42 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨(C1_4 alkylene)N(R48)2, ¨(C1_4 alkylene)paryl optionally substituted with 1-
10 R46, ¨(C1-4
alkylene)pheterocycly1 optionally substituted with 1-12 R43, and ¨(C1_4
alkylene)pcarbocycly1
optionally substituted with 1-12 R44; wherein each ¨(C1_4 alkylene) is,
independently, optionally
substituted with one or more substituents as defined anywhere herein;
each R43 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
5 alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
¨CN, ¨OH, ¨C(=0)R51, ¨N(R50)2, and ¨(C1_4 alkylene)pcarbocycly1 optionally
substituted with 1-
12 R44; wherein each ¨(C1_4 alkylene) is, independently, optionally
substituted with one or more
substituents as defined anywhere herein;
each R44 is selected from the group consisting of halide, unsubstituted ¨(C1_5
alkyl),
unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), unsubstituted
¨(C1_5 haloalkyl), and ¨
CN;
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
each R46 is independently selected from the group consisting of halide,
unsubstituted ¨(Cl_
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C15 haloalkyl),
and ¨CN;
each R47 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R48 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R49 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl), and
unsubstituted ¨(C1_5
haloalkyl);
each R5 is independently selected from the group consisting of H,
unsubstituted ¨(C1-5
alkyl), unsubstituted ¨(C2_5 alkenyl), unsubstituted ¨(C2_5 alkynyl),
unsubstituted ¨(C1_5 haloalkyl),
and ¨(C1_4 alkylene)N(R48)2; wherein ¨(C1_4 alkylene) is optionally
substituted with one or more
substituents as defined anywhere herein;
each R51 is a heteroaryl optionally substituted with 1-6 R52;
each R52 is a ¨heterocyclyl optionally substituted with 1-10 R46;
each X is selected from the group consisting of 0, S, and NV;
each Y is selected from the group consisting of 0 and S; and
each p is independently 0 or 1.
[011] Some embodiments include stereoisomers and pharmaceutically
acceptable
salts of a compound of Formula (I). Some embodiments include pharmaceutically
acceptable salts
of a compound of Formula (I).
[012] Some embodiments include pro-drugs of a compound of Formula (I).
[013] Some embodiments of the present disclosure include pharmaceutical
compositions comprising a compound of Formula (I) and a pharmaceutically
acceptable carrier,
diluent, or excipient.
[014] Other embodiments disclosed herein include methods of inhibiting one
or
more members of the Wnt pathway, including one or more Wnt proteins by
administering to a
patient affected by a disorder or disease in which aberrant Wnt signaling is
implicated, such as
cancer and other diseases associated with abnormal angiogenesis, cellular
proliferation, cell cycling
and mutations in Wnt signaling components, a compound according to Formula
(I). Accordingly,
the compounds and compositions provided herein can be used to treat cancer, to
reduce or inhibit
21
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
angiogenesis, to reduce or inhibit cellular proliferation and correct a
genetic disorder due to
mutations in Wnt signaling components.
[015] Non-limiting examples of diseases which can be treated with the
compounds
and compositions provided herein include a variety of cancers, diabetic
retinopathy, pulmonary
fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis,
scleroderma, mycotic and
viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease,
bone/osteoporotic
(wrist, spine, shoulder and hip) fractures, articular cartilage (chondral)
defects, degenerative disc
disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-
pseudoglioma syndrome,
familial exudative vitreoretinopathy, retinal angiogenesis, early coronary
disease, tetra-amelia
syndrome, Mi.i.11erian-duct regression and virilization, SERKAL syndrome,
diabetes mellitus type
2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome,
odonto-
onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal
duplication syndrome,
tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia,
autosomal recessive
anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X
syndrome, ICF
syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann
Syndrome, Norrie
disease, and Rett syndrome.
[016] Some embodiments of the present disclosure include methods to prepare
compounds of Formula (I).
[017] It is to be understood that both the foregoing general description
and the
following detailed description are exemplary and explanatory only and are not
restrictive of the
invention, as claimed.
DETAILED DESCRIPTION
[018] Provided herein are compositions and methods for inhibiting one or
more
members of the Wnt pathway, including one or more Wnt proteins.
[019] Some embodiments provided herein relate to a method for treating a
disease
or disorder including, but not limited to, cancers, diabetic retinopathy,
pulmonary fibrosis,
rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma,
mycotic and viral
infections, bone and cartilage diseases, Alzheimer's disease, lung disease,
osteoarthritis,
bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular
cartilage (chondral) defects,
degenerative disc disease (or intervertebral disc degeneration), polyposis
coli, bone density and
vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG),
familial exudative
vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia,
Mullerian-duct
regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann
syndrome, Al-
22
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal
dysplasia,
obesity, split-hand/foot malformation, caudal duplication, tooth agenesis,
Wilms tumor, skeletal
dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube
defects, alpha-
thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman
syndrome, Prader-
Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett
syndrome.
[020] In some embodiments, non-limiting examples of bone and cartilage
diseases
which can be treated with the compounds and compositions provided herein
include bone spur
(osteophytes), craniosynostosis, fibrodysplasia ossificans progressiva,
fibrous dysplasia, giant cell
tumor of bone, hip labral tear, meniscal tears, bone/osteoporotic (wrist,
spine, shoulder and hip)
fractures, articular cartilage (chondral) defects, degenerative disc disease
(or intervertebral disc
degeneration), osteochondritis dissecans, osteochondroma (bone tumor),
osteopetrosis, relapsing
polychondritis, and Salter-Harris fractures.
[021] In some embodiments, pharmaceutical compositions are provided that
are
effective for treatment of a disease of an animal, e.g., a mammal, caused by
the pathological
activation or mutations of the Wnt pathway. The composition includes a
pharmaceutically
acceptable carrier and a compound as described herein.
Definitions
[022] Unless defined otherwise, all technical and scientific terms used
herein have
the same meaning as is commonly understood by one of ordinary skill in the art
to which this
disclosure belongs. All patents, applications, published applications, and
other publications are
incorporated by reference in their entirety. In the event that there is a
plurality of definitions for a
term herein, those in this section prevail unless stated otherwise.
[023] As used herein, "alkyl" means a branched, or straight chain chemical
group
containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-
propyl, n-butyl, iso-
butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl.
Alkyl groups can either
be unsubstituted or substituted with one or more substituents. In some
embodiments, alkyl groups
include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon
atoms, or 1 to 2 carbon
atoms).
[024] As used herein, "alkenyl" means a straight or branched chain chemical
group
containing only carbon and hydrogen and containing at least one carbon-carbon
double bond, such
as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl,
and the like. In
various embodiments, alkenyl groups can either be unsubstituted or substituted
with one or more
23
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
substituents. Typically, alkenyl groups will comprise 2 to 9 carbon atoms (for
example, 2 to 6
carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
[025] As used herein, "alkynyl" means a straight or branched chain chemical
group
containing only carbon and hydrogen and containing at least one carbon-carbon
triple bond, such
as ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, and the like. In various
embodiments, alkynyl groups
can either be unsubstituted or substituted with one or more substituents.
Typically, alkynyl groups
will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4
carbon atoms, or 2
carbon atoms).
[026] As used herein, "alkylene" means a bivalent branched, or straight
chain
chemical group containing only carbon and hydrogen, such as methylene,
ethylene, n-propylene,
iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-
pentylene, iso-pentylene,
sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted
or substituted with
one or more substituents. Alkylene groups can be saturated or unsaturated
(e.g., containing -C=C-
or -CC- subunits), at one or several positions. In some embodiments, alkylene
groups include 1
to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1
to 2 carbon atoms).
[027] As used herein, "alkenylene" means a bivalent branched, or straight
chain
chemical group containing only carbon and hydrogen and containing at least one
carbon-carbon
double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-l-
propenylene, 1-
butenylene, 2-butenylene, and the like. In various embodiments, alkenylene
groups can either be
unsubstituted or substituted with one or more substituents. Typically,
alkenylene groups will
comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon
atoms, or 2 carbon
atoms).
[028] As used herein, "alkynylene" means a bivalent branched, or straight
chain
chemical group containing only carbon and hydrogen and containing at least one
carbon-carbon
triple bond, such as ethynylene, 1-propynylene, 1-butynylene, 2-butynylene,
and the like. In various
embodiments, alkynylene groups can either be unsubstituted or substituted with
one or more
substituents. Typically, alkynylene groups will comprise 2 to 9 carbon atoms
(for example, 2 to 6
carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
[029] As used herein, "carbocycly1" means a cyclic ring system containing
only
carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl,
cyclopentyl,
cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings.
Carbocyclyls may
have any degree of saturation provided that at least one ring in the ring
system is not aromatic.
Carbocyclyl groups can either be unsubstituted or substituted with one or more
substituents. In
24
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for
example, 3 to 6 carbon
atoms.
[030] As used herein, "aryl" means a mono-, bi-, tri- or polycyclic group
with only
carbon atoms present in the ring backbone having 5 to 14 ring atoms,
alternatively 5, 6, 9, or 10
ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array;
wherein at least one ring
in the system is aromatic. Aryl groups can either be unsubstituted or
substituted with one or more
substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl,
2,3-dihydro-1H-
indenyl, and others. In some embodiments, the aryl is phenyl.
[031] As used herein, "arylalkylene" means an aryl-alkylene- group in which
the aryl
and alkylene moieties are as previously described. In some embodiments,
arylalkylene groups
contain a C14alkylene moiety. Exemplary arylalkylene groups include benzyl and
2-phenethyl.
[032] As used herein, the term "heteroaryl" means a mono-, bi-, tri- or
polycyclic
group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and
having 6, 10, or 14 pi
electrons shared in a cyclic array; wherein at least one ring in the system is
aromatic, and at least
one ring in the system contains one or more heteroatoms independently selected
from the group
consisting of N, 0, and S. Heteroaryl groups can either be unsubstituted or
substituted with one or
more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl,
oxazolyl, oxadiazolyl,
pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl,
thiadiazolyl, pyranyl, pyrazinyl,
pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl,
benzofuranyl,
benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl,
isothiazolyl,
naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3 -al pyrimidinyl,
pyrrolo[2,3 -b] pyridinyl,
quinazolinyl, quinolinyl, thieno[2,3-clpyridinyl, pyrazolo[3,4-blpyridinyl,
pyrazolo [3,4-
clpyridinyl, pyrazolo[4,3-clpyridine, pyrazolo [4,3 -b] pyridinyl, tetrazolyl,
chromane, 2,3-
dihydrobenzo[b] [1,4]dioxine, benzo[d] [1,3]dioxole, 2,3-dihydrobenzofuran,
tetrahydroquinoline,
2,3-dihydrobenzo[b][1,41oxathiine, and others. In some embodiments, the
heteroaryl is selected
from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, pyranyl, pyrazinyl, and
pyrimidinyl.
[033] As used herein, "halo", "halide" or "halogen" is a chloro, bromo,
fluoro, or
iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro.
For example, a halide
can be fluoro.
[034] As used herein, "haloalkyl" means a hydrocarbon substituent, which is
a linear
or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro,
bromo, fluoro, and/or
iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one
or more of the
hydrogen atoms have been substituted by fluoro. In some embodiments,
haloalkyls are of 1 to about
3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in
length). The term
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
"haloalkylene" means a diradical variant of haloalkyl, and such diradicals may
act as spacers
between radicals, other atoms, or between a ring and another functional group.
[035] As used herein, "heterocyclyl" means a nonaromatic cyclic ring system
comprising at least one heteroatom in the ring system backbone. Heterocyclyls
may include
multiple fused rings. Heterocyclyls may be substituted or unsubstituted with
one or more
substituents. In some embodiments, heterocycles have 3-11 members. In six
membered monocyclic
heterocycles, the heteroatom(s) are selected from one to three of 0, N or S,
and wherein when the
heterocycle is five membered, it can have one or two heteroatoms selected from
0, N, or S.
Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl,
thietanyl, 1,4,2-
dithiazolyl, dihydropyridinyl, 1,3 -dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl,
morpholinyl,
thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl,
tetrahydropyridinyl, oxazinyl,
thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl,
isoxazolidinyl, piperidinyl,
pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some
embodiments, the heterocyclyl
is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and
tetrahydropyridinyl.
[036] As used herein, "monocyclic heterocyclyl" means a single nonaromatic
cyclic
ring comprising at least one heteroatom in the ring system backbone.
Heterocyclyls may be
substituted or unsubstituted with one or more substituents. In some
embodiments, heterocycles
have 3-7 members. In six membered monocyclic heterocycles, the heteroatom(s)
are selected from
one to three of 0, N or S, and wherein when the heterocycle is five membered,
it can have one or
two heteroatoms selected from 0, N, or S. Examples of heterocyclyls include
azirinyl, aziridinyl,
azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-
dioxanyl, 1,4-dioxanyl, 1,3-
dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl,
tetrahydrofuryl,
tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl,
isothiazolidinyl, oxazolidinyl,
isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl,
and others.
[037] As used herein, "bicyclic heterocyclyl" means a nonaromatic bicyclic
ring
system comprising at least one heteroatom in the ring system backbone.
Bicyclic heterocyclyls may
be substituted or unsubstituted with one or more substituents. In some
embodiments, bicyclic
heterocycles have 4-11 members with the heteroatom(s) being selected from one
to five of 0, N or
S. Examples of bicyclic heterocyclyls include 2-azabicyclo[1.1.0]butane, 2-
azabicyclo[2.1.01pentane, 2-azabicyclo[1.1.1]pentane, 3
-azabicyclo [3 . 1. Olhexane, 5-
azabicyclo [2.1.1] hexane, 3 -azabicyclo [3 .2 . 0] heptane,
octahydrocyclopenta[c]pyrrole, 3 -
azabicyclo [4. 1 .01heptane, 7-azabicyclo [2.2. 11heptane,
6 -azabicyclo [3 . 1 . 11heptane, 7-
azabicyclo [4.2 . 0] octane, 2-azabicyclo [2 .2 .2] octane, and the like.
26
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[038] As used herein, "spirocyclic heterocycly1" means a nonaromatic
bicyclic ring
system comprising at least one heteroatom in the ring system backbone and with
the rings
connected through just one atom. Spirocyclic heterocyclyls may be substituted
or unsubstituted
with one or more substituents. In some embodiments, spirocyclic heterocycles
have 5-11 members
with the heteroatom(s) being selected from one to five of 0, N or S. Examples
of spirocyclic
heterocyclyls include 2-azaspiro 112 .2] pentane , 4-azaspiro 112 .5 1 octane,
1 -azaspiro 113. 5 1 nonane, 2-
azaspiro 113. 5] nonane, 7 -azaspiro 113 .5 1 nonane , 2-azaspiro 114 . 4]
nonane , 6 -azaspiro [2. 6] nonane, 1,7-
diazaspiro [4 .5 1 de cane , 2,5 -diazaspiro 113 .6] de cane , and the like.
[039] The term "substituted" refers to moieties having substituents
replacing a
hydrogen on one or more non-hydrogen atoms of the molecule. It will be
understood that
"substitution" or "substituted with" includes the implicit proviso that such
substitution is in
accordance with permitted valence of the substituted atom and the substituent,
and that the
substitution results in a stable compound, e.g., which does not spontaneously
undergo
transformation such as by rearrangement, cyclization, elimination, etc.
Substituents can include,
for example, ¨(C1_9 alkyl) optionally substituted with one or more of
hydroxyl, -NH2, -NH(C1-3
alkyl), and ¨N(C1_3 alky1)2; -(C1_9 haloalkyl); a halide; a hydroxyl; a
carbonyl [such as -C(0)0R,
and -C(0)R]; a thiocarbonyl [such as -C(S)OR, -C(0)SR, and -C(S)R]; ¨(C1_9
alkoxyl) optionally
substituted with one or more of halide, hydroxyl, -NH2, -NH(C1_3 alkyl), and
¨N(C1_3 alky02; -
OPO(OH)2; a phosphonate [such as -P0(OH)2 and -PO(OR')21; -OPO(OR')R"; -NRR'; -
C(0)NRR'; -C(NR)NR'R"; -C(NR')R"; a cyano; a nitro; an azido; -SH; -S-R; -
0502(0R); a
sulfonate [such as -502(OH) and -502(0R)1; -SO2NR'R"; and -502R; in which each
occurrence of
R, R' and R" are independently selected from H; ¨(C1_9 alkyl); C6-10 aryl
optionally substituted with
from 1-3R"; 5-10 membered heteroaryl having from 1-4 heteroatoms independently
selected from
N, 0, and S and optionally substituted with from 1-3 R¨; C3-7 carbocyclyl
optionally substituted
with from 1-3 R"; and 3-8 membered heterocyclyl having from 1-4 heteroatoms
independently
selected from N, 0, and S and optionally substituted with from 1-3 R"; wherein
each R" is
independently selected from ¨(C1-6 alkyl), ¨(C1_6 haloalkyl), a halide (e.g.,
F), a hydroxyl, -C(0)0R,
-C(0)R, ¨(C1_6 alkoxy), -NRR', -C(0)NRR', and a cyano, in which each
occurrence of R and R'
is independently selected from H and ¨(C1_6 alkyl). In some embodiments, the
substituent is selected
from ¨(C1_6 alkyl), -(C1_6 haloalkyl), a halide (e.g., F), a hydroxyl, -
C(0)0R, -C(0)R, ¨(C1-6
alkoxyl), -NRR', -C(0)NRR', and a cyano, in which each occurrence of R and R'
is independently
selected from H and ¨(C1_6 alkyl).
[040] As used herein, when two groups are indicated to be "linked" or
"bonded" to
form a "ring", it is to be understood that a bond is formed between the two
groups and may involve
27
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
replacement of a hydrogen atom on one or both groups with the bond, thereby
forming a
carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will
recognize that such rings
can and are readily formed by routine chemical reactions. In some embodiments,
such rings have
from 3-7 members, for example, 5 or 6 members.
[041] The skilled artisan will recognize that some structures described
herein may
be resonance forms or tautomers of compounds that may be fairly represented by
other chemical
structures, even when kinetically, the artisan recognizes that such structures
are only a very small
portion of a sample of such compound(s). Such compounds are clearly
contemplated within the
scope of this disclosure, though such resonance forms or tautomers are not
represented herein.
[042] The compounds provided herein may encompass various stereochemical
forms. The compounds also encompass diastereomers as well as optical isomers,
e.g., mixtures of
enantiomers including racemic mixtures, as well as individual enantiomers and
diastereomers,
which arise as a consequence of structural asymmetry in certain compounds.
Separation of the
individual isomers or selective synthesis of the individual isomers is
accomplished by application
of various methods which are well known to practitioners in the art. Unless
otherwise indicated,
when a disclosed compound is named or depicted by a structure without
specifying the
stereochemistry and has one or more chiral centers, it is understood to
represent all possible
stereoisomers of the compound.
[043] The present disclosure includes all pharmaceutically acceptable
isotopically
labeled compounds of Formula I wherein one or more atoms are replaced by atoms
having the same
atomic number, but an atomic mass or mass number different from the atomic
mass or mass number
which predominates in nature. Examples of isotopes suitable for inclusion in
the compounds of the
disclosure include, but are not limited to, isotopes of hydrogen, such as 2H
(deuterium) and 31-1
(tritium), carbon, such as "C, "C and "C, chlorine, such as 36C1, fluorine,
such as "F, iodine, such
as 121 and 125I, nitrogen, such as "N and '5N, oxygen, such as '50, 170 and
180, phosphorus, such
as 32P, and sulfur, such as 355.
[044] The term "administration" or "administering" refers to a method of
providing
a dosage of a compound or pharmaceutical composition to a vertebrate or
invertebrate, including a
mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally,
subcutaneously,
intravenously, intralymphatic, intranasally, topically, transdermally,
intraperitoneally,
intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-
otologically,
intraocularly, subconjuctivally, via anterior eye chamber injection,
intravitreally, intraperitoneally,
intrathecally, intracystically, intrapleurally, via wound irrigation,
intrabuccally, intra-abdominally,
intra-articularly, intra-aurally, intrabronchially, intracapsularly,
intrameningeally, via inhalation,
28
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
via endotracheal or endobronchial instillation, via direct instillation into
pulmonary cavities,
intraspinally, intrasynovially, intrathoracically, via thoracostomy
irrigation, epidurally,
intratympanically, intracisternally, intravascularly, intraventricularly,
intraosseously, via irrigation
of infected bone, or via application as part of any admixture with a
prosthetic device. The method
of administration can vary depending on various factors, e.g., the components
of the pharmaceutical
composition, the site of the disease, the disease involved, and the severity
of the disease.
[045] A "diagnostic" as used herein is a compound, method, system, or
device that
assists in the identification or characterization of a health or disease
state. The diagnostic can be
used in standard assays as is known in the art.
[046] The term "mammal" is used in its usual biological sense. Thus, it
specifically
includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep,
pigs, goats, and non-
human primates, but also includes many other species.
[047] The term "pharmaceutically acceptable carrier", "pharmaceutically
acceptable
diluent" or "pharmaceutically acceptable excipient" includes any and all
solvents, co-solvents,
complexing agents, dispersion media, coatings, isotonic and absorption
delaying agents and the
like which are not biologically or otherwise undesirable. The use of such
media and agents for
pharmaceutically active substances is well known in the art. Except insofar as
any conventional
media or agent is incompatible with the active ingredient, its use in the
therapeutic compositions is
contemplated. Supplementary active ingredients can also be incorporated into
the compositions. In
addition, various adjuvants such as are commonly used in the art may be
included. These and other
such compounds are described in the literature, e.g., in the Merck Index,
Merck & Company,
Rahway, NJ. Considerations for the inclusion of various components in
pharmaceutical
compositions are described, e.g., in Gilman et al. (Eds.) (2010); Goodman and
Gilman's: The
Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.
[048] The term "pharmaceutically acceptable salt" refers to salts that
retain the
biological effectiveness and properties of the compounds provided herein and,
which are not
biologically or otherwise undesirable. In many cases, the compounds provided
herein are capable
of forming acid and/or base salts by virtue of the presence of amino and/or
carboxyl groups or
groups similar thereto. Many such salts are known in the art, for example, as
described in WO
87/05297. Pharmaceutically acceptable acid addition salts can be formed with
inorganic acids and
organic acids. Inorganic acids from which salts can be derived include, for
example, hydrochloric
acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the
like. Organic acids from
which salts can be derived include, for example, acetic acid, propionic acid,
glycolic acid, pyruvic
acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid,
tartaric acid, citric acid,
29
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid,
ethanesulfonic acid, p-
toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically
acceptable base addition salts
can be formed with inorganic and organic bases. Inorganic bases from which
salts can be derived
include, for example, sodium, potassium, lithium, ammonium, calcium,
magnesium, iron, zinc,
copper, manganese, aluminum, and the like; particularly preferred are the
ammonium, potassium,
sodium, calcium, and magnesium salts. Organic bases from which salts can be
derived include, for
example, primary, secondary, and tertiary amines, substituted amines including
naturally occurring
substituted amines, cyclic amines, basic ion exchange resins, and the like,
specifically such as
isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine,
and ethanolamine.
[049] "Patient" as used herein, means a human or a non-human mammal, e.g.,
a dog,
a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or
a bird, e.g., a chicken,
as well as any other vertebrate or invertebrate. In some embodiments, the
patient is a human.
[050] A "therapeutically effective amount" of a compound as provided herein
is one
which is sufficient to achieve the desired physiological effect and may vary
according to the nature
and severity of the disease condition, and the potency of the compound.
"Therapeutically effective
amount" is also intended to include one or more of the compounds of Formula I
in combination
with one or more other agents that are effective to treat the diseases and/or
conditions described
herein. The combination of compounds can be a synergistic combination.
Synergy, as described,
for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-
55, occurs when
the effect of the compounds when administered in combination is greater than
the additive effect
of the compounds when administered alone as a single agent. In general, a
synergistic effect is most
clearly demonstrated at sub-optimal concentrations of the compounds. It will
be appreciated that
different concentrations may be employed for prophylaxis than for treatment of
an active disease.
This amount can further depend upon the patient's height, weight, sex, age and
medical history.
[051] A therapeutic effect relieves, to some extent, one or more of the
symptoms of
the disease.
[052] "Treat," "treatment," or "treating," as used herein refers to
administering a
compound or pharmaceutical composition as provided herein for therapeutic
purposes. The term
"therapeutic treatment" refers to administering treatment to a patient already
suffering from a
disease thus causing a therapeutically beneficial effect, such as ameliorating
existing symptoms,
ameliorating the underlying metabolic causes of symptoms, postponing or
preventing the further
development of a disorder, and/or reducing the severity of symptoms that will
or are expected to
develop.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Compounds
[053] The compounds and compositions described herein can be used as anti-
proliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or
as inhibitors of the Wnt
signaling pathway, e.g., for treating diseases or disorders associated with
aberrant Wnt signaling.
In addition, the compounds can be used as inhibitors of one or more kinases,
kinase receptors, or
kinase complexes. Such compounds and compositions are also useful for
controlling cellular
proliferation, differentiation, and/or apoptosis.
[054] Some embodiments of the present disclosure include compounds of
Formula
R4 R5
123 N R6
R2 N 0
R1
or salts, pharmaceutically acceptable salts, or prodrugs thereof.
[055] In some embodiments, RI, R2, R4, and R5 are independently selected
from the
group consisting of H, halide, unsubstituted ¨(C1_3 haloalkyl), and
unsubstituted ¨(C1_3 alkyl);
[056] In some embodiments, RI, R2, R4, and R5 are independently selected
from the
group consisting of H, halide, amino, unsubstituted ¨(C1_3 haloalkyl), and
unsubstituted ¨(C1-3
alkyl).
[057] In some embodiments, RI, R2, R4, and R5 are independently selected
from the
group consisting of H and halide.
[058] In some embodiments, RI, R2, R4, and R5 are independently selected
from the
group consisting of H and F.
[059] In some embodiments, RI, R2, R4, and R5 are all H.
[060] In some embodiments, RI is F, and R2, R4, and R5 are all H.
[061] In some embodiments, R2 is F, and RI, R4, and R5 are all H.
[062] In some embodiments, R4 is F, and RI, R2, and R5 are all H.
[063] In some embodiments, R5 is F, and RI, R2, and R4 are all H.
[064] In some embodiments, R3 is a 5-membered heteroaryl ring optionally
substituted as defined anywhere herein.
[065] In some embodiments, R3 is 5-membered heteroaryl ring optionally
substituted
with 1-4 (e.g., 1-3, 1-2, 1) R45;
31
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[066] In some embodiments, R3 is selected from the group consisting of:
furanyl
optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R45, thiophenyl optionally
substituted with 1-4
(e.g., 1-3, 1-2, 1) R45, pyrrolyl optionally substituted with 1-4 (e.g., 1-3,
1-2, 1) R45,
ii-(R456 r_N, (R456,,,,iN>_.(R45,4__N, (R456
tf, Nii N-fl Niisi/ Np Wipe Np
N.---S____45)rn l'O___\____456 111-....Ø_...___(R45)in 1-(R456 riV(R45),
iirS.._______(R45)mr0\ (R456
V N if Nil Nil( Np N-b5r Np
S
N' R45)mr'S._.--(R45614--S____--(R45),,
gle
wherein each m is independently 1 to 4 (e.g., 1-3, 1-2, 1).
[067] In some embodiments, R3 is selected from the group consisting of:
R7 R11 R15 R18 R21
/ RI 4 / / R19 / /
N N Nr--N N NY
)Nt 12 N---....t_16
R i!Li / K I. /N
Fe P9YR8 IN R2.2I--< N29?-/ R
N9 ,L Nu ,4 Ri7 R23 R25
,
R2y kv--Y Ft32
id----Y
1m \
NT/I -R27 q _____ R39 fi -Ft33 y41
R34
R28 / R31 R39
and = , ,
wherein each of R7-R" is, independently, a substituent as defined anywhere
herein or a single bond
connecting R3 to the isoquinoline ring; wherein only one of R7-R1 (when
present) is a bond, only
one of R"-R'4 (when present) is a bond, only one of 12}-5-R17 (when present)
is a bond, only one of
R18-- 20
K (when
present) is a bond, only one of R21-R23 (when present) is a bond, only one of
R24-R26
(when present) is a bond, only one of R27-R29 (when present) is a bond, only
one of R30-R31 (when
present) is a bond, only one of R32-R" (when present) is a bond, and only one
of R34-R" (when
present) is a bond; for purposes of clarification, any one of the nitrogen
atoms attached to R7, RH,
R15, R18, or R21 can serve as the point of attachment of R3 to the
isoquinoline ring; likewise, any
one of the carbon atoms attached to R8, R9, RE), R12, Ro, R14, R16, R17, R19,
R20, R22, R23, R24, R25,
R26, R27, R28, R29, R30, R31, R32, R33, K-.,34,
or R35 can serve as the point of attachment of R3 to the
isoquinoline ring.
[068] In some embodiments, R6 is selected from the group consisting of -
aryl
substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R36 and a 6-membered heteroaryl
optionally substituted
with 1-6 (e.g., 1-5, 1-4, 1-3, 1-2, 1) R37.
32
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[069] In some embodiments, R6 is selected from the group consisting of -
phenyl
substituted with 1-5 R36, -(C1_3 alkylene)ppyridinyl optionally substituted
with 1-6 R37, and a 6-10
membered heteroaryl optionally substituted with 1-6 R37; wherein the carbonyl
of Formula I is
attached to an aromatic ring of the heteroaryl; wherein -(C1_3 alkylene) is
optionally substituted
with one or more substituents as defined anywhere herein;
[070] In some embodiments, R7 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C19 haloalkyl), -(C1-4 alkylene)pheterocycly1 optionally
substituted with 1-10 (e.g.,
1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl optionally
substituted with 1-12 (e.g.,
1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39; wherein -(C1-4
alkylene) is optionally
substituted with one or more substituents as defined anywhere herein.
[071] In some embodiments, R7 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)0R49, -C(=0)N(R48)2, -
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and -
carbocyclyl optionally
substituted with 1-12 R39; wherein -(C1_4 alkylene) is optionally substituted
with one or more
substituents as defined anywhere herein.
[072] In some embodiments, R8, R9, and R11) are independently selected from
the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1-
4
alkylene)pheterocycly1 optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7,
1-6, 1-5, 1-4, 1-3, 1-2,
1) R38, and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-
9, 1-8, 1-7, 1-6, 1-5,
1-4, 1-3, 1-2, 1) R39; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with
one or more substituents as defined anywhere herein.
[073] In some embodiments, R8, R9, and R11) are independently selected from
the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -
(C1_4 alkylene)pN(R48)2, -
(C1_4 alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-
R38, and -carbocyclyl optionally substituted with 1-12 R39; wherein each -
(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[074] In some embodiments, one of R7 and R8, R8 and R9, or R9 and R11) are
taken
together to form a ring which is selected from the group consisting of -
heterocyclyl optionally
substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4
and -carbocyclyl optionally
substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R41.
33
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[075] In some embodiments, R" is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C19 haloalkyl), -(C1-4alkylene)pheterocycly1 optionally
substituted with 1-10 (e.g.,
1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl optionally
substituted with 1-12 (e.g.,
1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39; wherein-(C1-4
alkylene) is optionally
substituted with one or more substituents as defined anywhere herein.
[076] In some embodiments, R" is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)0R49, -C(=0)N(R48)2, -
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and -
carbocyclyl optionally
substituted with 1-12 R39; wherein -(C1_4 alkylene) is optionally substituted
with one or more
substituents as defined anywhere herein.
[077] In some embodiments, R12, R13, and R14 are independently selected
from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1-
4
alkylene)pheterocycly1 optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7,
1-6, 1-5, 1-4, 1-3, 1-2,
1) R38, and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-
9, 1-8, 1-7, 1-6, 1-5,
1-4, 1-3, 1-2, 1) R39; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with
one or more substituents as defined anywhere herein.
[078] In some embodiments, R12, R13, and R14 are independently selected
from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -
(C1_4 alkylene)pN(R48)2, -
(C1_4 alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-
R38, and -carbocyclyl optionally substituted with 1-12 R39; wherein each -
(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[079] In some embodiments, one of R" and R12, R12 and R13, or R14 and R11
are taken
together to form a ring which is selected from the group consisting of -
heterocyclyl optionally
substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4
and -carbocyclyl optionally
substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R41.
[080] In some embodiments, R15 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C19 haloalkyl), -(C1-4alkylene)pheterocycly1 optionally
substituted with 1-10 (e.g.,
1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl optionally
substituted with 1-12 (e.g.,
34
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39; wherein-(C1-4
alkylene) is optionally
substituted with one or more substituents as defined anywhere herein.
[081] In some embodiments, R15 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)0R49, -C(=0)N(R48)2, -
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and -
carbocyclyl optionally
substituted with 1-12 R39; wherein -(C1_4 alkylene) is optionally substituted
with one or more
substituents as defined anywhere herein.
[082] In some embodiments, R16 and R17 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[083] In some embodiments, R16 and R17 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)N(R48)2, -(C1-4
alkylene)0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and -carbocyclyl optionally substituted with 1-12 R39; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[084] In some embodiments, one of R15 and R16 or R16 and R17 are taken
together to
form a ring which is selected from the group consisting of -heterocyclyl
optionally substituted with
1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[085] In some embodiments, R18 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C19 haloalkyl), -(C1-4 alkylene)pheterocycly1 optionally
substituted with 1-10 (e.g.,
1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl optionally
substituted with 1-12 (e.g.,
1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39; wherein -(C1-4
alkylene) is optionally
substituted with one or more substituents as defined anywhere herein.
[086] In some embodiments, R18 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)0R49, -C(=0)N(R48)2, -
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and -
carbocyclyl optionally
substituted with 1-12 R39; wherein -(C1_4 alkylene) is optionally substituted
with one or more
substituents as defined anywhere herein.
[087] In some embodiments, R19 and R2 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[088] In some embodiments, R19 and R2 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pN(R48)2, -(C1-4
alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and -carbocyclyl optionally substituted with 1-12 R39; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[089] In some embodiments, one of R18 and R19 or R18 and R2 are taken
together to
form a heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-
6, 1-5, 1-4, 1-3, 1-2, 1)
R4 .
[090] In some embodiments, R21 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C19 haloalkyl), -(C1-4 alkylene)pheterocycly1 optionally
substituted with 1-10 (e.g.,
1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl optionally
substituted with 1-12 (e.g.,
1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39; wherein-(C1-4
alkylene) is optionally
substituted with one or more substituents as defined anywhere herein.
[091] In some embodiments, R21 is selected from the group consisting of a
single
bond, H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl),
unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)0R49, -C(=0)N(R48)2, -
(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10 R38, and -
carbocyclyl optionally
substituted with 1-12 R39; wherein -(C1_4 alkylene) is optionally substituted
with one or more
substituents as defined anywhere herein.
[092] In some embodiments, R22 and R23 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
36
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[093] In some embodiments, R22 and R23 are independently selected from the
group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pN(R48)2, -(C1-4
alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and -carbocyclyl optionally substituted with 1-12 R"; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[094] In some embodiments, R22 and R23 are taken together to form a ring
which is
selected from the group consisting of -heterocyclyl optionally substituted
with 1-10 (e.g., 1-9, 1-8,
1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl optionally substituted
with 1-12 (e.g., 1-11, 1-
10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[095] In some embodiments, R24, R25, and R26 are independently selected
from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1-
4
alkylene)pheterocycly1 optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7,
1-6, 1-5, 1-4, 1-3, 1-2,
1) R38, and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-
9, 1-8, 1-7, 1-6, 1-5,
1-4, 1-3, 1-2, 1) R"; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with
one or more substituents as defined anywhere herein.
[096] In some embodiments, R24, R25, and R26 are independently selected
from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -
(C1_4 alkylene)pN(R48)2, -
(C1_4 alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-
R38, and -carbocyclyl optionally substituted with 1-12 R"; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[097] In some embodiments, one of R24 and R25 or R25 and R26 are taken
together to
form a ring which is selected from the group consisting of -heterocyclyl
optionally substituted with
1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[098] In some embodiments, R27, R28, and R29 are independently selected
from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1-
4
37
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
a1ky1ene)pheterocyc1y1 optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7,
1-6, 1-5, 1-4, 1-3, 1-2,
1) R38, and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-
9, 1-8, 1-7, 1-6, 1-5,
1-4, 1-3, 1-2, 1) R39; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with
one or more substituents as defined anywhere herein.
10991 In some
embodiments, R27, R28, and R29 are independently selected from the
group consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2-9
alkenyl), unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -
(C1_4 alkylene)pN(R48)2, -
(C1_4 alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-
R38, and -carbocyclyl optionally substituted with 1-12 R39; wherein each -
(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0100] In some
embodiments, R27 and R28 are taken together to form a ring which is
selected from the group consisting of -heterocyclyl optionally substituted
with 1-10 (e.g., 1-9, 1-8,
1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl optionally substituted
with 1-12 (e.g., 1-11, 1-
10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[0101] In some
embodiments, R" and R31 are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[0102] In some
embodiments, R" and R31 are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pN(R48)2, -(C1-4
alkylene)p0R49, -C(=0)N(R48)2, -(C1_4alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and -carbocyclyl optionally substituted with 1-12 R39; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0103] In some
embodiments, R3 and R31 are taken together to form a ring which is
selected from the group consisting of -heterocyclyl optionally substituted
with 1-10 (e.g., 1-9, 1-8,
1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl optionally substituted
with 1-12 (e.g., 1-11, 1-
10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[0104] In some
embodiments, R32 and R" are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
38
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[0105] In some
embodiments, R32 and R33 are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pN(R48)2, -(C1-4
alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10 R38,
and -carbocyclyl optionally substituted with 1-12 R"; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0106] In some
embodiments, R34 and R35 are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R38, and -carbocyclyl
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[0107] In some
embodiments, R34 and R35 are independently selected from the group
consisting of a single bond, H, halide, unsubstituted -(C1_9 alkyl),
unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2_9 alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4
alkylene)pN(R48)2, -(C1-4
alkylene)p0R49, -C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-10
and -carbocyclyl optionally substituted with 1-12 R"; wherein each -(C1_4
alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0108] In some
embodiments, R34 and R35 are taken together to form a ring which is
selected from the group consisting of -heterocyclyl optionally substituted
with 1-10 (e.g., 1-9, 1-8,
1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl optionally substituted
with 1-12 (e.g., 1-11, 1-
10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[0109] In some
embodiments, each R36 is independently selected from the group
consisting of halide, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9
alkenyl), unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -XR42, -C(0)N(R47)2, -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R43, and -(C1-4
alkylene)pcarbocycly1 optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9,
1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R44; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with one
or more substituents as defined anywhere herein.
39
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0110] In some
embodiments, each R36 is independently selected from the group
consisting of halide, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9
alkenyl), unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -XR42,-C(=0)N(R47)2, -(C1_4
alkylene)pN(R50)2, -(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R43, and -(C1_4
alkylene)pcarbocycly1
optionally substituted with 1-12 R44; wherein each -(C1_4 alkylene) is,
independently, optionally
substituted with one or more substituents as defined anywhere herein.
101 1 1] In some
embodiments, each R37 is independently selected from the group
consisting of halide, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9
alkenyl), unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -XR42, -C(0)N(R47)2, -(C1_4
alkylene)pheterocycly1
optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-
2, 1) R43, and -(C1-4
alkylene)pcarbocycly1 optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9,
1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R44; wherein each -(C1_4 alkylene) is, independently,
optionally substituted with one
or more substituents as defined anywhere herein.
[0112] In some
embodiments, each R37 is independently selected from the group
consisting of halide, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9
alkenyl), unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -XR42, -C(=0)N(R47)2, -(C1_4
alkylene)pN(R50)2, -(C1-4
alkylene)pheterocycly1 optionally substituted with 1-10 R43, and -(C1_4
alkylene)pcarbocycly1
optionally substituted with 1-12 R44; wherein each -(C1_4 alkylene) is,
independently, optionally
substituted with one or more substituents as defined anywhere herein.
[0113] In some
embodiments, each R38 is selected from the group consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), -CN, and -(C1_4 alkylene)pcarbocycly1
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R44;
wherein each -(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0114] In some
embodiments, each R39 is selected from the group consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), -CN, and -(C1_4 alkylene)pcarbocycly1
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R44;
wherein each -(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0115] In some
embodiments, each R4 is selected from the group consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), -CN, and -(C1_4 alkylene)pcarbocycly1
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R44;
wherein each -(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0116] In some embodiments, each 124' is selected from the group
consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), and -CN.
[0117] In some embodiments, each R42 is selected from the group
consisting of
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), ), -(C1_4 alkylene)paryl optionally
substituted with 1-10 (e.g., 1-9,
1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R46, -(C1_4 alkylene)pheterocycly1
optionally substituted with 1-
12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R43, and -(C1-
4 alkylene)pcarbocycly1
optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-
4, 1-3, 1-2, 1) R44;
wherein each -(C1_4 alkylene) is, independently, optionally substituted with
one or more
substituents as defined anywhere herein.
[0118] In some embodiments, each R42 is independently selected from
the group
consisting of H, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), unsubstituted -(C1_5 haloalkyl), -(C1_4 alkylene)N(R48)2, -(C1_4
alkylene)paryl optionally
substituted with 1-10 R46, -(C1_4 alkylene)pheterocycly1 optionally
substituted with 1-12 R43, and -
(C1_4 alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each
-(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0119] In some embodiments, each R43 is selected from the group
consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), -CN, and -(C1_4 alkylene)pcarbocycly1
optionally substituted with
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R44;
wherein each -(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0120] In some embodiments, each R43 is independently selected from
the group
consisting of halide, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5
alkenyl), unsubstituted -(C2-5
alkynyl), unsubstituted -(C1_5 haloalkyl), -CN, -OH, -C(=0)R51, -N(R50)2, and -
(C1_4
alkylene)pcarbocycly1 optionally substituted with 1-12 R44; wherein each -
(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0121] In some embodiments, each R44 is selected from the group
consisting of halide,
unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl), unsubstituted -
(C2_5 alkynyl),
unsubstituted -(C1_5 haloalkyl), and -CN.
[0122] In some embodiments, each R45 is independently selected from
the group
consisting of H, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9 alkenyl),
unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)pheterocycly1
optionally substituted with
1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R38, and -carbocyclyl
optionally substituted with
41
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R39;
wherein each -(C1_4 alkylene) is,
independently, optionally substituted with one or more substituents as defined
anywhere herein.
[0123] In some
embodiments, each R45 is independently selected from the group
consisting of halide, unsubstituted -(C1_9 alkyl), unsubstituted -(C2_9
alkenyl), unsubstituted -(C2-9
alkynyl), unsubstituted -(C1_9 haloalkyl), -(C1_4 alkylene)pN(R48)2, -(C1_4
alkylene)p0R49, -
C(=0)N(R48)2, -(C1_4 alkylene)pheterocycly1 optionally substituted with 1-10
R", and -carbocyclyl
optionally substituted with 1-12 R39; wherein each -(C1_4 alkylene) is,
independently, optionally
substituted with one or more substituents as defined anywhere herein.
[0124] In some
embodiments, two adjacent R45 groups are taken together to form a
ring which is selected from the group consisting of -heterocyclyl optionally
substituted with 1-10
(e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R4 and -carbocyclyl
optionally substituted with 1-12
(e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R41.
[0125] In some
embodiments, each R46 is independently selected from the group
consisting of halide, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5
alkenyl), unsubstituted -(C2-5
alkynyl), unsubstituted -(C1_5 haloalkyl), and -CN.
[0126] In some
embodiments, each R47 is independently selected from the group
consisting of unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), and unsubstituted -(C1_5 haloalkyl).
[0127] In some
embodiments, each R47 is independently selected from the group
consisting of H, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), and unsubstituted -(C1_5 haloalkyl).
[0128] In some
embodiments, each R48 is independently selected from the group
consisting of H, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), and unsubstituted -(C1_5 haloalkyl).
[0129] In some
embodiments, each R49 is independently selected from the group
consisting of H, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), and unsubstituted -(C1_5 haloalkyl).
[0130] In some
embodiments, each R5 is independently selected from the group
consisting of H, unsubstituted -(C1_5 alkyl), unsubstituted -(C2_5 alkenyl),
unsubstituted -(C2-5
alkynyl), unsubstituted -(C1_5 haloalkyl), and -(C1_4 alkylene)N(R48)2;
wherein -(C1_4 alkylene) is
optionally substituted with one or more substituents as defined anywhere
herein.
[0131] In some
embodiments, each R51 is a heteroaryl optionally substituted with 1-6
R52.
42
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0132] In some embodiments, each R52 is a ¨heterocyclyl optionally
substituted with
1-10 R46.
[0133] In some embodiments, the heterocyclyl of ¨(C1_4
a1ky1ene)pheterocyc1y1 is
optionally substituted with 1-10 R38.
[0134] In some embodiments, the ¨(C1_4 alkylene) of ¨(C1_4
a1ky1ene)pheterocyc1y1 is
optionally substituted with 1-10 R38.
[0135] In some embodiments, the heterocyclyl of ¨(C1_4
a1ky1ene)pheterocyc1y1 is
optionally substituted with 1-10 R43.
[0136] In some embodiments, the ¨(C1_4 alkylene) of ¨(C1_4
alkylene)pheterocycly1 is
optionally substituted with 1-10 R43.
[0137] In some embodiments, the carbocyclyl of ¨(C1_4
alkylene)pcarbocycly1 is
optionally substituted with 1-12 R44.
[0138] In some embodiments, the ¨(C1_4 alkylene) of ¨(C1_4
alkylene)pcarbocycly1
optionally substituted with 1-12 R44.
[0139] In some embodiments, the aryl of ¨(C1_4 alkylene)paryl is
optionally substituted
with 1-10 R46.
[0140] In some embodiments, the ¨(C1_4 alkylene) of ¨(C1_4
alkylene)paryl is
optionally substituted with 1-10 R46.
[0141] In some embodiments, ¨(C1_4 alkylene) is optionally substituted
with 1-5 halide
or 1-5 unsubstituted ¨(C1_3 alkyl).
[0142] In some embodiments, ¨(C1_4 alkylene) is substituted with 1-2
fluorines.
[0143] In some embodiments, ¨(C1_4 alkylene) is substituted with 1-2
methyls.
[0144]
[0145] In some embodiments, each X is selected from the group
consisting of 0, S,
and NH.
[0146] In some embodiments, each X is selected from the group
consisting of 0, S,
and NR48.
[0147] In some embodiments, each X is selected from the group
consisting of 0 and
S.
[0148] In some embodiments, each X is selected from the group
consisting of 0 and
NH.
[0149] In some embodiments, X is 0.
[0150] In some embodiments, X is S.
[0151] In some embodiments, X is NH.
43
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0152] In some embodiments, X is NV.
[0153] In some embodiments, X is NMe.
[0154] In some embodiments, each Y is selected from the group
consisting of 0 and
S.
[0155] In some embodiments, Y is 0.
[0156] In some embodiments, Y is S.
[0157] In some embodiments, each m is independently 1 to 4 (e.g., 1-3,
1-2, 1).
[0158] In some embodiments, each n is independently 0 to 3 (e.g., 0-2,
0-1, 0).
[0159] In some embodiments, each p is independently 0 or 1.
[0160] In some embodiments, each q is independently 0 to 12 (e.g., 0-
11, 0-10, 0-9,
0-8, 0-7, 0-6, 0-5, 0-4, 0-3, 0-2, 0-1, 0).
R7
N
111 R9
[0161] In some embodiments, R3 is
[0162] In certain embodiments, R9 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R7
\ FE-
N,/
N*,
=
R40
rj n
\
.Oss
[0163] In some embodiments, R3 is Ri and n is 1 to 3.
[0164] In some embodiments, R7 is selected from the group consisting
of H,
unsubstituted ¨(C1_3 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨(C3_4
carbocycly1) optionally
substituted with 1-2 R39.
[0165] In some embodiments, R7 is selected from the group consisting
of H, methyl,
¨CF3, and cyclopropyl optionally substituted with 1-2 R39.
[0166] In some embodiments, R7 is selected from the group consisting
of H and
methyl.
[0167] In some embodiments, R7 is methyl.
44
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0168] In some embodiments, R7 is ¨CD3.
[0169] In some embodiments, R8 is selected from the group consisting
of H, halide,
unsubstituted ¨(C1_2 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨(C1_2
alkylene)0R42.
[0170] In some embodiments, 128 is selected from the group consisting
of H, F, methyl,
¨CF3, ¨(CH2)0H, and ¨(CH2)0Me.
[0171] In some embodiments, 128 is selected from the group consisting
of H, F, methyl,
and ¨CF3.
[0172] In some embodiments, R8 is selected from the group consisting
of H, F, and
methyl.
[0173] In some embodiments, R8 is H.
[0174] In some embodiments, RI is selected from the group consisting
of H and
halide.
[0175] In some embodiments, RI is selected from the group consisting
of H and F.
[0176] In some embodiments, RI is H.
R11
R14
IR _______________________________________ R12
R13
[0177] In some embodiments, R3 is "^-,'
[0178] In certain embodiments, R12 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R"
RIti4
1213
R40
chN In
13
[0179] In some embodiments, R3 is Rand n is 1 to 3.
[0180] In some embodiments, R11 is selected from the group consisting
of H,
unsubstituted ¨(C1_3 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨(C3_4
carbocycly1) optionally
substituted with 1-2 R39.
[0181] In some embodiments, R11 is selected from the group consisting
of H, methyl,
¨CF3, and cyclopropyl optionally substituted with 1-2 R39.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0182] In some embodiments, R" is selected from the group consisting
of H and
methyl.
[0183] In some embodiments, R" is methyl.
[0184] In some embodiments, R" is ¨CD3.
[0185] In some embodiments, R13 is selected from the group consisting
of H and
halide.
[0186] In some embodiments, R13 is selected from the group consisting
of H and F.
[0187] In some embodiments, R" is selected from the group consisting
of H, halide,
unsubstituted ¨(C1_2 alkyl), and unsubstituted ¨(C1_2 haloalkyl).
[0188] In some embodiments, R" is selected from the group consisting
of H, F,
methyl, and ¨CF3.
[0189] In some embodiments, R" is selected from the group consisting
of H and
methyl.
[0190] In some embodiments, R" and R" are both methyl.
R29 y
R28
[0191] In some embodiments, R3 is "L'1^-
R29 y
N-
R28
[0192] In some embodiments, R3 is ''"- and Y is S.
R29 y
N-
R28
[0193] In some embodiments, R3 is "-"^- and Y is 0.
[0194] In certain embodiments, R27 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R29
ilq
R28
R2s
R28
[0195] In some embodiments, R3 is
46
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
R2c:s
11),H
R28
[0196] In some embodiments, R3 is
[0197] In some embodiments, R28 is selected from the group consisting
of H and
halide.
[0198] In some embodiments, R28 is selected from the group consisting
of H and F.
[0199] In some embodiments, R29 is selected from the group consisting
of H, halide,
unsubstituted ¨(C1_2 alkyl), and unsubstituted ¨(C1_2 haloalkyl).
[0200] In some embodiments, R29 is selected from the group consisting
of H, F,
methyl, and ¨CF3.
- ¨R33
[0201] In some embodiments, R3 is
fi - ¨R33
[0202] In some embodiments, R3 is ="^-- and X is S.
R3x
R33
111-/ N
[0203] In some embodiments, R3 is and X is 0.
[0204] In certain embodiments, R33 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R3x
=
Rs
[0205] In some embodiments, R3 is
R3
till¨
[0206] In some embodiments, R3 is
[0207] In some embodiments, R32 is selected from the group consisting
of H, halide,
unsubstituted ¨(C1_2 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨N(R53)2.
47
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0208] In some embodiments, R32 is selected from the group consisting
of H, F,
methyl, ¨CF3, ¨NHMe, and ¨NMe2.
[0209] In some embodiments, R32 is selected from the group consisting
of H and
methyl.
[0210] In some embodiments, R32 is methyl.
R18
II -R29
[0211] In some embodiments, R3 is '^^^'
[0212] In certain embodiments, R2 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R18
R19
1>-i
R15
R16
/ R17
[0213] In some embodiments, R3 is
[0214] In certain embodiments, R" is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R15
/
R17
[0215] In certain embodiments, R17 is a single bond connecting R3 to
the isoquinoline
ring, i.e., R3 has the following formula:
R15
LIN
N
[0216] In some embodiments, R" is selected from the group consisting
of H and
unsubstituted ¨(C12 alkyl).
[0217] In some embodiments, R" is selected from the group consisting
of H and
methyl.
48
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0218] In some embodiments, R15 is methyl.
[0219] In some embodiments, R15 is ¨CD3.
Rao
NIn
N [0220] In some embodiments, R3 is N and n is 1 to
3.
[0221] In some embodiments, R18 is selected from the group consisting of H,
unsubstituted ¨(C1_3 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨(C3_4
carbocycly1) optionally
substituted with 1-2 R39.
[0222] In some embodiments, R18 is selected from the group consisting of H,
methyl,
¨CF3, and cyclopropyl optionally substituted with 1-2 R39.
[0223] In some embodiments, R19 is selected from the group consisting of H,
halide,
unsubstituted ¨(C1_2 alkyl), and unsubstituted ¨(C1_2 haloalkyl).
[0224] In some embodiments, R19 is selected from the group consisting of H,
F,
methyl, and ¨CF3.
[0225] In some embodiments, R39 is selected from the group consisting of
halide,
unsubstituted ¨(C1_3 alkyl), and unsubstituted ¨(C1_2 haloalkyl).
[0226] In some embodiments, R39 is selected from the group consisting of F,
methyl,
and ¨CF3.
[0227] In some embodiments, R4 is selected from the group consisting of H
and
unsubstituted ¨(C1_2 alkyl).
[0228] In some embodiments, R4 is selected from the group consisting of H
and
methyl.
[0229] In some embodiments, R6 is selected from the group consisting of
¨aryl
substituted with 1-5 R36 and a 6-membered heteroaryl optionally substituted
with 1-6 R37.
[0230] In some embodiments, R6 is selected from the group consisting of
¨phenyl
substituted with 1-5 R36, and ¨pyridinyl optionally substituted with 1-4 R37.
[0231] In some embodiments, R6 is a ¨phenyl substituted with one R36.
[0232] In some embodiments, R6 is a ¨pyridinyl substituted with one R37.
[0233] In some embodiments, R6 is a ¨pyridin-2-y1 substituted with one R37.
[0234] In some embodiments, R6 is a ¨pyridin-3-y1 substituted with one R37.
[0235] In some embodiments, R6 is a ¨pyridin-4-y1 substituted with one R37.
49
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0236] In some
embodiments, R36 is selected from the group consisting of halide,
unsubstituted ¨(C1_3 alkyl), unsubstituted ¨(C1_3 haloalkyl), ¨NHR42,
¨C(0)N(C1_3 alky1)2, ¨
C(0)NH(C1_3 alkyl), ¨heterocyclyl optionally substituted with 1-2 R43,
¨(CH2)heterocycly1
optionally substituted with 1-2 R43, ¨(C3_4 carbocyclyl) optionally
substituted with 1-2 R44, and ¨
(CH2)(C3_4 carbocyclyl) optionally substituted with 1-2 R44.
[0237] In some
embodiments, R37 is selected from the group consisting of halide,
unsubstituted ¨(C1_3 alkyl), unsubstituted ¨(C1_3 haloalkyl), ¨0R42, ¨NHR42,
¨C(0)N(C1_3 alky1)2, ¨
C(0)NH(C1_3 alkyl), ¨heterocyclyl optionally substituted with 1-2 R43,
¨(CH2)heterocycly1
optionally substituted with 1-2 R43, ¨(C3_4 carbocyclyl) optionally
substituted with 1-2 R44, and ¨
(CH2)(C3_4 carbocyclyl) optionally substituted with 1-2 R44.
[0238] In some
embodiments, the heterocyclyl is selected from the group consisting
of azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl,
piperazinyl, morpholinyl, and
tetrahydropyranyl.
[0239] In some
embodiments, R42 is selected from the group consisting of
unsubstituted ¨(C1_3 alkyl), and unsubstituted ¨(C1_3 haloalkyl), ¨CH2phenyl
optionally substituted
with 1-2 halides, ¨heterocyclyl optionally substituted with one ¨(C1_3 alkyl),
¨CH2heterocycly1
optionally substituted with one ¨(C1_3 alkyl), an unsubstituted ¨carbocyclyl,
and an unsubstituted ¨
CH2carbocyclyl.
[0240] In some
embodiments, R42 is selected from the group consisting of methyl,
ethyl, propyl, isopropyl, ¨CHF2, ¨CF3, and ¨heterocyclyl optionally
substituted with one Me.
[0241] In some
embodiments, R42 is selected from the group consisting of methyl,
ethyl, propyl, isopropyl, ¨CHF2, ¨CF3, ¨ , and
[0242] In some
embodiments, R43 is selected from the group consisting of halide,
unsubstituted ¨(C1_2 alkyl), unsubstituted ¨(C1_2 haloalkyl), and ¨carbocyclyl
optionally substituted
with 1-2 halides.
[0243] In some
embodiments, R43 is selected from the group consisting of F, methyl,
ethyl, ¨CF3, and a cyclopropyl.
[0244] In some
embodiments, R44 is selected from the group consisting of halide,
unsubstituted ¨(C1_2 alkyl), and unsubstituted ¨(C1_2 haloalkyl).
[0245] In some
embodiments, R44 is selected from the group consisting of F, methyl,
ethyl, ¨CF3.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0246] In some
embodiments, R36 is selected from the group consisting of F, methyl,
o
,0 c) ro <_
N N N
ethyl, n-propyl, isopropyl, ¨0(C1_3 alkyl), ¨0(C1_3 haloalkyl), ¨1¨ , ¨ ,
1 y y NH2 HN 1417
H NH2 Hie
N N 8 N /I\ o o N) E ) EN)
N N N N N N N N N N N N
-I-
, ,
y
Li 1
N NH Isl
p y 0
vNH µ,.(NH ,,(NH ,,<NH ,,<NH ,vNH ,,<NH ,vNH <vNH v Lv
H I Yy
c....... JN I41 n c ..)N
N NH Isl 110
Y y Y Y 0
, õ...0 \,....x
-4 ,and
l'
[0247] In some
embodiments, R37 is selected from the group consisting of F, methyl,
H I Y N
0 N N N
C 0 0 EN) EN
N N N
ethyl, n-propyl, isopropyl, ¨0(C1_3 alkyl), ¨0(C1_3 haloalkyl), -1- , -I- , -1-
, -1- ,
NI
V NH2 HN H
Iti p
NH2 HN
lki N N
y y
N) N N N O
N N N
LVNH LVNH VNH LVNH µVNH
,
YY H
IYYy
40
N rsi N N y N
YYp Y y Y Yn Y
0 0 0
\...õ.NH \....NH vO \,- \.,.0 \., vO v... Lv,
, and
51
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0248] In some
embodiments, R3 is selected from the group consisting of:
R18 R15 R7 R11
R19 / N/
N/ R14 / R 2, 9, . _ ...
... .... y R 3_ ......2 x
Nõ...-N N
II ¨R213 4/
NI -1 t R1 6 riltR8 11...tR12 r!- /
R27 fi ¨R33
:IZN,
Rl / I
R17 R9 R13 R28
and
, , ' , ,
wherein Y is S or 0 and R6 is a ¨aryl substituted with 1-5 R36.
[0249] In some
embodiments, R3 is selected from the group consisting of:
R18 R15 R7 R"
R19 / N/
N/ R14 / R2,..õ....9
y R3 ___...2 x
N N
II R28 4
Ni-itR16 Irto ille¨R12 r! / R27 fi ¨R33
IN' iN N
R1 / I
/ R17 R9 R13 R28
, and
, , ' , ,
wherein Y is S or 0 and R6 is a 6-membered heteroaryl optionally substituted
with 1-6 R37.
[0250] In some
embodiments, R3 is selected from the group consisting of:
R18 R18 R7
\ R8 R11
R18 N N/
I
.?
N N/ N----/ R14 N/ N, 122c:4 R2 s
N
R19 I : /* riq ,I,), __ q
I 1t 4-....-1
-If- H N
N"-N R17 R10
, , R13 , D28 ra28
" , r% ,
R3s R3 co
Li, and NII-N
,and R6 is a ¨phenyl substituted with 1-5 R36.
[0251] In some
embodiments, R3 is selected from the group consisting of:
R15 R15 R7 ia R11
/
N/ \N R8 R /
N,N RR290R29 s
R18
R19 i
N irN l ZR ____ 1 /41/ss q iq q
Nii H N
Pt-N R17 , 10 R13 , 028 ri28
, , " , r% ,
R3s R30
LiI 1
, and N-N , and
R6 is a ¨pyridinyl optionally substituted with 1-4 R37.
[0252] In some
embodiments, R3 is selected from the group consisting of:
. D7
R 15 = ', R8 1/111
R18 N N/ N R14Nr____ 1120
R19 /
N 717....?õ, 111 __ I I....._ Ic s q
/INH N /
010 505 N /
II 1
R13 141-- , R28
, and , and
R6 is a ¨phenyl
, , ¨
substituted with one R36.
52
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
[0253] In some
embodiments, R3 is selected from the group consisting of:
Rio R7 8 R"
\ rt 14 /
R13 / N¨_/ 12_......N R20
N
R1, _9 ill 111...,..?, 141'\ 1 __ q R3s rlq
11 H / ns'
R13 i!J__N , and
N-1,1 , Rio , rt28
I% , and
126 is a -pyridin-
2-y1 substituted with one R37.
[0254] In some
embodiments, R3 is selected from the group consisting of:
Rio R7 rt 8 R"
\ 14 /
R13 / N--/ IR__N R20
R1,9i Z-N N/\ 1 _______ q R3,2 s Itq
1111_11H ns'
, Rio , R13 mu I!J-.1 , and
R28 , and 126 is a -pyridin-
3-y1 substituted with one R37.
[0255] In some
embodiments, R3 is selected from the group consisting of:
R15 R7 rt8 R"
\ /
R13 / N¨_/ R14 N R20
R1, _9 r,i N--..... w3 ,!),_Z N', 1 R3s Itq
T¨N H k / l'is lisqN
N , R19 , n28
, and rµ , and 126 is a -pyridin-
4-y1 substituted with one R37.
[0256] In some
embodiments, R3 is selected from the group consisting of:
Rio R7 R11
R13 / \N__..../ R8 R14 Ni
R20
N
R19 ill r...,?,.. Ni\ \ NINTR R32
s q
)1 H ' l'I
R13 ilLN, and
N¨N , R19 , rt28
Iµ , and
R6 is a -phenyl
substituted with one R36; and R36 is selected from the group consisting of F,
methyl, ethyl, n-propyl,
H I N
Y Y
N N N NH2 HN N
EN) (N ) C N
N N N N
isopropyl, ¨0(C13 alkyl), ¨0(C13 haloalkyl), ¨1¨ , ¨1¨ , -I- , -I- ,
H I H I Y
NH2 HN N N N N N N
0
YY Y
N N N 0
NH VNH V Vo ¨1.- .
53
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0257] In some
embodiments, R3 is selected from the group consisting of:
R15 R7 pe R11
R18 /
N \N_____/¨ Ria I4
R213
R19 N/ ikkil, 141' \ 1 R32
N,S Ilq
Y H / ns
R13 LI __ , and
N¨N , Rio , R29 , and
12_6 is a ¨pyridin-
2-y1 substituted with one R37; and R37 is selected from the group consisting
of F, methyl, ethyl, n-
H I Y Y
EN
NH2 HN
(N..,..1 N EN)
1-.N...2 __________________ EN) '-.N.) L.N) -,..N.-- =====,N.---
propyl, isopropyl, ¨0(C13 alkyl), ¨0(C13 haloalkyl), -I- , -I- , -I- , -I- , -
I- , -I- ,
N.N..-- H I H
N Y
N
0
NH2 HN N N ....õ..N,.... N ,-- ,.....
N O Y Y
N N N NH NH 0 0
Jr,
, and
[0258] In some
embodiments, R3 is selected from the group consisting of:
07
R15 m 108 R"
R19 / \N____/¨ Ria 14
RU8 0
R19 N/ 111¨N 1 N/\ \ __ )R R32 s q
)1¨ H N N Nri
N--N , Rio ' , R13 N¨
R28 ,and n28
, and 12_6 is a ¨pyridin-
3-y1 substituted with one R37; and R37 is selected from the group consisting
of F, methyl, ethyl, n-
H I Y Y
N
NH2 HN
EN)., r N N LN) N) EN) N N
propyl, isopropyl, ¨0(C13 alkyl), ¨0(C13 haloalkyl), ¨I¨ , -I- , -I- , -I- , -
I- , -I- ,
=-..N....-- H I H
N Y
0
2 Hr.( 1.11- N N iN1 c )N
N 6 6
N N N NH NH 0 0
,,,,L,
,and
[0259] In some
embodiments, R3 is selected from the group consisting of:
07
R15 r% D8 R11
R18 / \N/.= R14 ill
RU8 0q
N
R19 / IrN t N/\ \ ) R ______ R3s
);--- H N N II 1
N---N r% , Rio ' , Ri3 N¨
, and n28
, and 12_6 is a ¨pyridin-
54
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
4-y1 substituted with one R37; and R37 is selected from the group consisting
of F, methyl, ethyl, n-
Y
H I Y
NH2
rN HN
(N,..1 N rN
1-..N...2--'-.N)
propyl, isopropyl, ¨0(C13 alkyl), ¨0(C13 haloalkyl), -I- , -I- , -I- , -I- , -
I- , -I- ,
N/ H I H I Y
1
N .1
111H2 HN N N ..,....N,,,, ....,N,....
6 'YY Y
N N N N NH NH 0 0 0
and
I
, d .
/
[0260] In some embodiments, R3 is selected from the group consisting
of: ¨N ,
/ H I
N N
NiiS
I ____ 14
N 11) ijIHN 110 IsD
irs
4
R6 is a ¨phenyl substituted with one R36; and R36 is selected from the group
consisting
H
111
H
}L ryi
(N.-- LN Y
of F, methyl, ¨0(C1_3 alkyl), ¨0(Ch3 haloalkyl), ¨1-- , --1¨ , V ,and
/
N ,
I.?
[0261] In some embodiments, R3 is selected from the group consisting
of: ri ,
/ H
N NI
110 tEH Nr!j, 10 rj¨, '
141-141 ,
IiN , R6 is
a ¨pyridin-2-y1 substituted with one R37; and R37 is selected from the group
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
H I Y Y NH2 Hle Isl H
N
1 I -12 liN N 141
NN ,......--........
O 0 C CN
õ õ \/
N N N N N N N N N N NH
consisting of ¨I¨ , ¨1¨ , -I- , -1- , -1- , -I- , -I- , -I- , -1- , -I- , 5-,
I H
NI Y
N
---N-.. ---N-.. y .---
y
Y
NH vO v ,a 0
nd ''' .
/
r-N\
[0262] In some embodiments,
IV is selected from the group consisting of: ¨N ,
/ H I
1 N
N N
/
N,N 41 NI- jlt N,Ni ,13 0 s
NI
11) ON 10 1114 ,
iS
R6 is a ¨pyridin-3-y1 substituted with one R37; and R37 is selected from the
group
H I Y Y NH2 )Flie H;c H
N N
N N N
0 cN ) C C O \./
1,1
N N N N N N N N N NH
consisting of -1- , -1- , -I- , -1- , -I- , -1- , -I- , -1-, , -I- , -I- , 5-,
I H
NI Y
N
NH vO v ,,,A
, a
y nd
/
N s
r;1 1[0263] In some embodiments, IV
is selected from the group consisting of: ,
/ H /
I
N7_ N N¨N NN
N t
/ /
ô,rioN trir
I.)---N N
, , , ,
56
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
S
I!) 1
, , R6 is
a ¨pyridin-4-y1 substituted with one R37; and R37 is selected from the group
I Y Y H
N
rN N
H riki r rN NH 1-1;c 1
NH2 Hle 14,1
\./
I-. ) L.N,---1 1--.N.--' L.N.-- -., --- =====, =====, ---
N N N N N N N NH
consisting of -1- , -1- , -I- , -I- , -I- , -1- , -I- , -I- , -I- , -I- , 5-,
NI H I Y
...- ,... y
N 141 i IN
y
T
NH V V , and y.
, .
DD
y-D
rrN\
r4 /r-z
[0264] In some
embodiments, R3 is selected from the group consisting of:
DD DD
D D D D
D
D,
N N D D i--D D D
DNi.--- DD
N-N
DDYN 5 141µ , c
D N
> D>r-0
NI ________________________________ 1.), r11,1 tO
D
D
D>r-S
NI-
N , R6 is a -pyridin-3-y1 substituted with one R37; and R37 is
selected from the group
H I Y Y NH2 Hie Isl H
N
-12 il 1
N N 0 }`I rsl
;
0 L \/
Isi
N N N r N N N N N N NH
consisting of -I- , -I- , -1- , -I- , -1- , -I- , -I- , -I- , -1- , -I- , 5-,
I H
NI Y
N
y
Y
NH te \r ,0
, and 5- .
57
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
DD
y-D
n..._N\
[0265] In some
embodiments, IV is selected from the group consisting of: ¨N ,
D D
D D
1: D
D D D D
Q34 \F-13 D N. N N N D D
D---- \..-N N!---..?, -L?,, DD>1
cr-N, Ll 5 141, - , D>Y0
i
D
D
D>_-S
NI-
N , R6 is
a ¨pyridin-4-y1 substituted with one R37; and R37 is selected from the group
H I Y Y NH2 HN N H
I I NH2 H N N 141
N N N ,......---.......
O 0 ( C N
N N N N N N N N N N NH
consisting of -1- , ¨I¨ , ¨I¨ , ¨I¨ , ¨I¨ , ¨I¨ , ¨I¨ , ¨I¨ , ¨1¨ , ¨I¨ , 5-,
NI H I Y
....- ..... y
N 141 iN1
y
T
\-NH V Vo , and V
, .
/
N N
iq
[0266] In some
embodiments, IV is selected from the group consisting of: ,
/
liNlt \---S,
N,0
NQ ILI
R6 is selected from the group consisting of ¨phenyl optionally
substituted with 1-2 R36 and ¨(C1_2 alkylene)ppyridinyl optionally substituted
with 1-2 R37.
58
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
/
[0267] In some embodiments, R3 is selected from the group consisting
of:
--N
, R6 is selected from the group consisting of¨phenyl substituted
with 1-2 R36 and ¨pyridinyl substituted with 1-2 R37, and R36 is selected from
the group consisting
of ¨XR42, ¨(C1_4 alkylene)pheterocycly1 optionally substituted with 1-2 R43,
and ¨(C1-4
alkylene)pcarbocycly1 optionally substituted with 1-2 R44, and R37 is selected
from the group
consisting of ¨XR42, ¨(C1_4 alkylene)pheterocycly1 optionally substituted with
1-2 R43, and ¨(C1_4
alkylene)pcarbocycly1 optionally substituted with 1-2 R44.
N N
4:.?õ
[0268] In some embodiments, R3 is selected from the group consisting
of:
Nj
N,0
L)/
, R6 is selected from the group consisting of¨phenyl substituted
with 1 R36 and ¨pyridinyl substituted with 1 R37, and R36 is selected from the
group consisting of ¨
Xheterocycly1 optionally substituted with 1-2 R43, ¨heterocyclyl optionally
substituted with 1-2
R43, and R37 is selected from the group consisting of ¨Xheterocyclyl
optionally substituted with 1-
2 R43, ¨heterocyclyl optionally substituted with 1-2 R43.
/
[0269] In some embodiments, R3 is selected from the group consisting
of:
--N
14)
¨.N , R6 is
¨pyridinyl substituted with 1 R37, and R37 is selected
from the group consisting of ¨Xheterocyclyl optionally substituted with 1-2
R43, ¨heterocyclyl
optionally substituted with 1-2 R43, and X is selected from the group
consisting of 0, S, ¨NH.
[0270] Illustrative compounds of Formula (I) are shown in Table 1.
59
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
Table 1.
HN 1 11 \N \N
2 L N 3 rL, ri\ I
I 41 r.1\ I Ai II,
------i , -,... ,, N M
...N 6 1-,N--, `-... ,
I
,..-41 = [,,NH I õ.,. l!I
1--õN--,
\N \ \N_Th
yl NH N.-
4 Ni , NH 411 0 5 N H \
N 6 "I\
.-----
\N.Th \N \N
Aim 0.,.,....õ, ,
7 li \ 11 H
^.., .N 41110 (....,,,NH 8 Pci,( 14 11 L) 9
id\ 1 H11., N
11
.N --.,
---õN.---,1
\- --I'r --,,
\ N \N
,N Hp
N \ r 11 ,c).õ11
,.22, )1 .N ,..
N 12
11--) I I
, N 1--,.õ-N----...
I --- -\----"
V
\ CN
N \N \ N
j...rõ.. 41 p ..õ.. N
13 N j N
I -11 pi\ I H 15 Nz \ 1
tivirLj, _OH
,, NI Cc `--- 0
..--- N
7-------Iv-------F 14 ...N
,N
\N \ \
--- N NH N õ --" N N'' N N
Plz \ 1 H
17 N
,N =-..õ I j n 1
..õ,. -..õ .N --., 18 16 NH
, NI 0 ,4 i -41 H
N
19 N/\ I
1.1 ,..' I N,0' 20 N
Ilz 1 ,
H
`,.. ----.. N-IrC 21 N \ 1
H .., N
--N
(---.\Pi
-7/ 1
\----<
N 0.,,
22 Nz, H RP L,NH 23 ND H ;;CT,
24 N F
- - i i..--INi
Ili
4'I'l-g NO N', 1 H
N N
---.. .
----,
i
,..-N .
\ \
14--- \
II
---\
\--- F (--
N
0
25 \---<
N N
N
Nj., H 0 04,F 26 27 \--<
N.r.\ `...
H,.....jj'
I ,[ YI' \ N'\ N -..,p I
NH
N l =
..--N 0 ,..-N
01'F
4_1 H 4/ F
----
IS
N IN pe--.)/ H
28 ...-- ..., N 010 29 N 30
---
--,.. , 41
I ---'-- -if '-=.,
,i11
,
...-1.1 0 ,..-N = 11 ..-'
.,,,- N = 7,......_,NH
N/
dr- NH
N 32 N N'
31 ...., NH . I* N H H
.--- N
I"----) ,.....
,.-- N =
0
dr-N/
"-Z
H /7N ,y,O,T,Th
Hp
34 " II\----1-1%i--ky" NH 35 "õ1---T ,
L. .1i 1..---N 36 N ---,
Hp ,N/ ,- õ--, N
N'
37 --. N ===., I N,-) 38 N H 1 il of: :11H
N I .,,,.,.__. ' 39 N H
N N., I
,..-N --,1 ---ir
\--1-)
. _.
/ o,yõ...-
7-"---N/.
j--1.1
0 I LI 140
40 " -- H
N 41 " -- NH 411 42 " --
--. , --. , --, ,
1 1 N
I tl'i
...--N = ,..1.1 = 1-,...õõNH
.---N = 1--õ,,,,N----,
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
ra.....õ,
1,17---N"14 0 ea--
45 " -- H
43 44 N' --. \
1,,,,,,,,111H
I
N , N = ,-N
0,--,
>--NZ
11, -, I L, i!,, 47 N Hp
46 Hp 48 N ---
N ---.,
\
,-N
>11/ 49 z---1.1/
---r.,'
50 N\i-t-- I.I,L to _if
H
51
N
NH--.)
\
),1 N
1. Hp Ta 54 NAcccuirci
52 "--14 H 0 0 53 N \ 1
,.,N -----
10,
N I \
I,
NH2 NH
,..-N =
1
\
Hp 1.\
11 Hf
,j,
55 N711- .-------,r- N ...' Nr) 56 - JJ 57 N'3
N,..rõ
...). ,N
, ..,.=.-N ,..-- N 0
NH2
1
\
\N
N
ri \ I til, r
59 Pi'\ 1 Hpi
58 Nn , N ---,,
60 N
N\---\
1.1 \
,-N \---"--N----
H I ,..41 =
\N \ \
61 'I\ Ho
N Na N
\ N --, 1 Hip
...,,, 63 NI7-11
62 PI
\
N \N \N
64
N Ct)
65 1.I\ HiaG
o NH
1
, 66
,N
pf\ll..iT
N \N F \N 0T F
ir(,, hi 1 H
I. 011
67 1 --Ill KY - 68 \
\ N 69 "( \
1.11 I
,..-N = ...-N =
\N \N \N
N H H
70 l'I\ ....,_ N 0 71 -- N'*\ I
N et I 72
N
\ \
I I
...-N = ,..-N =
\
\
0
N
N
7314 0 N 74 NiN mi.( uu. 75 is( I
HiCI)L4 i
-Th
,N 0 L.s.z.N
N
\ \ \
N il N N N
76 N( \
\ H
N I 77 ti\ I ilirc,,,AL, 78 N' \ N -,
1 Hp
.., I
OH
N N 0 ...-N
\ \N \N
N ====,---7
i
H
H.I.r:CL,0
1
7 Hnj N )110L., y-ome 80 PC \ N
81 II\ N =-=, ,..--y-
,-N 0
\ \N \
'N
N
84 83
pi\ I irt,r(, !I
11 II\ Hp
,_,.. N --, I No II\ 1 HI --
.1a
82 o
--, --\
,i
,-
61
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
11\ 1 NI ri
0 0
\ \
N N
85 "I\ HN.õ..il%
--, I 86 H
`----
I 87 I
,N N c,NH =,--
,
..N
L.N)
I
\ \ \
NTh
,., N-Th
H ---- r
Il
88 NJ , i N 0
i, 89 Pi\Nµ Pi ,i,,, 90 l'(-11 --. -.-
I rii tz----j
i_
---,
1 \ \N
Id\ 1 Hp
l'
" I 11.". 92 NJ N I NH
'N It
91 --L, -L N N
93 Nat _1,1, ,k k
N
,N Ly6 I 1 g
...--- I
....' ) g
\N \
N
\I
N
H CIN-
1
94 Pi\ 1p ----, 95 N\ 1 , NH pooi 96 pi\
I H
..1%.3,14,-1-õ,_>
õ-N --N
--N g H
\N \ \
N'
97 NAT, .,,, LI ,,---- r 98 N/\ 1
N ----. 02--/ 99 N\ 1 H
g.,-c,---.,Nti,, o-
, N, I s
I .- 1 II I .--N
\ \ \
N Hi'll N--i N -----.
---- N
N
101
100 1µ\ 1 LI, ,'T Pi\ \ N.------I 102
1 ,..., N N'Th
IN---õ
\N \N \N
H H H
103 104 4\ 1 N 105 11\ \
N
\
jr4
N 0 0
\N \N \N
/ N
H
106
N 107 14 \ 1 H
N 108 1.1\
N
*-,-.
',..
,N 0
\
N \
N
109
N H H
110 11\ N 111 l'ir\ \H N NH
',. ,..
,N 0 ,N 0 ,N 0
\ \N \
N
N N
--- NH
112 P"\ \ H
N N N'\ I N H
PI\ H
N
',.. -.... -1- 113 s-,XTJCJ 114
,..
,N ,N ,-N 0
_ ¨ . \N \N NH \N
115 N'\ I H
N \
116 N'\ I H ri\ I H SI
i
....-N 0 ,N 0 1
N =
- - 0
\N \ S \N \
N
118 Ni\ I pi , I 119 Pi\ I H
N 120 ri I
\ H
N
N
N 0 N N 0
S
\N \ \N N \N 0
I.,
121 Ni\ I H
N 122 N'= \ -. H
N 0 1:) 123 N\1 --. H
N S
\
N 0 ..õ-N 0
N 0
62
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
\N \N \
N
0 H H
124 H
\ ri 1 N N N 125 11\ 1 N 0 126 N'\\ 1
N . >
\ \ ---..
N = 0-1/ N 0 S-2/ ,N 0
\ \N \
N S N
S
127 N'\ \ H
N 0 i 128 14/\ 1 H 0
129
N 11\ NH 0
`--.. = "....
,..-141 = N 0 N.-----/ ,..-N 0
N------I
---- 1 N / N
\N \N \ I
/
130 ri I H 131 ri\ I H 132 N' H
N \ N
\ "..... `....
0 N
Nn \N
\N N N 1 LIIL t
Hi:CLI
133 Nf 1 H 0 134 113 N =--, 1 N.,.-,1 135
-.
--.
\ N N li
`,..
0
F ====,
,N 0
\N \N , I \N pi, H
_O.
136 iI\ ' H
N10, r.(11, 138 ,N ii -..
--,.. ` N 137 1 '''Y'll-Ni'l
1 CN ,õ-J-, N 8
.., N CI .....-2. N ---,
NI1.12
\N \N
,1---1
H rrji Hp
139 Na 140 P"\\ \ N ---.. I 141 l'i..)-
k 11 r
' -..., )[ -I No
N 1,,,,N-,.. ---= N N,
\ DD DD\ (13
142
N3) ,NO D .1,:il Cri D-X
N N
143 N'\ 1 H 144
I: NTN-
I'D CL-
'---D
HN -----'-'-N F
Plz \ 1,1,), F.---(
S.1
145 --..
NO, D 146 '471 Hpi 147 N'
\ 1 Hp
,
õ, N -.. N,,,,,i
õ, N 1-,_,N,,, õ,
.õ N
HO
\N__ /NH2
\N F
H a,
0
H
N ---. 1 148 %-NPN-Th 149 l'U- ii N 150
N'\ I H
N
d= 1-õ_,N, '-...
I
...PI =
LL-
HO HO HO
\N 0,F 0 \N
151 N'\ I 1;1 =152 W\ I H
N 0 153 N'\ I H
N 0 111 --.... , --.....
, --....
. I
..õ N = ..., N = ...-N =
HO HO HO
\N \ \N N -
-
154 rd\ I 11 0 0 155
NH 156 N'\ 1 H
-,, I
\ ,
I
ciCJ
..-N = ,N ..- N
HO HO 0 HO i--
---"N"---
\ \
'.1 Nõ...,..)
N N
H1N
157 N' I LI 0 158 ri\ I N \ 1.1 H 159 l'i\
,..... ..... ,
1 WM
õ41 = ...41
HO HO HO
\PI\ \
N \N
ii I Hp,i 161 N\ 160 H
N N 162 1
'II 3 II
,-1,1 0 NrA
""----N"-.
0 NH2 1
63
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
HO HO HO
\N \N \N
--- N
163 r.( I Hp 164 N\ I H 1 165 Pi\ I
Hp,c1
N ---.
LL1N 1.1 &
HO
HO HO
\N\4 \N
Nz I H / N ica,
166 \ ' = . 1 -. " - " --1 N 167 Id\ I H I 168 W\ I
H
pi NT.C.H., 0.3
---,
V.)
N 1-..,õõ,N
I --
.
HO HO
169
HO
\ ) \N
_.,,, ri.10.,,---a
N N \N )
N\ I H
Nica-- N,1 170 Nz\ I 171
1,---N---õ
..-N
I V
HO HO HO
\N \
N 7-if
172 "1\ I H
.,,, 173 N H
174 N'
--N rLõk:NH I )01' rCkPl.--
N,,
HO HO HO
\ \ \
N
175 N \ I 176 N'N\ I
N ,.... tiõZiNH 177 r
11.-
--N I
--N .-N 0
HO HO HO
".1 \ \N
'\\,_ 1 Hp o------ 179 180 N'\ I H
,.. ,õ1.,N ,... ' s N N NH
'-.. ---.
178 N
,N ,N
HO \N 0 0 N N
V \
182 F
183 \N
181 W\ I H F
N
--... riN 1 H .
0 ...-N \ \ N
.õ-N 0 0
F 0 F Q
Q
N ,I.,..
184 \N \
185 ,J, 0 186 Nj'1\ 1 H
0
Plz 1 NI ,., N ,... N
, N
---.. ,
I el: --'
....- N . ,-- ,...,- N 14,,
N N N
187 \N F 188 \N 0 OF 189 N\,N 0
N pi\ I H
N H
N 0
\
1 I
,N = ,N =
(0-) (....0-....) (0.....)
''"Pi N N
190 \N pr 191 \N 192 \Nõ
..õ,õ.,,,
N I H
N 0 I N'
\ I iiii 0 0 N I H
..... 11
I..,,,,,NH
I i '1"NI
,.- N = ,..-1.1 = ,,,, N
(.,0......) (....0-..)
N N N 0
193 \N\4 -N 194 I \,,,i) 195 ---
V
Nz \ I N H
--, ,N 0 td\ I H H
N ,...
,.....,NiIN I X:111 II N-Th
Ai 0
64
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
(c) (c)
(.) N N
196 197 \ 198 \N pi
H a Hpi
ri, 1 li, 1 N,.,(\1 -n,i
... , p
II n,'N'g \ Ha
, ...)_N L..Nõ NH2
N', \
199 \,"\' -- r 200 \N NO 201 \N
\ H
N
Hp, 1.1 ...--="' N
1.1'\ I
.----
N
N N
\
202 \N --- N 203 NN 1 H 204 \N
N' \ 1 H I Pi\ Hp
N --,
)C -r:NPC0 N --... 1
I N
("4-31,-1) N
\
205 \N 206 \N 207 NN 1 II in!
PI\ 1 Hp N 1 H
N,Th I '1111Clia,F I 'g"--111Th
co (0
N N N
208 \I rj \
N 209 p 210 \N H p
z \ 1 ', r N \ I H PI\ I
`-. Na,,,,_ õ N --.., N
c0
211 \IIIIIIN ,., \
N,N 1 p cir 213 N\!.11
H Hpi
H
0
I
..-NiaH 21. .-N 0
cs....0-.)
c0
N N N
214 NN , \, 216 \,N
\ 1hipCy
o_- 215 N\'NI) H H N-
--., N \ 1 N
liCtS,c1 `,..
...-N 0
0
C-NH
(C--)1.-1) N F
N
217 \N 218 \N
NH 219 N'\ I H
0
pi\ I H H N
N'\ `,..
N N I
\ \
,N *
õ-N õ.-N 0
F F F
0 c-N r---
--N--
220 14 , 221 , N' 222 " N,4)
pi\ i 11 I. N'\ 1 H
N = ..., i.I H N' \ \
INI pi-
. . . ... . . . . . . .
I puTh
õ-N = 1,õ_õ/.1--, õ-N 0 õ41
F
7---/ \N
C-N F \N 0 F
A ii , H NI el T
223 N., _y
-- 74 f"--NH 224 14 -,-... N 0 225 N',4 -
--.
pi\ j,0),õ. j 1
II 44 õ-N 0 õ-N =
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N 0 \N \c,
226 It\ H c
N lei 227 H 0 r 11
,CL ,0
N',) ---.. , 4,N N
228 N1
"--.. ,
I I 0 )
.õ-N = ,-N = ..-- ,
\P1- 0.õ...,,, \ \N-Th
N-.., N'
229 N, A H
1,,_,NH 230 N,N-11 ri I 231 N"\N)-
N a) N
OC4 11 X
'1)11N1'
0 CN \N ,,,, 234 1.-
1 c, I
NJ \N
232 Pi, tql Ill 233 N' ----.)
,3 H 1\\ ,[ H
,N ,
--,... -"NP NH
[ I
N Q...--- N
\N-
\ \N N
235 41 ra, 236 N ' I
il H
N__\ 237
I
N fri N
NH2
I ...-N 0
N--,
---- ---- i 1j, H
238 Nzi,, H
N -.., I
239
N '''\ ) N p
- H , I
240 41- /-"Yi " II
',......,--N 0 NaN' ,_.--- -, N----,.
I
\N \N \
241 '1' N Hp
-.... I
= 242 N \ Hp, N
N/ 243
\
\ N
N N Nz \ 1 NI ,,QJJ N1"1 H N
244 k0 I
, ' -e'r Y1.'110 245 41-
:-N T..,_,A,µ, 246 \N-
i,rõ,)' PO
.--- 0 N,-õ,F
I 11.1.,.,7,
\ \
N \
247 C Illa r N FIN N
I Hp
248 i4- y, .r-il Tql, 249
N\i, õ J 0
NH
-r-
, ..,......N
\ \N \
,---" 0.01,
250 N\i, I , 11 P NJO 251 N3I Ii.,.,.,. ri crzNH
252 N a
, \ H
\ \N \N
N
253 l'I'N-IT, IN1 ri sQ' 254 lc, H
N 255 N'Nµµ 1 N H
NH
---,
...-N 0 ,41
1.1--- 1 '11
256 "(i,1 H
N Ici H
,, N --.. I NõTh
--.. Nr-'
257
258 ---------r-, -r NH
0
...-N 0 N 0
F,---' ---
,
259 0
/j---N/
H H r
N N\....),õ,( th-
0
,
" --- --... N 0 260 --
S *--... N 261
,-N õ.= N = I
O CN
262 263
/
N,-
----- / ,..õ Nõ,1
264 Hp
tr- H
N --.., H Pr" N
--
PIP NH 1
,N 1,......,N,. ,---'
Hpli
,c.,,,
265 " I.µ
--- 266 -- , -'(N No 267
31.1 N I I ---- ,-- N 0 NH2
I
Hp H 'N
H
268 " -- --, N --, I
NO 269 N'---'="1 ---. -N-id jLji 270 "
N
---
,-1.1 J-
Iy.,1
.41 8
/7"-N/
I 0N'
271 " --- --. Hp
I
NO 272 Ncõ3
273
,.... HI -0,
,41 õAV Na
1
66
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
/7-NZ
õci, Hp
N i
Hp \ ....), _.,. ii ,,, I N ,
274 N __
.,... N \ 1 0,1
275 I X:ili 0 276
,
I 4'7
Hp /7-N
HIc----1,
Hp
277 N\-,..,--1-.- - ..,\,. , ..,, ./.1 --., I N
f j `1 N\ ,LT ,õ, _,, .õ_ I
278 1 .1 N 279
NH
trN/
N HC,11 NH HIC.I' N, ,..C11
H 280 -N N 281 k 172,..x.
,,,,,
282
I I H 1 I 1
ki r --Pr Nr-N/
H NH
283 N ) , H
284 " --- 11-1 -- P) 285
N
H N¨ N H n H
286 " --- N 287 -- ,,..._ N NH 288 " N
H
/
r)r-N
0 F
H Hp N......,
___. )
289 N ...., 1 290 " -- .., N --õ, 1 w...-
291 N
N()
...-N 0
H
N---.\
rõ...,_ ) F F
H
N H
N-.
292 / N H 0 293 , 1.// N LI K ill 294
N
I -Al H
--N 0
,..-N =
0 F 0 F 11,
7/-0 47-0
INI T N H I
295 " ---- N 296 0 297 0 N ..-- --- N
\
....- N 0 ,..- N = ..., N
0
0
298 299
N/7-0
" --- N ..- , 1,:j 1 0
300 " ---- ., 14 (Li' fõ. OH
I
õ--1.1 = .-11 ,.- N
0
301 " H . criC7 /7-0
N ,
--- "
I 302 ,,,, N
H a
i -.....- N-----, 303
N =-=.,
H
.--- N = ,-N = 1_,N \
Cl./
1.I) ----0
Hp 0N
304 N/7"- H 305 '1 \---j-T -- " I 306
Na,
NT CI' I 1 NH 1
\
..-' - N L \ NH2
,N
1-0
H
,, C) 1 .=(.0, 47-0 N
N N H I .....,_
307 -- i NN 308 -- H õ.... N \ I
N3 309 ,, N1.1--,
...-N
I
I-0 ---- N /7-0
HICt--
H I N \ A
310 -- N '...,..
311 1 Xli 0, 312 N .....,
I N'
,..,N 0 õ.=41 0 NO) N\ I
=-=13 11 ----' N /7"-C)
H
I k tr,,C) H I N p
313 N\...,),,c 314 ..,,, N \ N,-,,,
315
I I A
IN 0
..41
.--11
,111,F Ny
Hp, i, ,
, H
1,1
N A
..- p N,
316 w...-1
317 \ I N
318 i X)4
.N
Pl..
H
67
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
./7---0 Hp NHHiall
H jllllj
N'
N/1"-- !I
TN ,LN
319 - --"" N --.., N
320 N -- .,õ N ----., N
321 --,...A0 H
I
N ,N ,N
NJ'
H N/7-0 N 322 PC, , 1, t tc0 323 N 1.1õ,:r0,0,. ' Q''-'
324 ,
-L-9"----
,-N ii=
N/
325
N N .--' NH
326 NH 327
N N A.1
01
328 329
r)s Nic)1
H
N \, 1
N-Th NµNr- -, Pl'i 330
1\---N\ ___O
H
1
_S Hica
1 2N (---,
331 N--- N --, .,.....,
332
N Ni 333 / H
CN
334
N,I irS H --' N
I Pl..-
---- NirL, j[i riC1, H
336
\---',
N.--A
I I ,
p . . = . , N 8 N NI / N
/7-S Flial
N' 1 f-S Hi /7-8 1 RI 338 , N
N"--) 339 N .....C.:X-
r1H-11
0
I
H2N
N4---S F H2N
H 117---S
I. H
340 ` --- N NH
341 H
N 342 lb 0 0
FI
\
,.--N 0 I ' .."' N =
,..-N = ./'
H2N H2N
H2N
)---S >---$
pir'S 0
0 0 7 345
H
343 N 344 N
\ \
H I
,..-N = .., N =
H2N H2N H2N
... 0,,
N(j---S N' rir-S
H Igl _,rlai 347 "/ s H
348 H 140
346 , N N N
\
N'Th
,,,-N = ..-N õAl =
L---,N\
0 rN
H2No H2N H2N
1.?"--S N) /----S H
349 hi , II 350 ess N H
Npl 351 "\,--1. ,
.---- "p
' NH \ \ Pi ,4 ,r1,
H2N H2N H2N
>,---- Hp Hp
352 " -- 353 I4 -- ,, N -... N 354 N
==., 1
,N 'HH2
I A.I
H2N H2N H2N
)/--S
rai /-----s
356 s
357
IIIL ,T-1- 355 1.1 --- H
N N \, 1
\
- fll - -II I
,...41 --- õ,, N 0 N .,
N\ 1
H2N H2N H2N
\--...
358 r./
359 " -- ---s
360 " --- 11-,
NL1-) \ 1 II jUN
,N 0 1,,N. , N 8 N--L,F
H2N HA HA
r?----s 14 k 1
H,C,1Hp
361 ---n- tr- `i 362
--=-='; N 363 11 ---- =-.... N
H2N H2N H2P1
N)7---S
HIJOL-' N -S NH ---s r---
,.,
N
364 -.,,,,. N -.... N 365 " --1.,, -,,,, ri,19
366 N\,),,,o,,,,,,,,,01--- -N N),,,,,,,,,J
--1A)õ4
NH
68
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
H2N H2N H2N\___
367 " õ1õ. Lo,LINH
368 r.)--s - N -11'1---
[411-k Kc,, 369 " -- -
ijirL. tsu-
H2N
)---s H2N H2N
370 I'll/
N N- 371 'ç ji(,..1 , NH )--s
,. , NH 372 H
N
I \
,IJZIIIIiCJ
N
HN/ --N/
H rr >7-
374 " -- HI:CKN
,d H
373 ri NH2 ,): i N'Il'''1=13
I Al 375
i
frr '1.13
MO ,..,,, N \---i--N,
---- ,,, N N---
I I
HN/
--N/ FIN/
376 N)/-s Hp 377 )--s ---s
,2.,Hici, N 378 .),,,c -.,
..õ}i,iici,õ.õ,,
N, ..õ
N --, I
\ N
)-s
pi F2C)___ r----N-
,..,,ciõN,J F2C
Hp
\ N/ 380 N.1 It , 381
ii-S
H s OTF
382 N't,r N /7---S
383 -4----- -11 384
,--N 0 I / Ill i
C3 0
LN rrS
385 \ PC 1 'K 111 I 386 N1
1 1 387 Nµpr H H
N ,-, N/
C-N''
,..... Nj
388 rrs H N LI J. III
11-.. NIO. 389 Nµrell -, y'l I
I 390 41--)/ r4- /
\---1,N
N
----- I
ir-S 11 NF-S HiCil
H err-S Hp
391 Nri---- II,N,, 392
/----s
F H )"-S H 0
H /..".-S 0 OiF
0
394 "44-- N 0 395 NI,r- N 396 \ pr N
L.L
I I \ I
,- N = ,-N =
i---
0 NI Li 0 r"- S -.11 =
j"---S .,0
397 N4rSH N 398 N 1,r
N/ 399 NJ (11111
..-- N = 'I Aili
0
-r--3 N' /.--s
400 " \N--1., -,.., ..rirl 401 PI el 402 )--, s
LI ri,
Q. J , , N'') 1.1--- \
N
.-N
CN
r-.... Nj
Hp, /._,._.
Hip
403 r):SL H 404 1.14( N --, 1 1
405 N \ pr' N ....,
114 PILILIL, \
,Il
= ,
NH2
t.,'
II
N I
406 1e- =K'r N H ,.>--"S
,, 407 ---- !C
4r-- N --, 408
NO \
I N .--1.1 N \
..--eir õ?7"-S p
01 H
411
409 N4r- 410 '1'1'11 -r' I li ''
,,,-:,N
TAI'
,N N
I
69
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
)-----s 7---s
Hp
412 4r- NE1,11 1 N/ 413 N\N-- ,,, NI --010,-.1 414
,--N 0
I
>--S 415 ,N Hp -.--. Hp
-4(
416 N.
N ' N\ 417 N4roiN --I ,l,
, N 1 --- -Al
>7._s a. III 11.11' r.>-
-S p r-
418 N\it -1 , 1- ' 1O H 419 N 1, ..,,, , .
420 `N.-=-3 :., 1. H
NH
a,4 A I
0: I
N---S
Hp, õCr'
Hp _01-
421 1.14( ,, N ,.. ' 0 422 N H N 423
_--N
.---S /---S H
'---S N
H N- H
424 N`i,r" ,... N 425 426
..--N 0 A,1 ....-N 0
/ 0 -N
N
427
428 117"-S rip ,---õI 429 \N
'ti--
,...41
H2N \N /
Hp,
),--s 1
430 "\,,r- H
N1r0, 431 N', \ N -,..,
---, I N 432
0 [.. ,... N --
....
"--- N'Th ,,, NO
..-1.1 N ,..4.1 LNH N
N Hpo HC.-- LI N Hp
433 --- N --, I me 434 NI
--- N --, 1 435
\N
\, lip
436 " N N 1.1 1 HiCK-' N
N ,.,., . Al --ci
N C .,1
I\ I- i 437 WM
7.0
\ 438 , EY; D
\
Hp
,,, --y, N Hp
440 N\ \ , NH I N, 441
D
I I ,
F
Hp N Hp I
To,
442 "I\ 1 N \ 443 -- N -, 1 444 "µ\ \ H
N ---. I
----- V...". ---, Nal
..- N NH
\N Z
Z
la'
H:Cr tr.N
HICijx._
445 "I\\N1 H
,,, N 446 N .--' ,....._ Ni --, 1il CN
447 =-, 1 CN
rn''
H....A .1-...1
448 " -- ,, N =-, 1 CN 449 Pc IA,,, õ.,,,
,I1, .,--' r ,C)
N 450 "I , , 1.1 r .L.)
I 1 g.- , N
\N \N \N
, r h31.I
451 "I\ 1 H
,,,, N --, 452 N'\ 1 LI 'J.' 0 453
,- N 0
\N \N
"Ikl
454 Na -
T HO
455 1143-10,-, r 0 456
LI -L1,10
1 'r I'N lil , ,
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
\ \
N N 01' Plz \ 1 Hp
457 Oi. 110 458 "' 1 H
,,,, N 459
.41
\ \
N
0
460 N\ 1 N
N\ 1 z NT k , ill 1
' H
ir ai, 461
N \ ,r ,NH 462 "\ 1 H -- 44 \ N
,N
,..41
\N /
N / /
H
463 "\ 1 H
N 101 N O
464 ..., t.1 465
\ - N --- N
1
,..- N = N N
Administration and Pharmaceutical Compositions
[0271] Some embodiments include pharmaceutical compositions
comprising: (a) a
therapeutically effective amount of a compound provided herein, or its
corresponding enantiomer,
diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a
pharmaceutically
acceptable carrier.
[0272] The compounds provided herein may also be useful in
combination
(administered together or sequentially) with other known agents.
[0273] Non-limiting examples of diseases which can be treated with a
combination of
a compound of Formula (I) and other known agents are colorectal cancer,
ovarian cancer, retinitis
pigmentosa, macular degeneration, diabetic retinopathy, idiopathic pulmonary
fibrosis/pulmonary
fibrosis, and osteoarthritis.
[0274] In some embodiments, colorectal cancer can be treated with a
combination of
a compound of Formula (I) and one or more of the following drugs: 5-
Fluorouracil (5-FU), which
can be administered with the vitamin-like drug leucovorin (also called folinic
acid); capecitabine
(XELODA ), irinotecan (CAMPOSTARA oxaliplatin (ELOXATIN ). Examples of
combinations
of these drugs which could be further combined with a compound of Formula (I)
are FOLFOX (5-
FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan),
FOLFOXIRI
(leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and
oxaliplatin). For
rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be
given before
surgery (neoadjuvant treatment).
[0275] In some embodiments, ovarian cancer can be treated with a
combination of a
compound of Formula (I) and one or more of the following drugs: Topotecan,
Liposomal
doxorubicin (DOXI1_2), Gemcitabine (GEMZAR ), Cyclophosphamide (CYTOXAN ),
Vinorelbine (NAVELBINE ), Ifosfamide (IFEX ), Etoposide (VP-16), Altretamine
(HEXALEN ), Capecitabine (XELODA ), Irinotecan (CPT-11, CAMPTOSAR ),
Melphalan,
Pemetrexed (ALIMTA ) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE ).
71
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Examples of combinations of these drugs which could be further combined with a
compound of
Formula (I) are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VeIP
(vinblastine, ifosfamide,
and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin).
[0276] In some
embodiments, a compound of Formula (I) can be used to treat cancer
in combination with any of the following methods: (a) Hormone therapy such as
aromatase
inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and
inhibitors, and others; (b)
Ablation or embolization procedures such as radiofrequency ablation (RFA),
ethanol (alcohol)
ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c)
Chemotherapy using
alkylating agents such as cisplatin and carboplatin, oxaliplatin,
mechlorethamine,
cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using anti-
metabolites such as
azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and
terpenoids such as
vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and
taxanes; (f)
Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g)
Chemotherapy
using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine,
etoposide, etoposide
phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such
as actinomycin,
anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin,
bleomycin,
plicamycin and mitomycin; (1) Chemotherapy using tyrosine-kinase inhibitors
such as Imatinib
mesylate (GLEEVEC , also known as STI-571), Gefitinib (Iressa, also known as
ZD1839),
Erlotinib (marketed as TARCEVA ), Bortezomib (VELCADE ) , tamoxifen ,
tofacitinib,
crizotinib, Bc1-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and
Gossypol), PARP
inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (e.g.
perifosine in a phase III
trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf
inhibitors (e.g.
vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and
MEK162), CDK
inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy
using monoclonal
antibodies such as Rituximab (marketed as MABTHERA or RITUXAN ), Trastuzumab
(Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX ), and
Bevacizumab
(marketed as AVASTIN ); and (k) radiation therapy.
[0277] In some
embodiments, diabetic retinopathy can be treated with a combination
of a compound of Formula (I) and one or more of the following natural
supplements: Bilberry,
Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).
[0278] In some
embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can
be treated with a combination of a compound of Formula (I) and one or more of
the following
drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under
the brand name
Esbriet ), prednisone, azathioprine, N-acetylcysteine, interferon-y lb,
bosentan (bosentan is
72
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
currently being studied in patients with IPF, The American Journal of
Respiratory and Critical
Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef),
QAX576 [British
Journal of Pharmacology (2011), 163(1), 141-1721, and anti-inflammatory agents
such as
corticosteroids.
[0279] In some
embodiments, a compound of Formula (I) can be used to treat
idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of
the following
methods: oxygen therapy, pulmonary rehabilitation and surgery.
[0280] In some
embodiments, a compound of Formula (I) can be used to treat
osteoarthritis in combination with any of the following methods: (a)
Nonsteroidal anti-
inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and
acetaminophen; (b)
physical therapy; (c) injections of corticosteroid medications; (d) injections
of hyaluronic acid
derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in
combination with braces
and/or shoe inserts or any device that can immobilize or support your joint to
help you keep pressure
off it (e.g., splints, braces, shoe inserts or other medical devices); (g)
realigning bones (osteotomy);
(h) joint replacement (arthroplasty); and (i) in combination with a chronic
pain class.
[0281] In some
embodiments, macular degeneration can be treated with a
combination of a compound of Formula (I) and one or more of the following
drugs: Bevacizumab
(Avastie), Ranibizumab (Lucentis ), Pegaptanib (Macugen), Aflibercept (Eylee),
verteporfin
(Visudyne ) in combination with photodynamic therapy (PDT) or with any of the
following
methods: (a) in combination with laser to destroy abnormal blood vessels
(photocoagulation); and
(b) in combination with increased vitamin intake of antioxidant vitamins and
zinc.
[0282] In some
embodiments, retinitis pigmentosa can be treated with a combination
of a compound of Formula (I) and one or more of the following drugs: UF-021
(OcusevaTm),
vitamin A palmitate and pikachurin or with any of the following methods: (a)
with the Argus II
retinal implant; and (b) with stem cell and/or gene therapy.
[0283]
Administration of the compounds disclosed herein or the pharmaceutically
acceptable salts thereof can be via any of the accepted modes of
administration, including, but not
limited to, orally, subcutaneously, intravenously, intranasally, topically,
transdermally,
intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally,
ontologically, neuro-
otologically, intraocularly, subconjuctivally, via anterior eye chamber
injection, intravitreally,
intraperitoneally, intrathecally, intracystically, intrapleurally, via wound
irrigation, intrabuccally,
intra-abdominally, intra-articularly, intra-aurally,
intrabronchially, intracapsularly,
intrameningeally, via inhalation, via endotracheal or endobronchial
instillation, via direct
instillation into pulmonary cavities, intraspinally, intrasynovially,
intrathoracically, via
73
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
thoracostomy irrigation, epidurally, intratympanically, intracisternally,
intravascularly,
intraventricularly, intraosseously, via irrigation of infected bone, or via
application as part of any
admixture with a prosthetic devices. In some embodiments, the administration
method includes
oral or parenteral administration.
[0284]
Compounds provided herein intended for pharmaceutical use may be
administered as crystalline or amorphous products. Pharmaceutically acceptable
compositions may
include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions,
suspensions,
complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets,
capsules, powders,
liquids, suspensions, suppositories, aerosols, implants, controlled release or
the like. They may be
obtained, for example, as solid plugs, powders, or films by methods such as
precipitation,
crystallization, milling, grinding, supercritical fluid processing,
coacervation, complex
coacervation, encapsulation, emulsification, complexation, freeze drying,
spray drying, or
evaporative drying. Microwave or radio frequency drying may be used for this
purpose. The
compounds can also be administered in sustained or controlled release dosage
forms, including
depot injections, osmotic pumps, pills (tablets and or capsules), transdennal
(including
electrotransport) patches, implants and the like, for prolonged and/or timed,
pulsed administration
at a predetermined rate.
[0285] The
compounds can be administered either alone or in combination with a
conventional pharmaceutical carrier, excipient or the like. Pharmaceutically
acceptable excipients
include, but are not limited to, ion exchangers, alumina, aluminum stearate,
lecithin, self-
emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene
glycol 1000
succinate, surfactants used in pharmaceutical dosage forms such as Tweens,
poloxamers or other
similar polymeric delivery matrices, serum proteins, such as human serum
albumin, buffer
substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate,
partial glyceride
mixtures of saturated vegetable fatty acids, water, salts or electrolytes,
such as protamine sulfate,
disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride,
zinc salts,
colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-
based substances,
polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes,
polyethylene -
polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as a-, 13,
and y-cyclodextrin,
or chemically modified derivatives such as hydroxyalkylcyclodextrins,
including 2- and 3-
hydroxypropyl-fl-cyclodextrins, or other solubilized derivatives can also be
used to enhance
delivery of compounds described herein. Dosage forms or compositions
containing a compound as
described herein in the range of 0.005% to 100% with the balance made up from
non-toxic carrier
may be prepared. The contemplated compositions may contain 0.001%-100% of a
compound
74
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a
further
embodiment 20-80%. Actual methods of preparing such dosage forms are known, or
will be
apparent, to those skilled in this art; for example, see Remington: The
Science and Practice of
Pharmacy, 2211d Edition (Pharmaceutical Press, London, UK. 2012).
[0286] In one
embodiment, the compositions will take the form of a unit dosage form
such as a pill or tablet and thus the composition may contain, along with a
compound provided
herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like;
a lubricant such as
magnesium stearate or the like; and a binder such as starch, gum acacia,
polyvinylpyrrolidine,
gelatin, cellulose, cellulose derivatives or the like. In another solid dosage
form, a powder,
marume, solution or suspension (e.g., in propylene carbonate, vegetable oils,
PEG's, poloxamer
124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base
capsule). Unit dosage
forms in which one or more compounds provided herein or additional active
agents are physically
separated are also contemplated; e.g., capsules with granules (or tablets in a
capsule) of each drug;
two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed
release oral dosage
forms are also contemplated.
[0287] Liquid
pharmaceutically administrable compositions can, for example, be
prepared by dissolving, dispersing, etc. a compound provided herein and
optional pharmaceutical
adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol,
glycols, ethanol or the like)
to form a solution, colloid, liposome, emulsion, complexes, coacervate or
suspension. If desired,
the pharmaceutical composition can also contain minor amounts of nontoxic
auxiliary substances
such as wetting agents, emulsifying agents, co-solvents, solubilizing agents,
pH buffering agents
and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives,
sorbitan monolaurate,
triethanolamine acetate, triethanolamine ole ate, and the like).
[0288] In some
embodiments, the unit dosage of compounds of Formula (I) is about
0.25 mg/Kg to about 50 mg/Kg in humans.
[0289] In some
embodiments, the unit dosage of compounds of Formula (I) is about
0.25 mg/Kg to about 20 mg/Kg in humans.
[0290] In some
embodiments, the unit dosage of compounds of Formula (I) is about
0.50 mg/Kg to about 19 mg/Kg in humans.
[0291] In some
embodiments, the unit dosage of compounds of Formula (I) is about
0.75 mg/Kg to about 18 mg/Kg in humans.
[0292] In some
embodiments, the unit dosage of compounds of Formula (I) is about
1.0 mg/Kg to about 17 mg/Kg in humans.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0293] In some
embodiments, the unit dosage of compounds of Formula (I) is about
1.25 mg/Kg to about 16 mg/Kg in humans.
[0294] In some
embodiments, the unit dosage of compounds of Formula (I) is about
1.50 mg/Kg to about 15 mg/Kg in humans.
[0295] In some
embodiments, the unit dosage of compounds of Formula (I) is about
1.75 mg/Kg to about 14 mg/Kg in humans.
[0296] In some
embodiments, the unit dosage of compounds of Formula (I) is about
2.0 mg/Kg to about 13 mg/Kg in humans.
[0297] In some
embodiments, the unit dosage of compounds of Formula (I) is about
3.0 mg/Kg to about 12 mg/Kg in humans.
[0298] In some
embodiments, the unit dosage of compounds of Formula (I) is about
4.0 mg/Kg to about 11 mg/Kg in humans.
[0299] In some
embodiments, the unit dosage of compounds of Formula (I) is about
5.0 mg/Kg to about 10 mg/Kg in humans.
[0300] In some
embodiments, the compositions are provided in unit dosage forms
suitable for single administration.
[0301] In some
embodiments, the compositions are provided in unit dosage forms
suitable for twice a day administration.
[0302] In some
embodiments, the compositions are provided in unit dosage forms
suitable for three times a day administration.
[0303]
Injectables can be prepared in conventional forms, either as liquid solutions,
colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in
solid forms suitable
for reconstitution in liquid prior to injection. The percentage of a compound
provided herein
contained in such parenteral compositions is highly dependent on the specific
nature thereof, as
well as the activity of the compound and the needs of the patient. However,
percentages of active
ingredient of 0.01% to 10% in solution are employable, and could be higher if
the composition is
a solid or suspension, which could be subsequently diluted to the above
percentages.
[0304] In some
embodiments, the composition will comprise about 0.1-10% of the
active agent in solution.
[0305] In some
embodiments, the composition will comprise about 0.1-5% of the
active agent in solution.
[0306] In some
embodiments, the composition will comprise about 0.1-4% of the
active agent in solution.
76
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0307] In some
embodiments, the composition will comprise about 0.15-3% of the
active agent in solution.
[0308] In some
embodiments, the composition will comprise about 0.2-2% of the
active agent in solution.
[0309] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-96
hours.
[0310] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-72
hours.
[0311] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-48
hours.
[0312] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-24
hours.
[0313] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-12
hours.
[0314] In some
embodiments, the compositions are provided in dosage forms suitable
for continuous dosage by intravenous infusion over a period of about 1-6
hours.
[0315] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 5 mg/m2 to about 300 mg/m2.
[0316] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 5 mg/m2 to about 200 mg/m2.
[0317] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 5 mg/m2 to about 100 mg/m2.
[0318] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 10 mg/m2 to about 50 mg/m2.
[0319] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 50 mg/m2 to about 200 mg/m2.
[0320] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 75 mg/m2 to about 175 mg/m2.
[0321] In some
embodiments, these compositions can be administered by intravenous
infusion to humans at doses of about 100 mg/m2 to about 150 mg/m2.
[0322] It is
to be noted that concentrations and dosage values may also vary depending
on the specific compound and the severity of the condition to be alleviated.
It is to be further
understood that for any particular patient, specific dosage regimens should be
adjusted over time
according to the individual need and the professional judgment of the person
administering or
77
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
supervising the administration of the compositions, and that the concentration
ranges set forth
herein are exemplary only and are not intended to limit the scope or practice
of the claimed
compositions.
[0323] In one
embodiment, the compositions can be administered to the respiratory
tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose
inhalers, atomizer,
mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other
suitable device or
technique.
[0324] In some
embodiments, aerosols intended for delivery to the nasal mucosa are
provided for inhalation through the nose. For optimal delivery to the nasal
cavities, inhaled particle
sizes of about 5 to about 100 microns are useful, with particle sizes of about
10 to about 60 microns
being preferred. For nasal delivery, a larger inhaled particle size may be
desired to maximize
impaction on the nasal mucosa and to minimize or prevent pulmonary deposition
of the
administered formulation. In some embodiments, aerosols intended for delivery
to the lung are
provided for inhalation through the nose or the mouth. For delivery to the
lung, inhaled
aerodynamic particle sizes of about less than 10 lam are useful (e.g., about 1
to about 10
microns). Inhaled particles may be defined as liquid droplets containing
dissolved drug, liquid
droplets containing suspended drug particles (in cases where the drug is
insoluble in the suspending
medium), dry particles of pure drug substance, drug substance incorporated
with excipients,
liposomes, emulsions, colloidal systems, coacervates, aggregates of drug
nanoparticles, or dry
particles of a diluent which contain embedded drug nanoparticles.
[0325] In some
embodiments, compounds of Formula (I) disclosed herein intended
for respiratory delivery (either systemic or local) can be administered as
aqueous formulations, as
non-aqueous solutions or suspensions, as suspensions or solutions in
halogenated hydrocarbon
propellants with or without alcohol, as a colloidal system, as emulsions,
coacervates, or as dry
powders. Aqueous formulations may be aerosolized by liquid nebulizers
employing either
hydraulic or ultrasonic atomization or by modified micropump systems (like the
soft mist inhalers,
the Aerodose or the AERX systems). Propellant-based systems may use suitable
pressurized
metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices
(DPIs), which
are capable of dispersing the drug substance effectively. A desired particle
size and distribution
may be obtained by choosing an appropriate device.
[0326] In some
embodiments, the compositions of Formula (I) disclosed herein can
be administered to the ear by various methods. For example, a round window
catheter (e.g., U.S.
Pat. Nos. 6,440,102 and 6,648,873) can be used.
78
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0327]
Alternatively, formulations can be incorporated into a wick for use between
the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to
collagen sponge or other
solid support (e.g., U.S. Pat. No. 4,164,559).
[0328] If
desired, formulations of the invention can be incorporated into a gel
formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).
[0329] In some
embodiments, compounds of Formula (I) disclosed herein intended
for delivery to the ear can be administered via an implanted pump and delivery
system through a
needle directly into the middle or inner ear (cochlea) or through a cochlear
implant stylet electrode
channel or alternative prepared drug delivery channel such as but not limited
to a needle through
temporal bone into the cochlea.
[0330] Other
options include delivery via a pump through a thin film coated onto a
multichannel electrode or electrode with a specially imbedded drug delivery
channel (pathways)
carved into the thin film for this purpose. In other embodiments the acidic or
basic solid compound
of Formula (I) can be delivered from the reservoir of an external or internal
implanted pumping
system.
[0331]
Formulations of the invention also can be administered to the ear by
intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S.
Pat. No. 6,377,849 and
Ser. No. 11/337,815).
[0332]
Intratympanic injection of therapeutic agents is the technique of injecting a
therapeutic agent behind the tympanic membrane into the middle and/or inner
ear. In one
embodiment, the formulations described herein are administered directly onto
the round window
membrane via transtympanic injection. In another embodiment, the ion channel
modulating agent
auris-acceptable formulations described herein are administered onto the round
window membrane
via a non-transtympanic approach to the inner ear. In additional embodiments,
the formulation
described herein is administered onto the round window membrane via a surgical
approach to the
round window membrane comprising modification of the crista fenestrae
cochleae.
[0333] In some
embodiments, the compounds of Formula (I) are formulated in rectal
compositions such as enemas, rectal gels, rectal foams, rectal aerosols,
suppositories, jelly
suppositories, or retention enemas, containing conventional suppository bases
such as cocoa butter
or other glycerides, as well as synthetic polymers such as
polyvinylpyrrolidone, PEG (like PEG
ointments), and the like.
[0334]
Suppositories for rectal administration of the drug (either as a solution,
colloid,
suspension or a complex) can be prepared by mixing a compound provided herein
with a suitable
non-irritating excipient that is solid at ordinary temperatures but liquid at
the rectal temperature
79
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
and will therefore melt or erode/dissolve in the rectum and release the
compound. Such materials
include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils,
poloxamers, mixtures of
polyethylene glycols of various molecular weights and fatty acid esters of
polyethylene glycol. In
suppository forms of the compositions, a low-melting wax such as, but not
limited to, a mixture of
fatty acid glycerides, optionally in combination with cocoa butter, is first
melted.
[0335] Solid
compositions can be provided in various different types of dosage forms,
depending on the physicochemical properties of the compound provided herein,
the desired
dissolution rate, cost considerations, and other criteria. In one of the
embodiments, the solid
composition is a single unit. This implies that one unit dose of the compound
is comprised in a
single, physically shaped solid form or article. In other words, the solid
composition is coherent,
which is in contrast to a multiple unit dosage form, in which the units are
incoherent.
[0336]
Examples of single units which may be used as dosage forms for the solid
composition include tablets, such as compressed tablets, film-like units, foil-
like units, wafers,
lyophilized matrix units, and the like. In one embodiment, the solid
composition is a highly porous
lyophilized form. Such lyophilizates, sometimes also called wafers or
lyophilized tablets, are
particularly useful for their rapid disintegration, which also enables the
rapid dissolution of the
compound.
[0337] On the
other hand, for some applications the solid composition may also be
formed as a multiple unit dosage form as defined above. Examples of multiple
units are powders,
granules, microparticles, pellets, mini-tablets, beads, lyophilized powders,
and the like. In one
embodiment, the solid composition is a lyophilized powder. Such a dispersed
lyophilized system
comprises a multitude of powder particles, and due to the lyophilization
process used in the
formation of the powder, each particle has an irregular, porous microstructure
through which the
powder is capable of absorbing water very rapidly, resulting in quick
dissolution. Effervescent
compositions are also contemplated to aid the quick dispersion and absorption
of the compound.
[0338] Another
type of multiparticulate system which is also capable of achieving
rapid drug dissolution is that of powders, granules, or pellets from water-
soluble excipients which
are coated with a compound provided herein so that the compound is located at
the outer surface
of the individual particles. In this type of system, the water-soluble low
molecular weight excipient
may be useful for preparing the cores of such coated particles, which can be
subsequently coated
with a coating composition comprising the compound and, for example, one or
more additional
excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a
film-forming polymer,
a plasticizer, or other excipients used in pharmaceutical coating
compositions.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0339] Also
provided herein are kits. Typically, a kit includes one or more compounds
or compositions as described herein. In certain embodiments, a kit can include
one or more delivery
systems, e.g., for delivering or administering a compound as provided herein,
and directions for
use of the kit (e.g., instructions for treating a patient). In another
embodiment, the kit can include
a compound or composition as described herein and a label that indicates that
the contents are to
be administered to a patient with cancer. In another embodiment, the kit can
include a compound
or composition as described herein and a label that indicates that the
contents are to be administered
to a patient with one or more of hepatocellular carcinoma, colon cancer,
leukemia, lymphoma,
sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid
arthritis, sepsis,
ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections,
bone and cartilage
diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine,
shoulder and hip)
fractures, articular cartilage (chondral) defects, degenerative disc disease
(or intervertebral disc
degeneration), polyposis coli, bone density and vascular defects in the eye
(Osteoporosis-
pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal
angiogenesis, early
coronary disease, tetra-amelia, Mullerian-duct regression and virilization,
SERKAL syndrome,
type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel
phocomelia syndrome,
odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal
duplication, tooth
agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal
recessive
anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X
syndrome, ICF
syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann
Syndrome, Norrie
disease, and Rett syndrome.
Methods of Treatment
[0340] The
compounds and compositions provided herein can be used as inhibitors
and/or modulators of one or more components of the Wnt pathway, which may
include one or more
Wnt proteins, and thus can be used to treat a variety of disorders and
diseases in which aberrant
Wnt signaling is implicated, such as cancer and other diseases associated with
abnormal
angiogenesis, cellular proliferation, and cell cycling. Accordingly, the
compounds and
compositions provided herein can be used to treat cancer, to reduce or inhibit
angiogenesis, to
reduce or inhibit cellular proliferation, to correct a genetic disorder,
and/or to treat a neurological
condition/disorder/disease due to mutations or dysregulation of the Wnt
pathway and/or of one or
more of Wnt signaling components. Non-limiting examples of diseases which can
be treated with
the compounds and compositions provided herein include a variety of cancers,
diabetic retinopathy,
pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral
infections, bone and
81
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
cartilage diseases, neurological conditions/diseases such as Alzheimer's
disease, amyotrophic
lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism,
lung disease,
bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli,
bone density and
vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG),
familial exudative
vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia,
Miillerian-duct
regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann
syndrome, Al-
Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal
dysplasia,
obesity, split-hand/foot malformation, caudal duplication, tooth agenesis,
Wilms tumor, skeletal
dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube
defects, alpha-
thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman
syndrome, Prader-
Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
[0341] With
respect to cancer, the Wnt pathway is known to be constitutively
activated in a variety of cancers including, for example, colon cancer,
hepatocellular carcinoma,
lung cancer, ovarian cancer, prostate cancer , pancreatic cancer and leukemias
such as CML, CLL
and T-ALL. Accordingly, the compounds and compositions described herein may be
used to treat
these cancers in which the Wnt pathway is constitutively activated. In certain
embodiments, the
cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia,
lymphoma, sarcoma and
ovarian cancer.
[0342] Other
cancers can also be treated with the compounds and compositions
de scribed herein.
[0343] More
particularly, cancers that may be treated by the compounds,
compositions and methods described herein include, but are not limited to, the
following:
[0344] 1)
Breast cancers, including, for example ER+ breast cancer, ER- breast cancer,
her2- breast cancer, her2 + breast cancer, stromal tumors such as
fibroadenomas, phyllodes tumors,
and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas
of the breast
including in situ (noninvasive) carcinoma that includes ductal carcinoma in
situ (including Paget's
disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma
including, but not
limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary
carcinoma, colloid
(mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and
miscellaneous
malignant neoplasms. Further examples of breast cancers can include luminal A,
luminal B, basal
A, basal B, and triple negative breast cancer, which is estrogen receptor
negative (ER-),
progesterone receptor negative, and her2 negative (her2-). In some
embodiments, the breast cancer
may have a high risk Oncotype score.
82
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0345] 2)
Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma,
fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma;
lipoma and
teratoma.
[0346] 3) Lung
cancers, including, for example, bronchogenic carcinoma, e.g.,
squamous cell, undifferentiated small cell, undifferentiated large cell, and
adenocarcinoma;
alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma;
chondromatous
hamartoma; and mesothelioma.
[0347] 4)
Gastrointestinal cancer, including, for example, cancers of the esophagus,
e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma;
cancers of the
stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the
pancreas, e.g., ductal
adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and
vipoma; cancers of
the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's
sarcoma,
leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large
bowel, e.g.,
adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.
[0348] 5)
Genitourinary tract cancers, including, for example, cancers of the kidney,
e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia;
cancers of the
bladder and urethra, e.g., squamous cell carcinoma, transitional cell
carcinoma, and
adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma;
cancer of the testis,
e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma,
choriocarcinoma, sarcoma,
interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and
lipoma.
[0349] 6)
Liver cancers, including, for example, hepatoma, e.g., hepatocellular
carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular
adenoma; and
hemangioma.
[0350] 7) Bone
cancers, including, for example, osteogenic sarcoma (osteosarcoma),
fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma,
malignant
lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell
tumor chordoma,
osteochrondroma (osteocartilaginous exostoses), benign chondroma,
chondroblastoma,
chondromyxofibroma, osteoid osteoma and giant cell tumors.
[0351] 8)
Nervous system cancers, including, for example, cancers of the skull, e.g.,
osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of
the meninges,
e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain,
e.g., astrocytoma,
medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma
multiform,
oligodendroglioma, schwannoma, retinoblastoma, and congenital tumors; and
cancers of the spinal
cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.
83
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0352] 9) Gynecological cancers, including, for example, cancers of
the uterus, e.g.,
endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and
pre tumor cervical
dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous
cystadenocarcinoma,
mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell
tumors, Sertoli Leydig
cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g.,
squamous cell
carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and
melanoma; cancers of
the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid
sarcoma, and embryonal
rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.
[0353] 10) Hematologic cancers, including, for example, cancers of the
blood, e.g.,
acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic
leukemia, chronic
lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and
myelodysplastic
syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and
Waldenstrom's macroglobulinemia.
[0354] 11) Skin cancers and skin disorders, including, for example,
malignant
melanoma and metastatic melanoma, basal cell carcinoma, squamous cell
carcinoma, Kaposi's
sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and
scleroderma.
[0355] 12) Adrenal gland cancers, including, for example,
neuroblastoma.
[0356] Cancers may be solid tumors that may or may not be metastatic.
Cancers may
also occur, as in leukemia, as a diffuse tissue. Thus, the term "tumor cell,"
as provided herein,
includes a cell afflicted by any one of the above identified disorders.
[0357] A method of treating cancer using a compound or composition as
described
herein may be combined with existing methods of treating cancers, for example
by chemotherapy,
irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound
or composition
can be administered before, during, or after another anticancer agent or
treatment.
[0358] The compounds and compositions described herein can be used as
anti-
angiogenesis agents and as agents for modulating and/or inhibiting the
activity of protein kinases,
thus providing treatments for cancer and other diseases associated with
cellular proliferation
mediated by protein kinases. For example, the compounds described herein can
inhibit the activity
of one or more kinases. Accordingly, provided herein is a method of treating
cancer or preventing
or reducing angiogenesis through kinase inhibition.
[0359] In addition, and including treatment of cancer, the compounds
and
compositions described herein can function as cell-cycle control agents for
treating proliferative
disorders in a patient. Disorders associated with excessive proliferation
include, for example,
cancers, scleroderma, immunological disorders involving undesired
proliferation of leukocytes,
84
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
and restenosis and other smooth muscle disorders. Furthermore, such compounds
may be used to
prevent de-differentiation of post-mitotic tissue and/or cells.
[0360]
Diseases or disorders associated with uncontrolled or abnormal cellular
proliferation include, but are not limited to, the following:
= a variety of cancers, including, but not limited to, carcinoma,
hematopoietic tumors
of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of
mesenchymal origin, tumors of the central and peripheral nervous system and
other
tumors including melanoma, seminoma and Kaposi's sarcoma.
= a disease process which features abnormal cellular proliferation, e.g.,
benign
prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis,
atherosclerosis, arthritis, glomerulonephritis, restenosis following
angioplasty or
vascular surgery, inflammatory bowel disease, transplantation rejection,
endotoxic
shock, and fungal infections. Fibrotic disorders such as skin fibrosis;
scleroderma;
progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney
fibrosis;
glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine
fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; fatty liver
disease (FLD);
adhesions, such as those occurring in the abdomen, pelvis, spine or tendons;
chronic
obstructive pulmonary disease; fibrosis following myocardial infarction;
pulmonary
fibrosis; fibrosis and scarring associated with diffuse/interstitial lung
disease;
central nervous system fibrosis, such as fibrosis following stroke; fibrosis
associated
with neuro-degenerative disorders such as Alzheimer's Disease or multiple
sclerosis;
fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis;
endometriosis; ischemic disease and radiation fibrosis.
= defective apoptosis-associated conditions, such as cancers (including but
not limited
to those types mentioned herein), viral infections (including but not limited
to
herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus),
prevention
of AIDS development in HIV-infected individuals, autoimmune diseases
(including
but not limited to systemic lupus erythematosus, rheumatoid arthritis, sepsis,
ankylosing spondylitis, psoriasis, scleroderma, autoimmune mediated
glomerulonephritis, inflammatory bowel disease and autoimmune diabetes
mellitus), neuro-degenerative disorders (including but not limited to
Alzheimer's
disease, lung disease, amyotrophic lateral sclerosis, retinitis pigmentosa,
Parkinson's
disease, AIDS-related dementia, spinal muscular atrophy and cerebellar
degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
associated with myocardial infarctions, stroke and reperfusion injury,
arrhythmia,
atherosclerosis, toxin-induced or alcohol related liver diseases,
hematological
diseases (including but not limited to chronic anemia and aplastic anemia),
degenerative diseases of the musculoskeletal system (including but not limited
to
osteoporosis and arthritis), tendinopathies such as tendinitis and tendinosis,
aspirin-
sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases
and
cancer pain.
= genetic diseases due to mutations in Wnt signaling components, such as
polyposis
coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma
Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis,
early
coronary disease, tetra-amelia, MUllerian-duct regression and virilization,
SERKAL
syndrome, type II diabetes, Fuhrmann syndrome, Al -Awadi/Raas-
Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia,
obesity, split-hand/foot malformation, caudal duplication, tooth agenesis,
Wilms
tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive
anonychia,
neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome,
ICF
syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann
Syndrome, Norrie disease and Rett syndrome.
[0361] The
compounds and compositions described herein can be used to treat neurological
conditions, disorders and/or diseases caused by dysfunction in the Wnt
signaling pathway. Non-
limiting examples of neurological conditions/disorders/diseases which can be
treated with the
compounds and compositions provided herein include Alzheimer's disease,
aphasia, apraxia,
arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity
disorder, auditory processing
disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus
injury, Canavan disease,
carpal tunnel syndrome, causalgia, central pain syndrome, central pontine
myelinolysis,
centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral
arteriosclerosis, cerebral
atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical
spinal stenosis, Charcot-
Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic
inflammatory
demyelinating polyneuropathy (CIDP), chronic pain, Coffin¨Lowry syndrome,
complex regional
pain syndrome, compression neuropathy, congenital facial diplegia,
corticobasal degeneration,
cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative
trauma disorder,
Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker
syndrome,
Dawson disease, de Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas
disease,
delayed sleep phase syndrome, dementia, dermatomyositis, developmental
dyspraxia, diabetic
86
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia,
dysgraphia, dyslexia,
dystonia, empty sella syndrome, encephalitis, encephalocele,
encephalotrigeminal angiomatosis,
encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's
disease, Fahr's
syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome,
Friedreich's ataxia,
fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome,
giant cell arteritis,
giant cell inclusion disease, globoid cell leukodystrophy, gray matter
heterotopia, Guillain-Barre
syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial
spasm,
hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes
zoster oticus, herpes
zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease,
hydranencephaly,
hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis,
inclusion body
myositis, incontinentia pigmenti, infantile phytanic acid storage disease,
infantile Refsum disease,
infantile spasms, inflammatory myopathy, intracranial cyst, intracranial
hypertension, Joubert
syndrome, Karak syndrome, Kearns-Sayre syndrome, Kennedy disease, Kinsbourne
syndrome,
Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru,
Lafora disease,
Lambert-Eaton myasthenic syndrome, Landau-Kleffner syndrome, lateral medullary
(Wallenberg)
syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome,
leukodystrophy,
Lewy body dementia, lissencephaly, locked-in syndrome, Lou Gehrig's disease,
lumbar disc
disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease
(Spinocerebellar ataxia
type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal
syndrome, Meniere's
disease, meningitis, Menkes disease, metachromatic leukodystrophy,
microcephaly, micropsia,
Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome,
monomelic
amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease,
mucopolysaccharidoses, multi-infarct dementia, multifocal motor neuropathy,
multiple sclerosis,
multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis,
myasthenia gravis,
myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants,
myoclonus, myopathy,
myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis,
neuroleptic malignant
syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis,
Niemann-Pick
disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal
Dysraphism Sequence,
Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus
syndrome, optic neuritis,
orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease,
paramyotonia congenita,
paraneoplastic diseases, paroxysmal attacks, Parry-Romberg syndrome, Pelizaeus-
Merzbacher
disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex,
phytanic acid storage
disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly,
post-polio syndrome,
postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome,
primary lateral
87
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
sclerosis, prion diseases, progressive hemifacial atrophy, progressive
multifocal
leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri,
Ramsay Hunt
syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III,
Rasmussen's
encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs
syndrome, retrovirus-
associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement
disorder, Romberg
syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's
disease, schizencephaly,
sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome,
SjOgren's syndrome,
snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors,
spinal muscular atrophy,
spinocerebellar ataxia, Steele-Richardson-Olszewski syndrome, Stiff-person
syndrome, stroke,
Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical
arteriosclerotic
encephalopathy, superficial siderosis, Sydenham's chorea, syncope,
synesthesia, syringomyelia,
tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst,
Tay-Sachs disease,
temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease,
thoracic outlet
syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic
encephalopathy, transient
ischemic attack, transmissible spongiform encephalopathies, transverse
myelitis, tremor, trigeminal
neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis,
ubisiosis, Von Hippel-
Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome,
Werdnig,
Hoffman disease, west syndrome, Williams syndrome, Wilson's disease and
Zellweger syndrome.
[0362] The
compounds and compositions may also be useful in the inhibition of the
development of invasive cancer, tumor angiogenesis and metastasis.
[0363] In some
embodiments, the disclosure provides a method for treating a disease
or disorder associated with aberrant cellular proliferation by administering
to a patient in need of
such treatment an effective amount of one or more of the compounds of Formula
(I), in combination
(simultaneously or sequentially) with at least one other agent.
[0364] In some
embodiments, the disclosure provides a method of treating or
ameliorating in a patient a disorder or disease selected from the group
consisting of: cancer,
pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc
disease,
bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis,
the method comprising
administering to the patient a therapeutically effective amount of a compound
according to claim
1, or a pharmaceutically acceptable salt thereof.
[0365] In some
embodiments, the pharmaceutical composition comprises a
therapeutically effective amount of a compound of Formula (I), or a
pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable excipient.
88
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0366] In some embodiments, the method of treats a disorder or disease
in which
aberrant Wnt signaling is implicated in a patient, the method comprises
administering to the patient
a therapeutically effective amount of a compound of Formula (I), or a
pharmaceutically acceptable
salt thereof
[0367] In some embodiments, the disorder or disease is cancer.
[0368] In some embodiments, the disorder or disease is systemic
inflammation.
[0369] In some embodiments, the disorder or disease is metastatic
melanoma.
[0370] In some embodiments, the disorder or disease is fatty liver
disease.
[0371] In some embodiments, the disorder or disease is liver fibrosis.
[0372] In some embodiments, the disorder or disease is tendon
regeneration.
[0373] In some embodiments, the disorder or disease is diabetes.
[0374] In some embodiments, the disorder or disease is degenerative
disc disease.
[0375] In some embodiments, the disorder or disease is osteoarthritis.
[0376] In some embodiments, the disorder or disease is diabetic
retinopathy.
[0377] In some embodiments, the disorder or disease is pulmonary
fibrosis.
[0378] In some embodiments, the disorder or disease is idiopathic
pulmonary fibrosis
(IPF).
[0379] In some embodiments, the disorder or disease is degenerative
disc disease.
[0380] In some embodiments, the disorder or disease is rheumatoid
arthritis.
[0381] In some embodiments, the disorder or disease is scleroderma.
[0382] In some embodiments, the disorder or disease is a mycotic or
viral infection.
[0383] In some embodiments, the disorder or disease is a bone or
cartilage disease.
[0384] In some embodiments, the disorder or disease is Alzheimer's
disease.
[0385] In some embodiments, the disorder or disease is osteoarthritis.
[0386] In some embodiments, the disorder or disease is lung disease
[0387] In some embodiments, the disorder or disease is a genetic
disease caused by
mutations in Wnt signaling components, wherein the genetic disease is selected
from: polyposis
coli, osteoporosis-pseudoglioma syndrome, familial exudative
vitreoretinopathy, retinal
angiogenesis, early coronary disease, tetra-amelia syndrome, Miillerian-duct
regression and
virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-
Awadi/Raas-
Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia,
obesity, split-
hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms
tumor, skeletal
dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube
defects, alpha-
89
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman
syndrome, Prader-
Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.
[0388] In some embodiments, the patient is a human.
[0389] In some embodiments, the cancer is chosen from: hepatocellular
carcinoma,
colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia
(CML), chronic
myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid
leukemia, acute
lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.
[0390] In some embodiments, the cancer is chosen from: lung cancer -
non-small cell,
lung cancer - small cell, multiple myeloma, nasopharyngeal cancer,
neuroblastoma, osteosarcoma,
penile cancer, pituitary tumors, prostate cancer, retinoblastoma,
rhabdomyosarcoma, salivary gland
cancer, skin cancer - basal and squamous cell, skin cancer ¨ melanoma, small
intestine cancer,
stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer,
uterine sarcoma,
vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney
cancer, Kaposi sarcoma,
gestational trophoblastic disease, gastrointestinal stromal tumor,
gastrointestinal carcinoid tumor,
gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus
cancer,
endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord
tumor, bone metastasis,
bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal
cortical cancer.
[0391] In some embodiments, the cancer is hepatocellular carcinoma.
[0392] In some embodiments, the cancer is colon cancer.
[0393] In some embodiments, the cancer is colorectal cancer.
[0394] In some embodiments, the cancer is breast cancer.
[0395] In some embodiments, the cancer is pancreatic cancer.
[0396] In some embodiments, the cancer is chronic myeloid leukemia
(CML).
[0397] In some embodiments, the cancer is chronic myelomonocytic
leukemia.
[0398] In some embodiments, the cancer is chronic lymphocytic leukemia
(CLL).
[0399] In some embodiments, the cancer is acute myeloid leukemia.
[0400] In some embodiments, the cancer is acute lymphocytic leukemia.
[0401] In some embodiments, the cancer is Hodgkin lymphoma.
[0402] In some embodiments, the cancer is lymphoma.
[0403] In some embodiments, the cancer is sarcoma.
[0404] In some embodiments, the cancer is ovarian cancer.
[0405] In some embodiments, the cancer is lung cancer - non-small
cell.
[0406] In some embodiments, the cancer is lung cancer - small cell.
[0407] In some embodiments, the cancer is multiple myeloma.
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0408] In some embodiments, the cancer is nasopharyngeal cancer.
[0409] In some embodiments, the cancer is neuroblastoma.
[0410] In some embodiments, the cancer is osteosarcoma.
[0411] In some embodiments, the cancer is penile cancer.
[0412] In some embodiments, the cancer is pituitary tumors.
[0413] In some embodiments, the cancer is prostate cancer.
[0414] In some embodiments, the cancer is retinoblastoma.
[0415] In some embodiments, the cancer is rhabdomyosarcoma.
[0416] In some embodiments, the cancer is salivary gland cancer.
[0417] In some embodiments, the cancer is skin cancer - basal and
squamous cell.
[0418] In some embodiments, the cancer is skin cancer ¨ melanoma.
[0419] In some embodiments, the cancer is small intestine cancer.
[0420] In some embodiments, the cancer is stomach (gastric) cancers.
[0421] In some embodiments, the cancer is testicular cancer.
[0422] In some embodiments, the cancer is thymus cancer.
[0423] In some embodiments, the cancer is thyroid cancer.
[0424] In some embodiments, the cancer is uterine sarcoma.
[0425] In some embodiments, the cancer is vaginal cancer.
[0426] In some embodiments, the cancer is vulvar cancer.
[0427] In some embodiments, the cancer is Wilms tumor.
[0428] In some embodiments, the cancer is laryngeal or hypopharyngeal
cancer.
[0429] In some embodiments, the cancer is kidney cancer.
[0430] In some embodiments, the cancer is Kaposi sarcoma.
[0431] In some embodiments, the cancer is gestational trophoblastic
disease.
[0432] In some embodiments, the cancer is gastrointestinal stromal
tumor.
[0433] In some embodiments, the cancer is gastrointestinal carcinoid
tumor.
[0434] In some embodiments, the cancer is gallbladder cancer.
[0435] In some embodiments, the cancer is eye cancer (melanoma and
lymphoma).
[0436] In some embodiments, the cancer is Ewing tumor.
[0437] In some embodiments, the cancer is esophagus cancer.
[0438] In some embodiments, the cancer is endometrial cancer.
[0439] In some embodiments, the cancer is colorectal cancer.
[0440] In some embodiments, the cancer is cervical cancer.
[0441] In some embodiments, the cancer is brain or spinal cord tumor.
91
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0442] In some embodiments, the cancer is bone metastasis.
[0443] In some embodiments, the cancer is bone cancer.
[0444] In some embodiments, the cancer is bladder cancer.
[0445] In some embodiments, the cancer is bile duct cancer.
[0446] In some embodiments, the cancer is anal cancer.
[0447] In some embodiments, the cancer is adrenal cortical cancer.
[0448] In some embodiments, the disorder or disease is a neurological
condition,
disorder or disease, wherein the neurological condition/disorder/disease is
selected from:
Alzheimer's disease, frontotemporal dementias, dementia with lewy bodies,
prion diseases,
Parkinson's disease, Huntington's disease, progressive supranuclear palsy,
corticobasal
degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS),
inclusion body
myositis, autism, degenerative myopathies, diabetic neuropathy, other
metabolic neuropathies,
endocrine neuropathies, orthostatic hypotension, multiple sclerosis and
Charcot-Marie-Tooth
disease.
[0449] In some embodiments, the compound of Formula (I) inhibits one
or more
proteins in the Wnt pathway.
[0450] In some embodiments, the compound of Formula (I) inhibits
signaling induced
by one or more Wnt proteins.
[0451] In some embodiments, the Wnt proteins are chosen from: WNT1,
WNT2,
WNT2B, WNT3, WNT3A, WNT4. WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A,
WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.
[0452] In some embodiments, the compound of Formula (I) inhibits a
kinase activity.
[0453] In some embodiments, the method treats a disease or disorder
mediated by the
Wnt pathway in a patient, the method comprises administering to the patient a
therapeutically
effective amount of a compound (or compounds) of Formula (I), or a
pharmaceutically acceptable
salt thereof
[0454] In some embodiments, the compound of Formula (I) inhibits one
or more Wnt
proteins.
[0455] In some embodiments, the method treats a disease or disorder
mediated by
kinase activity in a patient, the method comprises administering to the
patient a therapeutically
effective amount of a compound (or compounds) of Formula (I), or a
pharmaceutically acceptable
salt thereof
[0456] In some embodiments, the disease or disorder comprises tumor
growth, cell
proliferation, or angiogenesis.
92
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0457] In some
embodiments, the method inhibits the activity of a protein kinase
receptor, the method comprises contacting the receptor with an effective
amount of a compound
(or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
[0458] In some
embodiments, the method treats a disease or disorder associated with
aberrant cellular proliferation in a patient; the method comprises
administering to the patient a
therapeutically effective amount of a compound (or compounds) of Formula (I),
or a
pharmaceutically acceptable salt thereof
[0459] In some
embodiments, the method prevents or reduces angiogenesis in a
patient; the method comprises administering to the patient a therapeutically
effective amount of a
compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt
thereof
[0460] In some
embodiments, the method prevents or reduces abnormal cellular
proliferation in a patient; the method comprises administering to the patient
a therapeutically
effective amount of a compound (or compounds) of Formula (I), or a
pharmaceutically acceptable
salt thereof
[0461] In some
embodiments, the method treats a disease or disorder associated with
aberrant cellular proliferation in a patient, the method comprises
administering to the patient a
pharmaceutical composition comprising one or more of the compounds of claim 1
in combination
with a pharmaceutically acceptable carrier and one or more other agents.
[0462]
Moreover, the compounds and compositions, for example, as inhibitors of the
cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and
DNA synthesis and
therefore are expected to be useful in the treatment of viral infections such
as HIV, human
papilloma virus, herpes virus, Epstein-Barr virus, adenovirus, Sindbis virus,
pox virus and the like.
[0463]
Compounds and compositions described herein can inhibit the kinase activity
of, for example, CDK/cyclin complexes, such as those active in the Go. or G.1
stage of the cell
cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
Evaluation of Biological Activity
[0464] The biological activity of the compounds described herein can be tested
using
any suitable assay known to those of skill in the art, see, e.g., WO
2001/053268 and WO
2005/009997. For example, the activity of a compound may be tested using one
or more of the test
methods outlined below.
[0465] In one example, tumor cells may be screened for Wnt independent growth.
In
such a method, tumor cells of interest are contacted with a compound (i.e.
inhibitor) of interest, and
the proliferation of the cells, e.g. by uptake of tritiated thymidine, is
monitored. In some
93
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
embodiments, tumor cells may be isolated from a candidate patient who has been
screened for the
presence of a cancer that is associated with a mutation in the Wnt signaling
pathway. Candidate
cancers include, without limitation, those listed above.
[0466] In
another example, one may utilize in vitro assays for Wnt biological activity,
e.g. stabilization of 0-catenin and promoting growth of stem cells. Assays for
biological activity of
Wnt include stabilization of 0-catenin, which can be measured, for example, by
serial dilutions of
a candidate inhibitor composition. An exemplary assay for Wnt biological
activity contacts a
candidate inhibitor with cells containing constitutively active Wnt/13-catenin
signaling. The cells
are cultured for a period of time sufficient to stabilize 0-catenin, usually
at least about 1 hour, and
lysed. The cell lysate is resolved by SDS PAGE, then transferred to
nitrocellulose and probed with
antibodies specific for 0-catenin.
[0467] In a further example, the activity of a candidate compound can be
measured in
a Xenopus secondary axis bioassay (Leyns, L. etal. Cell (1997), 88(6), 747-
756).
[0468] To
further illustrate this invention, the following examples are included. The
examples should not, of course, be construed as specifically limiting the
invention. Variations of
these examples within the scope of the claims are within the purview of one
skilled in the art and
are considered to fall within the scope of the invention as described, and
claimed herein. The reader
will recognize that the skilled artisan, armed with the present disclosure,
and skill in the art is able
to prepare and use the invention without exhaustive examples.
EXAMPLES
Compound preparation
[0469] The
starting materials used in preparing the compounds of the invention are
known, made by known methods, or are commercially available. It will be
apparent to the skilled
artisan that methods for preparing precursors and functionality related to the
compounds claimed
herein are generally described in the literature. The skilled artisan given
the literature and this
disclosure is well equipped to prepare any of the compounds.
[0470] It is
recognized that the skilled artisan in the art of organic chemistry can
readily carry out manipulations without further direction, that is, it is well
within the scope and
practice of the skilled artisan to carry out these manipulations. These
include reduction of carbonyl
compounds to their corresponding alcohols, oxidations, acylations, aromatic
substitutions, both
electrophilic and nucleophilic, etherifications, esterification and
saponification and the like. These
manipulations are discussed in standard texts such as March's Advanced Organic
Chemistry:
Reactions, Mechanisms, and Structure 7111 Ed., John Wiley & Sons (2013), Carey
and Sundberg,
94
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Advanced Organic Chemistry 5th¨
Ea Springer (2007), Comprehensive Organic Transformations:
A Guide to Functional Group Transformations, 211d Ed., John Wiley & Sons
(1999) (incorporated
herein by reference in its entirety)and the like.
[0471] The skilled artisan will readily appreciate that certain
reactions are best carried
out when other functionality is masked or protected in the molecule, thus
avoiding any undesirable
side reactions and/or increasing the yield of the reaction. Often the skilled
artisan utilizes protecting
groups to accomplish such increased yields or to avoid the undesired
reactions. These reactions are
found in the literature and are also well within the scope of the skilled
artisan. Examples of many
of these manipulations can be found for example in T. Greene and P. Wuts
Protective Groups in
Organic Synthesis, 4th Ed., John Wiley & Sons (2007), incorporated herein by
reference in its
entirety.
[0472] Trademarks used herein are examples only and reflect
illustrative materials
used at the time of the invention. The skilled artisan will recognize that
variations in lot,
manufacturing processes, and the like, are expected. Hence the examples, and
the trademarks used
in them are non-limiting, and they are not intended to be limiting, but are
merely an illustration of
how a skilled artisan may choose to perform one or more of the embodiments of
the invention.
[0473] ('H) nuclear magnetic resonance spectra (NMR) were measured in
the
indicated solvents on a Bruker NMR spectrometer (Avance TM DRX300, 300 MHz for
11-1 or
Avance TM DRX500, 500 MHz for 11-1) or Varian NMR spectrometer (Mercury 400BB,
400 MHz
for 11-1). Peak positions are expressed in parts per million (ppm) downfield
from tetramethylsilane.
The peak multiplicities are denoted as follows, s, singlet; d, doublet; t,
triplet; q, quartet; ABq, AB
quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of
doublets; ddd, doublet of
doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets;
td, triplet of doublets;
dq, doublet of quartets; m, multiplet.
[0474] The following abbreviations have the indicated meanings:
Boc = tert-butyloxycarbonyl
brine = saturated aqueous sodium chloride
CDC13 = deuterated chloroform
CuI = copper (I) iodide or cuprous iodide
DCE = dichloroethane
DCM = dichloromethane
DIPEA = N,N-diisopropylethylamine
DMAP = 4-dimethylaminopyridine
DMF = N,N-dimethylformamide
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
DMSO = dimethylsulfoxide
DMSO-d6 = deuterated dimethylsulfoxide
ESIMS = electron spray mass spectrometry
Et0Ac = ethyl acetate
HATU = 1 4Bis(dimethylamino)methylene] -1H-1,2,3 -triazolo [4,5 -blpyridinium
3 -oxid
hexafluorophosphate
HC1 = hydrochloric acid
HOAc = acetic acid
LC/MS = Liquid chromatography¨mass spectrometry
MeCN = acetonitrile
Me0H = methanol
MgSO4 = magnesium sulfate
NaBH(OAc)3 = sodium triacetoxyborohydride
NMR = nuclear magnetic resonance
ON = overnight
Pd(dppf)C12 = 1,1 '-bi s (diphenylpho sphino)ferrocene -
palladium(II)dichloride
Pd(PPh3)4 = tetrakis(triphenylphosphine)palladium(0)
r.t. = room temperature
THF = tetrahydrofuran
TLC = thin layer chromatography
pTs0¨ = p-toluenesulfonate ester
[0475] The
following example schemes are provided for the guidance of the reader,
and collectively represent an example method for making the compounds provided
herein.
Furthermore, other methods for preparing compounds of the invention will be
readily apparent to
the person of ordinary skill in the art in light of the following reaction
schemes and examples. The
skilled artisan is thoroughly equipped to prepare these compounds by those
methods given the
literature and this disclosure. The compound numberings used in the synthetic
schemes depicted
below are meant for those specific schemes only, and should not be construed
as or confused with
same numberings in other sections of the application. Unless otherwise
indicated, all variables are
as defined above.
96
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
General procedure
[0476] Compounds of Formula I of the present disclosure can be
prepared as depicted
in Scheme 1.
0 /
Re R5 Re-CO2H
Re R5 \B--Br --r--0 R4 R5
Br Br N c126 7-131 \O-7
\ NH2 TU HA, DIPEA, DMAP
N 8 N
R2 MeCN, 60 C, ON R2 N KOAe, Pd(dpp0C12,
R2
Ill II R1 IV R1 v
dioxane, 90 C, 2-5 h
K2PO4, Pd(dpPOC12,
R3-13/\ VI VM R3-Br
dioxane, 90 C, 3-16 h
or
K2PO4,1M(dp0C12,
Pd(PPh3)4, Cu!
R3-SnBu3 VII diozane, 90 C, 2 h
DMF, 90 C, ON
Re R5
R3
\Re
N
R2
Ix
Scheme 1
[0477] Scheme 1 describes a method for preparation of isoquinoline-3-
carboxamide
derivatives (IX) by first coupling the amine with a variety of acids (III) to
produce amide IV. The
bromo derivative IV is then reacted with bis(pinacolato)diboron to give the
pinacol ester (V).
Suzuki coupling with a variety of 5-membered heteroaryl bromides (VIII) yields
the desired R3
substituted isoquinoline IX. Alternatively, the bromo derivative IV is Suzuki
coupled with a variety
of 5-membered heteroaryl pinacol esters (VI) or coupled to a variety of 5-
membered heteroaryl
stannanes (VII) to produce the final R3 substituted isoquinoline IX.
[0478] In some embodiments, compounds of Formula I of the present
disclosure can
be prepared as depicted in Scheme 2.
A = N or C, wherein N or C may be
substituted as defined for R3 herein
124 R5 A A R4 R5
3 A
Br R =
NyR6 A \A'n. NyR6
N 0 N 0
R2 K2CO3, Cu!, DMF R2
ON, 140 C
IV IXa
Scheme 2
97
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0479] Scheme
2 describes a method for preparation of isoquinoline-3-carboxamide
derivatives (IXa) starting with bromo intermediate IV and couple with the
nitrogen of a variety of
R3 NH heteroaryls to produce the final R3 substituted isoquinoline IXa.
Illustrative Compound Examples
[0480]
Preparation of intermediate 2-41-(tert-butoxycarbonyl)piperidin-4-yl)oxy)
isonicotinic acid (XII) is depicted below in Scheme 4.
XI
HO-( \NBoc
HO2CF 2Co
Nall, DMSO N NBoc
r.t., 48 h
X XII
Scheme 4
Step 1
[0481] To a
solution of 2-fluoropyridine-4-carboxylic acid (X) (6.65 g, 47.13 mmol)
in DMSO (180 mL) was added tert-butyl 4-hydroxypiperidine-1-carboxylate (XI)
(14.23 g, 70.69
mmol) and 2-fluoropyridine-4-carboxylic acid (6.65 g, 47.13 mmol). To this
mixture was added
NaH (8.48 g, 212.08 mmol) in 3 portions. this mixture was stirred at room
temperature for 48 h.
The reaction was poured into 1 N NaOH, the water layer was washed with Et0Ac,
the water layer
was then acidified with concentrated HC1 (20 mL), extracted with Et0Ac and
dried over Na2SO4.
The solvent was removed and the residue was purified by C18 Silica Gel column
chromatography
(0-40% MeCN/0.1% formic acid in water) to produce 2-41-(tert-
butoxycarbonyl)piperidin-4-
yl)oxy)isonicotinic acid (XII) (12.85 g, 39.9 mmol, 84.6% yield) as a white
solid. 1HNMR (499
MHz, DMSO-d6) 6 ppm 1.41 (s, 9 H), 1.52 - 1.62 (m, 2 H), 1.90 - 1.98 (m, 2 H),
3.12 -3.23 (m, 2
H), 3.64 -3.72 (m, 2 H), 5.21 (tt, J=8.13, 3.95 Hz, 1 H), 7.15 (s, 1 H), 7.36
(dd, J=5.21, 1.37 Hz, 1
H), 8.31 (d, J=5.21 Hz, 1 H), 13.62 (br s, 1 H); ESIMS found for Ci6H22N205
m/z 323.1 (M+H).
98
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0482]
Preparation of intermediate 4-41-(tert-butoxycarbonyl)piperidin-4-yl)oxy)
benzoic acid (XV) is depicted below in Scheme 5.
Hoc Hoc
rNI
rI
XI
OH HO-( N-Boc
Li0H, Me0H/THF
Et0 PPh3, DEAD, toluene/THF Et0 60 C 2 h HO WI
0 C to r.t. , 1 day
XIII 0 Kw 0XV
Scheme 5
Step 1
[0483] To a
solution of DEAD (12.3 mL, 27.08 mmol) (40% in toluene) was added
to a mixture of ethyl 4-hydroxybenzoate (XIII) (3.0 g, 18.05 mmol), tert-butyl
4-
hydroxypiperidine-1-carboxylate (XI) (4.72 g, 23.47 mmol) and
triphenylphosphane (6.16 g, 23.47
mmol) in THF (40 mL) at 0 C. The mixture was stirred from 0 C to room
temperature over 1 day
before concentrating in vacuo. The residue was diluted with Et0Ac, washed with
1 N NaOH and
brine, and then evaporated under vacuum. The crude product was purified by
chromatography
(0->30% Et0Ac/hexanes) to give tert-butyl 4-(4-
ethoxycarbonylphenoxy)piperidine-1-
carboxylate (XIV) (5.4 g, 15.45 mmol, 85.6% yield) as a colorless oil. ESIMS
found for CI9H27N05
m/z 372.1 (M+Na).
Step 2
[0484] To a
solution of tert-butyl 4-(4-ethoxycarbonylphenoxy)piperidine- 1-
carboxylate (XIV) (5.4 g, 15.45 mmol) in Me0H (10 mL) and THF (10 mL) was
added LiOH (15.5
mL, 61.82 mmol) and the mixture stirred at 60 C for 2h. The mixture was
concentrated and the
residue triturated with water. The resulting solution was acidified with 2 N
HC1 until a solid
precipitated. The solid was filtered and washed with water to afford 44(1-tert-
butoxycarbony1-4-
piperidyl)oxylbenzoic acid (XV) (4.7 g, 14.63 mmol, 94.6% yield) as a white
solid. IFINMR (499
MHz, DMSO-d6) 6 ppm 1.40 (9 H, s), 1.47 - 1.57 (2 H, m), 1.89 - 1.97 (2 H, m),
3.12 - 3.23 (2 H,
m), 3.63 - 3.70 (2 H, m), 4.63 - 4.71 (1 H, m), 7.04 (2 H, d, J=9.06 Hz), 7.87
(2 H, d, J=9.06 Hz);
ESIMS found for CFH23N05 m/z 344.1 (M+Na).
99
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
[0485]
Preparation of intermediate 1 -(methyl -d3)-4 -(4,4,5 ,5 -tetramethyl-1,3,2-
dioxaborolan-2-y1)-1H-pyrazole (XVII) is depicted below in Scheme 6.
0 0
D3C-I, DMF DNB
0 Cs2CO3, rt, ON
XVI xvn
Scheme 6
Step 1
[0486] To a
stirred suspension of 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-
1H-pyrazole (XVI) (1.435 g, 7.4 mmol) and Cs2CO3 (2.89 g, 8.87 mmol) in DMF
(15 mL) was
added trideuterio(iodo)methane (0.51 mL, 8.13 mmol) and the mixture was
stirred at room
temperature overnight. The reaction mixture was filtered and the filtrates
were concentrated and
dried under high vacuo to obtain 4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-
y1)-1-
(trideuteriomethyl) pyrazole (XVII) (3.9 g,18.48 mmol, 249.8% yield) as a
white solid which was
used for next step without purification. ESIMS found for Cl0H1412H31BN202 m/z
212. (M+1).
[0487]
Preparation of intermediate 6-bromoisoquinolin-1-d-3-amine (XIX) is
depicted below in Scheme 8.
Br 2 NH Br N H2
DCO2ND4, Pd(PPh3)4,
N DMF, 50oC, 48 h LLN
XVIII xix
Scheme 8
Step 1
[0488] To a
mixture of 1,6-dibromoisoquinolin-3-amine (XVIII) (0.5 g, 1.66 mmol),
ammonium formate-d5 (0.56 g, 8.28 mmol) and Pd(PPh3)4 (191.3 mg, 0.170 mmol)
in DMF (5 mL)
was heated to 50 C for 48 h. The solvents were concentrated and the residue
was suspended in
chloroform. The solid was collected by filtration and washed with water and
Et0Ac. The solid were
dried under high vacuo to obtain 6-bromo- 1 -deuterio-isoquinolin-3-amine
(XIX) (115 mg,0.513
mmol, 31.0% yield) as a pale yellow solid. 1HNMR (500 MHz, DMSO-d6) 6 ppm 6.11
(2 H, s),
6.55 (1 H, s), 7.22 (1 H, dd, J=8.78, 1.92 Hz), 7.73 (1 H, d, J=8.51 Hz), 7.79
(1 H, d, J=1.92 Hz);
ESIMS found for C9H6DBrN2m/z 224.0 (79BrM+H).
100
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0489]
Preparation of intermediate 6-bromo-4-chloroisoquinolin-3-amine (XXII) is
depicted below in Scheme 9.
XXI
CI
CI
Br NH2
Br NH2
DMF, 0 C, 6 h LJN
XX XXII
Scheme 9
Step 1
[0490] To a
stirred suspension of 6-bromoisoquinolin-3-amine (XX) (1.0 g, 4.48
mmol) in DMF (15 mL) at 0 C was added 1-chloropyrrolidine-2,5-dione (XXI)
(598.6 mg, 4.48
mmol) portionwise. The mixture was stirred at 0 C for 6 h. The reaction
mixture was added
to water (150 mL), stirred for 1 h and the resulting solids were collected by
filtration and air dried
overnight to obtain 6-bromo-4-chloro-isoquinolin-3-amine (XXII) (922 mg, 3.58
mmol, 79.9%
yield) as a beige solid which was used for next step without purification. 1-
E1 NWIR (499 MHz,
DMSO-d6) 6 ppm 6.55 (2 H, s), 7.40 (1 H, dd, J=8.64, 1.78 Hz), 7.88 (1 H, d,
J=8.51 Hz),
7.90(1 H, d, J=1.10 Hz), 8.86(1 H, s); ESIMS found for C9H6BrC1N2m/z 256.9
(79BrM+H).
[0491]
Preparation of intermediate 6-bromo-4-methylisoquinolin-3-amine (XXV) is
depicted below in Scheme 10.
XXIII
0
'B
N
o,o
Br NH2 Br NH2 Br NH2
K3PO4, Pd(dpp0C12,
N
DMF, 0 C, 1 h N dioxane/DMF, 90 C, 3 days N
XX XXIV XXV
Scheme 10
101
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Step 1
[0492] To a
stirred suspension of 6-bromoisoquinolin-3-amine (XX) (2.g,
8.97mmo1) in DMF (25.1 mL) at 0 C was added 1-iodopyrrolidine-2,5-dione
(XXIII) (2.02 g, 8.97
mmol) portionwise, The mixture was stirred at 0 C for 1 hr. LC-MS of the
mixture showed
completion of the reaction and the desired product. The solvent was removed
under vacuum, the
residue was purified by C18 Silica gel (240g) [0-400% H20/MeCN (0.1%Formic
acid)] to
produce 6-bromo-4-iodo-isoquinolin-3-amine (XXIV) (1.95 g, 5.58 mmol, 62.2%
yield) as a
brown solid. 1HNMR (499 MHz, DMSO-d6) 6 ppm 6.41 (2 H, br s), 7.40 (1 H, dd,
J=8.64, 1.78
Hz), 7.76 - 7.81 (1 H, m), 7.82(1 H, d, J=8.51 Hz), 8.81(1 H, s); ESIMS found
for C9H6BrIN2m/z
348.9 (79BrM+H).
Step 2
[0493] A
stirred solution of 6-bromo-4-iodo-isoquinolin-3-amine (XXIV) (1.0 g, 2.87
mmol), 2,4,6-trimethy1-1,3,5,2,4,6-trioxatriborinane (0.72 g, 2.87 mmol),
Pd(dppf)C12 (0.23 g, 0.29
mmol), and K3PO4 (5.73 mL, 5.73 mmol) in 1,4-dioxane (10 mL) was heated to 90
C for 3 days.
The solvent was removed under high vacuum and the residue was purified by C18
silica gel (240g)
[0->20% H20/MeCN (0.1%Formic acid)] to produce 6-bromo-4-methyl-isoquinolin-3-
amine
(XXV) (74 mg, 0.312 mmol, 10.9% yield) as an off-white solid. 1HNMR (499 MHz,
DMSO-d6) 6
ppm 2.23 (3 H, br s), 5.91 (2 H, br s), 7.27 (1 H, br d, J=2.20 Hz), 7.71 -
7.82 (1 H, m), 7.92 (1 H,
br s), 8.72 (1 H, br s); ESIMS found for CloH9BrN2m/z 239.0 (81BrM+H).
[0494]
Preparation of intermediate 6-bromo-7-fluoroisoquinolin-3-amine (XXVIII)
is depicted below in Scheme 11.
1. Me0H, Me0Na, rt, 18h Br NH
2
Et00Et 2. HOAc, 40 C, 24h N
XXVI Br XXVIII
NH2
xxvii
Scheme 11
102
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Step 1
[0495] To a vial was added 2,2-diethoxyacetonitrile (XXVI) (1.0 g,
7.74 mmol)
dissolved Me0H (7.74 mL) followed by addition of Me0Na/Me0H (0.18 mL, 0.77
mmol)
dropwise. The reaction was stirred at room temperature for 20 h. HOAc (44.3
[IL, 0.77 mmol) was
added until pH=7-8 (using pH strips). (4-Bromo-3-fluoro-phenyl)methanamine
hydrochloride
(XXVII) (1.86 g, 7.74 mmol) was added and stirred at 40 C for 4 h. The solvent
was removed
under vacuum. Sulfuric acid (12.6 mL, 232.3 mmol) was added and stirred at 40
C for 16
h. NH4OH (30.8 mL, 240.0 mmol) was added dropwise at 0 C. The solvent was
removed under
vacuum and the residue was purified by C18 silica gel (240g) [0¨>50% H20/MeCN
(0.1%Formic
acid)] to produce 6-bromo-7-fluoro-isoquinolin-3-amine (XXVIII) (1.33 g, 5.50
mmol, 71.1%
yield) as an off-white solid. 1H NMR (499 MHz, DMSO-d6) 6 ppm 6.07 (2 H, s),
6.61 (1 H,
s), 7.76 (1 H, d, J=9.33 Hz), 8.01 (1 H, d, J=6.86 Hz), 8.80 (1 H, s); ESIMS
found for
C9H6BrFN2m/z 242.9 (81BrM+H).
[0496] Preparation of intermediates 6-bromo-7-chloroisoquinolin-3-
amine (XXX)
and 6-bromo-5-chloroisoquinolin-3-amine (XXXI) is depicted below in Scheme 12.
CI
I
-.N.., I
1. Me0H, Me0Na, 35 C, 20h Br NH2 Br -.N.., NH2
Et00Et 2. HOAc, 35 C, 16h N A*1
CI
XXVI Br 401 XXX XXXI
Ci NH2
xxix
Scheme 12
103
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Step 1
[0497] To a stirred solution of 2,2-diethoxyacetonitrile (XXVI) (0.59
g, 4.57 mmol)
in a vial containing Me0H (4.57 mL) was added Me0Na (0.1 mL, 0.46 mmol)
dropwise. The
reaction was stirred at 35 C for 20 h. HOAc was added (26.1 uL, 0.46 mmol)
(checked that the pH
is 7-8 using pH strips) followed by (4-bromo-3-chloro-phenyl)methanamine
(XXIX) (1.01 g, 4.57
mmol). The mixture was stirred at 35 C for 40 h. The solvent was removed under
vacuum. Sulfuric
Acid (7.43 mL, 137.0 mmol) was then added and stirred at 35 C for 16 h. NH4OH
(60.6 mL, 141.6
mmol) was added at 0 C. The reaction was filtered through Celite and purified
by C18 silica gel
(240g) [0->30% H20/MeCN (0.1%Formic acid)] to produce a 1:1 mixture (by nmr)
of 6-bromo-
7-chloro-isoquinolin-3-amine (XXX) and 6-bromo-5-chloroisoquinolin-3-amine
(XXXI) (633.7
mg, 2.46 mmol, 53.9% yield). 1H NMR (499 MHz, DMSO-d6) 6 ppm 6.23 (2 H, s),
6.46 (2
H, s), 6.57 (1 H, s), 6.83 (1 H, s), 7.40 (1 H, d, J=8.51 Hz), 7.74 (1 H, d,
J=8.51 Hz), 8.05
(1 H, s), 8.09 (1 H, s), 8.81 (1 H, s), 8.88 (1 H, s); ESIMS found for
C9H6BrC1N2m/z 256.9
(79BrM+H).
[0498] Preparation of intermediates 6-bromo-7-methylisoquinolin-3-
amine (XXXIII)
and 6-bromo-5-methylisoquinolin-3-amine (XXXIV) is depicted below in Scheme
13.
I I Br NH2
1. Me0H, Me0Na, rt, 20h Br NH2
Et00Et 2. HOAc, 40 C, 20h N N
XXVI Br XXXIII XXXIV
NH2
XXXII
Scheme 13
Step 1
[0499] To a stirred solution of 2,2-diethoxyacetonitrile (XXVI) (0.33
g, 2.52 mmol)
in a vial containing Me0H (2.52 mL) was added Me0Na (0.23 mL, 0.25 mmol)
dropwise. The
reaction was stirred at 22 C for 20 h. HOAc was added (14.4 uL, 0.25 mmol)
(checked that the pH
is 7-8 using pH strips) followed by (4-bromo-3-methyl-phenyl)methanamine
(XXXII) (0.5 g, 2.52
mmol). The mixture was stirred at 40 C for 40 h. The solvent was removed under
vacuum. Sulfuric
Acid (4.09 mL, 75.49 mmol) was then added and stirred at 40 C for 16 h. NH4OH
(33.4 mL, 78
mmol) was added at 0 C. The reaction was filtered through Celite and purified
by C18 silica gel
(240g) [0->30% H20/MeCN (0.1%Formic acid)] to produce a 1:1 mixture (by nmr)
of 6-bromo-
104
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
7-methylisoquinolin-3-amine (XXXIII) and 6-bromo-5-methylisoquinolin-3-amine
(XXXIV)
(378 mg, 1.59 mmol, 63.4% yield). 1H NMR (499 MHz, DMSO-d6) 6 ppm 2.40(3 H,
s), 2.52
(3 H, s), 5.96 (2 H, s), 6.12 (1 H, s), 6.54 (1 H, s), 6.71 (1 H, s), 7.27 (1
H, d, J=8.78 Hz),
7.58 (1 H, d, J=8.78 Hz), 7.73 (1 H, s), 7.86 (1 H, s), 8.74 (1 H, s), 8.79 (1
H, s); ESIMS
found for CloH9BrN2m/z 237.0 (79BrM+H).
Example 1.
[0500] Preparation of 4-
(difluoromethoxy)-N-(6-(1 -methyl-1H-imidazol-5 -y1)
isoquinolin-3-yl)benzamide (29) is depicted below in Scheme 14.
VON F
XXXVII
HO2C 0>¨F
0 F I
H O,..-SnBu3
N¨'
OTF
Br NH2 HATU, DIPEA, DMAp Br
N DCE, 80 C, 17 h N = Pd(PPh3)4, CuI N =
DMF, 90 C, 21 h
XX XXXVI 29
Scheme 14
Step 1
[0501] A
mixture of 4-(difluoromethoxy)benzoic acid (XXXV) (337 mg, 1.79 mmol),
HATU (682 mg, 1.79 mmol) and DIPEA (0.47 mL, 2.69 mmol) in DCE (8 mL) was
stirred at room
temperature for 10 min. To the above mixture was added 6-bromoisoquinolin-3-
amine (XX) (200
mg, 0.900 mmol) and DMAP (110 mg, 0.900 mmol) and the resulting mixture was
stirred at 80 C
for 17 h. The reaction was poured into 1 N HC1 and extracted with DCM (2 X).
The combined
organic layers were dried, filtered and concentrated. The crude product was
purified by silica gel
chromatography with Et0Ac/Hexanes (0-25%) as the eluent to afford N-(6-
bromoisoquinolin-3-
y1)-4-(difluoromethoxy)benzamide (XXXVI) as a white solid (300 mg,0.763 mmol,
85.1% yield).
ESIMS found for CrthiBrF2N202 m/z 395.0 (MB'l+H).
Step 2
[0502] A
mixture of N-(6-bromoisoquinolin-3-y1)-4-(difluoromethoxy)benzamide
(XXXVI) (100 mg, 0.250 mmol) tributyl-(3-methylimidazol-4-yl)stannane (XXXVII)
(104 mg,
0.280 mmol) Pd(PPh3)4 (23 mg, 0.030 mmol) and CuI (5 mg, 0.030 mmol) was taken
in DMF (2
mL). N2 gas was bubbled into the mixture for 10 min and then heated at 90 C
for 21 h. The reaction
mixture was cooled to room temperature, concentrated, absorbed on silica gel
and purified by flash
column chromatography using 7 N NH3-Me0H/CHC13 (0 to 10%) as eluents. The pure
fractions
105
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
were concentrated, the residue suspended in diethyl ether, sonicated and the
resulting solids were
collected by filtration, and dried to obtain 4-(difluoromethoxy)-N-(6-(1-
methy1-1H-imidazol-5-
yl)isoquinolin-3-yl)benzamide (29) as a white solid (16 mg, 0.040 mmol, 15.6%
yield). 1HNMR
(499 MHz, DMSO-d6) 6 ppm 3.85 (s, 3 H), 7.40 (t, J=73.65 Hz, 1 H), 7.32 (d,
J=8.78 Hz, 2 H),
7.33 (br s, 1 H), 7.73 (dd, J=8.37, 1.51 Hz, 1 H), 7.81 (s, 1 H), 8.09 (s, 1
H), 8.15 (d, J=8.51 Hz, 1
H), 8.17 (d, J=8.78 Hz, 2 H), 8.69 (s, 1 H), 9.22 (s, 1 H), 10.96 (s, 1 H);
ESIMS found for
C211-116F2N402 m/z 395.1 (M+1).
Example 2.
[0503] Preparation of 2-(4-aminopiperidin-1-y1)-N-(6-(1-methy1-1H-
pyrazol-4-y1)
isoquinolin-3-yl)isonicotinamide (53) and 2-(4-(dimethylamino)piperidin-1 -y1)-
N-(6 -(1-methyl -
1H-pyrazol-4-ypisoquinolin-3-ypisonicotinamide (55) are depicted below in
Scheme 15.
XXXVIII
F..,proõ-0O21-1 XI,
N
Br NH2 HATU, DIPEA, DMAP 1,11 ---:õ. Br
\ --,
MeCN, reflux, 24 h
NHBoc
XX XXXDi XLI
r!IN--/. ci XLII
K3PO4, Pd(cIPPOCht
dioxane, 90 C, 16 h
\N \N
ri \ NI r4 ri, \ tli r
õ..... N Na NH2 __ Ha Me0H s---- Na
, N
60 C, 1 h NHBoc
HIE, 53
HOAc, NaBIHOAc)3
DCM, r.t., 16 h
/ XLIII
\N
Pi, \ ti r
,.... Na
,01
N
I
Scheme 15
Step 1
[0504] To a solution Added 2-fluoropyridine-4-carboxylic acid
(XXXVIII) (1.27 g,
8.97 mmol), HATU (1.7 g, 4.48 mmol), DMAP (0.55 g, 4.48 mmol) and 6-
bromoisoquinolin-3-
amine (XX) (1.0 g, 4.48 mmol) to MeCN (22.4 mL) followed by DIPEA (3.12 mL,
17.93 mmol)
at room temperature then stirred at stirred at 60 C for 90 min. One additional
eq of HATU (1.7 g,
4.48 mmol) was added and the reaction was stirred overnight. Another 0.05 eq
HATU was added
106
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
and stirred for another 1 h. The reaction was poured into 300 mL of water, the
solid was filtered
and washed with Me0H, to produce N-(6-bromoisoquinolin-3-y1)-2-
fluoroisonicotinamide
(XXXIX) as an off-white solid (1.38 g, 3.99 mmol, 89.0% yield). ESIMS found
for CI5H9BrFN30
m/z 346.2 (M+H).
Step 2
[0505] To a
suspension of N-(6-bromoisoquinolin-3-y1)-2-fluoroisonicotinamide
(XXXIX) (300 mg, 0.870 mmol) in MeCN (4.3 mL) was added tert-butyl N-(4-
piperidyl)carbamate
(XL) (868 mg, 4.33 mmol). The mixture was heated at reflux for 1 day and then
cooled to room
temperature. The reaction was concentrated in vacuo and purified by silica gel
(24 g) 0 to 100%
Et0Ac/hexanes to produce tert-butyl (1-(4-((6-bromoisoquinolin-3-
yl)carbamoyl)pyridin-2-
yl)piperidin-4-y1) carbamate (XLI) as an off-white solid (0.319 g, 0.606 mmol,
69.9% yield). 11-1
NMR (499 MHz, DMSO-d6) 6 ppm 1.31 - 1.45 (m, 2 H), 1.39 (s, 9 H), 1.80 (br d,
J=10.43 Hz, 2
H), 2.97 (br t, J=11.53 Hz, 2 H), 3.49 - 3.60 (m, 1 H), 4.35 (br d, J=13.17
Hz, 2 H), 6.85 (br d,
J=7.41 Hz, 1 H), 7.10 (dd, J=5.08, 1.23 Hz, 1 H), 7.46 (s, 1 H), 7.70 (dd,
J=8.78, 1.92 Hz, 1 H),
8.07 (d, J=8.78 Hz, 1 H), 8.24 (d, J=4.94 Hz, 1 H), 8.29 (d, J=1.37 Hz, 1 H),
8.61 (s, 1 H), 9.25 (s,
1 H), 11.16 (s, 1 H); ESIMS found for C25H28BrN503 m/z 528.1 (MB'l+H).
Step 3
[0506] To a
solution of tert-butyl (1-(4-((6-bromoisoquinolin-3-yl)carbamoyl)
pyridin-2-yl)piperidin-4-yl)carbamate (XLI) (95.0 mg, 0.220 mmol) in 1,4-
dioxane (6.0 mL) was
added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)-1H-pyrazole
(XLII) (55.6 mg,
0.270 mmol), K3PO4 (210 mg, 0.990 mmol), and Pd(dppf)C12 (0.05 g, 0.060 mmol).
The mixture
was degassed with Argon and heated to 90 C for 16 h. The solvent was removed
under vacuum
and the residue was purified by silica gel (220 g) using 0 to 10 % 1.7 N NH3
in CHC13. The solid
was tritrated with diethyl ether and placed under vacuum overnight, then
tritrated with hot ethanol
and dried in a vacuum oven at 50 C to produce tert-butyl (1-(4-46-(1-methy1-1H-
pyrazol-4-
ypisoquinolin-3-y1)carbamoyl)pyridin-2-yl)piperidin-4-yl)carbamate (XLIII) as
an off-white solid
(294..4 mg, 0.558 mmol, 93.0% yield). ESIMS found for C29H33N703 m/z 528.3
(M+H).
Step 4
[0507] To a
solution of tert-butyl (1-(4-((6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-
y1)carbamoyl)pyridin-2-yl)piperidin-4-yl)carbamate (XLIII) (294.0 mg, 0.560
mmol) in Me0H
(5.6 mL) was added HC1 (1.39 mL, 5.57 mmol). The reaction was stirred at 60 C
for 1 h. The
107
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
solvent was removed under vacuum and the residue was purified by silica gel
(24 g) using 0 to 10%
1.7 N NH3 in Me0H to produce 2-(4-aminopiperidin-l-y1)-N-(6-(1-methy1-1H-
pyrazol-4-
ypisoquinolin-3-ypisonicotinamide (53) as an off-white solid (195 mg, 0.456
mmol, 81.9% yield).
1H NMR (499 MHz, DMSO-d6) 6 ppm 1.20 - 1.29 (m, 2 H), 1.76 - 1.83 (m, 2 H),
2.82 -2.90 (m, 1
H), 2.93 -3.02 (m, 2 H), 3.91 (s, 3 H), 4.32 (br d, J=13.17 Hz, 2 H), 7.10
(dd, J=5.21, 1.10 Hz, 1
H), 7.45 (s, 1 H), 7.81 (dd, J=8.51, 1.65 Hz, 1 H), 8.07 (d, J=8.78 Hz, 1 H),
8.11 (s, 1 H), 8.13 (s,
1 H), 8.23 (d, J=4.94 Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12 (s, 1 H),
11.03 (br s, 1 H); ESIMS
found for C24H25N70 m/z 428.2 (M+1).
Step 5
[0508] To a
solution of 2-(4-aminopiperidin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
ypisoquinolin-3-ypisonicotinamide (53) (90.0 mg, 0.210 mmol) in DCM (2.1 mL)
was added
formaldehyde (170.9 mg, 2.11 mmol), HOAc (2.5 mg, 0.042 mmol) and NaBH(OAc)3
(178.5 mg,
0.840 mmol). The reaction was stirred at room temperature for 16 h. The
solvent was removed
under vacuum and the residue was purified by silica gel (12 g) using 0 to 30%
1.7N NH3 in
Me0H/CHC13 to produce 2-[4-(dimethylamino)-1-piperidyll-N46-(1-methylpyrazol-4-
y1)-3-
isoquinolyllpyridine-4-carboxamide (55) as an off-white solid (30.0 mg, 0.066
mmol, 31.3%
yield). 1HNMR (499 MHz, DMSO-d6) 6 ppm 1.37 (qd, J=11.94, 3.70 Hz, 2 H), 1.83
(br d, J=11.25
Hz, 2 H), 2.19 (s, 6 H), 2.30 -2.40 (m, 1 H), 2.84 -2.93 (m, 2 H), 3.91 (s, 3
H), 4.44 (br d, J=13.17
Hz, 2 H), 7.11 (dd, J=5.21, 1.10 Hz, 1 H), 7.45 (s, 1 H), 7.81 (dd, J=8.51,
1.65 Hz, 1 H), 8.07 (d,
J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.13 (s, 1 H), 8.24 (d, J=5.21 Hz, 1 H), 8.38
(s, 1 H), 8.59 (s, 1 H),
9.12(s, 1 H), 11.03 (s, 1 H); ESIMS found for C26H29N70 m/z 456.2 (M+1).
Example 3.
[0509] Preparation of N-(6-(1
-methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-2-
(piperidin-4-yloxy)i sonicotinamide (16) and N-(6-(1 -methyl-1H-pyrazol-4-ypi
soquinolin-3 -y1)-2-
((1-methylpiperidin-4-yl)oxy)isonicotinamide (17) are depicted below in Scheme
16.
108
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
XII
Br NH2 'CINBoc Br
HATO, MITA, DMAP N 0
DCE, 75 C, 16 h
XX XLIV XLII
K2PO4, Pig(IPPOC12, r
dioxane, 90 C, 16 h
\N \N
H !4I
HCl/dioxane, Me0H -"=-=
õ--N 0 60 C,1 h
HOAc, Na(CIA03BH 16 XLV
DCM, r.t., 16 h 0
HAH
\N N
N
17
Scheme 16
Step 1
[0510] To a solution of 6-bromoisoquinolin-3-amine (XX) (3.0 g, 13.45
mmol) and
2-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)isonicotinic acid (XII) (10.62
g, 32.94 mmol) in
DCE was added DMAP (1.64 g, 13.45 mmol), DIPEA (7.03 mL, 40.35 mmol), HATU
(12.32 g,
32.4 mmol) to DCE (67.2 mL) stirred at 75 C for 16 hours. The solvent was
removed under vacuum
and putified by silica gel (40g) using 0 to 50% Et0Ac/hexanes to produce tert-
butyl 4-((4-((6-
bromoisoquinolin-3-yl)carbamoyl)pyridin-2-yl)oxy)piperidine-1-carboxylate
(XLIV) as an off-
white solid (4.37 g, 8.29 mmol, 61.6% yield). ESIMS found for C25H27BrN404 m/z
426.1 (M-Boc).
Step 2
[0511] To a solution of 1-methy1-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)-
1H-pyrazole (XLII) (2.59 g, 12.43 mmol) in 1,4-dioxane (82.8 mL) was added
tert-butyl 4-((4-((6-
bromoi soquinolin-3 -yl)carbamoyl)pyridin-2 -yl)oxy)piperidine -1-carboxylate
(XLIV) (4.37 g,
8.29 mmol), K3PO4 (4.4 g, 20.7 mmol) and Pd(dppf)C12 (338.3 mg, 0.410 mmol).
The mixture was
degassed with Ar and heated to 90 C for 16 h. The solvent was removed under
vacuum and the
residue was purified by silica ge (120 g) using 0 to 100 % Et0Ac/hexanes to
produce tert-butyl 4-
((4-((6-(1-methyl -1H-pyrazol -4 -yl)i soquinolin-3 -yl)carbamoyl)pyridin-2 -
yl)oxy)pipe ridine -1 -
109
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
carboxylate (XLV) as a white solid (3.56 g, 6.73 mmol, 81.3% yield). ESIMS
found for C29H32N604
m/z 529.3 (M+H).
Step 3
[0512] To a
solution of tert-butyl 4-((4-((6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-
y1)carbamoyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (XLV) (5.56 g, 6.73
mmol) in Me0H
(67.4 mL) was added HC1 in dioxane (16.8 mL, 67.35 mmol). The reaction was
stirred at 60 C for
4 h. The solvent was neutralized by 7 N NH3 in Me0H and then removed under
vacuum and the
residue was purified by silica gel (120 g) using 0 to 10% 1.0 N NH3 in
Me0H/CHC13 to produce
N-(6-(1-methy1-1H-pyrazol-4-y1)isoquinolin-3-y1)-2-(piperidin-4-
yloxy)isonicotinamide (16) as a
white solid (2.51 g, 5.56 mmol, 82.6% yield). 1HNMR (499 MHz, DMSO-d6) 6 ppm
1.48 - 1.58
(m, 2 H), 1.92 -2.00 (m, 2 H), 2.56 -2.65 (m, 2 H), 2.98 (dt, J=12.49, 3.91
Hz, 2 H), 3.91 (s, 3 H),
5.06 - 5.15 (m, 1 H), 7.34 (s, 1 H), 7.50 (dd, J=5.21, 1.37 Hz, 1 H), 7.82
(dd, J=8.51, 1.37 Hz, 1
H), 8.06 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.15 (s, 1 H), 8.31 (d, J=5.21
Hz, 1 H), 8.38 (s, 1 H),
8.58 (s, 1 H), 9.12 (s, 1 H), 11.06 (br s, 1 H); ESIMS found for C24H24N602
m/z 429.2 (M+1).
Step 4
[0513] To a
solution of N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-
(piperidin-4-yloxy)isonicotinamide (16) (1.1 g, 2.57 mmol) in Me0H (25.7 mL)
was added
formaldehyde (275.2 mg, 3.35 mmol), HOAc (464 mg, 7.72 mmol) and NaBH(OAc)3
(818 mg,
3.86 mmol). The reaction was stirred at room temperature for 16 h. The solvent
was removed under
vacuum and the residue was purified by silica gel (40 g) using 0 to 30% 1.0 N
NH3 in Me0H/CHC13
to produce N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-((1-
methylpiperidin-4-y1)oxy)
isonicotinamide (17) as an off-white solid (1.02 g, 2.20 mmol, 85.4% yield).
1HNMR (499 MHz,
DMSO-d6) 6 ppm 1.66 - 1.76 (m, 2 H), 1.99 (br dd, J=9.47, 3.70 Hz, 2 H), 2.17
(br s, 2 H), 2.19 (s,
3 H), 2.61 -2.70 (m, 2 H), 3.91 (s, 3 H), 5.01 -5.09 (m, 1 H), 7.35 (s, 1 H),
7.51 (dd, J=5.21, 1.37
Hz, 1 H), 7.82 (dd, J=8.64, 1.51 Hz, 1 H), 8.06 (d, J=8.78 Hz, 1 H), 8.11 (s,
1 H), 8.15 (s, 1 H),
8.31 (d, J=5.21 Hz, 1 H), 8.38 (s, 1 H), 8.57 (s, 1 H), 9.12 (s, 1 H), 11.06
(s, 1 H); ESIMS found
for C25H26N602 m/z 443.2 (M+1).
Example 4.
[0514] Preparation of N-(6-(1-
methyl -1H-pyrazol -4 -yl)i soquinolin-3 -y1)-2 -(1-
methylpiperidin-4-yl)i sonicotinamide (84) and 1'-methyl-N-(6-(1-methy1-1H-
pyrazol-4-y1)
110
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
i soquinolin-3 -y1)-1',2',3 ',6'-tetrahydro-[2,4'-bipyridine] -4-carboxamide
(85) are depicted below in
Scheme 17.
XLVII
_(
\N
B N-
\ id\ NHH
K3PO4, POIPPOC129
N 0 dioxane, 70 C, 16h N 0
XLVI 85
- H2
Et0H, r.t., 16 h
N/\
N
0
4
Scheme 17
Step 1
[0515] In a
sealed tube containing 1-methy1-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-y1)-3,6-dihydro-2H-pyridine (XLVII) (0.29 g, 1.32 mmol), K3PO4
(2.2 mL, 2.2
mmol) Pd(dppf)C12-CH2C12 adduct (180 mg, 0.220 mmol) in 1,4-Dioxane (8 mL) was
added 2-
iodo-N46-(1-methylpyrazol-4-y1)-3 soquinolyll pyridine -4-carboxamide (XLVI)
(0.4 g, 0.880
mmol). This mixture was degassed with Ar sealed and heated to 70 C for 16 h.
The solvent was
removed and the residue was purified by silica gel, (0->10% 1.5 N NH3 in
Me0H/CHC13) to
produce 2-(1 -
methyl-3,6-dihydro-2H-pyridin-4 -y1)-N-[6-(1 -methylpyrazol -4 -y1)-3 -i
soquinolyll
pyridine-4-carboxamide (85) (247 mg,0.582 mmol, 66.2% yield) as an off-white
solid. ESIMS
found for C25H27BrN404 m/z 426.1 (M+H). NMR (499 MHz, DMSO-d6) 6 ppm 2.31 (3
H, s),
2.57 - 2.63 (2 H, m), 2.63 - 2.70 (2 H, m), 3.11 (2 H, br d, J=3.02 Hz), 3.91
(3 H, s), 6.89 (1 H, t,
J=3.43 Hz), 7.78(1 H, dd, J=4.94, 1.37 Hz), 7.82(1 H, dd, J=8.51, 1.65 Hz),
8.08(1 H, d, J=8.51
Hz), 8.11 (1 H, s), 8.16(2 H, d, J=6.04 Hz), 8.38 (1 H, s), 8.61 (1 H, s),
8.71 (1 H, d, J=4.94 Hz),
9.14(1 H, s), 11.23(1 H, s); ESIMS found for C25H24N60 m/z 425.0 (M+1).
Step 2
[0516] To a
solution of 2-(1-methy1-3,6-dihydro-2H-pyridin-4-y1)-N-[6-(1-
methylpyrazol-4-y1)-3-isoquinolyllpyridine-4-carboxamide (85) (200 mg, 0.470
mmol) to Et0H
(15 mL), degassed solvent with N2, added palladium on carbon (100.3 mg, 0.050
mmol) and stirred
111
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
the reaction over H2 for 16 h. The reaction was filtered through Celite, the
solvent was removed
under vacuum and the residue was purified by silca Gel (24g) (0->10% 1.5 N NH3
in CHC13) to
produce 2 -(1 -
methyl-4 -pipe ridy1)-N46 -(1 -methylpyrazol-4-y1)-3 soquinolyll pyridine-4-
carboxamide (84) (100 mg, 0.235 mmol, 49.8% yield) as an off-white solid.
NMR (500 MHz,
DMSO-d6) 6 ppm 1.77 - 1.92 (4 H, m), 2.00 (2 H, td, J=11.60, 2.61 Hz), 2.21 (3
H, s), 2.72 (1 H,
tt, J=11.49, 4.15 Hz), 2.85 -2.93 (2 H, m), 3.91 (3 H, s), 7.76(1 H, dd,
J=5.21, 1.65 Hz), 7.82 (1
H, dd, J=8.51, 1.65 Hz), 7.91 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 8.12 (1 H,
d, J=0.82 Hz), 8.15 (1
H, d, J=0.82 Hz), 8.39 (1 H, s), 8.60 (1 H, s), 8.66 - 8.71 (1 H, m), 9.13 (1
H, s), 11.17 (1 H, s);
ESIMS found for C25H26N60 m/z 427.0 (M+1).
Example 5.
[0517] Preparation of N-(6-
(1 -methyl-5 -(morpholinomethyl)-1H-pyrazol-4-y1)
isoquinolin-3-y1)-2-morpholinoisonicotinamide (204)
and N-(6-(1 -methyl-5 -(pipe ridin-1 -
ylmethyl)-1H-pyrazol-4-ypisoquinolin-3-y1)-2-morpholinoisonicotinamide (429)
are depicted
below in Scheme 18.
xi.vm
\ CHO \ CHO
o'
0
141
Br NH2 Br NH2
\ N112 KOAc, Pd(dppO --
CL2, 111
K3PO4, Pd(dPPOCL2,
N dioxane, 90 C, 1.5h N H20, 90 C, 19h N
XX XLVH XLIX
LI
DCE, HOAc
N \N Na(0Ac)31111 \N
rt, rN 12h
\
..õ.õ '"=-= F HATU, DIPEA,
DMAP NH2
N MeCN, 60 C, ON N
LH
H
DMSO, 120 C
0.5 h, MW
\N \N
\ r
N N
429 204
Scheme 18
112
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Steps 1-2
[0518] To a
mixture of 6-bromoisoquinolin-3-amine (XX) (4.0 g, 17.93 mmol),
Pd(dppf)C12-CH2C12 adduct (1.03 g, 1.26 mmol), KOAc (4.39 g, 44.83 mmol) and
4,4,5,5-
tetramethy1-2-(4,4,5 ,5 -tetramethyl -1,3 ,2 -dioxaborolan-2-y1)-1,3 ,2-
dioxaborolane (5.01 g, 19.72
mmol) in 1,4-dioxane (50 mL) was bubbled with N2 for 2 min. The reaction
mixture was sealed
and heated at 90 C for 1.5 h. The reaction was cooled to room temperature,
filtered and washed
with Et0Ac. The filtrate was concentrated and the residue taken in dioxane (50
mL). To the
suspension was added 4-bromo-2-methyl-pyrazole-3-carbaldehyde (XLVIII) (3.39
g, 17.93 mmol)
followed by K3PO4 (9.52 g, 44.83 mmol), Pd(dppf)C12-CH2C12 adduct (1.03 g,
1.26 mmol) and
water (15 mL). The mixture was purged with N2 for a min, sealed and heated
again at 90 C for 19
h. The mixture was cooled to room temperature and concentrated to about 20 mL.
The concentrate
was diluted with Et0Ac and filtered through a pad of Celite. The filtrate was
diluted with water
and the organic layer separated. The organic layer was washed with brine;
dried, filtered and
concentrated. The residue was triturated in ether and the resulting solid
filtered to afford 4-(3-
amino-6-isoquinoly1)-2-methyl-pyrazole-3-carbaldehyde (XLIX) (4.1 g, 16.2
mmol, 90.6% yield)
as a brown solid. 1HNMR (499 MHz, DMSO-d6) 6 ppm 0.01 (6 H, s), 0.86 (9 H, s),
0.88 - 1.00 (2
H, m), 1.23 - 1.35 (2 H, m), 1.35 - 1.46 (1 H, m), 1.69 - 1.79 (2 H, m), 1.85 -
1.95 (2 H, m), 2.21
(1 H, tt, J=12.21, 3.57 Hz), 3.38 (2 H, d, J=6.31 Hz), 3.57 (3 H, s)ESIMS
found for CHH12N40 m/z
252.95 (M+1).
Step 3
[0519] To a
mixture of 4-(3-amino-6-isoquinoly1)-2-methyl-pyrazole-3-carbaldehyde
(XLIX) (1.07 g, 4.25 mmol), piperidine (0.84 mL, 8.51 mmol) and catalytic HOAc
in DCE (10
mL) was stirred for 30 min. Na(0Ac)3BH (1.8 g, 8.51 mmol) was added and
stirring was continued
for 12 h at room temperature. The reaction mixture was quenched with minimum
amount of aq.
saturated ammonium chloride solution, and concentrated under vacuum. The
residue was adsorbed
on silica gel and purified by chromatography (0->20% 7N NH3-Me0H/CHC13) to
obtain 641-
methy1-5-(1-piperidylmethyppyrazol-4-yllisoquinolin-3-amine (L) (800 mg, 2.49
mmol, 58.5%
yield) as a white solid. ESIMS found for CI9H23N5 m/z 322.2 (M+1).
Step 4
[0520] To a suspension of 6-[1-methyl-5-(1-piperidylmethyppyrazol-4-yll
isoquinolin-3-amine (L) (0.14 g, 0.440 mmol), 2-fluoropyridine-4-carboxylic
acid (LI) (0.07 g,
0.520 mmol), DMAP (0.03 g, 0.220 mmol) and HATU (0.2 g, 0.520 mmol) in DMF (4
mL) was
113
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
added DIPEA (0.23 mL, 1.31 mmol). The resulting mixture was stirred at 80 C
for 1.5 h. Another
1.2 equiv. of HATU was added to the mixture and stirred at 80 C for additional
16 h. The reaction
mixture was diluted with water and the resulting solid filtered. The crude
product was purified by
silica gel chromatography (0->10% 7 N NH3-Me0H/CHC13) to produce 2-fluoro-N-[6-
[1-methyl-
-(1 -piperidylmethyppyrazol -4 -yll -3 -i soquinolyll pyridine-4-carboxamide
(LII) (85.0 mg, 0.191
mmol, 43.9% yield) as a brown solid. ESIMS found for C25H25FN60 m/z 444.9
(M+H).
Step 5
[0521] To a
solution of 2-fluoro-N-[6-[1-methy1-5-(1-piperidylmethyppyrazol-4-y11-
3-isoquinolyllpyridine-4-carboxamide (LII) (80 mg, 0.180 mmol) in DMSO (1 mL)
was added
morpholine (0.05 mL, 0.540 mmol). The mixture was sealed in a tube and
irradiated with MW at
120 C for 30 min. The reaction was heated at 90 C for additional 16 h and the
mixture cooled to
room temperature, poured into water and the resulting solid filtered. The
crude product was purified
by silica gel chromatography (0->5% Me0H/CHC13) as the eluent, followed by
HPLC purification
(0->65% MeCN/water). Two clean products were separated. The fractions for each
product were
combined and concentrated. The residue for each product was redissolved in
minimum amount of
CHC13/Me0H and filtered through the carbonate resin (loading: 0.23 mmol/S00
mg). The filtrate
was concentrated and the resiude triturated in ether. The resulting solid was
filtered to afford N-[6-
[1 -methy1-5 -(1 -piperidylmethyppyrazol -4 -yll -3 -i soquinoly11-2-
morpholino-pyridine-4-
carboxamide (429) (23 mg, 0.045 mmol, 25.0% yield) as a white solid; 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.32 - 1.44 (2 H, m), 1.45 - 1.55 (4 H, m), 2.38 (4 H, br s),
3.53 - 3.62 (4 H, m),
3.67(2 H, s), 3.71- 3.77 (4H, m), 3.92(3 H, s), 7.21(1 H, dd, J=5.21, 1.10
Hz), 7.47(1 H, s), 7.76
(1 H, dd, J=8.51, 1.65 Hz), 7.82 (1 H, s), 8.09 (1 H, d, J=8.51 Hz), 8.14 (1
H, s), 8.29 (1 H, d,
J=5.21 Hz), 8.61 (1 H, s), 9.17 (1 H, s), 11.01 (1 H, s); ESIMS found for
C29H33N702 m/z 512.0
(M+1) and N-[6- [1 -methyl-5 -(morpholinomethyppyrazol-4-yll -3 -i soquinolyll
-2 -morpholino-
pyridine -4-carboxamide (204) (10 mg, 0.020 mmol, 10.8% yield) as an off white
solid. 1HNMR
(499 MHz, DMSO-d6) 6 ppm 2.42 (4 H, br d, J=3.84 Hz), 3.53 - 3.61 (8 H, m),
3.70 - 3.78 (6 H,
m), 3.94 (3 H, s), 7.21 (1 H, dd, J=5.21, 1.37 Hz), 7.47 (1 H, s), 7.76 (1 H,
dd, J=8.51, 1.65 Hz),
7.83 (1 H, s), 8.11 (2 H, d, J=11.25 Hz), 8.29(1 H, d, J=4.94 Hz), 8.62(1 H,
s),9.18 (1 H, s), 11.02
(1 H, s); ESIMS found for C28H3IN703 m/z 514.0 (M+1).
Example 6.
[0522]
Preparation of N-(6-(5-(dimethylamino)-1,3,4-thiadiazol-2-ypisoquinolin-3-
y1)-2-(4-methylpiperazin-1-yl)isonicotinamide (428) and N-(6-(5-amino-1,3,4-
thiadiazol-2-y1)
114
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
isoquinolin-3-y1)-2-(4-methylpiperazin-1-yl)isonicotinamide (430) are depicted
below in Scheme
19.
Br
HõIra, 0
NI N,Th
Na0Ac, Mo(C0)6 Me0
N 0 Pd(dppf)C12, Me0H N 0
75 C, ON
LIB LIV
Li0H, THF/Me0H
H20, r.t., 3 h
¨N/
LVI
NL.JC)7"-S 0
,11. , 1,11
N I N,Th PiNH
' -
I H HO
N 0 LN
POC13, 80 C, 60 h N 0
428 LV
2 LVII
H2N N-
P003, 80 C, 60 h
H2N
)7¨S
N14( N I N.õTh
N
430
Scheme 19
Step 1
[0523] To a solution of
N-(6-bromo-3-isoquinoly1)-2-(4-methylpiperazin-1-y1)
pyridine-4-carboxamide (LIII) (328 mg, 0.770 mmol) in Me0H (4 mL) was added
molybdenum
hexacorbonyl (557 mg, 2.02 mmol), Pd(dppf)C12-CH2C12adduct (125.7 mg, 0.150
mmol) sonicated
for a while and stirred at 75 C for overnight. The reaction was diluted with
water, extracted into
Et0Ac, and purified on a silica gel column (0¨>100% (20% NH3 in Me0H-
CHC13/CHC13)) to yield
methyl 34 [244
-methylpipe razin-l-yl)pyridine -4-carbonyl] amino] i soquinoline -6-
carboxylate
(LIV) (232 mg,0.572 mmol, 74.4% yield). ESIMS found for C22H23N503 m/z 406.2
(M+H).
Step 2
[0524] To a solution of
methyl 34 [2-(4-methylpiperazin-1-yl)pyridine-4-carbonyl]
aminolisoquinoline-6-carboxylate (LIV) (232 mg, 0.570 mmol) in THF (4 mL) was
added Me0H
(4 mL) and LiOH (137 mg, 5.72 mmol) in water (3 mL). The reaction was stirred
for 3 h at room
temperature. The solvent was removed and the residue was suspended in water.
Aqueous HC1 was
115
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
added until pH=6 and the solid was collected by filtration to produce 34[2-(4-
methylpiperazin-l-
yl)pyridine-4-carbonyllaminolisoquinoline-6-carboxylic acid (LV) (162 mg,O.
414 mmol, 72.3%
yield) as a yellow solid. ESIMS found for C2,-121N503 m/z 392.0 (M+H).
Step 3
[0525] A
solution of 3-[[2-(4-methylpiperazin-1-yl)pyridine-4-carbonyllamino]
isoquinoline-6-carboxylic acid (LV) (45 mg, 0.110 mmol), 3-amino-1,1-dimethyl-
thiourea (LVI)
(20.6 mg, 0.170 mmol) in POC13 (2.25 mL, 24.14 mmol) was heated at 80 C for 60
h. The reaction
was concentrated and quenched with ice and had the pH adjusted to >12 using 1N
NaOH. The solid
was
collected by filtration to obtain N4645-(dimethylamino)-1,3,4-thiadiazol-2-yll
-3-
isoquinolyll -2-(4-methylpiperazin-l-yl)pyridine-4-carboxamide (428) (14.6 mg,
0.031 mmol,
26.8% yield) as a yellow solid. 1HNMR (499 MHz, DMSO-d6) 6 ppm 2.32 (3 H, br
s), 2.52 - 2.67
(4 H, m), 3.19 (6 H, s), 3.64 (4 H, br s), 7.14 - 7.21 (1 H, m), 7.48 (1 H,
s), 8.07 (1 H, dd, J=8.51,
1.65 Hz), 8.17 (1 H, s), 8.24 - 8.29 (2 H, m), 8.70 (1 H, s), 9.24 (1 H, s),
11.14 (1 H, s); ESIMS
found for C24H26N805 m/z 475.2 (M+1).
Step 4
[0526] A
solution of 3-[[2-(4-methylpiperazin-1-yl)pyridine-4-carbonyllamino]
isoquinoline-6-carboxylic acid (LV) (60 mg, 0.150 mmol), aminothiourea (LVII)
(21.0 mg, 0.230
mmol) in P0C13 (3 mL, 32.19 mmol) was heated at 80 C for 60 h. The reaction
was concentrated
and quenched with ice and had the pH adjusted to >12 using 1N NaOH. The solid
was collected by
filtration and purified by column chromatography (0-400% (10% NH3 Me0H in
Et0Ac/Hexanes)) to yield N-[6-(5-
amino-1,3,4-thiadiazol-2-y1)-3-isoquinoly11-2-(4-
methylpiperazin-1-y1)pyridine-4-carboxamide (430) (3.7 mg, 0.008 mmol, 5.4%
yield) as a yellow
solid. 1HNMR (499 MHz, DMSO-d6) 6 ppm 2.27 (3 H, br s), 3.62 (4 H, br s), 7.12
-7.20 (1 H, m),
7.48 (1 H, s), 7.60 (2 H, s), 8.07 (1 H, dd, J=8.51, 1.65 Hz), 8.16 (1 H, d,
J=8.78 Hz), 8.25 (1 H,
s), 8.27 (1 H, d, J=4.94 Hz), 8.71 (1 H, s), 9.24 (1 H, s), 11.13 (1 H, s);
ESIMS found for
C22H22N805 m/z 447.2 (M+1).
Example 7.
[0527]
Preparation of 1-methy1-4-(4-46-(1-methyl-1H-pyrazol-4-ypisoquinolin-3-
y1)carbamoyl)pyridin-2-yl)piperazine 1-oxide (87) is depicted below in Scheme
20.
116
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N \N
\ hi\
0-
MCBPA
N 0 DcM, r.t., 2 h 0JJ0
87
Scheme 20
Step 1
[0528] To a
suspension 2-(4-methylpiperazin-1-y1)-N-[6-(1-methylpyrazol-4-y1)-3-
isoquinolyl]pyridine-4-carboxamide (10) (109 mg, 0.250 mmol) in DCM (5 mL) was
added 3-
chlorobenzenecarboperoxoic acid (66 mg, 0.380 mmol). The mixture was stirred
at room
temperature for 2 h and concentrated. The crude product was purified by silica
gel chromatography
(0->10% 7 N NH3-Me0H/CHC13). The fractions containing the product were
concentrated and the
residue triturated in ether. The resulting solid was filtered and dried to
afford 2-(4-methy1-4-oxido-
piperazin-4-ium-1 -y1)-N- [6-(1 -methylpyrazol-4-y1)-3 soquinolyll pyridine -4
-carboxamide (87)
(65 mg, 0.147 mmol, 57.5% yield) as a white solid. 1HNMR (499 MHz, DMSO-d6) 6
ppm 2.99 (2
H, br d, J=10.70 Hz), 3.11(3 H, s), 3.41 (2 H, td, J=11.53, 3.29 Hz), 3.61 -
3.72 (2 H, m), 3.91 (3
H, s), 4.25 (2 H, br d, J=13.17 Hz), 7.20 (1 H, dd, J=5.08, 1.23 Hz), 7.55 (1
H, s), 7.82 (1 H, dd,
J=8.51, 1.65 Hz), 8.07(1 H, d, J=8.51 Hz), 8.11(1 H, s), 8.14(1 H, s), 8.29(1
H, d, J=5.21 Hz),
8.38 (1 H, s), 8.60(1 H, s), 9.13 (1 H, s), 11.10(1 H, s); ESIMS found for
C24H25N702 m/z 444.2
(M+1).
[0529] The
following compounds were prepared in accordance with the procedure
described in the above Examples 1-7.
HN
Ni\'cci
N I
[0530] N-(6-(1H-Pyrazol-4 -yl)i soquinolin-3 -y1)-2 -(4-methylpipe
razin-1 -y1)
isonicotinamide 1.
[0531] Off-
white solid (38.0 mg, 0.091 mmol, 39.2% yield). 11-1 NMR (499 MHz,
DMSO-d6) 6 ppm 2.24 (s, 3 H), 2.43 (br t, J=4.80 Hz, 4 H), 3.57 -3.65 (m, 4
H), 7.16 (dd, J=5.21,
0.82 Hz, 1 H), 7.46 (s, 1 H), 7.88 (dd, J=8.64, 1.51 Hz, 1 H), 8.07 (d, J=8.51
Hz, 1 H), 8.14 - 8.31
(m, 1 H), 8.19 (s, 1 H), 8.26 (d, J=5.21 Hz, 1 H), 8.38 - 8.51 (m, 1 H), 8.60
(s, 1 H), 9.13 (s, 1 H),
11.04 (s, 1 H), 13.12 (br s, 1 H); ESIMS found for C23H23N70 m/z 414.2 (M+1).
117
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Aki ; NNH
2
[0532] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-3 -(pipe
razin-l-y1)
benzamide 2.
[0533] Off-white solid (58.3 mg, 0.141 mmol, 49.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.94 (br d, J=3.29 Hz, 4 H), 3.22 (br d, J=3.84 Hz, 4 H), 3.91
(s, 3 H), 7.15 (dd,
J=8.23, 1.92 Hz, 1 H), 7.35 (t, J=7.96 Hz, 1 H), 7.48 (d, J=7.41 Hz, 1 H),
7.63 (s, 1 H), 7.79 (dd,
J=8.51, 1.65 Hz, 1 H), 8.06 (d, J=8.78 Hz, 1 H), 8.10 - 8.14 (m, 2 H), 8.38
(s, 1 H), 8.59 (s, 1 H),
9.11 (s, 1 H), 10.80(s, 1 H); ESIMS found for C24H24N60 m/z 413.2 (M+1).
1.1/\ 111
0
3
[0534] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-3 -(4-
methylpiperazin-1 -
yl)benzamide 3.
[0535] White solid (860 mg, 1.92 mmol, 69.3% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (s, 3 H), 2.48 (br d, J=4.94 Hz, 4 H), 3.22 - 3.28 (m, 4 H),
3.91 (s, 3 H), 7.15 (dd,
J=8.23, 2.20 Hz, 1 H), 7.35 (t, J=7.82 Hz, 1 H), 7.46 (d, J=7.68 Hz, 1 H),
7.64 (s, 1 H), 7.79 (dd,
J=8.51, 1.65 Hz, 1 H), 8.05 (d, J=8.51 Hz, 1 H), 8.09 - 8.14 (m, 2 H), 8.38
(s, 1 H), 8.59 (s, 1 H),
9.11 (s, 1 H), 10.80 (s, 1 H); ESIMS found for C25H26N60 m/z 427. (M+1).
141\ ill 0
;
4
[0536] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-3 -
(pyrrolidin-l-ylmethyl)
benzamide 4.
[0537] Light yellow solid (75.5 mg, 0.183 mmol, 41.1% yield). 1H NMR
(499 MHz,
DMSO-d6) 6 ppm 1.70- 1.76 (m, 4 H), 2.49 (br s,4 H), 3.68 (s, 2 H), 3.91 (s, 3
H), 7.43 -7.50 (m,
1 H), 7.52 -7.57 (m, 1 H), 7.80 (dd, J=8.51, 1.65 Hz, 1 H), 7.95 (d, J=7.68
Hz, 1 H), 8.00 (s, 1 H),
8.06 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.13 (s, 1 H), 8.38 (s, 1 H), 8.59
(s, 1 H), 9.11 (s, 1 H),
10.80 (s, 1 H); ESIMS found for C25H25N50 m/z 412.2 (M+1).
118
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
so 041H
0
o
[0538] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -(pipe
ridin-4-yloxy)
benzamide 5.
[0539] Off-white solid (540.6 mg, 1.20 mmol, 81.3% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.42 - 1.54 (m, 2 H), 1.92 - 1.99 (m, 2 H), 2.56 -2.64 (m, 2
H), 2.97 (dt, J=12 .62 ,
4.25 Hz, 2 H), 3.91 (s, 3 H), 4.49 -4.61 (m, 1 H), 7.16 (dd, J=8.10, 1.51 Hz,
1 H), 7.41 (t, J=8.23
Hz, 1 H), 7.59 - 7.68 (m, 2 H), 7.80 (dd, J=8.51, 1.65 Hz, 1 H), 8.06 (d,
J=8.78 Hz, 1 H), 8.10 -
8.16 (m, 2 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.11 (s, 1 H), 10.82 (s, 1 H);
ESIMS found for C25H25N502
m/z 428.2 (M+1).
xx
\N
Ni\ 11411 140
o
6
[0540] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -((1-
methylpiperidin-4-
yl)oxy)benzamide 6.
[0541] Off-white solid (115.9 mg, 0.249 mmol, 71.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.61 - 1.74 (m, 2 H), 1.92 - 2.02 (m, 2 H), 2.15 - 2.26 (m, 2
H), 2.19 (s, 3 H),
2.58 - 2.68 (m, 2 H), 3.91 (s, 3 H), 4.48 - 4.58 (m, 1 H), 7.16 (dd, J=7.96,
1.65 Hz, 1 H), 7.42 (t,
J=8.23 Hz, 1 H), 7.60 - 7.68 (m, 2 H), 7.80 (dd, J=8.51, 1.37 Hz, 1 H), 8.06
(d, J=8.51 Hz, 1 H),
8.08 - 8.16 (m, 2 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.11 (s, 1 H), 10.83 (s, 1
H); ESIMS found for
C26H27N502 m/z 442.2 (M+1).
\N 0
\ 1.1
\
;
7
[0542] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-4-(piperidin-4-
yloxy)
benzamide 7.
[0543] White solid (554 mg, 1.23 mmol, 91.5% yield). 'H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.42- 1.51 (m, 2 H), 1.90- 1.98 (m, 2 H), 2.55 -2.63 (m, 2 H), 2.95
(dt, J=12.69, 3.95
Hz, 2 H), 3.91 (s, 3 H), 4.51 -4.58 (m, 1 H), 7.05 (d, J=8.78 Hz, 2 H), 7.78
(dd, J=8.51, 1.37 Hz,
1 H), 8.02 - 8.08 (m, 3 H), 8.11 (s, 1 H), 8.11 (br s, 1 H), 8.37 (s, 1 H),
8.58 (s, 1 H), 9.10 (s, 1 H),
10.63 (s, 1 H); ESIMS found for C25H25N502 m/z 428.2 (M+1).
119
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Ni\
;
8
[0544] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-4-((1-
methylpiperidin-4-
y1)oxy)benzamide 8.
[0545] White solid (82.0 mg, 0.186 mmol, 89.4% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.61 - 1.72 (m, 2 H), 1.91 -2.02 (m, 2 H), 2.14 -2.26 (m, 2 H), 2.18
(s, 3 H), 2.58 -2.68
(m, 2H), 3.91 (s, 3 H), 4.51 (tt, J=8.16, 3.91 Hz, 1 H), 7.06 (d, J=8.78 Hz,
2H), 7.78 (dd, J=8.64,
1.51 Hz, 1 H), 8.01 - 8.07 (m, 3 H), 8.09 - 8.13 (m, 2 H), 8.37 (s, 1 H), 8.58
(s, 1 H), 9.10 (s, 1 H),
10.64 (s, 1 H); ESIMS found for C26H27N502 m/z 442.2 (M+1).
\N
141/\
N
NH
9
[0546] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(piperazin-1-
y1)
isonicotinamide 9.
[0547] Off-white solid (57.3 mg, 0.139 mmol, 91.4% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.78 - 2.85 (m, 4 H), 3.50 - 3.56 (m, 4 H), 3.91 (s, 3 H), 7.14
(dd, J=5.08, 1.24
Hz, 1 H), 7.42 (s, 1 H), 7.81 (dd, J=8.51, 1.65 Hz, 1 H), 8.07 (d, J=8.51 Hz,
1 H), 8.11 (s, 1 H),
8.14 (s, 1 H), 8.25 (d, J=4.94 Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12
(s, 1 H), 11.03 (s, 1 H);
ESIMS found for C23H23N70 m/z 414.2 (M+1).
14i\
N I
[0548] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-
y1)isonicotinamide 10.
[0549] Tan solid (71.6 mg, 0.168 mmol, 66.7% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (s, 3 H), 2.43 (br t, J=4.80 Hz, 4 H), 3.56 - 3.65 (m, 4 H),
3.91 (s, 3 H), 7.16 (dd,
J=5.08, 0.96 Hz, 1 H), 7.46 (s, 1 H), 7.81 (dd, J=8.37, 1.51 Hz, 1 H), 8.07
(d, J=8.51 Hz, 1 H), 8.10
-8.16 (m, 2 H), 8.26 (d, J=5.21 Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12
(s, 1 H), 11.05 (s, 1 H);
ESIMS found for C24H25N70 m/z 428.2 (M+1).
120
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Ni\
N I
11
[0550] 2-(4-Isopropy1piperazin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
ypisoquinolin-
3-ypisonicotinamide 11.
[0551] White solid (58.7 mg, 0.129 mmol, 88.8% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.01 (d, J=6.59 Hz, 6 H), 2.53 -2.59 (m, 4 H), 2.65 -2.76 (m, 1 H),
3.56 - 3.62 (m, 4 H),
3.91 (s, 3 H), 7.15 (d, J=5.21 Hz, 1 H), 7.44 (s, 1 H), 7.81 (dd, J=8.51, 1.65
Hz, 1 H), 8.07 (d,
J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.14 (s, 1 H), 8.25 (d, J=5.21 Hz, 1 H), 8.38
(s, 1 H), 8.59 (s, 1 H),
9.12(s, 1 H), 11.04(s, 1 H); ESIMS found for C26H29N70 m/z 456.2 (M+1).
Pi\
N I
V
12
[0552] 2-(4-Cyclopropylpiperazin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-y1)
isoquinolin-3-yl)isonicotinamide 12.
[0553] Off-white solid (124.0 mg, 0.273 mmol, 68.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 0.38 (br d, J=2.74 Hz, 2 H), 0.46 (br d, J=4.67 Hz, 2 H), 1.66
(dt, J=6.24, 3.05
Hz, 1 H), 2.61 -2.67 (m, 4 H), 3.57 (br s, 4 H), 3.91 (s, 3 H), 7.15 (d,
J=4.94 Hz, 1 H), 7.46 (s, 1
H), 7.81 (d, J=8.23 Hz, 1 H), 8.07 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.14
(s, 1 H), 8.25 (d, J=4.94
Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12 (s, 1 H), 11.04 (s, 1 H); ESIMS
found for C26H27N70
m/z 454.2 (M+1).
\
N I
13
[0554] 2-(4-(2-Fluoroethyl)piperazin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 13.
[0555] White solid (13.2 mg, 0.029 mmol, 17.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.55 - 2.61 (m, 4 H), 2.69 (dt, J=28.85, 4.95 Hz, 2 H), 3.59 - 3.64
(m, 4 H), 4.59 (dt,
J=47.85, 4.95 Hz, 2 H), 7.16 (dd, J=5.08, 0.96 Hz, 1 H), 7.47 (s, 1 H), 7.81
(dd, J=8.51, 1.37 Hz,
121
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
1 F1), 8.07 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.14 (s, 1 H), 8.26 (d, J=4.94
Hz, 1 H), 8.38 (s, 1 H),
8.59(s, 1 H), 9.13 (s, 1 H), 11.04(s, 1 H); ESIMS found for C25H26FN70 m/z
460.2 (M+1).
\N N)
NI\ \ [.11 N
o
14
[0556] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-6-(4-
methylpiperazin-1 -
yl)nicotinamide 14.
[0557] Beige solid (28.0 mg, 0.062 mmol, 66.3% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.22 (s, 3 H), 2.40 (t, J=5.08 Hz, 4 H), 3.60 - 3.67 (m, 4 H), 3.91
(s, 3 H), 6.90 (d, J=9.06
Hz, 1 H), 7.78 (dd, J=8.51, 1.65 Hz, 1 H), 8.04 (d, J=8.78 Hz, 1 H), 8.08 -
8.12 (m, 2 H), 8.19 (dd,
J=9.06, 2.47 Hz, 1 H), 8.37 (s, 1 H), 8.57 (s, 1 H), 8.84 (d, J=2.20 Hz, 1 H),
9.09 (s, 1 H), 10.63 (s,
1 H); ESIMS found for C24H25N70 m/z 428.2 (M+1).
\N
1.1/\
[0558] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-5 -(pipe
ridin-4-yloxy)
nicotinamide 15.
[0559] White solid (29.0 mg, 0.064 mmol, 75.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.45 - 1.55 (m, 2 H), 1.95 - 2.01 (m, 2 H), 2.57 - 2.65 (m, 2 H),
2.98 (dt, J=12.83, 4.15
Hz, 2 H), 3.91 (s, 3 H), 4.60 -4.69 (m, 1 H), 7.82 (dd, J=8.51, 1.37 Hz, 1 H),
7.98 - 8.02 (m, 1 H),
8.07 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.14 (s, 1 H), 8.38 (s, 1 H), 8.45
(d, J=2.74 Hz, 1 H), 8.60
(s, 1 H), 8.75 (d, J=1.65 Hz, 1 H), 9.13 (s, 1 H), 11.11 (br s, 1 H); ESIMS
found for C24H24N602
m/z 429.2 (M+1).
\N 111H
Ni\
N
o
16
[0560] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(pipe
ridin-4-yloxy)
isonicotinamide 16.
[0561] Off-white solid (113.3 mg, 0.264 mmol, 58.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.47 - 1.61 (2 H, m), 1.92 - 2.01 (2 H, m), 2.57 - 2.67 (2 H,
m), 2.98 (2 H, dt,
J=12.49, 3.91 Hz), 3.91 (3 H, s), 5.06 - 5.15 (1 H, m), 7.34 (1 H, s), 7.50 (1
H, dd, J=5.21, 1.37
122
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Hz), 7.82(1 H, dd, J=8.51, 1.37 Hz), 8.06(1 H, d, J=8.51 Hz), 8.11(1 H, s),
8.15(1 H, s), 8.31(1
H, d, J=5.21 Hz), 8.38 (1 H, s), 8.58 (1 H, s), 9.12 (1 H, s), 11.06 (1 H, br
s); ESIMS found for
C24H24N602 m/z 429.2 (M+1).
\N
Ni\ Hpeal
N
17
[0562] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-((1-
methylpiperidin-4-
y1)oxy)isonicotinamide 17.
[0563] Off-white solid (1.02 g, 2.20 mmol, 85.4% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.64 - 1.77 (2 H, m), 1.99 (2 H, br dd, J=8.92, 3.98 Hz), 2.17
(2 H, br s), 2.19 (3
H, s), 2.60 -2.70 (2 H, m), 3.91 (3 H, s), 5.04 (1 H, tt, J=8.40, 3.95 Hz),
7.35 (1 H, s), 7.51 (1 H,
dd, J=5.21, 1.37 Hz), 7.82(1 H, dd, J=8.51, 1.65 Hz), 8.06(1 H, d, J=8.78 Hz),
8.11 (1 H, s), 8.15
(1 H, s), 8.31(1 H, d, J=5.21 Hz), 8.38(1 H, s), 8.57(1 H, s), 9.12(1 H, s),
11.06(1 H, s); ESIMS
found for C25H26N602 m/z 443.2 (M+1).
\N
04/H
Ni\ N1rCN;
H
N
o
18
[0564] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-5 -(pipe
ridin-4-ylamino)
nicotinamide 18.
[0565] Off-white solid (274.3 mg, 0.610 mmol, 65.6% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.22 - 1.36 (m, 3 H), 1.86 (br d, J=9.88 Hz, 2 H), 2.52 - 2.60
(m, 2 H), 2.92 -
3.01 (m, 2 H), 3.73 - 3.84 (m, 1 H), 3.91 (s, 3 H), 6.70 (d, J=7.68 Hz, 1 H),
6.98 (s, 1 H), 6.99 -
7.04 (m, 1 H), 7.81 (dd, J=8.51, 1.37 Hz, 1 H), 8.06 (d, J=8.51 Hz, 1 H), 8.09
(d, J=5.21 Hz, 1 H),
8.11 (s, 1 H), 8.14 (s, 1 H), 8.38 (s, 1 H), 8.55 (s, 1 H), 9.11 (s, 1 H),
10.78 (br s, 1 H); ESIMS
found for C24H25N70 m/z 428.2 (M+1).
141/\ I
1:11
19
[0566] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-5 -((l-
methylpiperidin-4-
yl)amino)nicotinamide 19.
[0567] Off-white solid (42.3 mg, 0.091 mmol, 51.9% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.41 - 1.53 (m, 2 H), 1.84- 1.93 (m, 2 H), 2.00 (br t, J=10.84
Hz, 2 H), 2.17 (s,
123
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
3 H), 2.73 (br d, J=11.80 Hz, 2 H), 3.65 -3.76 (m, 1 H), 3.91 (s, 3 H), 6.69
(d, J=7.41 Hz, 1 H),
6.99 (s, 1 H), 7.01 (dd, J=5.35, 1.51 Hz, 1 H), 7.81 (dd, J=8.51, 1.65 Hz, 1
H), 8.06 (d, J=8.51 Hz,
1 H), 8.09 (d, J=5.21 Hz, 1 H), 8.11 (s, 1 H), 8.14 (s, 1 H), 8.38 (s, 1 H),
8.55 (s, 1 H), 9.11 (s, 1
H), 10.79 (s, 1 H); ESIMS found for C25H27N70 m/z 442.2 (M+1).
Ni\
0)1 H
[0568] N-(6-(1-Isopropy1-1H-pyrazol-4-ypisoquinolin-3-y1)-3-(piperidin-
4-yloxy)
benzamide 20.
[0569] White solid (77.3 mg, 0.170 mmol, 77.3% yield). IFINMR (500
MHz, DMSO-
d6) 6 ppm 1.44 - 1.54 (m, 2 H), 1.49 (d, J=6.59 Hz, 6 H), 1.92 -2.01 (m, 2 H),
2.61 (ddd, J=12.49,
10.02, 2.74 Hz, 2 H), 2.98 (dt, J=12.69, 4.22 Hz, 2 H), 4.50 -4.60 (m, 2 H),
7.13 - 7.19 (m, 1 H),
7.41 (t, J=8.10 Hz, 1 H), 7.61 -7.65 (m, 2 H), 7.83 (dd, J=8.51, 1.65 Hz, 1
H), 8.05 (d, J=8.51 Hz,
1 H), 8.11 (s, 1 H), 8.15 (s, 1 H), 8.48 (s, 1 H), 8.59 (s, 1 H), 9.11 (s, 1
H), 10.80 (s, 1 H); ESIMS
found for C27H29N502m/z 456.2 (M+1).
N/\ H o
N
0
0
21
[0570] N-(6-(1-Isopropy1-1H-pyrazol-4-ypisoquinolin-3-y1)-3-((1-
methylpiperidin-
4-y1)oxy)benzamide 21.
[0571] Off-white solid (54.6 mg, 0.116 mmol, 92.8% yield). NMR
(500 MHz,
DMSO-d6) 6 ppm 1.49 (d, J=6.59 Hz, 6 H), 1.63 - 1.74 (m, 2 H), 1.93 -2.02 (m,
2 H), 2.16 -2.26
(m, 2 H), 2.19 (s, 3 H), 2.58 - 2.68 (m, 2 H), 4.50 - 4.59 (m, 2 H), 7.13 -
7.21 (m, 1 H), 7.42 (t,
J=8.23 Hz, 1 H), 7.61 - 7.67 (m, 2 H), 7.83 (dd, J=8.51, 1.65 Hz, 1 H), 8.06
(d, J=8.51 Hz, 1 H),
8.11 (s, 1 H), 8.16 (s, 1 H), 8.49 (s, 1 H), 8.59 (s, 1 H), 9.11 (s, 1 H),
10.81 (s, 1 H); ESIMS found
for C28H3N502m/z 470.3 (M+1).
141\
NH
\
0
22
124
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0572] N-(6-(1-Isopropy1-1H-pyrazol-4-ypisoquinolin-3-y1)-4-(piperidin-
4-yloxy)
benzamide 22.
105731 White solid (52.0 mg, 0.108 mmol, 75.3% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.42 - 1.54 (m, 2 H), 1.48 (d, J=6.59 Hz, 6 H), 1.91 - 1.99 (m, 2
H), 2.55 -2.64 (m, 2 H),
2.95 (dt, J=12.83, 4.15 Hz, 2 H), 4.50 -4.59 (m, 2 H), 7.05 (d, J=8.78 Hz, 2
H), 7.82 (dd, J=8.51,
1.37 Hz, 1 H), 8.02 - 8.08 (m, 3 H), 8.11 (s, 1 H), 8.14 (s, 1 H), 8.48 (s, 1
H), 8.58 (s, 1 H), 9.09 (s,
1 H), 10.62 (s, 1 H); ESIMS found for C27H29N502 m/z 456.2 (M+1).
N
Ni\
0
23
[0574] N-(6-(1-Cyclopropy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 23.
[0575] Off-white solid (83.0 mg, 0.183 mmol, 78.0% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 0.99 - 1.04 (m, 2 H), 1.09 - 1.14 (m, 2 H), 2.24 (s, 3 H), 2.43
(br t, J=4.94 Hz, 4
H), 3.58 - 3.65 (m, 4 H), 3.79 (tt, J=7.38, 3.88 Hz, 1 H), 7.12 - 7.19 (m, 1
H), 7.46 (s, 1 H), 7.84
(dd, J=8.64, 1.51 Hz, 1 H), 8.06 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.16 (s,
1 H), 8.26 (d, J=4.94
Hz, 1 H), 8.49 (s, 1 H), 8.59 (s, 1 H), 9.12 (s, 1 H), 11.04 (s, 1 H); ESIMS
found for C26H27N70
m/z 454.2 (M+1).
F
11\ \
N
24
[0576] 4-Fluoro-N-(6-(1-(1 -methylpiperidin-4-y1)-1H-pyrazol-4-ypi
soquinolin-3 -y1)
benzamide 24.
[0577] Beige solid (49.0 mg, 0.108 mmol, 53.4% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.94 - 2.13 (m, 6 H), 2.22 (s, 3 H), 2.88 (br d, J=11.25 Hz, 2 H),
4.11 -4.21 (m, 1 H),
7.36 (t, J=8.92 Hz, 2H), 7.83 (dd, J=8.51, 1.37 Hz, 1 H), 8.06 (d, J=8.51 Hz,
1 H), 8.12 - 8.20 (m,
4 H), 8.51 (s, 1 H), 8.59 (s, 1 H), 9.11 (s, 1 H), 10.89 (s, 1 H); ESIMS found
for C25H24FN50 m/z
430.2 (M+1).
125
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
NI\ \ OF
141 0
[0578] 4-(Difluoromethoxy)-N-(6-(1-(1-methylpipe ridin-4-y1)-1H-
pyrazol-4 -y1)
isoquinolin-3-yl)benzamide 25.
[0579] Beige solid (67.0 mg, 0.133 mmol, 52.4% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 1.95 -2.11 (m, 6 H), 2.22 (s, 3 H), 2.88 (br d, J=10.98 Hz, 2 H),
4.11 -4.20 (m, 1 H),
7.40 (t, J=73.95 Hz, 1 H), 7.31 (d, J=8.78 Hz, 2 H), 7.83 (dd, J=8.51, 1.37
Hz, 1 H), 8.06 (d, J=8.51
Hz, 1 H), 8.13 (s, 1 H), 8.15 -8.18 (m, 3 H), 8.51 (s, 1 H), 8.59 (s, 1 H),
9.11 (s, 1 H), 10.88 (s, 1
H); ESIMS found for C26H25F2N502 m/z 478.2 (M+1).
14(.1R
N'\
o
26
[0580] 5 -Fluoro-N-(6-(1-(1 -methylpiperidin-4 -y1)-1H-pyrazol-4-yl)i
soquinolin-3 -y1)
nicotinamide 26.
[0581] White solid (38.0 mg, 0.088 mmol, 75.9% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 1.95 -2.11 (m, 6 H), 2.22 (s, 3 H), 2.88 (br d, J=11.25 Hz, 2 H),
4.11 -4.20 (m, 1 H),
7.86 (dd, J=8.78, 1.37 Hz, 1 H), 8.07 (d, J=8.51 Hz, 1 H), 8.14 (s, 1 H), 8.19
(s, 1 H), 8.33 (dt,
J=9.47, 2.26 Hz, 1 H), 8.52 (s, 1 H), 8.60 (s, 1 H), 8.80 (d, J=2.74 Hz, 1 H),
9.07 (s, 1 H), 9.13 (s,
1 H), 11.24 (s, 1 H); ESIMS found for C24H23FN60 m/z 431.2 (M+1).
0
Ni&LNH
I\ H I
N
27
[0582] N2-Methyl-N5-(6-(1-(1-methylpiperidin-4-y1)-1H-pyrazol-4-
ypisoquinolin-3-
yl)pyridine -2,5 -dicarboxamide 27.
[0583] Beige solid (23.0 mg, 0.049 mmol, 31.4% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 1.96 -2.12 (m, 6 H), 2.22 (s, 3 H), 2.89 (br s, 2 H), 2.85 (d,
J=4.67 Hz, 3 H), 4.12 -4.20
126
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(m, 1 F1), 7.86 (dd, J=8.51, 1.65 Hz, 1 H), 8.07 (d, J=8.51 Hz, 1 H), 8.13 -
8.17 (m, 2 H), 8.19 (s, 1
H), 8.52 (s, 1 H), 8.55 (dd, J=7.96, 2.20 Hz, 1 H), 8.62 (s, 1 H), 8.94 (q,
J=4.85 Hz, 1 H), 9.13 (s,
1 H), 9.21 (d, J=1.92 Hz, 1 H), 11.30 (s, 1 H); ESIMS found for C26H27N702 m/z
470.2 (M+1).
F
0
28
[0584] 4-Fluoro-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-3 -
yl)benzamide 28.
[0585] Beige solid (43.0 mg, 0.122 mmol, 46.7% yield). NMR
(499 MHz,
METHANOL-d4) 6 ppm 3.86 (s, 3 H), 7.28 (t, J=8.78 Hz, 2 H), 7.45 (br s, 1 H),
7.68 (d, J=8.51
Hz, 1 H), 7.94 (br s, 1 H), 8.00 (s, 1 H), 8.06 - 8.15 (m, 3 H), 8.66 (s, 1
H), 9.13 (br s, 1 H); ESIMS
found for C201-115FN40 m/z 347.1 (M+1).
OF
A4I
29
[0586] 4-(Difluoromethoxy)-N-(6-(1-methy1-1H-imidazol-5 -yl)i
soquinolin-3 -y1)
benzamide 29.
[0587] White solid (16.0 mg, 0.040 mmol, 15.6% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 3.85 (3 H, s), 7.41 (1 H, t, J=73.70 Hz), 7.31(1 H, s), 7.32 (1 H,
s), 7.33 (1 H, br s), 7.73
(1 H, dd, J=8.37, 1.51 Hz), 7.81(1 H, s), 8.09(1 H, s), 8.15(1 H, d, J=8.51
Hz), 8.16 - 8.17 (1 H,
m), 8.17 -8.21 (1 H, m), 8.69 (1 H, s), 9.22(1 H, s), 10.96 (1 H, s); ESIMS
found for C2IHI6F2N402
m/z 395.1 (M+1).
HicõN I
37
[0588] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-
y1)isonicotinamide 37.
[0589] White solid (102.0 mg, 0.239 mmol, 82.9% yield). 11-1 NMR (500
MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.38 -2.46 (4 H, m), 3.55 - 3.64 (4 H, m), 3.85
(3 H, s), 7.16 (1 H,
dd, J=5.08, 1.23 Hz), 7.33 (1 H, d, J=1.10 Hz), 7.48 (1 H, s), 7.74 (1 H, dd,
J=8.51, 1.65 Hz), 7.81
(1 H, s), 8.10(1 H, d, J=0.82 Hz), 8.15(1 H, d, J=8.51 Hz), 8.24 - 8.28 (1 H,
m), 8.70(1 H, s), 9.23
(1 H, s), 11.11(1 H, s); ESIMS found for C24H25N70 m/z 428.2 (M+1).
127
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
;
[0590] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-4-
isopropoxybenzamide 40.
[0591] Light green solid (33.0 mg, 0.082 mmol, 31.7% yield). IFINMR
(500 MHz,
DMSO-d6) 6 ppm 1.31 (d, J=6.04 Hz, 6 H), 2.47 (br s, 3 H), 3.71 (br s, 3 H),
4.75 (dquin, J=12 .06 ,
5.97, 5.97, 5.97, 5.97 Hz, 1 H), 7.03 (d, J=9.06 Hz, 2 H), 7.32 (br s, 1 H),
7.65 (br d, J=8.23 Hz, 1
H), 8.02 (br s, 1 H), 8.05 - 8.09 (m, 2 H), 8.15 (br d, J=8.51 Hz, 1 H), 8.68
(br s, 1 H), 9.22 (br s, 1
H), 10.71 (br s, 1 H); ESIMS found for C24H24N402 m/z 401.2 (M+1).
c),
141-1
;
[0592] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-4-
(piperidin-4-
yloxy)benzamide 45.
[0593] White solid (30.0 mg, 0.065 mmol, 41.1% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.42 - 1.53 (m, 2 H), 1.91 - 1.98 (m, 2 H), 2.40 (s, 3 H), 2.55 -
2.63 (m, 2 H), 2.95 (dt,
J=12.62, 4.12 Hz, 2 H), 3.68 (s, 3 H), 4.49 -4.58 (m, 1 H), 7.06 (d, J=8.78
Hz, 2 H), 7.13 (s, 1 H),
7.64 (dd, J=8.51, 1.65 Hz, 1 H), 7.97 (s, 1 H), 8.06 (d, J=8.78 Hz, 2 H), 8.12
(d, J=8.51 Hz, 1 H),
8.66 (s, 1 H), 9.19 (s, 1 H), 10.69 (s, 1 H); ESIMS found for C26H27N502 m/z
442.1 (M+1).
O
el
;
47
[0594] 4-(B enzyloxy) -N-(6-(1,2-dimethy1-1H-imidazol-5 -yl)i
soquinolin-3 -y1)
benzamide 47.
[0595] Beige solid (114.0 mg, 0.254 mmol, 64.8% yield). "H NMR (499
MHz,
DMSO-d6) 6 ppm 2.41 (s, 3 H), 3.69 (s, 3 H), 5.22 (s, 2 H), 7.12 -7.19 (m, 3
H), 7.31 -7.38 (m, 1
H), 7.42 (t, J=7.41 Hz, 2 H), 7.48 (d, J=7.14 Hz, 2 H), 7.64 (dd, J=8.64, 1.51
Hz, 1 H), 7.99 (s, 1
H), 8.10 (d, J=8.78 Hz, 2 H), 8.13 (d, J=8.51 Hz, 1 H), 8.67 (s, 1 H), 9.20
(s, 1 H), 10.73 (s, 1 H);
ESIMS found for C28H24N402 m/z 449.2 (M+1).
128
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
N
49
[0596] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 49.
[0597] Beige solid (12.0 mg, 0.027 mmol, 11.4% yield). NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.40 (3 H, s), 2.41 -2.44 (4 H, m), 3.53 -3.64 (4 H,
m), 3.68 (3 H, s), 7.14
(1 H, s), 7.16(1 H, dd, J=5.21, 1.10 Hz), 7.47(1 H, s), 7.67(1 H, dd, J=8.51,
1.65 Hz), 8.00(1 H,
s), 8.14(1 H, d, J=8.51 Hz), 8.26(1 H, d, J=4.94 Hz), 8.67(1 H, s), 9.22(1 H,
s), 11.09(1 H, s);
ESIMS found for C25H27N70 m/z 442.0 (M+1).
NN--\
o
52
[0598] 4-Isopropoxy-N-(6-(5,6,7,8-tetrahydroimidazo [1,2-alpyrazin-3 -
y1)
isoquinolin-3-y1) benzamide 52.
[0599] Beige solid (20.0 mg, 0.044 mmol, 27.0% yield). NMR (499 MHz,
DMSO-
d6) 6 ppm 1.31 (d, J=6.04 Hz, 6 H), 2.79 (br s, 1 H), 3.08 (br t, J=5.21 Hz, 2
H), 3.96 (s, 2 H), 4.13
(t, J=5.21 Hz, 2 H), 4.75 (spt, J=6.04 Hz, 1 H), 7.03 (d, J=8.78 Hz, 2 H),
7.31 (s, 1 H), 7.69 (dd,
J=8.64, 1.51 Hz, 1 H), 8.01 (s, 1 H), 8.07 (d, J=8.78 Hz, 2 H), 8.10 (d,
J=8.78 Hz, 1 H), 8.66 (s, 1
H), 9.17 (s, 1 H), 10.67 (s, 1 H); ESIMS found for C25H25N502 m/z 428.2 (M+1).
\N
141\ Ny
A.1 0
NNH2
53
[0600] 2-(4-Aminopiperidin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
ypisoquinolin-3-
y1)isonicotinamide 53.
[0601] Off-white solid (195.0 mg, 0.456 mmol, 81.9% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.19- 1.29(2 H, m), 1.76- 1.85 (2 H, m), 2.80 - 2.90 (1 H, m),
2.93 - 3.04 (2 H,
m), 3.91 (3 H, s), 4.32(2 H, br d, J=13.17 Hz), 7.10(1 H, dd, J=5.21, 1.10
Hz), 7.45 (1 H, s), 7.81
(1 H, dd, J=8.51, 1.65 Hz), 8.07 (1 H, d, J=8.78 Hz), 8.11 (1 H, s), 8.13 (1
H, s), 8.23 (1 H, d,
J=4.94 Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 11.03 (1 H, br s);
ESIMS found for C24H25N70
m/z 428.2 (M+1).
129
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
N
NNH
54
[0602] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(4-
(methylamino)
piperidin-l-yl)isonicotinamide 54.
[0603] White solid (69.0 mg, 0.156 mmol, 41.0% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.17 - 1.31 (m, 2 H), 1.88 (br d, J=10.43 Hz, 2 H), 2.31 (s, 3 H),
2.52 - 2.60 (m, 1 H),
3.01 (br t, J=11.11 Hz, 2 H), 3.91 (s, 3 H), 4.29 (br d, J=13.17 Hz, 2 H),
7.10 (d, J=5.21 Hz, 1 H),
7.44 (s, 1 H), 7.81 (d, J=8.51 Hz, 1 H), 8.07 (d, J=8.51 Hz, 1 H), 8.11 (s, 1
H), 8.13 (s, 1 H), 8.23
(d, J=4.94 Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12 (s, 1 H), 11.03 (br s,
1 H); ESIMS found for
C25H27N70 m/z 442.2 (M+1).
\N
Ni\
A4 0
[0604] 2-(4-(Dimethylamino)piperidin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 55.
[0605] Off-white solid (30.0 mg, 0.066 mmol, 31.3% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.37 (2 H, qd, J=11.94, 3.70 Hz), 1.83 (2 H, br d, J=11.25 Hz),
2.19 (6 H, s),
2.30 -2.40 (1 H, m), 2.83 -2.94 (2 H, m), 3.91 (3 H, s), 4.44 (2 H, br d,
J=13.17 Hz), 7.11 (1 H,
dd, J=5.21, 1.10 Hz), 7.45 (1 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.07 (1
H, d, J=8.51 Hz), 8.11
(1 H, s), 8.13(1 H, s), 8.24(1 H, d, J=5.21 Hz), 8.38(1 H, s), 8.59(1 H, s),
9.12(1 H, s), 11.03(1
H, s); ESIMS found for C26H29N70 m/z 456.2 (M+1).
\N
141\ r
56
[0606] 2-((1-Isopropylpiperidin-4-yl)oxy)-N-(6-(1-methyl-1H-pyrazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 56.
[0607] White solid (20.0 mg, 0.043 mmol, 12.1% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 0.99 (d, J=6.31 Hz, 6 H), 1.61 - 1.71 (m, 2 H), 1.96 -2.05 (m, 2 H),
2.28 - 2.39 (m, 2 H),
2.68 -2.79 (m, 3 H), 3.91 (s, 3 H), 4.98 -5.07 (m, 1 H), 7.35 (s, 1 H), 7.50
(dd, J=5.35, 1.51 Hz, 1
130
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
F1), 7.82 (dd, J=8.64, 1.51 Hz, 1 H), 8.06 (d, J=8.51 Hz, 1 H), 8.11 (d,
J=0.82 Hz, 1 H), 8.15 (s, 1
H), 8.31 (d, J=5 .76 Hz, 1 H), 8.38 (s, 1 H), 8.57 (s, 1 H), 9.12 (s, 1 H),
11.06 (s, 1 H); ESIMS found
for C27H30N602m/z 471.2 (M+1).
\N
\ r
N
57
[0608] 2-(3 -Aminoazetidin-1 -y1)-N-(6-(1-methy1-1H-pyrazol-4-ypi
soquinolin-3 -y1)
isonicotinamide 57.
[0609] Off-white solid (200.4 mg, 0.502 mmol, 65.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.17 (br s, 2 H), 3.62 (dd, J=8.10, 5.90 Hz, 2 H), 3.80 - 3.89
(m, 1 H), 4.19 (t,
J=7.68 Hz, 2 H), 7.01 (s, 1 H), 7.14 (dd, J=5.21, 1.37 Hz, 1 H), 7.81 (dd,
J=8.64, 1.51 Hz, 1 H),
8.07 (d, J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.13 (s, 1 H), 8.19 (d, J=5.21 Hz, 1
H), 8.38 (s, 1 H), 8.58
(s, 1 H), 9.12 (s, 1 H), 10.97 (s, 1 H); ESIMS found for C22H21N70 m/z 400.2
(M+1).
\N
\ r
N\N
N
59
[0610] 2-(3 -(Dimethylamino)azetidin-1 -y1)-N-(6-(1-methy1-1H-pyrazol-
4 -y1)
isoquinolin-3-yl)isonicotinamide 59.
[0611] Off-white solid (286.7 mg, 0.671 mmol, 77.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.14 (6 H, s), 3.19 - 3.26 (1 H, m), 3.81 (2 H, dd, J=8.51,
5.21 Hz), 3.91 (3 H,
s), 4.04 -4.12 (2 H, m), 7.03 (1 H, s), 7.15 (1 H, dd, J=5.21, 1.65 Hz), 7.81
(1 H, dd, J=8.51, 1.65
Hz), 8.06 (1 H, d, J=8.78 Hz), 8.10 (1 H, d, J=0.82 Hz), 8.13 (1 H, s), 8.21
(1 H, d, J=5.21 Hz),
8.37 (1 H, s), 8.57 (1 H, s), 9.12 (1 H, s), 10.92 (1 H, s); ESIMS found for
C24H25N70 m/z 428.0
(M+1).
\N
111
141 0 F
[0612] 2-Fluoro-N-(6-(1-methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-
y1)benzamide
60.
[0613] Off-white solid (18.0 mg, 0.052 mmol, 13.0% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 4.15 (s, 3 H), 7.32 - 7.39 (m, 2 H), 7.55 - 7.65 (m, 1 H), 7.76
(td, J=7.55, 1.65
131
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Hz, 1 H), 8.08 (dd, J=8.51, 1.65 Hz, 1 H), 8.16 (d, J=8.78 Hz, 1 H), 8.39 (s,
1 H), 8.64 (s, 1 H),
8.75 (s, 1 H), 9.17 (s, 1 H), 10.88 (s, 1 H); ESIMS found for CI9H14FN50 m/z
348.2 (M+1).
\N
\ r
N
61
[0614] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-
morpholinoisonicotinamide 61.
[0615] Tan solid (72.9 mg, 0.176 mmol, 60.9% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 3.54 -3.61 (m, 4 H), 3.71 -3.77 (m, 4 H), 3.91 (s, 3 H), 7.21 (dd,
J=5.08, 1.23 Hz, 1 H),
7.47 (s, 1 H), 7.81 (dd, J=8.51, 1.65 Hz, 1 H), 8.07 (d, J=8.78 Hz, 1 H), 8.11
(s, 1 H), 8.14 (s, 1 H),
8.29 (d, J=5.21 Hz, 1 H), 8.38 (s, 1 H), 8.60 (s, 1 H), 9.13 (s, 1 H), 11.05
(s, 1 H); ESIMS found
for C23H22N602m/z 415.2 (M+1).
\N
\ r
N
62
[0616] 2-((2-(Dimethylamino)ethyl)amino)-N-(6-(1-methy1-1H-pyrazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 62.
[0617] Tan solid (79.2 mg, 0.191 mmol, 66.0% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.19 (s, 6 H), 2.43 (t, J=6.72 Hz, 2 H), 3.35 -3.43 (m, 2 H), 3.91
(s, 3 H), 6.61 (t, J=5.49
Hz, 1 H), 7.02 (dd, J=5.21, 1.37 Hz, 1 H), 7.04 (s, 1 H), 7.81 (dd, J=8.51,
1.65 Hz, 1 H), 8.06 (d,
J=8.78 Hz, 1 H), 8.08 - 8.12 (m, 2 H), 8.14 (s, 1 H), 8.38 (s, 1 H), 8.56 (s,
1 H), 9.11 (s, 1 H), 10.80
(s, 1 H); ESIMS found for C23H25N70 m/z 416.2 (M+1).
\N
\ r r!I
N
63
[0618] 2-(2-(Dimethylamino)ethoxy)-N-(6-(1-methy1-1H-pyrazol-4-
ypisoquinolin-
3-ypisonicotinamide 63.
[0619] Tan solid (84.1 mg, 0.202 mmol, 70.1% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.23 (s, 6 H), 2.65 (t, J=5.76 Hz, 2 H), 3.91 (s, 3 H), 4.41 (t,
J=5.90 Hz, 2 H), 7.39 (d,
J=0.82 Hz, 1 H), 7.53 (dd, J=5.21, 1.37 Hz, 1 H), 7.82 (dd, J=8.51, 1.65 Hz, 1
H), 8.07 (d, J=8.51
Hz, 1 H), 8.11 (s, 1 H), 8.15 (s, 1 H), 8.33 (d, J=5.21 Hz, 1 H), 8.38 (s, 1
H), 8.58 (s, 1 H), 9.12 (s,
1 H), 11.08 (s, 1 H); ESIMS found for C23H24N602m/z 417.2 (M+1).
132
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
14/\
N1HN
0
64
[0620] 2-(4-Isobutylpiperazin-1-y1)-N-(6-(1-methy1-1H-pyrazol-4-
ypisoquinolin-3-
ypisonicotinamide 64.
[0621] Off-white solid (61.3 mg, 0.131 mmol, 45.2% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 0.90 (d, J=6.59 Hz, 6 H), 1.83 (dquin, J=13.48, 6.85, 6.85,
6.85, 6.85 Hz, 1 H),
2.09 (d, J=7.41 Hz, 2 H), 2.45 (br t, J=4.94 Hz, 4 H), 3.57 - 3.64 (m, 4 H),
3.91 (s, 3H), 7.12 - 7.18
(m, 1 H), 7.45 (s, 1 H), 7.81 (dd, J=8.51, 1.37 Hz, 1 H), 8.07 (d, J=8.51 Hz,
1 H), 8.11 (s, 1 H),
8.14 (s, 1 H), 8.25 (d, J=5.21 Hz, 1 H), 8.38 (s, 1 H), 8.59 (s, 1 H), 9.12
(s, 1 H), 11.04 (s, 1 H);
ESIMS found for C27H311\170 m/z 470.2 (M+1).
\N
14/\
N
[0622] 2-(Azetidin-3-yloxy)-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-
3-y1)
isonicotinamide 65.
[0623] Off-white solid (64.9 mg, 0.162 mmol, 23.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.51 -3.58 (m, 2 H), 3.77 (br t, J=7.68 Hz, 2 H), 3.91 (s, 3
H), 5.39 (quin, J=6.24
Hz, 1 H), 7.40 (s, 1 H), 7.54 (dd, J=5.21, 1.37 Hz, 1 H), 7.82 (dd, J=8.51,
1.37 Hz, 1 H), 8.07 (d,
J=8.51 Hz, 1 H), 8.11 (s, 1 H), 8.15 (s, 1 H), 8.30 (d, J=5.21 Hz, 1 H), 8.38
(s, 1 H), 8.58 (s, 1 H),
9.13 (s, 1 H), 11.09 (br s, 1 H); ESIMS found for C22H20N602m/z 401.2 (M+1).
\N
NI\ efir=K
o
66
[0624] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-((1-
methylazetidin-3-
y1)oxy)isonicotinamide 66.
[0625] Off-white solid (144.0 mg, 0.347 mmol, 48.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.30(3 H, s), 2.99 - 3.05 (2 H, m), 3.69 - 3.77 (2 H, m), 3.91
(3 H, s), 5.16(1 H,
quin, J=5.76 Hz), 7.40 (1 H, d, J=1.37 Hz), 7.55 (1 H, dd, J=5.21, 1.37 Hz),
7.82 (1 H, dd, J=8.51,
1.65 Hz), 8.07 (1 H, d, J=8.78 Hz), 8.11 (1 H, s), 8.15 (1 H, s), 8.30(1 H, d,
J=5.49 Hz), 8.38 (1
H, s), 8.58 (1 H, s), 9.12 (1 H, s), 11.09 (1 H, s); ESIMS found for
C23H22N602m/z 415.0 (M+1).
133
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Ni\ H(C;N
N I
0
67
106261 2-(4-Ethylpiperazin-1-y1)-N-(6-(1 -methyl-1H-pyrazol-4-ypi
soquinolin-3 -y1)
isonicotinamide 67.
106271 Tan solid (98.3 mg, 0.223 mmol, 77.1% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 1.05 (3 H, t, J=7.27 Hz), 2.38 (2 H, q, J=7.14 Hz), 2.46 -2.49 (4 H,
m), 3.57 - 3.64 (4 H,
m), 3.91 (3 H, s), 7.16 (1 H, dd, J=4.94, 1.10 Hz), 7.46 (1 H, s), 7.81 (1 H,
dd, J=8.51, 1.65 Hz),
8.07(1 H, d, J=8.51 Hz), 8.11 (1 H, s), 8.14(1 H, s), 8.26(1 H, d, J=5.21 Hz),
8.38 (1 H, s), 8.59
(1 H, s), 9.12 (1 H, s), 11.04 (1 H, s) ESIMS found for C25H27N70 m/z 442.2
(M+1).
\N
Ni\
A.1 o
71
[0628] 44(Dimethylamino)methyl)-N-(6-(1-methyl-1H-pyrazol-4-
ypisoquinolin-3-
y1)benzamide 71.
[0629] Off-white solid (15.2 mg, 0.039 mmol, 14.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.19 (6 H, s), 3.49 (2 H, s), 3.91 (3 H, s), 7.44 (2 H, d,
J=8.23 Hz), 7.79 (1 H,
dd, J=8.51, 1.65 Hz), 8.05 (3 H, d, J=8.23 Hz), 8.10 (1 H, s), 8.12 (1 H, s),
8.36 (1 H, s), 8.59 (1
H, s), 9.11 (1 H, s), 10.70(1 H, s); ESIMS found for C23H23N50 m/z 386.0
(M+1).
\N
Ni\
0
72
[0630] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -(1-
methylpiperidin-4-
yl)benzamide 72.
[0631] Off-white solid (78.0 mg, 0.174 mmol, 75.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.72 - 1.84 (4 H, m), 2.00 (2 H, td, J=10.91, 3.16 Hz), 2.22 (3
H, s), 2.52 -2.60
(1 H, m), 2.90(2 H, br d, J=11.25 Hz), 3.91 (3 H, s), 7.40 -7.51 (2 H, m),
7.79(1 H, dd, J=8.51,
1.37 Hz), 7.89(1 H, br d, J=7.41 Hz), 8.01(1 H, s), 8.05(1 H, d, J=8.51 Hz),
8.10(1 H, s), 8.12(1
H, s), 8.37 (1 H, s), 8.59 (1 H, s), 9.11 (1 H, s), 10.80 (1 H, s); ESIMS
found for C26H27N50 m/z
426.05 (M+1).
134
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
NI\
Nj4
74
[0632] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -((4-
methylpiperazin-1-
yl)methyl)benzamide 74.
[0633] Off-white solid (65.0 mg, 0.196 mmol, 33.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.16 (3 H, s), 2.27 -2.38 (4 H, m), 2.38 - 2.45 (4 H, m), 3.54
(2 H, s), 3.92 (3 H,
s), 7.44 - 7.50 (1 H, m), 7.50 - 7.55 (1 H, m), 7.79 (1 H, dd, J=8.64, 1.51
Hz), 7.96 (1 H, br d,
J=7.68 Hz), 7.98(1 H, s), 8.06(1 H, d, J=8.51 Hz), 8.10(1 H, s), 8.12(1 H, s),
8.37(1 H, s), 8.58
(1 H, s), 9.11(1 H, s), 10.74(1 H, s); ESIMS found for C26H28N60 m/z 441.0
(M+1).
\N
Hi\ N11(01
0
76
[0634] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)isonicotinamide
76.
[0635] Brown solid (80 mg, 0.243 mmol, 41.9% yield). 'H NMR (499 MHz,
DMSO-
d6) 6 ppm 3.91 (3 H, s), 7.84 (1 H, dd, J=8.51, 1.65 Hz), 8.09 (1 H, d, J=8.51
Hz), 8.12 (1 H, s),
8.16 - 8.21 (3 H, m), 8.39(1 H, s), 8.60(1 H, s), 8.92(2 H, d, J=6.31 Hz),
9.16(1 H, s), 11.38 (1
H, s); ESIMS found for CI9H15N50 m/z 330.1 (M+1).
\N
NC1
1411\
OH
0
78
[0636] 2-Hydroxy-N-(6-(1 -methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)
isonicotinamide 78.
[0637] Off-white solid (89.0 mg, 0.258 mmol, 21.0% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.91 (3 H, s), 6.62 (1 H, dd, J=6.72, 1.51 Hz), 6.92 (1 H, d,
J=1.10 Hz), 7.50 (1
H, d, J=6.59 Hz), 7.81(1 H, dd, J=8.51, 1.37 Hz), 8.06(1 H, d, J=8.51 Hz),
8.10(1 H, s), 8.14(1
H, s), 8.37(1 H, s), 8.53 (1 H, s), 9.11 (1 H, s), 10.97(1 H, s), 11.81 (1 H,
br s); ESIMS found for
CI9H15N502 m/z 345.9 (M+1).
\N
Ni\
0
135
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0638] 2-Isopropoxy-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)
isonicotinamide 80.
[0639] Off-white solid (49.2 mg, 0.127 mmol, 38.0% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.33 (6H, d, J=6.31 Hz), 3.91(3 H, s), 5.30(1 H, spt, J=6.17
Hz), 7.30(1 H, s),
7.50(1 H, dd, J=5.35, 1.51 Hz), 7.82(1 H, dd, J=8.51, 1.65 Hz), 8.06(1 H, d,
J=8.51 Hz), 8.11(1
H, s), 8.15(1 H, s), 8.32(1 H, d, J=5.21 Hz), 8.38(1 H, s), 8.58(1 H, s),
9.12(1 H, s), 11.05(1 H,
s); ESIMS found for C22H211\1502 m/z 388.2 (M+1).
\N N
hi\ 1
N
0
84
[0640] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(1-
methylpiperidin-4 -
yl)isonicotinamide 84.
[0641] Off-white solid (100.0 mg, 0.235 mmol, 49.8% yield). 11-1 NMR
(500 MHz,
DMSO-d6) 6 ppm 1.77 - 1.92 (4 H, m), 2.00 (2 H, td, J=11.60, 2.61 Hz), 2.21 (3
H, s), 2.72 (1 H,
tt, J=11.49, 4.15 Hz), 2.85 -2.93 (2 H, m), 3.91 (3 H, s), 7.76(1 H, dd,
J=5.21, 1.65 Hz), 7.82 (1
H, dd, J=8.51, 1.65 Hz), 7.91 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 8.12 (1 H,
d, J=0.82 Hz), 8.15 (1
H, d, J=0.82 Hz), 8.39 (1 H, s), 8.60 (1 H, s), 8.66 - 8.71 (1 H, m), 9.13 (1
H, s), 11.17 (1 H, s);
ESIMS found for C25H26N60 m/z 427.0 (M+1).
\N N
\ 1
N
A4I 0
[0642] 1'-Methyl-N-(6-(1-methy1-1H-pyrazol-4-y1)isoquinolin-3-y1)-
1',2',31,6'-
tetrahydro-12,4'-bipyridinel-4-carboxamide 85.
[0643] Off-white solid (89.0 mg, 0.210 mmol, 17.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.31 (3 H, s), 2.57 - 2.63 (2 H, m), 2.63 - 2.70 (2 H, m), 3.11
(2 H, br d, J=3.02
Hz), 3.91 (3 H, s), 6.89 (1 H, t, J=3.43 Hz), 7.78 (1 H, dd, J=4.94, 1.37 Hz),
7.82 (1 H, dd, J=8.51,
1.65 Hz), 8.08 (1 H, d, J=8.51 Hz), 8.11 (1 H, s), 8.16(2 H, d, J=6.04 Hz),
8.38 (1 H, s), 8.61 (1
H, s), 8.71 (1 H, d, J=4.94 Hz), 9.14(1 H, s), 11.23(1 H, s); ESIMS found for
C25H24N60 m/z 425.0
(M+1).
136
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
NrN\
0 0
86
[0644] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-(6-(4-
methylpiperazin-1-y1)nicotinoyl)piperazin-1-yl)isonicotinamide 86.
[0645] Off-white solid (30.0 mg, 0.049 mmol, 89.4% yield). 1I-1 NMR
(499 MHz,
Solvent) 6 ppm 2.21 (3 H, s), 2.36 - 2.41 (4 H, m), 3.42 (2 H, br s), 3.49 -
3.56 (4 H, m), 3.64 (2 H,
br s), 3.75 (4 H, br s), 3.91 (3 H, s), 6.64 (1 H, dd, J=5.08, 0.96 Hz), 6.82
(1 H, s), 7.20 (1 H, dd,
J=5.21, 1.10 Hz), 7.49 (1 H, s), 7.81 (1 H, dd, J=8.64, 1.51 Hz), 8.07 (1 H,
d, J=8.51 Hz), 8.11 (1
H, d, J=0.82 Hz), 8.14 (1 H, s), 8.18 (1 H, d, J=4.94 Hz), 8.29 (1 H, d,
J=5.21 Hz), 8.38 (1 H, s),
8.60(1 H, s), 9.13 (1 H, s), 11.06(1 H, s); ESIMS found for C34H36N1002 m/z
617.3 (M+1).
\N
Nix \
N 1
0
87
[0646] I-Methyl-4444(641 -methyl-1H-pyrazol-4-ypi soquinolin-3 -
yl)carbamoyl)
pyridin-2-yl)piperazine 1-oxide 87.
[0647] White solid (65.0 mg, 0.147 mmol, 57.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.99(2 H, br d, J=10.70 Hz), 3.11(3 H, s), 3.41(2 H, td, J=11.53,
3.29 Hz), 3.61 - 3.72
(2 H, m), 3.91 (3 H, s), 4.25 (2 H, br d, J=13.17 Hz), 7.20 (1 H, dd, J=5.08,
1.23 Hz), 7.55 (1 H, s),
7.82(1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d, J=8.51 Hz), 8.11(1 H, s), 8.14(1
H, s), 8.29(1 H, d,
J=5.21 Hz), 8.38 (1 H, s), 8.60 (1 H, s), 9.13 (1 H, s), 11.10 (1 H, s); ESIMS
found for C24H25N702
m/z 444.2 (M+1).
\N
Hi\ Hra
N I
0
88
[0648] 2-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-6-(4-
methylpiperazin-1-y1)isonicotinamide 88.
137
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0649] Brown solid (33.2 mg, 0.075 mmol, 26.8% yield). '1-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.39 (3 H, s), 2.40 - 2.44 (4 H, m), 3.54 - 3.62
(4 H, m), 3.91 (3 H,
s), 7.04 (1 H, s), 7.26(1 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.06 (1 H,
d, J=8.51 Hz), 8.11 (1
H, s), 8.14 (1 H, d, J=0.82 Hz), 8.38 (1 H, s), 8.58 (1 H, s), 9.12 (1 H, s),
10.94 (1 H, s); ESIMS
found for C25H27N70 m/z 442.2 (M+1).
Ni\
N
0
89
[0650] 3 -Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypi soquinolin-3 -y1)-2-
(4-
methylpiperazin-1 -yl)isonicotinamide 89.
[0651] Brown solid (18.8 mg, 0.043 mmol, 11.2% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.29 (3 H, s), 2.45 - 2.54 (4 H, m), 3.09 (4 H,
br s), 3.91 (3 H, s),
7.08 (1 H, d, J=4.94 Hz), 7.80(1 H, dd, J=8.51, 1.65 Hz), 8.04(1 H, d, J=8.78
Hz), 8.11 (1 H, s),
8.16 (1 H, s), 8.21 (1 H, d, J=4.94 Hz), 8.38 (1 H, s), 8.58 (1 H, s), 9.07 (1
H, s), 11.00 (1 H, s);
ESIMS found for C25H27N70 m/z 442.2 (M+1).
Hi\ r
[0652] 2-(4-Methyl-1,4-diazepan-l-y1)-N-(6-(1-methyl-1H-pyrazol-4-y1)
isoquinolin-3-yl)isonicotinamide 90.
[0653] Off-white solid (82.0 mg, 0.186 mmol, 32.3% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.93 (2 H, quin, J=5.76 Hz), 2.27 (3 H, s), 2.48 (2 H, br s),
2.59 -2.67 (2 H, m),
3.69 (2 H, t, J=6.17 Hz), 3.78 - 3.85 (2 H, m), 3.91 (3 H, s), 7.05 (1 H, dd,
J=5.08, 0.96 Hz), 7.21
(1 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d, J=8.78 Hz), 8.11 (1 H,
s), 8.13 (1 H, s), 8.20
(1 H, d, J=4.94 Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 11.02 (1 H,
s); ESIMS found for
C25H27N70 m/z 442.2 (M+1).
N'JJL
0
91
[0654] 2-((2S,6R)-2,6-Dimethylmorpholino)-N-(6-(1-methy1-1H-pyrazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 91.
138
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0655] Tan solid (32.0 mg, 0.072 mmol, 31.9% yield). NMR
(499 MHz, DMSO-
d6) 6 ppm 1.20 (6 H, d, J=6.04 Hz), 2.44 - 2.49 (2 H, m), 3.60 - 3.70 (2 H,
m), 3.91 (3 H, s), 4.28
(2 H, br dd,J=12.76, 1.51Hz), 7.18 (1 H, dd,J=5.21, 1.37Hz), 7.44 (1H, s),
7.81 (1 H, dd,J=8.51,
1.65 Hz), 8.07 (1 H, d, J=8.78 Hz), 8.10 (1 H, d, J=0.82 Hz), 8.13 (1 H, s),
8.27 (1 H, d, J=5.49
Hz), 8.37 (1 H, s), 8.58 (1 H, s), 9.12 (1 H, s), 10.94 (1 H, s); ESIMS found
for C25H26N602 m/z
443.0 (M+1).
r
N\-3
92
[0656] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(2,7-
diazaspiro [3 .51
nonan-2-yl)isonicotinamide 92.
[0657] Off-white solid (120.0 mg, 0.265 mmol, 47.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.66 (4 H, br t, J=4.94 Hz), 2.66 (4 H, br s), 3.73 (4 H, s),
3.91 (3 H, s), 7.02 (1
H, s), 7.12 (1 H, dd, J=5.21, 1.37 Hz), 7.81 (1 H, dd, J=8.64, 1.51 Hz), 8.07
(1 H, d, J=8.51 Hz),
8.11 (1 H, s), 8.13 (1 H, s), 8.19 (1 H, d, J=4.94 Hz), 8.38 (1 H, s), 8.58 (1
H, s), 9.12 (1 H, s),
10.96 (1 H, br s); ESIMS found for C26H27N70 m/z 454.2 (M+1).
\N
Ni\ NN
A./ 0
93
[0658] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(7-
methy1-2,7-
diazaspiro [3 .51nonan-2 -yl)i soni cotinamide 93.
[0659] White solid (63.9 mg, 0.137 mmol, 77.5% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 1.76 (4 H, br t, J=5.21 Hz), 2.15 (3 H, s), 2.27 (4 H, br s), 3.74
(4 H, s), 3.91 (3 H, s),
7.03 (1H, s), 7.13 (1H, dd,J=5.21, 1.37 Hz), 7.81 (1H, dd, J=8.51, 1.65 Hz),
8.07 (1H, d,J=8.51
Hz), 8.11 (1 H, s), 8.13 (1 H, s), 8.20 (1 H, d, J=5.76 Hz), 8.38 (1 H, s),
8.58 (1 H, s), 9.12 (1 H,
s), 10.96 (1 H, s); ESIMS found for C27H29N70 m/z 468.1 (M+1).
\N
Ni\ r
NH
94
139
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0660] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(2,7-
diazaspiro [3 .51
nonan-7-yl)isonicotinamide 94.
[0661] Off-white solid (190.0 mg, 0.419 mmol, 76.0% yield). II-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.72 - 1.79 (4 H, m), 3.32 - 3.43 (4 H, m), 3.54 - 3.60 (4 H,
m), 3.91 (3 H, s),
7.11(1 H, dd, J=5.21, 1.10 Hz), 7.46(1 H, s), 7.81(1 H, dd, J=8.64, 1.51 Hz),
8.07(1 H, d, J=8.51
Hz), 8.11 (1 H, s), 8.13 (1 H, s), 8.23 (1 H, d, J=5.21 Hz), 8.38 (1 H, s),
8.59 (1 H, s), 9.12 (1 H,
s), 11.02 (1 H, br s); ESIMS found for C26H27N70 m/z 454.1 (M+1).
141\
0
[0662] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(2-
methy1-2,7-
diazaspiro [3 .51nonan-7-yl)i soni cotinamide 95.
[0663] White solid (136.0 mg, 0.291 mmol, 79.5% yield). II-1 NMR (499
MHz,
DMSO-d6) 6 ppm 1.66- 1.76(4 H, m), 2.24(3 H, s), 2.97(4 H, s), 3.53 - 3.62 (4
H, m), 3.91 (3 H,
s), 7.10 (1 H, dd, J=5.08, 1.23 Hz), 7.45 (1 H, s), 7.81 (1 H, dd, J=8.51,
1.65 Hz), 8.07 (1 H, d,
J=8.51 Hz), 8.11(1 H, s), 8.13(1 H, s), 8.23(1 H, d, J=4.94 Hz), 8.38(1 H, s),
8.59(1 H, s), 9.12
(1 H, s), 11.02 (1 H, s); ESIMS found for C27H29N70 m/z 468.0 (M+1).
Hp -
Ni\
N
97
[0664] 2-(Methyl(1-methylpiperidin-4-yl)amino)-N-(6-(1-methyl-1H-
pyrazol-4-y1)
isoquinolin-3-yl)isonicotinamide 97.
[0665] Tan solid (72.9 mg, 0.160 mmol, 55.4% yield). NMR
(499 MHz, DMSO-
d6) 6 ppm 1.50 - 1.62 (2 H, m), 1.80 (2 H, qd, J=12.08, 3.84 Hz), 1.97 -2.08
(2 H, m), 2.19 (3 H,
s), 2.86 (2 H, br d, J=11.25 Hz), 2.93 (3 H, s), 3.91 (3 H, s), 4.49 (1 H,
ddt, J=11.63, 7.79, 4.01,
4.01 Hz), 7.07 (1 H, dd, J=5.08, 1.23 Hz), 7.18 (1 H, s), 7.81 (1 H, dd,
J=8.51, 1.65 Hz), 8.07 (1
H, d, J=8.51 Hz), 8.11(1 H, s), 8.13(1 H, s), 8.22(1 H, d, J=5.21 Hz), 8.38(1
H, s), 8.58(1 H, s),
9.12(1 H, s), 10.99 (1 H, s); ESIMS found for C26H29N70 m/z 456.2 (M+1).
Ni\
99
140
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0666] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-((1-
methylpiperidin-4-
y1)thio)isonicotinamide 99.
106671 Off-white solid (50.0 mg, 0.109 mmol, 15.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.60 - 1.72 (2 H, m), 1.99 -2.08 (2 H, m), 2.12 (2 H, br t,
J=10.84 Hz), 2.17 (3
H, s), 2.65 -2.73 (2 H, m), 3.78 -3.88 (1 H, m), 3.91 (3 H, s), 7.64(1 H, dd,
J=5.08, 1.51 Hz), 7.79
-7.85 (2 H, m), 8.07 (1 H, d, J=8.51 Hz), 8.11 (1 H, s), 8.15 (1 H, s), 8.38
(1 H, s), 8.57(1 H, s),
8.59 - 8.64 (1 H, m), 9.12 (1 H, s), 11.14 (1 H, s); ESIMS found for
C25H26N60S m/z 458.9 (M+1).
\N
N3QJL
0 NON
100
[0668] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(4-
methylpiperazin-1 -
yl)pyrimidine -4 -carboxamide 100.
[0669] Tan solid (78.0 mg, 0.182 mmol, 63.0% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.25 (3 H, s), 2.44 (4 H, br t, J=4.94 Hz), 3.82 - 3.89 (4 H, m),
3.91 (3 H, s), 7.30 (1 H,
d, J=4.67 Hz), 7.83 (1 H, dd, J=8.64, 1.51 Hz), 8.08 (1 H, d, J=8.78 Hz), 8.12
(1 H, s), 8.17 (1 H,
s), 8.39(1 H, s), 8.58(1 H, s), 8.69(1 H, d, J=4.67 Hz), 9.12(1 H, s), 10.36(1
H, s); ESIMS found
for C23H24N80 m/z 429.2 (M+1).
\N Hr)(111
NI\
N
0
101
[0670] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-6-(4-
methylpiperazin-1 -
yl)pyridazine -4-carboxamide 101.
[0671] Off-white solid (6.2 mg, 0.015 mmol, 3.4% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.16 (3 H, br s), 2.40 (4 H, br s), 3.43 (4 H, br d, J=3.57
Hz), 3.91 (3 H, s), 7.72
(1 H, s), 7.80 (1 H, dd, J=8.51, 1.65 Hz), 8.04 (1 H, d, J=8.78 Hz), 8.10 (1
H, d, J=0.82 Hz), 8.14
(1 H, s), 8.36 (1 H, s), 8.54 (1 H, br s), 9.08 (1 H, s), 11.04 (1 H, s),
12.68 (1 H, s); ESIMS found
for C23H24N80 m/z 429.0 (M+1).
\N NN
Hi\
N1N
0
102
[0672] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-6-(4-
methylpiperazin-1 -
yl)pyrimidine -4 -carboxamide 102.
141
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0673] White solid (72.1 mg, 0.168 mmol, 39.1% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.25 (3 H, s), 2.44 (3 H, br s), 3.76 (4 H, br s), 3.91 (3 H, s),
7.48 (1 H, d, J=0.82 Hz),
7.82 (1 H, dd, J=8.51, 1.65 Hz), 8.07 (1 H, d, J=8.51 Hz), 8.11 (1 H, s), 8.16
(1 H, s), 8.38 (1 H,
s), 8.58(1 H, s), 8.67(1 H, d, J=1.10 Hz), 9.11(1 H, s), 10.41(1 H, s); ESIMS
found for C23H24N80
m/z 429.0 (M+1).
A.1 = 101
103
[0674] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-
phenylacetamide 103.
[0675] Beige solid (57.0 mg, 0.167 mmol, 37.3% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.77 (2 H, s), 3.89 (3 H, s), 7.20 - 7.27 (1 H, m), 7.33 (2 H, t,
J=7.68 Hz), 7.37 - 7.44 (2
H, m), 7.75 (1 H, dd, J=8.51, 1.65 Hz), 8.00 (1 H, d, J=8.51 Hz), 8.03 (1 H,
s), 8.07 (1 H, s), 8.34
(1 H, s), 8.40(1 H, s), 9.04(1 H, s), 10.75 (1 H, s); ESIMS found for C211-
1181\140 m/z 343.1 (M+1).
\N
\
N o
104
[0676] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -
phenylpropanamide
104.
[0677] Beige solid (67.0 mg, 0.188 mmol, 42.2% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.72 -2.80 (2 H, m), 2.92 -2.96 (2 H, m), 3.90 (3 H, s), 7.15 - 7.22
(1 H, m), 7.26 - 7.32
(4 H, m), 7.74 (1 H, dd, J=8.51, 1.37 Hz), 7.99 (1 H, d, J=8.51 Hz), 8.06 (1
H, s), 8.09 (1 H, s),
8.36 (1 H, s), 8.44 (1 H, s), 9.02 (1 H, s), 10.54 (1 H, s); ESIMS found for
C22H201\140 m/z 357.2
(M+1).
\
N
105
[0678] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(pyridin-3-
y1)acetamide
105.
[0679] Brownish orange solid (21.0 mg, 0.061 mmol, 13.7% yield). 11-1
NMR (499
MHz, DMSO-d6) 6 ppm 3.83 (2 H, s), 3.89 (3 H, s), 7.37 (1 H, dd, J=7.82, 4.80
Hz), 7.76 (1 H, dd,
J=8.51, 1.65 Hz), 7.79 (1 H, dt, J=7.82, 1.85 Hz), 8.01 (1 H, d, J=8.51 Hz),
8.03 (1 H, s), 8.07 (1
142
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
H, s), 8.34 (1 H, s), 8.39 (1 H, s), 8.47 (1 H, dd, J=4.67, 1.65 Hz), 8.57 (1
H, d, J=1.65 Hz), 9.05
(1 H, s), 10.86 (1 H, s); ESIMS found for C201-117N50 m/z 344.1 (M+1).
\N
Hr0,1
106
[0680] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -(pyridin-3
-y1)
propanamide 106.
[0681] Brown solid (65.0 mg, 0.182 mmol, 40.8% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.76 - 2.83 (2 H, m), 2.93 - 3.00 (2 H, m), 3.90(3 H, s), 7.31
(1 H, dd, J=7.82,
4.80 Hz), 7.69 (1 H, dt, J=7.82, 1.85 Hz), 7.75 (1 H, dd, J=8.51, 1.65 Hz),
7.99 (1 H, d, J=8.51
Hz), 8.06(1 H, s), 8.09(1 H, d, J=0.82 Hz), 8.36(1 H, s), 8.40(1 H, dd,
J=4.80, 1.51 Hz), 8.43(1
H, s), 8.51 (1 H, d, J=1.92 Hz), 9.01(1 H, s), 10.56(1 H, s); ESIMS found for
C211-119N50 m/z 358.1
(M+1).
\N
rr
1.11\
Ny
A4I 0
107
[0682] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(pyridin-4-
y1)acetamide
107.
[0683] Beige solid (30.0 mg, 0.087 mmol, 19.6% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 3.84 (2 H, s), 3.89 (3 H, s), 7.39 (2 H, d, J=6.04 Hz), 7.76 (1 H,
dd, J=8.64, 1.51 Hz),
8.01 (1 H, d, J=8.51 Hz), 8.04(1 H, s), 8.07(1 H, s), 8.35(1 H, s), 8.40(1 H,
s), 8.49 - 8.55 (2 H,
m), 9.05 (1 H, s), 10.88 (1 H, s); ESIMS found for C201-117N50 m/z 344.1
(M+1).
Hi\
108
[0684] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-3 -(pyridin-4-
y1)
propanamide 108.
[0685] Beige solid (45.0 mg, 0.126 mmol, 28.2% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.77 - 2.85 (2 H, m), 2.92 - 3.00 (2 H, m), 3.90 (3 H, s), 7.27 -
7.33 (2 H, m), 7.75 (1 H,
dd, J=8.51, 1.37 Hz), 8.00 (1 H, d, J=8.78 Hz), 8.06 (1 H, s), 8.09 (1 H, d,
J=0.82 Hz), 8.35 (1 H,
s), 8.43 (1 H, s), 8.44 - 8.50 (2 H, m), 9.02 (1 H, s), 10.58 (1 H, s); ESIMS
found for C211-119N50
m/z 358.2 (M+1).
143
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Ni\
109
[0686] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)i
soindoline -5 -carboxamide
109.
[0687] Off-white solid (120.0 mg, 0.325 mmol, 33.7% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.91 (3 H, s), 4.14 (4 H, s), 7.39 (1 H, d, J=7.68 Hz), 7.79 (1
H, dd, J=8.51, 1.65
Hz), 7.92(1 H, dd, J=7.96, 1.37 Hz), 7.97(1 H, s), 8.05(1 H, d, J=8.51 Hz),
8.11(1 H, s), 8.13(1
H, s), 8.37 (1 H, s), 8.59 (1 H, s), 9.10 (1 H, s), 10.70 (1 H, s); ESIMS
found for C22H19N50 m/z
369.95 (M+1).
\N
Ni\ N-
N
0
110
[0688] 2-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-
ypisoindoline-5-
carboxamide 110.
[0689] Off-white solid. IFINMR (499 MHz, DMSO-d6) 6 ppm 2.52 (3 H, s),
3.88 (4
H, s), 3.91 (3 H, s), 7.37 (1 H, d, J=7.68 Hz), 7.79 (1 H, dd, J=8.51, 1.65
Hz), 7.90 -7.97 (2 H, m),
8.05 (1 H, d, J=8.78 Hz), 8.10 (1 H, d, J=0.82 Hz), 8.12 (1 H, s), 8.37 (1 H,
s), 8.58 (1 H, s), 9.10
(1 H, s), 10.70 (1 H, s); ESIMS found for C23H21N50 m/z 383.95 (M+1).
NI\ \
NH
A.1 0
111
[0690] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-1,2,3,4-
tetrahydroisoquinoline-7-carboxamide 111.
[0691] Off-white solid (120.0 mg, 0.313 mmol, 32.5% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.73 - 2.78 (2 H, m), 2.97 (2 H, t, J=5.90 Hz), 3.90 - 3.93 (2
H, m), 3.91 (3 H,
s), 7.20(1 H, d, J=7.96 Hz), 7.75 -7.85 (3 H, m), 8.05 (1 H, d, J=8.51 Hz),
8.11 (1 H, s), 8.12 (1
H, s), 8.37 (1 H, s), 8.58 (1 H, s), 9.10 (1 H, s), 10.63 (1 H, s); ESIMS
found for C23H21N50 m/z
384.0 (M+1).
Hi\
144
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
112
[0692] 2-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-
1,2,3,4-
tetrahydroisoquinoline-7-carboxamide 112.
[0693] Off-white solid (115.9 mg, 0.277 mmol, 93.2% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.37 (3 H, s), 2.63 (2 H, br t, J=5.90 Hz), 2.89 (2 H, br t,
J=5.76 Hz), 3.52 -3.59
(2 H, m), 3.91 (3 H, s), 7.25 (1 H, d, J=7.96 Hz), 7.76 - 7.89 (3 H, m), 8.05
(1 H, d, J=8.51 Hz),
8.10 (1 H, s), 8.12 (1 H, s), 8.37 (1 H, s), 8.58 (1 H, s), 9.10 (1 H, s),
10.65 (1 H, s); ESIMS found
for C24H23N50 m/z 398.0 (M+1).
\N
Ni\
141
113
[0694] 2-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3 -y1)-
1,2,3,4-
tetrahydroisoquinoline-6-carboxamide 113.
[0695] Off-white solid (115.9 mg, 0.277 mmol, 65.2% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.36 (3 H, s), 2.64 (2 H, t, J=5.90 Hz), 2.91 (2 H, br t,
J=5.63 Hz), 3.55 (2 H, s),
3.91 (3 H, s), 7.19(1 H, d, J=7.96 Hz), 7.81 (2 H, ddd, J=17.36, 8.30, 1.51
Hz), 7.86 (1 H, s), 8.05
(1 H, d, J=8.51 Hz), 8.10(1 H, s), 8.12(1 H, s), 8.37(1 H, s), 8.58(1 H, s),
9.10(1 H, s), 10.66(1
H, s); ESIMS found for C24H23N50 m/z 398.0 (M+1).
\N NH
NI\
A.1
114
[0696] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1)-1,2,3,4-
tetrahydroisoquinoline-6-carboxamide 114.
[0697] Off-white solid (170.0 mg, 0.443 mmol, 31.3% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.78 (2 H, br t, J=5.76 Hz), 2.98 (2 H, t, J=5.90 Hz), 3.86 -
3.97 (5 H, m), 7.15
(1 H, d, J=7.68 Hz), 7.76 - 7.82 (2 H, m), 7.83(1 H, s), 8.05(1 H, d, J=8.78
Hz), 8.11 (1 H, s), 8.12
(1 H, s), 8.37 (1 H, s), 8.58 (1 H, s), 9.10 (1 H, s), 10.64 (1 H, s); ESIMS
found for C23H21N50 m/z
384.0 (M+1).
NH
Ni\
o
116
145
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0698] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-1H-indole-5-
carboxamide
116.
106991 White solid (18.0 mg, 0.049 mmol, 10.9% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 3.91 (3 H, s), 6.59 (1 H, ddd, J=2.95, 1.99, 0.82 Hz), 7.44 - 7.48
(1 H, m), 7.49 (1 H, d,
J=8.51 Hz), 7.78(1 H, dd, J=8.51, 1.65 Hz), 7.86(1 H, dd, J=8.64, 1.78 Hz),
8.05(1 H, d, J=8.78
Hz), 8.11 (1 H, s), 8.12(1 H, d, J=0.82 Hz), 8.38 (1 H, s), 8.42(1 H, d,
J=1.65 Hz), 8.62(1 H, s),
9.11(1 H, s), 10.53 (1 H, s), 11.39 (1 H, br s); ESIMS found for CA-II-Ns m/z
368.1 (M+1).
\N
Ni\
o
117
[0700] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)benzofuran-
5 -carboxamide
117.
[0701] Light yellow solid (8.7 mg, 0.024 mmol, 7.2% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.91 (3 H, s), 7.11 (1 H, d, J=1.37 Hz), 7.73 (1 H, d, J=8.51
Hz), 7.80(1 H, dd,
J=8.51, 1.65 Hz), 8.06 (2H, d, J=8.51 Hz), 8.11(1 H, s), 8.12(1 H, d, J=2.20
Hz), 8.14(1 H, s),
8.38 (1 H, s), 8.45 (1 H, d, J=1.92 Hz), 8.62 (1 H, s), 9.12 (1 H, s), 10.83
(1 H, s); ESIMS found
for C221-116N402 m/z 369.1 (M+1).
0
\
N
0
118
[0702] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)furo [2,3 -
clpyridine -5 -
carboxamide 118.
[0703] Light yellow solid (10.8 mg, 0.029 mmol, 9.4% yield). II-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.92 (3 H, s), 7.30 (1 H, d, J=1.92 Hz), 7.82 (1 H, dd, J=8.51,
1.37 Hz), 8.07 (1
H, d, J=8.51 Hz), 8.13 (1 H, s), 8.18 (1 H, s), 8.39 (1 H, s), 8.43 (1 H, d,
J=1.92 Hz), 8.64 (1 H, s),
8.65 (1 H, s), 9.12 (1 H, s), 9.15 (1 H, s), 10.59 (1 H, s); ESIMS found for
C2,-115N502 m/z 370.1
(M+1).
N/\
o
119
146
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0704] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)benzo
[b]thiophene -5 -
carboxamide 119.
[0705] Yellow solid (20.0 mg, 0.052 mmol, 14.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.92(3 H, s), 7.61(1 H, d, J=5.49 Hz), 7.80(1 H, dd, J=8.51,
1.65 Hz), 7.90(1
H, d, J=5.49 Hz), 8.02 - 8.09 (2 H, m), 8.12 (1 H, s), 8.13 - 8.19 (2 H, m),
8.39 (1 H, s), 8.63 (1 H,
s), 8.66(1 H, d, J=1.10 Hz), 9.13 (1 H, s), 10.89 (1 H, s); ESIMS found for
C22H16N40S m/z 385.1
(M+1).
0
Hi\ \
o
120
[0706] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)benzofuran-6-
carboxamide
120.
[0707] Light yellow solid (6.9 mg, 0.019 mmol, 6.0% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.92 (3 H, s), 7.08 (1 H, dd, J=2.20, 0.82 Hz), 7.80 (1 H, d,
J=8.23 Hz), 7.80 (1
H, dd, J=8.51, 1.65 Hz), 8.01 (1 H, dd, J=8.10, 1.51 Hz), 8.06 (1 H, d, J=8.78
Hz), 8.12 (1 H, s),
8.14 (1 H, s), 8.19 (1 H, d, J=2.20 Hz), 8.39 (1 H, s), 8.39 (1 H, s), 8.62 (1
H, s), 9.13 (1 H, s),
10.88 (1 H, s); ESIMS found for C22H16N402 m/z 369.1 (M+1).
\N
QOI
1411\
0
0
122
[0708] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)benzo [d]
oxazole -6-
carboxamide 122.
[0709] Yellow solid (33.4 mg, 0.090 mmol, 20.3% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.91(3 H, s), 7.81(1 H, dd, J=8.51, 1.65 Hz), 7.94(1 H, d,
J=8.51 Hz), 8.07(1
H, d, J=8.51 Hz), 8.12 (1 H, s), 8.13 - 8.17 (2 H, m), 8.38 (1 H, s), 8.54 (1
H, d, J=1.10 Hz), 8.63
(1 H, s), 8.93 (1 H, s), 9.13 (1 H, s), 11.00 (1 H, s); ESIMS found for C2J-
115N502m/z 370.1 (M+1).
\N
\ 011 NS
N o
123
147
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0710] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)benzo[d]thiazo1e-
6-
carboxamide 123.
107111 Yellow solid (35.0 mg, 0.091 mmol, 20.4% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 3.92(3 H, s), 7.81(1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d,
J=8.51 Hz), 8.12(1
H, s), 8.16 (1 H, s), 8.18 - 8.25 (2 H, m), 8.38 (1 H, s), 8.64 (1 H, s), 8.91
- 8.96 (1 H, m), 9.13 (1
H, s), 9.58 (1 H, s), 10.98 (1 H, s); ESIMS found for C211-115N50S m/z 386.1
(M+1).
\N
\ so 0?
N 0
126
[0712] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)benzo [d]
oxazole -5 -
carboxamide 126.
[0713] Yellow solid (52.7 mg, 0.143 mmol, 32.0% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 3.92 (3 H, s), 7.81 (1 H, dd, J=8.51, 1.37 Hz), 7.92 (1 H, d,
J=8.51 Hz), 8.07 (1
H, d, J=8.78 Hz), 8.12 (1 H, s), 8.15 (1 H, s), 8.18 (1 H, dd, J=8.51, 1.65
Hz), 8.38 (1 H, s), 8.57
(1 H, d, J=1.65 Hz), 8.62 (1 H, s), 8.88 (1 H, s), 9.13 (1 H, s), 10.99 (1 H,
s); ESIMS found for
C211-115N502m/z 370.1 (M+1).
\N S
\
Aki 0
127
[0714] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)benzo[d]thiazole-
5-
carboxamide 127.
[0715] Yellow solid (41.7 mg, 0.108 mmol, 24.3% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 3.92(3 H, s), 7.81(1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d,
J=8.51 Hz), 8.12(1
H, d, J=0.82 Hz), 8.14 - 8.16 (1 H, m), 8.18 (1 H, dd, J=8.51, 1.65 Hz), 8.33
(1 H, d, J=8.51 Hz),
8.39 (1 H, s), 8.64 (1 H, s), 8.82 (1 H, d, J=1.37 Hz), 9.14 (1 H, s), 9.52 (1
H, s), 11.06 (1 H, s);
ESIMS found for C211-115N50S m/z 386.1 (M+1).
\
N
130
[0716] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)quinoline-3 -
carboxamide
130.
148
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0717] Beige solid (55.0 mg, 0.145 mmol, 32.5% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.92 (3 H, s), 7.70 - 7.78 (1 H, m), 7.82 (1 H, dd, J=8.51, 1.65
Hz), 7.91 (1 H, ddd,
J=8.30, 6.93, 1.23 Hz), 8.08 (1 H, d, J=8.51 Hz), 8.10 - 8.14 (2 H, m), 8.15
(1 H, d, J=7.96 Hz),
8.17 (1 H, s), 8.40 (1 H, s), 8.66 (1 H, s), 9.11 (1 H, d, J=2.20 Hz), 9.15 (1
H, s), 9.43 (1 H, d,
J=2.20 Hz), 11.26(1 H, s); ESIMS found for C23I-117N50 m/z 380.2 (M+1).
N'\
131
[0718] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)quinoline-6-
carboxamide
131.
[0719] Beige solid (57.0 mg, 0.150 mmol, 33.7% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.92 (3 H, s), 7.65 (1 H, dd, J=8.23, 4.12 Hz), 7.82 (1 H, dd,
J=8.51, 1.65 Hz), 8.08 (1
H, d, J=8.51 Hz), 8.10 - 8.16 (2 H, m), 8.17 (1 H, s), 8.35 (1 H, dd, J=8.78,
2.20 Hz), 8.39 (1 H, s),
8.52 - 8.57 (1 H, m), 8.66 (1 H, s), 8.81 (1 H, d, J=2.20 Hz), 9.03 (1 H, dd,
J=4.25, 1.78 Hz), 9.15
(1 H, s), 11.08 (1 H, s); ESIMS found for C23I-117N50 m/z 380.1 (M+1).
N
\N
Hi\
o
132
[0720] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)i
soquinoline -6-
carboxamide 132.
[0721] Beige solid (10.0 mg, 0.026 mmol, 5.9% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 3.92 (3 H, s), 7.82 (1 H, dd, J=8.51, 1.65 Hz), 7.99 (1 H, d, J=5.76
Hz), 8.08 (1 H, d,
J=8.51 Hz), 8.13 (1 H, s), 8.17 (1 H, s), 8.21 - 8.30 (2 H, m), 8.39 (1 H, s),
8.62 (1 H, d, J=5.76
Hz), 8.65 (1 H, s), 8.74 (1 H, s), 9.15 (1 H, s), 9.44 (1 H, s), 11.15 (1 H,
s); ESIMS found for
C231117N50 m/z 380.1 (M+1).
\N N41
NI\ \
133
[0722] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -yl)quinoxaline
-6-
carboxamide 133.
149
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0723] Beige solid (29.0 mg, 0.076 mmol, 17.1% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.92 (3 H, s), 7.83 (1 H, dd, J=8.51, 1.65 Hz), 8.08 (1 H, d, J=8.51
Hz), 8.13 (1 H, s),
8.17 (1 H, s), 8.23 (1 H, d, J=8.78 Hz), 8.39 (1 H, s), 8.44 (1 H, dd, J=8.78,
1.92 Hz), 8.66 (1 H,
s), 8.84(1 H, d, J=1.92 Hz), 9.06 (1 H, d, J=1.65 Hz), 9.08 (1 H, d, J=1.65
Hz), 9.15 (1 H, s), 11.31
(1 H, s); ESIMS found for C22H16N60 m/z 381.1 (M+1).
Ni\
A4 0
134
[0724] N-(7-Fluoro-6-(1-methy1-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2 -
(4-
methylpiperazin-1 -yl)isonicotinamide 134.
[0725] Off-white solid (36.0 mg, 0.081 mmol, 26.0% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.42 (4 H, t, J=4.94 Hz), 3.55 - 3.65 (4 H, m),
3.94 (3 H, s), 7.15
(1 H, dd, J=5.08, 1.23 Hz), 7.46 (1 H, s), 7.97 (1 H, d, J=11.80 Hz), 8.14 (1
H, s), 8.26 (1 H, d,
J=4.94 Hz), 8.33 (1 H, d, J=2.74 Hz), 8.37(1 H, d, J=7.41 Hz), 8.65 (1 H, s),
9.14(1 H, s), 11.08
(1 H, s); ESIMS found for C24H24FN70 m/z 446.2 (M+1).
\N
LJ.
NI\
N I
1*1 0 LN
135
[0726] N-(8-Fluoro-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 135.
[0727] Off-white solid (65.0 mg, 0.146 mmol, 64.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.42 (4 H, br t, J=4.80 Hz), 3.56 - 3.64 (4 H,
m), 3.91 (3 H, s), 7.09
- 7.20 (1 H, m), 7.46 (1 H, s), 7.66 (1 H, d, J=12.08 Hz), 8.02 (1 H, s), 8.15
(1 H, s), 8.26 (1 H, d,
J=5.21 Hz), 8.42(1 H, s), 8.65(1 H, s), 9.24(1 H, s), 11.19(1 H, s); ESIMS
found for C24H24FN70
m/z 446.2 (M+1).
N
Hi\
0
136
[0728] N-(5 -Chloro-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3 -y1)-2-(4-
methylpiperazin-1 -yl)isonicotinamide 136.
150
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0729] White solid (20.0 mg, 0.043 mmol, 41.3% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.26 (3 H, s), 2.47 (4 H, br s), 3.62 (4 H, br s), 3.96 (3 H, s),
7.19 (1 H, dd, J=5.08, 0.96
Hz), 7.49 (1 H, s), 7.84 (1 H, d, J=8.51 Hz), 8.08 - 8.12 (2 H, m), 8.27 (1 H,
d, J=5.21 Hz), 8.48 (1
H, s), 9.05(1 H, s), 9.24(1 H, s), 11.24 (1 H, s); ESIMS found for C24H24C1N70
m/z 462.2 (M+1).
Ni\
N1r)N
A4 0 LN
137
[0730] N-(7-Chloro-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 137.
[0731] White solid (18.0 mg, 0.039 mmol, 37.2% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.27 (3 H, s), 2.47 (4 H, br s), 3.61 (4 H, br s), 3.94 (3 H, s),
7.15 (1 H, dd, J=5.21, 1.10
Hz), 7.46 (1 H, s), 8.01 (1 H, d, J=0.82 Hz), 8.20 (1 H, s), 8.26 (1 H, d,
J=5.49 Hz), 8.32 (1 H, s),
8.34 (1 H, s), 8.64 (1 H, s), 9.18 (1 H, s), 11.13 (1 H, s); ESIMS found for
C24H24C1N70 m/z 462.2
(M+1).
\N
cI:
Ni\
N I
NH2
138
[0732] N-(1-Amino-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 138.
[0733] Tan solid (4.8 mg, 0.011 mmol, 7.4% yield). 1HNMR (499 MHz, DMSO-
d6)
6 ppm 2.24 (3 H, s), 2.39 - 2.46 (4 H, m), 3.53 - 3.62 (4 H, m), 3.89 (3 H,
s), 6.89 (1 H, s), 7.07 (1
H, dd, J=5.08, 1.24 Hz), 7.26 (1 H, s), 7.60 (1 H, dd, J=8.23, 1.65 Hz), 7.81
(1 H, d, J=1.65 Hz),
8.03 (1 H, s), 8.08 (1 H, d, J=8.51 Hz), 8.28 - 8.33 (2 H, m), 10.39 (1 H, br
s), 11.08 (1 H, br s);
ESIMS found for C24H26N80 m/z 444.2 (M+2).
\N
141i\
N I
141
139
[0734] N-(7-Methy1-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 139.
[0735] Beige solid (28.0 mg, 0.063 mmol, 63.7% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, br t, J=4.94 Hz), 2.67 (3 H, s), 3.57 -
3.64 (4 H, m), 3.94 (3 H,
151
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
s), 7.18 (1 H, dd, J=5.08, 1.23 Hz), 7.48 (1 H, s), 7.58 (1 H, d, J=8.51 Hz),
7.79 (1 H, d, J=0.82
Hz), 7.95 (1 H, d, J=8.78 Hz), 8.10 (1 H, s), 8.26 (1 H, d, J=5.76 Hz), 8.85
(1 H, s), 9.16 (1 H, s),
11.10 (1 H, s); ESIMS found for C25H27N70 m/z 442.2 (M+1).
\N
Ni\
0
140
[0736] N-(5-Methy1-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 140.
[0737] White solid (20.0 mg, 0.045 mmol, 54.6% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, br t, J=4.94 Hz), 2.67 (3 H, s), 3.58 -
3.63 (4 H, m), 3.94 (3 H,
s), 7.18 (1 H, dd, J=5.21, 1.10 Hz), 7.48 (1 H, s), 7.58 (1 H, d, J=8.51 Hz),
7.79 (1 H, s), 7.95 (1
H, d, J=8.51 Hz), 8.10(1 H, s), 8.26(1 H, d, J=5.21 Hz), 8.85(1 H, s), 9.16(1
H, s), 11.10(1 H,
s); ESIMS found for C25H27N70 m/z 442.2 (M+1).
\N
Ni\
N I
A4I 0
141
[0738] N-(4-Methy1-6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 141.
[0739] Off-white solid (16.5 mg, 0.037 mmol, 12.4% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.40 -2.45 (4 H, m), 2.51 (3 H, br s), 3.55 -
3.63 (4 H, m), 3.92 (3
H, s), 7.16(1 H, dd, J=5.08, 0.96 Hz), 7.40(1 H, s), 7.92(1 H, dd, J=8.51,
1.65 Hz), 8.12(1 H, d,
J=8.23 Hz), 8.16(1 H, s), 8.23(1 H, s), 8.28(1 H, d, J=4.94 Hz), 8.46(1 H, s),
9.04(1 H, s), 10.73
(1 H, s); ESIMS found for C25H27N70 m/z 442.2 (M+1).
\N
NI\
141 0
142
[0740] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-(methyl-
d3)
piperazin-l-yl)isonicotinamide 142.
[0741] Beige solid (38.0 mg, 0.088 mmol, 94.7% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.45 (4 H, br s), 3.61 (4 H, br s), 3.91 (3 H, s), 7.16 (1 H, dd,
J=5.21, 1.10 Hz), 7.46 (1
H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d, J=8.51 Hz), 8.11(1 H, s),
8.14(1 H, s), 8.26
152
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(1 H, d, J=5.21 Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 11.04 (1 H,
s); ESIMS found for
C24H22 [2H31N70 M/Z 431.2 (M+1).
D-?-\ (ND
Nix \
N I
0
143
[0742] N-(6-(1-(Methyl-d3)-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 143.
[0743] Beige solid (27.0 mg, 0.063 mmol, 38.2% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.58 - 3.63 (4 H, m), 7.16
(1 H, dd, J=5.21, 1.10
Hz), 7.46(1 H, s), 7.81(1 H, dd, J=8.51, 1.65 Hz), 8.07(1 H, d, J=8.51 Hz),
8.11(1 H, s), 8.14(1
H, s), 8.26 (1 H, d, J=5.21 Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s),
11.04 (1 H, s); ESIMS
found for C24H2212H311\170 m/z 431.2 (M+1).
14141\
A4 0 D
144
[0744] N-(6-(1-(Methyl-d3)-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
(methyl-d3)
piperazin-l-yl)isonicotinamide 144.
[0745] Beige solid (30.0 mg, 0.069 mmol, 70.7% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.42 (4 H, br t, J=4.80 Hz), 3.56 -3.64 (4 H, m), 7.15 (1 H, dd,
J=5.21, 0.82 Hz), 7.46
(1 H, s), 7.81 (1 H, dd, J=8.51, 1.37 Hz), 8.07(1 H, d, J=8.51 Hz), 8.11 (1 H,
s), 8.14(1 H, s), 8.26
(1 H, d, J=5.21 Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 11.04 (1 H,
s); ESIMS found for
C24F11912H611\170 m/z 434.2 (M+1).
HN
NJftJ
0
145
[0746] N-(6-(1H-Pyrazol-4-ypisoquinolin-3-y1)-2-(4-(methyl-d3)piperazin-
1-y1)
isonicotinamide 145.
[0747] White solid (80.0 mg, 0.173 mmol, 37.1% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.39 -2.46 (4 H, m), 3.57 - 3.65 (4 H, m), 7.16 (1 H, dd, J=5.08,
1.24 Hz), 7.46 (1 H, s),
153
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
7.88 (1 H, dd, J=8.51, 1.65 Hz), 8.07 (1 H, d, J=8.51 Hz), 8.19 (2 H, br s),
8.26 (1 H, d, J=4.94
Hz), 8.46 (1 H, br s), 8.60 (1 H, s), 9.13 (1 H, s), 11.04 (1 H, s), 13.12 (1
H, br s); ESIMS found
for C23H2012H311\170 m/z 417.2 (M+1).
Ni\
N1HN
0
146
[0748] N-(6-(1-(Difluoromethyl)-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 146.
[0749] Beige solid (60.0 mg, 0.130 mmol, 78.8% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.58 - 3.64 (4 H, m), 7.16
(1 H, dd, J=5.21, 1.10
Hz), 7.47(1 H, s), 7.89(1 H, t, J=59.40 Hz), 7.94(1 H, dd, J=8.51, 1.65 Hz),
8.14(1 H, d, J=8.51
Hz), 8.26 (1 H, d, J=5.21 Hz), 8.34 (1 H, s), 8.52 (1 H, s), 8.65 (1 H, s),
8.97 (1 H, s), 9.18 (1 H,
s), 11.09 (1 H, s); ESIMS found for C24H23F2N70 m/z 464.2 (M+1).
Ni\
0
147
[0750] N-(6-(1-Ethy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)
isonicotinamide 147.
[0751] Off-white solid (25.0 mg, 0.057 mmol, 34.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.44 (3 H, t, J=7.27 Hz), 2.23 (3 H, s), 2.43 (4 H, t, J=5.08
Hz), 3.57 - 3.64 (4
H, m), 4.20 (2 H, q, J=7.41 Hz), 7.16 (1 H, dd, J=5.21, 1.37 Hz), 7.46 (1 H,
s), 7.83 (1 H, dd,
J=8.51, 1.65 Hz), 8.07 (1 H, d, J=8.78 Hz), 8.12 (1 H, s), 8.15 (1 H, s), 8.26
(1 H, d, J=5.21 Hz),
8.45 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 11.04 (1 H, s); ESIMS found for
C25H27N70 m/z 442.2
(M+1).
148
[0752] N-(6-(1-Methy1-1H-pyrazol-3-y1)isoquinolin-3-y1)-2-(4-
methylpiperazin-1-
y1)isonicotinamide 148.
[0753] Beige solid (53.0 mg, 0.124 mmol, 75.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.58 - 3.64 (4 H, m), 3.94
(3 H, s), 6.97 (1 H, d,
154
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
J=2.47 Hz), 7.16 (1 H, dd, J=4.94, 1.10 Hz), 7.47 (1 H, s), 7.82 (1 H, d,
J=2.20 Hz), 8.02 - 8.08 (1
H, m), 8.08 - 8.13 (1 H, m), 8.26 (1 H, d, J=4.94 Hz), 8.31 (1 H, s), 8.64 (1
H, s), 9.17 (1 H, s),
11.06 (1 H, s); ESIMS found for C24H25N70 m/z 428.2 (M+1).
\N NH2
Ni\
N)HN
A4I 0 LN
149
[0754] N-(6-(5-Amino-l-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 149.
[0755] Off-white solid (15.0 mg, 0.034 mmol, 12.0% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.40 -2.46 (4 H, m), 3.57 - 3.62 (4 H, m), 3.64
(3 H, s), 5.72 (2 H,
s), 7.15 (1 H, d, J=4.12 Hz), 7.46 (1 H, s), 7.67 (1 H, s), 7.72 (1 H, dd,
J=8.64, 1.51 Hz), 7.93 (1
H, s), 7.99 (1 H, d, J=8.51 Hz), 8.26 (1 H, d, J=5.21 Hz), 8.59 (1 H, s), 9.06
(1 H, s), 10.92 (1 H,
s); ESIMS found for C24H261\180 m/z 443.0 (M+1).
HO
\N 0 F
Ni\
411
\
;
151
[0756] 4-(Difluoromethoxy)-N-(6-(5 -(hydroxymethyl) -1 -methyl-1H-
pyrazol-4-y1)
isoquinolin-3-yl)benzamide 151.
[0757] White solid (11.2 mg, 0.026 mmol, 5.1% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 3.94 (3 H, s), 4.66 (2 H, d, J=5.49 Hz), 5.58 (1 H, t, J=5.49 Hz),
7.40 (1 H, t, J=74.00
Hz), 7.31 (2H, d, J=8.78 Hz), 7.73(1 H, dd, J=8.37, 1.51 Hz), 7.84(1 H, s),
8.03(1 H, s), 8.11(1
H, d, J=8.51 Hz), 8.14 - 8.20 (2 H, m), 8.63 (1 H, s), 9.18 (1 H, s), 10.92 (1
H, s); ESIMS found
for C22H18F2N403 m/z 424.9 (M+1).
HO
GCflO
\N
NI\
N I
168
[0758] N-(6-(5-(Hydroxymethyl)-1-methy1-1H-pyrazol-4-ypisoquinolin-3-
y1)-2-(4-
methylpiperazin-l-y1)isonicotinamide 168.
[0759] White solid (73.0 mg, 0.160 mmol, 45.1% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.56 - 3.64 (4 H, m), 3.94
(3 H, s), 4.66 (2 H, d,
J=5.21 Hz), 5.58 (1 H, t, J=5.35 Hz), 7.16 (1 H, dd, J=5.21, 1.10 Hz), 7.47 (1
H, s), 7.75 (1 H, dd,
155
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
J=8.51, 1.65 Hz), 7.84 (1 H, s), 8.03 (1 H, s), 8.12 (1 H, d, J=8.51 Hz), 8.26
(1 H, d, J=5.21 Hz),
8.64 (1 H, s), 9.19 (1 H, s), 11.08 (1 H, s); ESIMS found for C25H27N702 m/z
458.2 (M+1).
HO
141/
N
172
[0760] N-(6-(5 -(Hydroxymethyl) -1-methyl-1H-pyrazol-4-ypi soquinolin-
3 -y1)-2-(7-
methy1-2,7-diazaspiro [3 .51nonan-2-yl)i sonicotinamide 172.
[0761] Off-white solid (6.0 mg, 0.012 mmol, 24.7% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.76 (4 H, br t, J=5.08 Hz), 2.15 (3 H, s), 2.28 (4 H, br s),
3.74 (4 H, s), 3.94 (3
H, s), 4.66 (2 H, br d, J=3.84 Hz), 5.54 - 5.62 (1 H, m), 7.03 (1 H, s), 7.13
(1 H, dd, J=5.21, 1.37
Hz), 7.74(1 H, dd, J=8.51, 1.65 Hz), 7.84(1 H, s), 8.03(1 H, s), 8.12(1 H, d,
J=8.51 Hz), 8.20(1
H, d, J=5.21 Hz), 8.62 (1 H, s), 9.18 (1 H, s), 11.00 (1 H, s); ESIMS found
for C28H3IN702 m/z
498.3 (M+1).
\N F
\
A4I ;
182
[0762] 4-Fluoro-N-(6-(1-methy1-5-(pyrrolidin-1-ylmethyl)-1H-pyrazol-4-
y1)
isoquinolin-3-yl)benzamide 182.
[0763] White solid (15.0 mg, 0.033 mmol, 22.6% yield). 1H NMR (500
MHz, DMSO-
d6) 6 ppm 1.68 (4 H, br t, J=3.02 Hz), 2.43 -2.48 (4 H, m), 3.85 (2 H, s),
3.93 (3 H, s), 7.36 (2 H,
t, J=8.78 Hz), 7.74 (1 H, dd, J=8.51, 1.65 Hz), 7.81 (1 H, s), 8.05 (1 H, s),
8.09 (1 H, d, J=8.51
Hz), 8.13 - 8.21 (2 H, m), 8.59 (1 H, s), 9.16 (1 H, s), 10.90 (1 H, s); ESIMS
found for C25H24FN50
m/z 430.0 (M+1).
F
\
N 0
183
[0764] 4-Fluoro-N-(6-(1-methy1-5-(piperidin-1-ylmethyl)-1H-pyrazol-4-
y1)
isoquinolin-3-yl)benzamide 183.
156
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0765] Beige foam (43.0 mg, 0.092 mmol, 34.5% yield). 'FINMR (499 MHz,
DMSO-
d6) 6 ppm 1.33 - 1.42 (2 H, m), 1.46 - 1.55 (4 H, m), 2.37 (4 H, br s), 3.67
(2 H, s), 3.92 (3 H, s),
7.35 (2 H, t, J=8.92 Hz), 7.74 (1 H, dd, J=8.51, 1.37 Hz), 7.82 (1 H, s), 8.08
(1 H, d, J=8.51 Hz),
8.13 (1 H, s), 8.14 - 8.21 (2 H, m), 8.60 (1 H, s), 9.16 (1 H, s), 10.85 (1 H,
s); ESIMS found for
C26H26FN50 m/z 444.0 (M+1).
F
\N
11411
N 0
184
[0766] 4-(Difluoromethoxy)-N-(6-(1-methy1-5-(piperidin-1-ylmethyl)-1H-
pyrazol-
4-ypisoquinolin-3-y1)benzamide 184.
[0767] White solid (13.4 mg, 0.026 mmol, 5.0% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.34 - 1.43 (2 H, m), 1.46 - 1.55 (4 H, m), 2.38 (4 H, br s), 3.67
(2 H, s), 3.92 (3 H, s),
7.40 (2 H, t, J=73.70 Hz), 7.31 (2 H, d, J=8.51 Hz), 7.75 (1 H, dd, J=8.51,
1.37 Hz), 7.83 (1 H, s),
8.09 (1 H, d, J=8.51 Hz), 8.14 (1 H, s), 8.15 - 8.20 (2 H, m), 8.61 (1 H, s),
9.16 (1 H, s), 10.90 (1
H, s); ESIMS found for C27H27F2N502 m/z 491.9 (M+1).
\N
\
N
185
[0768] N-(6-(1-Methy1-5-(piperidin-1-ylmethyl)-1H-pyrazol-4-
ypisoquinolin-3-y1)-
3-(pyrrolidin-1-ylmethyl)benzamide 185.
[0769] White solid (35.0 mg, 0.065 mmol, 9.6% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.34 - 1.44 (2 H, m), 1.47 - 1.55 (4 H, m), 1.71 (4 H, dt, J=6.66,
3.12 Hz), 2.38 (4 H, br
s), 2.44 - 2.49 (4 H, m), 3.66 (2 H, s), 3.67 (2 H, s), 3.92 (3 H, s), 7.41 -
7.50 (1 H, m), 7.50 - 7.58
(1 H, m), 7.75 (1 H, dd, J=8.51, 1.65 Hz), 7.83 (1 H, s), 7.95 (1 H, d, J=7.68
Hz), 8.00 (1 H, s),
8.08 (1 H, d, J=8.78 Hz), 8.14 (1 H, s), 8.60 (1 H, s), 9.16 (1 H, s), 10.82
(1 H, s); ESIMS found
for C311-136N60 m/z 509.3 (M+1).
157
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
N/\
0
186
[0770] N-(6-(1-
Methy1-5-(piperidin-1-ylmethyl)-1H-pyrazol-4-ypisoquinolin-3-y1)-
2-(7-methyl-2,7-diazaspiro[3.51nonan-2-ypisonicotinamide 186.
[0771] Off-
white solid (8.0 mg, 0.014 mmol, 23.2% yield). 11-1 NMR (499 MHz,
DMSO-d6) 6 ppm 1.39 (2 H, br d, J=4.39 Hz), 1.46 - 1.53 (4 H, m), 1.76 (4 H,
br t, J=5.08 Hz),
2.15(3 H, s), 2.19 - 2.33 (4 H, m), 2.38(4 H, br s), 3.67(2 H, s), 3.74(4 H,
s), 3.92(3 H, s), 7.03
(1 H, s), 7.13(1 H, dd, J=5.21, 1.37 Hz), 7.77(1 H, dd, J=8.51, 1.37 Hz),
7.83(1 H, s), 8.09(1 H,
d, J=8.51 Hz), 8.15(1 H, s), 8.20(1 H, d, J=5.21 Hz), 8.60(1 H, s), 9.17(1 H,
s), 10.98(1 H, s);
ESIMS found for C33H401\180 m/z 565.4 (M+1).
\N
Id\ \
N46,
204
[0772] N-(6-(1-
Methy1-5-(morpholinomethyl)-1H-pyrazol-4-ypisoquinolin-3-y1)-2-
morpholinoisonicotinamide 204.
[0773] Off-
white solid (10.0 mg, 0.020 mmol, 10.8% yield). 11-1 NMR (499 MHz,
DMSO-d6) 6 ppm 2.42 (4 H, br d, J=3.84 Hz), 3.53 - 3.61 (8 H, m), 3.70 - 3.78
(6 H, m), 3.94 (3
H, s), 7.21 (1 H, dd, J=5.21, 1.37 Hz), 7.47 (1 H, s), 7.76 (1 H, dd, J=8.51,
1.65 Hz), 7.83 (1 H, s),
8.11 (2 H, d, J=11.25 Hz), 8.29 (1 H, d, J=4.94 Hz), 8.62 (1 H, s), 9.18 (1 H,
s), 11.02 (1 H, s);
ESIMS found for C28H311\1703 m/z 514.0 (M+1).
F
1.11\
141 o
219
[0774] 4-
Fluoro-N-(6-(4,5,6,7-tetrahydropyrazolo [1,5 -alpyrazin-3 -yl)i soquinolin-3 -
yl)benzamide 219.
[0775] Off-
white solid (20.0 mg, 0.052 mmol, 22.3% yield). 11-1 NMR (499 MHz,
DMSO-d6) 6 ppm 3.18 (2 H, br t, J=5.21 Hz), 4.07 (2 H, br t, J=5.21 Hz), 4.25
(2 H, s), 7.33 - 7.41
158
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(2 H, m), 7.68 (1 H, dd, J=8.51, 1.37 Hz), 7.86 (1 H, s), 8.00 (1 H, s), 8.07
(1 H, d, J=8.51 Hz),
8.12 - 8.21 (2 H, m), 8.61 (1 H, s), 9.13 (1 H, s), 10.86(1 H, s); ESIMS found
for C22HBFN50 m/z
387.9 (M+1).
1.1'\ 111
220
[0776] N-(6-(5 -(2-Fluoroethyl)-4,5,6,7-tetrahydropyrazolo [1,5 -a]
pyrazin-3 -y1)
isoquinolin-3-y1)-3-(4-methylpiperazin-1-yl)benzamide 220.
[0777] Yellow solid (2.0 mg, 0.004 mmol, 2.1% yield). NMR
(499 MHz,
METHANOL-d4) 6 ppm 2.37 (3 H, s), 2.65 - 2.69 (4 H, m), 3.00 - 3.05 (1 H, m),
3.14 (4 H, dt,
J=57.10, 5.50 Hz), 3.33 - 3.36 (4 H, m), 3.70 - 3.77 (1 H, m), 4.15 (2 H, s),
4.28 (2 H, t, J=5.49
Hz), 4.62 -4.76 (2 H, m), 6.70 (1 H, br d, J=6.31 Hz), 7.23 (1 H, dd, J=7.96,
2.20 Hz), 7.39 -7.46
(1 H, m), 7.46 - 7.52 (1 H, m), 7.60 (1 H, d, J=1.65 Hz), 7.67 (1 H, dd,
J=8.51, 1.65 Hz), 7.81 (1
H, s), 7.95 (1 H, s), 8.59 (1 H, s), 9.05 (1 H, s); ESIMS found for C29H32FN70
m/z 514.3 (M+1).
0
141\ H
221
[0778] N5-(6-(5 -(2 -Fluoroethyl)-4,5,6,7-tetrahydropyrazolo [1,5 -
alpyrazin-3 -y1)
isoquinolin-3-y1)-N2-methylpyridine-2,5-dicarboxamide 221.
[0779] White solid (66.0 mg, 0.139 mmol, 62.9% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.85 (3 H, br d, J=4.39 Hz), 2.94 -3.04 (2 H, m), 3.08 (2 H, br s),
4.10 (2 H, s), 4.19 (2
H, br s), 4.59 -4.75 (2 H, m), 7.71 (1 H, br d, J=8.51 Hz), 7.87 (1 H, s),
8.04 (1 H, s), 8.10 (1 H, br
d, J=8.51 Hz), 8.16 (1 H, br d, J=7.96 Hz), 8.56 (1 H, br d, J=7.68 Hz), 8.66
(1 H, s), 8.94 (1 H, br
d, J=4.67 Hz), 9.16 (1 H, s), 9.22 (1 H, s), 11.31(1 H, s); ESIMS found for
C25H24FN702m/z 474.2
(M+1).
Ni\
222
159
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0780] N-(6-(5 -(2-Fluoroethyl)-4,5,6,7-tetrahydropyrazolo [1,5 -a]
pyrazin-3 -y1)
isoquinolin-3-y1)-6-(4-methylpiperazin-1-yl)nicotinamide 222.
[0781] Yellow solid (21.0 mg, 0.041 mmol, 11.6% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.38 - 2.43 (4 H, m), 3.00 (3 H, dt, J=28.60,
4.70 Hz), 3.09 (2 H,
br t, J=5.35 Hz), 3.61 - 3.70 (4 H, m), 4.10(2 H, s), 4.19(2 H, br t, J=5.35
Hz), 4.67(2 H, dt,
J=47.80, 5.00 Hz), 6.90 (1 H, d, J=9.06 Hz), 7.66 (1 H, dd, J=8.64, 1.51 Hz),
7.81 (1 H, s), 8.01 (1
H, s), 8.07 (1 H, d, J=8.51 Hz), 8.20 (1 H, dd, J=9.06, 2.47 Hz), 8.60 (1 H,
s), 8.85 (1 H, d, J=2.47
Hz), 9.12 (1 H, s), 10.58 (1 H, s); ESIMS found for C28H3IFN80 m/z 515.0
(M+1).
C--N
u efINH
141/\
o
223
[0782] 2-(Azetidin-3-yloxy)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-
tetrahydropyrazolo[1,5-
alpyrazin-3 -yl)i soquinolin-3 -yl)i sonicotinamide 223.
[0783] Beige solid (5.0 mg, 0.010 mmol, 10.0% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.99 (2 H, dt, J=28.60, 5.00 Hz), 3.08 (2 H, br t, J=5.35 Hz), 3.71
(2 H, br d, J=4.67 Hz),
3.96 (2 H, br s), 4.10 (2 H, s), 4.19 (2 H, br t, J=5.35 Hz), 4.67 (2 H, dt,
J=47.80, 4.70 Hz), 5.41 (1
H, quin, J=5.90 Hz), 7.43 (1 H, s), 7.59 (1 H, br d, J=4.67 Hz), 7.71 (1 H,
dd, J=8.51, 1.65 Hz),
7.87 (1 H, s), 8.03 (1 H, s), 8.10 (1 H, d, J=8.51 Hz), 8.31 (1 H, d, J=5.21
Hz), 8.63 (1 H, s), 9.16
(1 H, s), 11.12 (1 H, br s); ESIMS found for C26H26FN702 m/z 488.2 (M+1).
\N
'141 0
A4I o
230
[0784] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-3-((1-
methylpiperidin-4-y1)oxy)benzamide 230.
[0785] Off-yellow solid (34.5 mg, 0.074 mmol, 40.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.62 - 1.75 (2 H, m), 1.93 - 2.02 (2 H, m), 2.15 - 2.27 (2 H,
m), 2.20 (3 H, s),
2.58 - 2.67 (2 H, m), 4.15 (3 H, s), 4.47 - 4.59 (1 H, m), 7.17 (1 H, ddd,
J=8.30, 2.40, 1.10 Hz),
7.42(1 H, t, J=8.10 Hz), 7.59 - 7.69 (2 H, m), 8.06(1 H, dd, J=8.51, 1.65 Hz),
8.17(1 H, d, J=8.51
Hz), 8.37 (1 H, s), 8.65 (1 H, s), 8.74 (1 H, s), 9.20 (1 H, s), 10.83 (1 H,
s); ESIMS found for
C25H26N602 m/z 443.0 (M+1).
160
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
NI
N H
'141'
0
232
[0786] N2-methyl-N5-(6-(1-methy1-1H-1,2,3 -triazol-4 -yl)i soquinolin-
3 -yl)pyridine -
2,5-dicarboxamide 232.
[0787] Yellow solid (12.7 mg, 0.033 mmol, 7.4% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.86 (3 H, d, J=4.67 Hz), 4.15 (3 H, s), 8.09 (1 H, dd, J=8.51, 1.65
Hz), 8.17 (2 H, dd,
J=12.21, 8.37 Hz), 8.40(1 H, s), 8.57(1 H, dd, J=8.10, 2.33 Hz), 8.67(1 H, s),
8.75(1 H, s), 8.89
(1 H, q, J=4.48 Hz), 9.22 (2 H, s), 11.31(1 H, s); ESIMS found for C201-
117N702m/z 387.9. (M+1).
\N
'141
233
[0788] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-6-(4-
methylpiperazin-l-y1)nicotinamide 233.
[0789] Yellow solid (42.7 mg, 0.100 mmol, 28.3% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.38 -2.43 (4 H, m), 3.61 - 3.68 (4 H, m), 4.15
(3 H, s), 6.89 (1 H,
d, J=9.06 Hz), 8.04 (1 H, dd, J=8.51, 1.65 Hz), 8.14 (1 H, d, J=8.51 Hz), 8.20
(1 H, dd, J=9.06,
2.47 Hz), 8.34 (1 H, s), 8.63 (1 H, s), 8.73 (1 H, s), 8.85 (1 H, d, J=2.47
Hz), 9.17 (1 H, s), 10.64
(1 H, s); ESIMS found for C23H24N80 m/z 429.0 (M+1).
\N
1411, r.1
'141
0
236
[0790] 2-(3-(Dimethylamino)azetidin-l-y1)-N-(6-(1-methy1-1H-1,2,3-
triazol-4-y1)
isoquinolin-3-yl)isonicotinamide 236.
[0791] Beige solid (30.0 mg, 0.070 mmol, 24.4% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.14 (6 H, s), 3.19 -3.25 (1 H, m), 3.81 (2 H, dd, J=8.37, 5.35 Hz),
4.07 (2 H, t, J=7.68
Hz), 4.15 (3 H, s), 7.04 (1 H, s), 7.16 (1 H, dd, J=5.21, 1.37 Hz), 8.08 (1 H,
dd, J=8.51, 1.37 Hz),
8.17(1 H, d, J=8.51 Hz), 8.20 - 8.26 (1 H, m), 8.38(1 H, s), 8.64(1 H, s),
8.74(1 H, s), 9.20(1 H,
s), 10.99 (1 H, s); ESIMS found for C23H24N80 m/z 429.0 (M+1).
161
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N N
N
µ14
238
[0792] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-(1-
methylpiperidin-4-y1)isonicotinamide 238.
107931 Off-white solid (36.0 mg, 0.084 mmol, 68.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.77 - 1.93 (4 H, m), 2.00 (2 H, td, J=11.53, 2.47 Hz), 2.21 (3
H, s), 2.73 (1 H,
tt, J=11.46, 4.05 Hz), 2.90 (2 H, br d, J=11.25 Hz), 4.15 (3 H, s), 7.77 (1 H,
dd, J=4.94, 1.65 Hz),
7.92 (1 H, s), 8.09 (1 H, dd, J=8.51, 1.65 Hz), 8.18 (1 H, d, J=8.78 Hz), 8.40
(1 H, s), 8.67 (1 H,
s), 8.69(1 H, d, J=5.21 Hz), 8.76 (1 H, s), 9.22(1 H, s), 11.23 (1 H, s);
ESIMS found for C24H25N70
m/z 428.2 (M+1).
µ14)
N
240
[0794] 2-(4-(Dimethylamino)piperidin-1-y1)-N-(6-(1-methy1-1H-1,2,3-
triazol-4-y1)
isoquinolin-3-yl)isonicotinamide 240.
[0795] White solid (18.0 mg, 0.039 mmol, 28.6% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 1.40 (2 H, qd, J=11.98, 3.84 Hz), 1.85 (2 H, br d, J=11.80 Hz), 2.24
(6 H, s), 2.37 -2.46
(1 H, m), 2.81 - 2.92 (2 H, m), 4.15 (3 H, s), 4.44 (2 H, br d, J=13.17 Hz),
7.13 (1 H, dd, J=5.08,
0.96 Hz), 7.46 (1 H, s), 8.07 (1 H, dd, J=8.51, 1.37 Hz), 8.17 (1 H, d, J=8.51
Hz), 8.25 (1 H, d,
J=5.21 Hz), 8.38 (1 H, s), 8.65 (1 H, s), 8.74 (1 H, s), 9.21 (1 H, s), 11.04
(1 H, s); ESIMS found
for C25H281\180 m/z 457.0 (M+1).
241
[0796] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-
morpholinoisonicotinamide 241.
[0797] Off-white solid (70.0 mg, 0.169 mmol, 53.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.52 - 3.63 (4 H, m), 3.70 - 3.78 (4 H, m), 4.15 (3 H, s), 7.22
(1 H, dd, J=5.08,
1.23 Hz), 7.47 (1 H, s), 8.08 (1 H, dd, J=8.51, 1.65 Hz), 8.17 (1 H, d, J=8.78
Hz), 8.29 (1 H, d,
162
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
J=4.94 Hz), 8.38 (1 H, s), 8.66(1 H, s), 8.74 (1 H, s), 9.21 (1 H, s), 11.06
(1 H, s); ESIMS found
for C22H21N702 m/z 415.9 (M+1).
N(N,
N
242
[0798] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 242.
[0799] White solid (38.0 mg, 0.089 mmol, 37.8% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, br t, J=4.67 Hz), 3.56 - 3.66 (4 H, m),
4.15 (3 H, s), 7.17(1 H,
d, J=4.94 Hz), 7.47 (1 H, s), 8.04 - 8.10 (1 H, m), 8.18 (1 H, d, J=8.51 Hz),
8.26 (1 H, d, J=4.94
Hz), 8.38 (1 H, s), 8.66 (1 H, s), 8.75 (1 H, s), 9.21 (1 H, s), 11.10 (1 H,
s); ESIMS found for
C23H241\180 m/z 429.0 (M+1).
\N
0
243
[0800] 2-(4-Methy1-1,4-diazepan-1-y1)-N-(6-(1-methyl-1H-1,2,3-triazol-
4-y1)
isoquinolin-3-yl)isonicotinamide 243.
[0801] Beige solid (47.0 mg, 0.106 mmol, 37.0% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.93 (2 H, dt, J=11.39, 5.83 Hz), 2.27 (3 H, s), 2.48 (2 H, br s),
2.63 (2 H, dd, J=5.63,
4.25 Hz), 3.69 (2 H, t, J=6.17 Hz), 3.78 - 3.85 (2 H, m), 4.15 (3 H, s), 7.06
(1 H, dd, J=5.21, 1.10
Hz), 7.21 (1 H, s), 8.08 (1 H, dd, J=8.51, 1.65 Hz), 8.18 (1 H, d, J=8.51 Hz),
8.21 (1 H, d, J=4.94
Hz), 8.38 (1 H, s), 8.65 (1 H, s), 8.76 (1 H, s), 9.21 (1 H, s), 11.08 (1 H,
s); ESIMS found for
C24H261\180 m/z 443.2 (M+1).
\N
0
245
[0802] 2-(4-Isopropylpiperazin-1-y1)-N-(6-(1-methy1-1H-1,2,3-triazol-4-
y1)
isoquinolin-3-yl)isonicotinamide 245.
[0803] Beige solid (198.0 mg, 0.434 mmol, 36.8% yield). 11-1 NMR (500
MHz,
DMSO-d6) 6 ppm 1.01 (6 H, d, J=6.59 Hz), 2.53 - 2.59 (4 H, m), 2.65 -2.75 (1
H, m), 3.53 - 3.63
(4 H, m), 4.15 (3 H, s), 7.16 (1 H, dd, J=5.21, 1.37 Hz), 7.45 (1 H, s), 8.08
(1 H, dd, J=8.51, 1.37
163
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Hz), 8.18 (1 H, d, J=8.78 Hz), 8.26 (1 H, d, J=5.21 Hz), 8.38 (1 H, s), 8.66
(1 H, s), 8.76 (1 H, s),
9.21(1 H, s), 11.11(1 H, s); ESIMS found for C25H281\180 m/z 457.2 (M+1).
\N
0 1H
µ14µ
N
o
249
[0804] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-
(piperidin-4-
ylamino)isonicotinamide 249.
[0805] White solid (7.0 mg, 0.016 mmol, 57.6% yield). 'H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.33 - 1.46 (2 H, m), 1.93 (2 H, br d, J=10.15 Hz), 2.69 (2 H, br t,
J=10.98 Hz), 3.06 (2
H, br d, J=12.62 Hz), 3.81 - 3.93 (1 H, m), 4.15 (3 H, s), 6.78 (1 H, d,
J=7.68 Hz), 7.00 (1 H, s),
7.03 (1 H, dd, J=5.21, 1.37 Hz), 8.07 (1 H, dd, J=8.51, 1.37 Hz), 8.10 (1 H,
d, J=5.49 Hz), 8.17 (1
H, d, J=8.51 Hz), 8.39(1 H, s), 8.62(1 H, s), 8.75(1 H, s), 9.20(1 H, s),
10.88(1 H, br s); ESIMS
found for C23H241\180 m/z 429.0 (M+1).
\N
irjraN01
µ1.1µ
Aki 0
250
[0806] 2-(Methyl(1-methylpiperidin-4-yl)amino)-N-(6-(1-methyl-1H-1,2,3-
triazol-
4-ypisoquinolin-3-ypisonicotinamide 250.
[0807] Brown solid (19.0 mg, 0.042 mmol, 14.5% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 1.49 - 1.64 (2 H, m), 1.75 - 1.87 (2 H, m), 2.05 (2 H, br t,
J=10.84 Hz), 2.20 (3
H, s), 2.82 -2.90 (2 H, m), 2.94 (3 H, s), 4.15 (3 H, s), 4.45 -4.56 (1 H, m),
7.08 (1 H, dd, J=5.08,
1.23 Hz), 7.19 (1 H, s), 8.07 (1 H, dd, J=8.37, 1.51 Hz), 8.17 (1 H, d, J=8.51
Hz), 8.23 (1 H, d,
J=5.21 Hz), 8.37 (1 H, s), 8.65 (1 H, s), 8.74 (1 H, s), 9.21 (1 H, s), 11.01
(1 H, s); ESIMS found
for C25H281\180 m/z 457.0 (M+1).
\N
NJQJ1
1:111(s)
o
253
[0808] N-(6-(1 -Methyl-1H-1,2,3 -triazol-4 -yl)i soquinolin-3 -y1)-2-
((1-
methylpiperidin-4-yl)thio)isonicotinamide 253.
[0809] Off-white solid (28.0 mg, 0.061 mmol, 19.4% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.58 - 1.72 (2 H, m), 1.99 -2.07 (2 H, m), 2.12 (2 H, br t,
J=10.29 Hz), 2.17 (3
H, s), 2.69(2 H, br d, J=10.70 Hz), 3.84(1 H, br t, J=9.74 Hz), 4.15(3 H, s),
7.64(1 H, dd, J=5.21,
164
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
1.65 Hz), 7.82 (1 H, s), 8.09 (1 H, dd, J=8.51, 1.65 Hz), 8.18 (1 H, d, J=8.51
Hz), 8.39 (1 H, s),
8.62 (1 H, d, J=5.21 Hz), 8.64 (1 H, s), 8.75 (1 H, s), 9.21 (1 H, s), 11.22(1
H, s); ESIMS found
for C24H25N70S m/z 460.2 (M+1).
µ1.1µ
o
OC
256
[0810] 2-Methyl-N-(6-(1-methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-
1,2,3,4-
tetrahydroisoquinoline-6-carboxamide 256.
[0811] Off-white solid (39.0 mg, 0.093 mmol, 85.9% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.37 (3 H, s), 2.64 (2 H, t, J=5.90 Hz), 2.92 (2 H, br t,
J=5.76 Hz), 3.56 (2 H, s),
4.15 (3 H, s), 7.19 (1 H, d, J=7.96 Hz), 7.83 (1 H, dd, J=7.96, 1.92 Hz), 7.88
(1 H, s), 8.06 (1 H,
dd, J=8.51, 1.65 Hz), 8.16 (1 H, d, J=8.78 Hz), 8.36 (1 H, d, J=0.82 Hz), 8.64
(1 H, s), 8.74 (1 H,
s), 9.18 (1 H, s), 10.69 (1 H, s); ESIMS found for C23H22N60 m/z 399.0 (M+1).
N
257
[0812] N-(7-Fluoro-6-(1-methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-
2-(4-
methylpiperazin-l-y1)isonicotinamide 257.
[0813] Light brown solid (14.0 mg, 0.031 mmol, 17.8% yield). 1HNMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, brt, J=4.94 Hz), 3.57 -3.66 (4 H, m),
4.17 (3 H, s), 7.17
(1 H, dd, J=5.21, 1.10 Hz), 7.47(1 H, s), 8.07(1 H, d, J=11.25 Hz), 8.26(1 H,
d, J=5.49 Hz), 8.60
(1 H, d, J=4.39 Hz), 8.67 (1 H, d, J=6.86 Hz), 8.71 (1 H, s), 9.22(1 H, s),
11.11 (1 H, s); ESIMS
found for C23H23F1\180 m/z 447.2 (M+1).
H
NNJ
NCN
,...-N 0
258
[0814] N-(6-(1H-1,2,4-Triazol-1-yl)isoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)
isonicotinamide 258.
[0815] Beige solid (40.0 mg, 0.097 mmol, 41.1% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.56 - 3.66 (4 H, m), 7.16
(1 H, dd, J=5.21, 1.10
Hz), 7.47(1 H, s), 8.11 (1 H, dd, J=8.78, 1.92 Hz), 8.26(1 H, d, J=5.21 Hz),
8.32(1 H, d, J=9.06
165
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Hz), 8.35 (1 H, s), 8.48 (1 H, d, J=1.92 Hz), 8.73 (1 H, s), 9.29(1 H, s),
9.53 (1 H, s), 11.18 (1 H,
s); ESIMS found for C22H221\180 m/z 415.2 (M+1).
111 el to
Aki ;
261
[0816] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-3-(pyrrolidin-
1-
ylmethyl)benzamide 261.
[0817] White solid (25.0 mg, 0.061 mmol, 27.2% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 1.72 (4 H, dt, J=6.66, 3.12 Hz), 2.48 (4 H, br s), 3.67 (2 H, s),
3.85 (3 H, s), 7.32 (1 H,
d, J=0.82 Hz), 7.41 - 7.51 (1 H, m), 7.54 (1 H, br d, J=7.68 Hz), 7.72 (1 H,
dd, J=8.51, 1.65 Hz),
7.80 (1 H, s), 7.96 (1 H, br d, J=7.96 Hz), 8.01 (1 H, s), 8.08 (1 H, s), 8.14
(1 H, d, J=8.51 Hz),
8.68 (1 H, s), 9.21 (1 H, s), 10.81 (1 H, s); ESIMS found for C25H25N50 m/z
412.0 (M+1).
265
[0818] 2-(Dimethylamino)-N-(6-(1-methy1-1H-imidazol-5 -ypisoquinolin-3
-y1)
isonicotinamide 265.
[0819] White solid (16.0 mg, 0.043 mmol, 14.9% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.11(6 H, s), 3.85(3 H, s), 7.09(1 H, dd, J=5.08, 1.23 Hz), 7.25(1
H, s), 7.33(1 H, d,
J=1.10 Hz), 7.29 - 7.29 (1 H, m), 7.74(1 H, dd, J=8.51, 1.65 Hz), 7.81(1 H,
s), 8.10(1 H, d, J=0.82
Hz), 8.15(1 H, d, J=8.51 Hz), 8.23(1 H, d, J=5.21 Hz), 8.69(1 H, s), 9.22(1 H,
s), 11.07(1 H, s);
ESIMS found for C211-120N60 m/z 373.2 (M+1).
r41
14\_
0 N112
266
[0820] 2-(3-Aminoazetidin-1-y1)-N-(6-(1-methy1-1H-imidazol-5-
y1)isoquinolin-3-
y1)isonicotinamide 266.
[0821] Yellow solid (25.3 mg, 0.063 mmol, 51.0% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.15 (2 H, br s), 3.62(2 H, dd, J=8.23, 5.76 Hz), 3.79 - 3.89
(4 H, m), 4.19(2 H,
t, J=7.68 Hz), 7.02 (1 H, s), 7.14 (1 H, dd, J=5.21, 1.37 Hz), 7.33 (1 H, d,
J=1.10 Hz), 7.74 (1 H,
dd, J=8.51, 1.65 Hz), 7.81 (1 H, s), 8.09 (1 H, s), 8.15 (1 H, d, J=8.51 Hz),
8.20 (1 H, d, J=5.21
Hz), 8.68 (1 H, s), 9.22(1 H, s), 11.04(1 H, br s); ESIMS found for
C22H211\170 m/z 400.2 (M+1).
166
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
NQJfL
NO
N
268
[0822] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-(pyrrolidin-1-
y1)
isonicotinamide 268.
[0823] White solid (69.0 mg, 0.173 mmol, 62.6% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.94 - 2.03 (4 H, m), 3.47 (4 H, br t, J=6.59 Hz), 3.85 (3 H, s),
7.06 (1 H, dd, J=5.21,
1.37 Hz), 7.08 (1 H, s), 7.33 (1 H, s), 7.74 (1 H, dd, J=8.51, 1.65 Hz), 7.81
(1 H, s), 8.09 (1 H, s),
8.15 (1 H, d, J=8.78 Hz), 8.21 (1 H, d, J=5.21 Hz), 8.69 (1 H, s), 9.22 (1 H,
s), 11.04 (1 H, s);
ESIMS found for C23H22N60 m/z 399.2 (M+1).
N I
N 0
271
[0824] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-(piperidin-1-
y1)
isonicotinamide 271.
[0825] White solid (85.0 mg, 0.206 mmol, 74.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.53 - 1.62 (4 H, m), 1.62 - 1.69 (2 H, m), 3.61 -3.66 (4 H, m),
3.85 (3 H, s), 7.09 (1 H,
dd, J=5.21, 1.37 Hz), 7.33 (1 H, s), 7.44 (1 H, s), 7.74 (1 H, dd, J=8.51,
1.65 Hz), 7.81 (1 H, s),
8.09(1 H, s), 8.15(1 H, d, J=8.51 Hz), 8.23(1 H, d, J=5.21 Hz), 8.69(1 H, s),
9.22(1 H, s), 11.09
(1 H, s); ESIMS found for C24H24N60 m/z 413.2 (M+1).
NJfL1
273
[0826] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-
morpholinoisonicotinamide 273.
[0827] White solid (70.0 mg, 0.169 mmol, 61.0% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 3.54 -3.59 (4 H, m), 3.71 - 3.77 (4 H, m), 3.85 (3 H, s), 7.21 (1 H,
dd, J=5.08, 1.23 Hz),
7.33 (1 H, s), 7.48 (1 H, s), 7.74 (1 H, dd, J=8.51, 1.65 Hz), 7.81 (1 H, s),
8.10 (1 H, s), 8.16 (1 H,
d, J=8.51 Hz), 8.29(1 H, d, J=4.94 Hz), 8.70(1 H, s), 9.23 (1 H, s), 11.11 (1
H, s); ESIMS found
for C23H22N602 m/z 415.2 (M+1).
167
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
N I
275
[0828] 2-(4-Isopropylpiperazin-1-y1)-N-(6-(1-methy1-1H-imidazol-5-
y1)isoquinolin-
3-y1)isonicotinamide 275.
[0829] Beige solid (85.0 mg, 0.187 mmol, 64.8% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 1.02 (6 H, d, J=6.59 Hz), 2.53 -2.59 (4 H, m), 2.66 -2.75 (1 H, m),
3.52 -3.63 (4 H, m),
3.85 (3 H, s), 7.15 (1 H, dd, J=5.08, 1.23 Hz), 7.32 (1 H, d, J=1.10 Hz), 7.44
(1 H, s), 7.73 (1 H,
dd, J=8.51, 1.65 Hz), 7.80 (1 H, s), 7.77 - 7.78 (1 H, m), 8.09 (1 H, s), 8.15
(1 H, d, J=8.51 Hz),
8.26(1 H, d, J=5.21 Hz), 8.69(1 H, s), 9.22(1 H, s), 11.04(1 H, s); ESIMS
found for C26H29N70
m/z 456.0 (M+1).
A.1 0
V
276
[0830] 2-(4 -Cyclopropylpipe razin-l-y1)-N-(6-(1-methy1-1H-imidazol-5 -
y1)
isoquinolin-3-yl)isonicotinamide 276.
[0831] White solid (46.0 mg, 0.101 mmol, 73.6% yield). 1H NMR (500
MHz, DMSO-
d6) 6 ppm 0.34 - 0.41 (2 H, m), 0.41 - 0.49 (2 H, m), 1.66 (1 H, tt, J=6.62,
3.53 Hz), 2.62 -2.68 (4
H, m), 3.52 -3.61 (4 H, m), 3.85 (3 H, s), 7.15 (1 H, dd, J=5.08, 1.23 Hz),
7.33 (1 H, d, J=1.10
Hz), 7.47(1 H, s), 7.74(1 H, dd, J=8.51, 1.65 Hz), 7.81(1 H, s), 8.10(1 H, s),
8.15(1 H, d, J=8.78
Hz), 8.26 (1 H, d, J=5.21 Hz), 8.69 (1 H, s), 9.23 (1 H, s), 11.12 (1 H, s);
ESIMS found for
C26H27N70 m/z 454.0 (M+1).
Nftcj
277
[0832] N-(6-(1 -Methyl-1H-imidazol-5 -yl)i soquinolin-3 -y1)-2-(2,7-
diazaspiro [3 .51
nonan-2-yl)isonicotinamide 277.
[0833] Off-white solid (131.6 mg, 0.290 mmol, 31.2% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.62 - 1.71 (4 H, m), 2.66 (4 H, br s), 3.73 (4 H, s), 3.85 (3
H, s), 7.03 (1 H, s),
7.12 (1 H, dd, J=5.21, 1.37 Hz), 7.33 (1 H, s), 7.74 (1 H, dd, J=8.51, 1.65
Hz), 7.81 (1 H, s), 8.10
168
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(1 H, s), 8.15(1 H, d, J=8.51 Hz), 8.20(1 H, d, J=5.21 Hz), 8.68(1 H, s),
9.22(1 H, s), 11.04(1
H, br s); ESIMS found for C26H27N70 m/z 454.2 (M+1).
N
141\.3
0
111
278
[0834] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-(7-methyl-2,7-
diazaspiro[3.51nonan-2-ypisonicotinamide 278.
[0835] Off-white solid (39.0 mg, 0.079 mmol, 35.9% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.76 (4 H, br t, J=5.08 Hz), 2.14 (3 H, s), 2.27 (4 H, br s),
3.73 (4 H, s), 3.85 (3
H, s), 7.03(1 H, s), 7.13(1 H, dd, J=5.08, 1.51 Hz), 7.33(1 H, s), 7.74(1 H,
dd, J=8.51, 1.65 Hz),
7.81 (1 H, s), 8.10 (1 H, s), 8.15 (1 H, d, J=8.51 Hz), 8.20 (1 H, d, J=5.21
Hz), 8.68 (1 H, s), 9.22
(1 H, s), 11.04 (1 H, s); ESIMS found for C27H29N70 m/z 468.2 (M+1).
NQj3NH
141
285
[0836] N-(6-(1-Methy1-1H-imidazol-5-ypisoquinolin-3-ypisoindoline-5-
carboxamide 285.
[0837] Off-white solid (233.7 mg, 0.633 mmol, 68.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.85 (4 H, s), 4.07 (1 H, s), 4.27 (3 H, s), 7.33 (1 H, s),
7.44 (1 H, d, J=7.96 Hz),
7.72 (1 H, dd, J=8.51, 1.65 Hz), 7.81 (1 H, s), 7.97 (1 H, dd, J=7.82, 1.24
Hz), 8.01 (1 H, s), 8.09
(1 H, s), 8.14 (1 H, d, J=8.51 Hz), 8.69 (1 H, s), 9.21 (1 H, s), 10.84 (1 H,
s); ESIMS found for
C221-119N50 m/z 370.2 (M+1).
NJfJtCN
141 o
286
[0838] 2-Methyl-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-3 -yl)i
soindoline -5 -
carboxamide 286.
[0839] Off-white solid (39.0 mg, 0.097 mmol, 17.8% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.51 (3 H, br s), 3.85 (3 H, s), 3.87 (4 H, s), 7.33 (1 H, s),
7.37 (1 H, d, J=7.96
Hz), 7.72 (1 H, dd, J=8.64, 1.51 Hz), 7.81 (1 H, s), 7.89 - 7.98 (2 H, m),
8.09 (1 H, s), 8.14 (1 H,
d, J=8.51 Hz), 8.68 (1 H, s), 9.20 (1 H, s), 10.80 (1 H, s); ESIMS found for
C23H21N50 m/z 384.2
(M+1).
169
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
A4 0
289
[0840] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-
morpholinoisonicotinamide 289.
[0841] Beige solid (37.0 mg, 0.085 mmol, 35.0% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.40 (3 H, s), 3.54 -3.61 (4 H, m), 3.68 (3 H, s), 3.70 -3.77 (4 H,
m), 7.14 (1 H, s), 7.21
(1 H, dd, J=5.08, 1.23 Hz), 7.47(1 H, s), 7.67(1 H, dd, J=8.51, 1.65 Hz),
8.00(1 H, s), 8.14(1 H,
d, J=8.78 Hz), 8.29 (1 H, d, J=4.94 Hz), 8.67 (1 H, s), 9.21 (1 H, s), 11.05
(1 H, s); ESIMS found
for C24H24N602 m/z 429.0 (M+1).
141 0
290
[0842] N-(6-(1,2-Dimethy1-1H-imi dazol-5 -y1)-7-fluoroi soquinolin-3 -
y1)-2-(4-
methylpiperazin-1-yl)isonicotinamide 290.
[0843] Off-white solid (54.0 mg, 0.118 mmol, 42.4% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.41 (3 H, s), 2.41 - 2.45 (4 H, m), 3.54 (3 H,
d, J=0.82 Hz), 3.58
-3.63 (4 H, m), 7.07 (1 H, d, J=0.82 Hz), 7.15 (1 H, dd, J=5.21, 1.10 Hz),
7.47 (1 H, s), 8.05 (1 H,
d, J=10.43 Hz), 8.08 (1 H, d, J=7.14 Hz), 8.26 (1 H, d, J=5.21 Hz), 8.71 (1 H,
s), 9.23 (1 H, s),
11.14(1 H, s); ESIMS found for C25H26FN70 m/z 460.2 (M+1).
F
NI N
o
291
[0844] 4-Fluoro-N-(6-(5,6,7,8-tetrahydroimidazo[1,2-alpyrazin-3-
ypisoquinolin-3-
yl)benzamide 291.
[0845] Beige solid (55.0 mg, 0.142 mmol, 83.4% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.79 (1 H, br s), 3.09 (2 H, t, J=5.21 Hz), 3.96 (2 H, s), 4.14 (2
H, t, J=5.21 Hz), 7.31 (1
H, s), 7.36 (2 H, t, J=8.78 Hz), 7.71 (1 H, dd, J=8.64, 1.51 Hz), 8.03 (1 H,
s), 8.11 (1 H, d, J=8.51
Hz), 8.14 - 8.21 (2 H, m), 8.67 (1 H, s), 9.18 (1 H, s), 10.92 (1 H, s); ESIMS
found for C221-118FN50
m/z 387.9 (M+1).
170
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
FF
NI N 11:11
o
292
[0846] 4-(Difluoromethoxy)-N-(6-(5,6,7,8-tetrahydroimidazo[1,2-
alpyrazin-3-y1)
isoquinolin-3-yl)benzamide 292.
[0847] Yellow solid (12.7 mg, 0.029 mmol, 12.4% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.78 (1 H, br s), 3.09(2 H, br t, J=5.21 Hz), 3.96(2 H, s),
4.14 (2 H, t, J=5.35
Hz), 7.40 (1 H, t, J=73.70 Hz), 7.31 (3 H, t, J=4.25 Hz), 7.71 (1 H, dd,
J=8.51, 1.65 Hz), 8.03 (1
H, s), 8.12 (1 H, d, J=8.51 Hz), 8.14 - 8.20 (2 H, m), 8.68 (1 H, s), 9.19 (1
H, s), 10.93 (1 H, s);
ESIMS found for C23H19F2N502 m/z 435.9 (M+1).
N/ N
N I
N
293
[0848] 2-((2-(Dimethylamino)ethyl)amino)-N-(6-(5,6,7,8-
tetrahydroimidazo[1,2-a]
pyrazin-3-yl)isoquinolin-3-yl)isonicotinamide 293.
[0849] Beige solid (8.0 mg, 0.018 mmol, 11.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.20 (6 H, s), 2.44 (2 H, br t, J=6.59 Hz), 3.09 (2 H, br t, J=5.35
Hz), 3.39 (2 H, q, J=6.31
Hz), 3.96(2 H, s), 4.13 (2 H, br t, J=5.35 Hz), 6.57(1 H, br t, J=5.63 Hz),
7.03 (1 H, dd, J=5.21,
1.37 Hz), 7.05 (1 H, s), 7.31 (1 H, s), 7.72(1 H, dd, J=8.64, 1.51 Hz), 8.03
(1 H, s), 8.11 (2 H, d,
J=6.04 Hz), 8.64 (1 H, s), 9.17 (1 H, s), 10.79 (1 H, br s); ESIMS found for
C25H28N80 m/z 457.0
(M+1).
NHLI N 11;11
o
294
[0850] 2-((1-Isopropylpiperidin-4 -yl)oxy)-N-(6-(5,6,7,8-
tetrahydroimidazo [1,2-a]
pyrazin-3-yl)isoquinolin-3-yl)isonicotinamide 294.
[0851] Beige solid (22.0 mg, 0.043 mmol, 21.9% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 0.99 (6 H, d, J=6.59 Hz), 1.60 - 1.72 (2 H, m), 1.95 -2.04 (2 H, m),
2.30 -2.39 (2 H, m),
2.68 -2.84 (4 H, m), 3.08 (2 H, br t, J=5.21 Hz), 3.96 (2 H, s), 4.14 (2 H, t,
J=5.35 Hz), 5.02 (1 H,
171
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
tt, J=8.54, 4.08 Hz), 7.32 (1 H, s), 7.35 (1 H, s), 7.50 (1 H, dd, J=5.49,
1.37 Hz), 7.73 (1 H, dd,
J=8.64, 1.51 Hz), 8.05 (1 H, s), 8.12 (1 H, d, J=8.51 Hz), 8.31 (1 H, d,
J=5.21 Hz), 8.66 (1 H, s),
9.19(1 H, s), 11.10 (1 H, s); ESIMS found for C29H33N702m/z 512.3 (M+1).
OF
o
296
[0852] 4-(Difluoromethoxy)-N-(6-(oxazol-5-yl)isoquinolin-3-
y1)benzamide 296.
[0853] Brown solid (16.1 mg, 0.042 mmol, 7.4% yield). 1HNMR (500 MHz,
DMSO-
d6) 6 ppm 7.41 (1 H, t, J=73.60 Hz), 7.29 - 7.34 (2 H, m), 7.92 (1 H, dd,
J=8.51, 1.65 Hz), 7.98 (1
H, s), 8.14 - 8.22 (3 H, m), 8.29 (1 H, s), 8.59 (1 H, s), 8.69 (1 H, s), 9.22
(1 H, s), 10.99 (1 H, s);
ESIMS found for C201-113F2N303 m/z 381.9 (M+1).
/7-0 0
H -
N
0
0
301
[0854] 3-((1-Methylpiperidin-4-yl)oxy)-N-(6-(oxazol-5-ypisoquinolin-3-
y1)
benzamide 301.
[0855] Yellow solid (35.1 mg, 0.078 mmol, 58.6% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 1.61 - 1.75 (2 H, m), 1.92 - 2.02 (2 H, m), 2.14 - 2.25 (2 H,
m), 2.19 (3 H, s),
2.58 - 2.67 (2H, m), 4.48 - 4.59 (1 H, m), 7.14 - 7.21 (1 H, m), 7.42(1 H, t,
J=8.10 Hz), 7.61 -7.68
(2 H, m), 7.92 (1 H, dd, J=8.51, 1.65 Hz), 7.98 (1 H, s), 8.19 (1 H, d, J=8.51
Hz), 8.29 (1 H, s),
8.24 - 8.25 (1 H, m), 8.60 (1 H, s), 8.69 (1 H, s), 9.22 (1 H, s), 10.93 (1 H,
s); ESIMS found for
C25H24N403 m/z 429.1 (M+1).
r
141\_
NH2
306
[0856] 2-(3 -Aminoazetidin-1 -y1)-N-(6-(oxazol-5 -yl)i soquinolin-3 -
y1)
isonicotinamide 306.
[0857] Yellow solid (5.1 mg, 0.013 mmol, 3.5% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 3.62 (2 H, dd, J=8.23, 5.76 Hz), 3.85 (1 H, quin, J=6.38 Hz), 4.19
(2 H, t, J=7.68 Hz),
7.01 (1 H, s), 7.14 (1 H, dd, J=5.21, 1.37 Hz), 7.94 (1 H, dd, J=8.51, 1.65
Hz), 7.98 (1 H, s), 8.19
(1 H, d, J=2.47 Hz), 8.21(1 H, s), 8.29(1 H, s), 8.59(1 H, s), 8.68(1 H, s),
9.23(1 H, s), 11.07(1
H, br s); ESIMS found for C211-118N602m/z 387.2 (M+1).
172
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
NQJ1
N
N
309
[0858] 2-(1 -Methylpiperidin-4-y1)-N-(6-(oxazol-5 -yl)i soquinolin-3 -
y1)
isonicotinamide 309.
[0859] Off-white solid (15.0 mg, 0.036 mmol, 51.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.78 - 1.92 (4 H, m), 2.00 (2 H, td, J=11.53, 2.47 Hz), 2.21 (3
H, s), 2.73 (1 H,
tt, J=11.49, 4.15 Hz), 2.90 (2 H, br d, J=11.25 Hz), 7.77 (1 H, dd, J=5.21,
1.65 Hz), 7.92 (1 H, s),
7.94 (1 H, dd, J=8.51, 1.65 Hz), 7.98 (1 H, s), 8.20 (1 H, d, J=8.51 Hz), 8.31
(1 H, s), 8.60 (1 H,
s), 8.69 (1 H, d, J=4.94 Hz), 8.70(1 H, s), 9.24 (1 H, s), 11.26(1 H, s);
ESIMS found for C24H23N502
m/z 414.2 (M+1).
N
1
N
0
310
[0860] 11-Methyl-N-(6-(oxazol-5-yl)isoquinolin-3-y1)-1',2',3',6'-
tetrahydro-[2,4'-
bipyridinel-4-carboxamide 310.
[0861] Tan solid (51.0 mg, 0.124 mmol, 54.8% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.31 (3 H, s), 2.56 - 2.63 (2 H, m), 2.65 (2 H, br d, J=2.74 Hz),
3.11 (2 H, br d, J=3.02
Hz), 6.89 (1 H, br s), 7.78 (1 H, dd, J=4.94, 1.37 Hz), 7.94 (1 H, dd, J=8.51,
1.65 Hz), 7.98 (1 H,
s), 8.17(1 H, s), 8.21 (1 H, d, J=8.51 Hz), 8.31 (1 H, s), 8.59 (1 H, s), 8.65
-8.75 (2 H, m), 9.24 (1
H, s), 11.33 (1 H, s); ESIMS found for C24H2IN502 m/z 412.2 (M+1).
0
313
[0862] 2-(4-Methylpiperazin-1-y1)-N-(6-(oxazol-5-ypisoquinolin-3-y1)
isonicotinamide 313.
[0863] Brown solid (13.0 mg, 0.031 mmol, 19.1% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.55 - 3.64 (4 H, m),
7.16(1 H, dd, J=5.21,
1.10 Hz), 7.47 (1 H, s), 7.93 (1 H, dd, J=8.51, 1.65 Hz), 7.98 (1 H, s), 8.20
(1 H, d, J=8.51 Hz),
8.26 (1 H, d, J=4.94 Hz), 8.30 (1 H, s), 8.59 (1 H, s), 8.69 (1 H, s), 9.23 (1
H, s), 11.13 (1 H, s);
ESIMS found for C23H22N602 m/z 415.2 (M+1).
173
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[41
0
111
317
[0864] 2-(7-Methy1-2,7-diazaspiro[3.51nonan-2-y1)-N-(6-(oxazol-5-
ypisoquinolin-3-
y1)isonicotinamide 317.
[0865] Off-white solid (24.0 mg, 0.050 mmol, 57.7% yield). '1-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.76 (4 H, br t, J=5.08 Hz), 2.15 (3 H, s), 2.27 (4 H, br s),
3.74 (4 H, s), 7.03 (1
H, s), 7.13 (1 H, dd, J=5.35, 1.51 Hz), 7.94 (1 H, dd, J=8.51, 1.65 Hz), 7.98
(1 H, s), 8.19 (1 H, d,
J=2.74 Hz), 8.21 (1 H, s), 8.30 (1 H, s), 8.59 (1 H, s), 8.68 (1 H, s), 9.23
(1 H, s), 11.06 (1 H, s);
ESIMS found for C26H26N602 m/z 455.2 (M+1).
r
0
NH
318
[0866] N-(6-(Oxazol-5 -yl)i soquinolin-3 -y1)-2 -(2,7-diazaspiro13
.51nonan-7-y1)
isonicotinamide 318.
[0867] Beige solid (9.0 mg, 0.020 mmol, 50.2% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 1.74 (4 H, br s), 3.27 (4 H, br s), 3.58 (4 H, br d, J=4.67 Hz),
7.11(1 H, br d, J=4.67 Hz),
7.46 (1 H, s), 7.94 (1 H, dd, J=8.51, 1.37 Hz), 7.98 (1 H, s), 8.20 (1 H, d,
J=8.51 Hz), 8.24 (1 H, d,
J=4.94 Hz), 8.30(1 H, s), 8.60(1 H, s), 8.69(1 H, s), 9.24(1 H, s), 11.13 (1
H, br s); ESIMS found
for C25H24N602 m/z 441.2 (M+1).
N
o
319
[0868] N-(6-(Oxazol-5 -yl)i soquinolin-3 -y1)-2 -(piperidin-4-
ylamino)i sonicotinamide
319.
[0869] White solid (18.0 mg, 0.043 mmol, 8.3% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 1.65- 1.76 (2 H, m), 2.04 -2.13 (2H, m), 2.97 - 3.07 (2 H, m), 3.25 -
3.30 (2H, m), 4.05
(1 H, br s), 7.09 (1 H, br d, J=4.12 Hz), 7.93 (1 H, dd, J=8.51, 1.65 Hz),
7.98 (1 H, s), 8.12 (1 H,
d, J=5.49 Hz), 8.19 (1 H, d, J=8.78 Hz), 8.31 (1 H, s), 8.59 (1 H, s), 8.65 (1
H, s), 8.99 (2 H, br s),
9.22 (1 H, s), 10.94 (1 H, br s); ESIMS found for C23H22N602 m/z 415.2 (M+1).
174
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
325
[0870] 2-Methyl-N-(6-(oxazol-5 -yl)i soquinolin-3 -yl)i soindoline-5 -
carboxamide 325.
[0871] Off-white solid (39.0 mg, 0.100 mmol, 57.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.51 (3 H, br s), 3.88 (4 H, s), 7.37 (1 H, d, J=7.96 Hz), 7.88
- 7.96 (3 H, m),
7.98 (1 H, s), 8.18 (1 H, d, J=8.78 Hz), 8.29 (1 H, s), 8.59 (1 H, s), 8.68 (1
H, s), 9.21 (1 H, s),
10.83 (1 H, s); ESIMS found for C22F118N402m/z 371.1 (M+1).
NQQNH
326
[0872] N-(6-(Oxazol-5 -yl)i soquinolin-3 -y1)-1,2,3,4-
tetrahydroisoquinoline -7-
carboxamide 326.
[0873] Off-white solid (17.0 mg, 0.046 mmol, 26.0% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.74 -2.81 (2 H, m), 2.99 (2 H, br t, J=5.76 Hz), 3.90 - 3.96
(2 H, m), 7.22 (1 H,
d, J=7.96 Hz), 7.80 (1 H, s), 7.81 - 7.85 (1 H, m), 7.91 (1 H, dd, J=8.51,
1.65 Hz), 7.98 (1 H, s),
8.18 (1 H, d, J=8.78 Hz), 8.28 (1 H, s), 8.59 (1 H, s), 8.68 (1 H, s), 9.21 (1
H, s), 10.76 (1 H, s);
ESIMS found for C22H18N402 m/z 371.2 (M+1).
NJ
NCN
141 0
328
[0874] N-(6-(2-Methyloxazol-5 -yl)i soquinolin-3 -y1)-2-(4-methylpipe
razin-l-y1)
isonicotinamide 328.
[0875] Beige solid (149.0 mg, 0.348 mmol, 74.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 2.55 (3 H, s), 3.56 -
3.66 (4 H, m), 7.16
(1 H, dd, J=5.21, 1.10 Hz), 7.46 (1 H, s), 7.82 (1 H, s), 7.88 (1 H, dd,
J=8.51, 1.65 Hz), 8.16 (1 H,
d, J=8.78 Hz), 8.20(1 H, s), 8.26(1 H, d, J=5.21 Hz), 8.66(1 H, s), 9.20(1 H,
s), 11.11(1 H, s);
ESIMS found for C24H24N602m/z 429.2 (M+1).
NQL N I
329
175
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0876] N-(6-(5-Methy1-1,3,4-oxadiazol-2-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-
1-y1)isonicotinamide 329.
[0877] Beige solid (20.0 mg, 0.047 mmol, 19.9% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, br t, J=4.80 Hz), 2.65 (3 H, s), 3.56 -
3.67 (4 H, m), 7.17 (1 H,
dd, J=5.08, 1.23 Hz), 7.47(1 H, s), 8.11 (1 H, dd, J=8.51, 1.65 Hz), 8.27(1 H,
d, J=4.94 Hz), 8.30
(1 H, d, J=8.51 Hz), 8.58 (1 H, s), 8.78 (1 H, s), 9.34 (1 H, s), 11.20 (1 H,
s); ESIMS found for
C23H23N702 m/z 430.0 (M+1).
ci
t_s
N
330
[0878] N-(6-(5-Chlorothiazol-2-ypisoquinolin-3-y1)-2-(4-methylpiperazin-
1-y1)
isonicotinamide 330.
[0879] Yellow solid (1.3 mg, 0.003 mmol, 1.1% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.40 -2.46 (4 H, m), 3.58 - 3.64 (4 H, m), 7.10 -7.20
(1 H, m), 7.46 (1 H,
s), 7.89 (1 H, dd, J=8.64, 1.78 Hz), 8.18 (1 H, d, J=8.23 Hz), 8.26 (1 H, d,
J=5.21 Hz), 8.28 (1 H,
s), 8.38 (1 H, s), 8.69 (1 H, s), 9.24 (1 H, s), 11.09 (1 H, s); ESIMS found
for C23H21C1N60S m/z
464.9 (M+1).
0
331
[0880] 2-(4-Methylpiperazin-1-y1)-N-(6-(5 -methylthiazol-2-yl)i
soquinolin-3 -y1)
isonicotinamide 331.
[0881] Off-yellow solid (11.5 mg, 0.026 mmol, 9.4% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.38 - 2.47 (4 H, m), 2.56 (3 H, d, J=1.10 Hz),
3.56 - 3.66 (4 H,
m), 7.17(1 H, dd, J=5.21, 1.10 Hz), 7.47(1 H, s), 7.73(1 H, d, J=1.37 Hz),
8.09(1 H, dd, J=8.51,
1.65 Hz), 8.19 (1 H, d, J=8.51 Hz), 8.26 (1 H, d, J=5.21 Hz), 8.43 (1 H, s),
8.71 (1 H, s), 9.25 (1
H, s), 11.09 (1 H, s); ESIMS found for C24H24N60S m/z 444.9 (M+1).
Ny)LN
14/ 0
332
[0882] 2-(4-Methylpiperazin-1-y1)-N-(6-(4-methylthiazol-2-ypi
soquinolin-3 -y1)
isonicotinamide 332.
176
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0883] Black solid (23.6 mg, 0.053 mmol, 18.4% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.40 -2.46 (4 H, m), 2.49 (3 H, br s), 3.55 - 3.65 (4
H, m), 7.17 (1 H, dd,
J=5.08, 1.24 Hz), 7.46(1 H, br s), 7.47(1 H, d, J=0.82 Hz), 8.11 (1 H, dd,
J=8.51, 1.65 Hz), 8.20
(1 H, d, J=8.51 Hz), 8.26 (1 H, d, J=4.94 Hz), 8.49(1 H, s), 8.72(1 H, s),
9.26 (1 H, s), 11.09 (1
H, s); ESIMS found for C24H24N60S m/z 444.9 (M+1).
H2N
NI-11(04 I
A4 0 LN
333
[0884] 2-(3 -(2-(4-Methylpiperazin-1 -yl)i soni cotinamido)i
soquinolin-6-yl)thiazole-
5-carboxamide 333.
[0885] Yellow solid (7.6 mg, 0.016 mmol, 5.8% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.41 -2.45 (4 H, m), 3.58 -3.64 (4 H, m), 7.17 (1 H,
dd, J=5.08, 1.23 Hz),
7.47 (1 H, s), 7.69 (1 H, br s), 8.15 (1 H, dd, J=8.64, 1.78 Hz), 8.24 (2 H,
br d, J=8.78 Hz), 8.27 (1
H, d, J=4.94 Hz), 8.54 (1 H, s), 8.60 (1 H, s), 8.75 (1 H, s), 9.29 (1 H, s),
11.13 (1 H, s); ESIMS
found for C24H23N702S m/z 473.9 (M+1).
r'rr
NQI H
141 o
334
[0886] 6-(4-Methylpiperazin-1-y1)-N-(6-(thiazol-5-yl)isoquinolin-3-
y1)nicotinamide
334.
[0887] White solid (64.1 mg, 0.149 mmol, 42.3% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.37 - 2.45 (4 H, m), 3.60 - 3.68 (4 H, m), 6.90 (1
H, d, J=9.06 Hz), 7.89
(1 H, dd, J=8.51, 1.92 Hz), 8.14(1 H, d, J=8.51 Hz), 8.20(1 H, dd, J=9.06,
2.47 Hz), 8.25 (1 H, d,
J=0.82 Hz), 8.57 (1 H, s), 8.66 (1 H, s), 8.85 (1 H, d, J=2.47 Hz), 9.19 (2 H,
d, J=2.47 Hz), 10.66
(1 H, s); ESIMS found for C23H22N60S m/z 430.9 (M+1).
N
N
0
335
[0888] 11-Methyl-N-(6-(thiazol-5-ypisoquinolin-3-y1)-1',2',3',6'-
tetrahydro42,4'-
bipyridinel-4-carboxamide 335.
177
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0889] Off-white solid (7.6 mg, 0.018 mmol, 33.9% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.31 (3 H, s), 2.56 - 2.63 (2 H, m), 2.63 - 2.69 (2 H, m), 3.11
(2 H, br d, J=3.02
Hz), 6.85 - 6.93 (1 H, m), 7.78 (1 H, dd, J=4.94, 1.37 Hz), 7.94 (1 H, dd,
J=8.51, 1.65 Hz), 8.13 -
8.22 (2 H, m), 8.32 (1 H, d, J=0.82 Hz), 8.60 (1 H, s), 8.71 (2 H, dd, J=3.43,
1.51 Hz), 9.21 (1 H,
s), 9.24 (1 H, s), 11.33 (1 H, s); ESIMS found for C24H21N5OS m/z 428.2 (M+1).
336
[0890] 2-(3 -(Dimethylamino)azetidin-1 -y1)-N-(6-(thiazol-5 -yl)i
soquinolin-3 -y1)
isonicotinamide 336.
[0891] Beige solid (15.0 mg, 0.035 mmol, 12.2% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.14 (6 H, s), 3.19 -3.25 (1 H, m), 3.81 (2 H, dd, J=8.23, 5.21 Hz),
4.07 (2 H, t, J=7.68
Hz), 7.04 (1 H, s), 7.15 (1 H, dd, J=5.21, 1.37 Hz), 7.93 (1 H, dd, J=8.51,
1.65 Hz), 8.17 (1 H, d,
J=8.78 Hz), 8.21 (1 H, d, J=5.21 Hz), 8.30 (1 H, s), 8.58 (1 H, s), 8.67 (1 H,
s), 9.20 (1 H, s), 9.22
(1 H, s), 11.01(1 H, s); ESIMS found for C23H22N60S m/z 430.9 (M+1).
/7--S
0
337
[0892] 2-(4-(Dimethylamino)piperidin-1-y1)-N-(6-(thiazol-5-
ypisoquinolin-3-y1)
isonicotinamide 337.
[0893] Off-white solid (390.0 mg, 0.851 mmol, 80.6% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.31 - 1.46 (2 H, m), 1.84 (2 H, br d, J=10.70 Hz), 2.19 (6 H,
s), 2.34 (1 H, ddd,
J=10.98, 7.41, 3.29 Hz), 2.88 (2 H, br t, J=11.80 Hz), 4.44 (2 H, br d,
J=12.62 Hz), 7.05 - 7.15 (1
H, m), 7.46(1 H, s), 7.93 (1 H, dd, J=8.51, 1.65 Hz), 8.17(1 H, d, J=8.51 Hz),
8.24(1 H, d, J=5.21
Hz), 8.31 (1 H, s), 8.59 (1 H, s), 8.69(1 H, s), 9.21 (1 H, s), 9.23 (1 H, s),
11.12(1 H, s); ESIMS
found for C25H26N60S m/z 459.2 (M+1).
N I
338
[0894] 2-(4 -Methylpiperazin-l-y1)-N-(6-(thiazol-5 -yl)i soquinolin-3 -
y1)
isonicotinamide 338.
178
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0895] Off-yellow solid (42.9 mg, 0.100 mmol, 42.5% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.37 - 2.46 (4 H, m), 3.55 - 3.66 (4 H, m), 7.16
(1 H, d, J=4.12
Hz), 7.46 (1 H, s), 7.92 (1 H, dd, J=8.51, 1.65 Hz), 8.17 (1 H, d, J=8.51 Hz),
8.26 (1 H, d, J=5.21
Hz), 8.30(1 H, s), 8.58 (1 H, s), 8.68 (1 H, s), 9.20(1 H, s), 9.22 (1 H, s),
11.07(1 H, s); ESIMS
found for C23H22N60S m/z 430.9 (M+1).
H r
N
339
[0896] 2-((1-Methylpiperidin-4-yl)thio)-N-(6-(thiazol-5-ypisoquinolin-
3-y1)
isonicotinamide 339.
[0897] Off-white solid (54.7 mg, 0.119 mmol, 41.3% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.58 - 1.74 (2 H, m), 1.98 -2.07 (2 H, m), 2.12 (2 H, br t,
J=10.15 Hz), 2.17 (3
H, s), 2.65 -2.75 (2 H, m), 3.79 - 3.90 (1 H, m), 7.64(1 H, dd, J=5.08, 1.51
Hz), 7.82(1 H, s), 7.94
(1 H, dd, J=8.51, 1.65 Hz), 8.17 (1 H, d, J=8.51 Hz), 8.32 (1 H, s), 8.59 (1
H, s), 8.62 (1 H, d,
J=5.21 Hz), 8.68 (1 H, s), 9.21 (1 H, s), 9.23 (1 H, s), 11.24 (1 H, s); ESIMS
found for C24H23N50S2
m/z 462.1 (M+1).
NQJfJ/7--S
NH
340
[0898] N-(6-(Thiazol-5 -yl)i soquinolin-3 -y1)-1,2,3,4-tetrahydroi
soquinoline-7-
carboxamide 340.
[0899] Off-white solid (57.3 mg, 0.148 mmol, 39.0% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.73 - 2.80 (2 H, m), 2.98 (2 H, br t, J=5.76 Hz), 3.93 (2 H,
s), 7.22 (1 H, d,
J=8.23 Hz), 7.71 (1 H, br d, J=5.76 Hz), 7.79 (1 H, s), 7.89 - 7.96 (1 H, m),
8.16 (1 H, d, J=8.78
Hz), 8.29 (1 H, s), 8.59 (1 H, s), 8.67 (1 H, s), 9.20 (2 H, s), 10.75 (1 H,
s); ESIMS found for
C22I-118N40S m/z 387.1 (M+1).
H2N
N1HN
0
359
[0900] N-(6-(2-Aminothiazol-5-ypisoquinolin-3-y1)-2-(4-methylpiperazin-
1-y1)
isonicotinamide 359.
179
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0901] Off-yellow solid (3.8 mg, 0.009 mmol, 3.1% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.40 - 2.44 (4 H, m), 3.57 - 3.64 (4 H, m), 7.15
(1 H, dd, J=5.08,
1.24 Hz), 7.33 -7.38 (2 H, m), 7.45 (1 H, s), 7.71 (1 H, s), 7.73 -7.80 (2 H,
m), 8.01 (1 H, d, J=8.23
Hz), 8.26 (1 H, d, J=4.94 Hz), 8.55 (1 H, s), 9.09 (1 H, s), 10.98 (1 H, s);
ESIMS found for
C23H23N70S m/z 445.9 (M+1).
-141/
141 o
373
[0902] 2-(3 -Aminoazetidin-1 -y1)-N-(6-(2-(dimethylamino)thiazol-5 -
yl)i soquinolin-
3-yl)isonicotinamide 373.
[0903] Yellow solid (21.5 mg, 0.048 mmol, 39.3% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 3.13 (6 H, s), 3.63 (2 H, dd, J=8.23, 5.76 Hz), 3.85 (1 H,
quin, J=6.45 Hz), 4.19
(2 H, t, J=7.82 Hz), 7.00 (1 H, s), 7.13 (1 H, dd, J=5.21, 1.37 Hz), 7.80 (1
H, dd, J=8.64, 1.78 Hz),
7.85 (1 H, s), 7.91 (1 H, s), 8.03 (1 H, d, J=8.51 Hz), 8.19 (1 H, d, J=5.21
Hz), 8.54 (1 H, s), 9.10
(1 H, s), 10.97 (1 H, s); ESIMS found for C23H23N70S m/z 446.1 (M+1).
11141/
14/)f-S
QCJ
374
[0904] 2-(3 -(Dimethylamino)azetidin-1 -y1)-N-(6-(2-
(methylamino)thiazol-5 -y1)
isoquinolin-3-yl)isonicotinamide 374.
[0905] Yellow solid (10.3 mg, 0.022 mmol, 5.7% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.13 (6 H, s), 2.90 (3 H, d, J=4.67 Hz), 3.19 - 3.26 (1 H, m), 3.80
(2 H, dd, J=8.37, 5.35
Hz), 4.06 (2 H, t, J=7.68 Hz), 7.03 (1 H, s), 7.14 (1 H, dd, J=5.21, 1.37 Hz),
7.77 - 7.80 (2 H, m),
7.81 (1 H, s), 7.95 (1 H, q, J=4.67 Hz), 8.02 (1 H, d, J=8.23 Hz), 8.21 (1 H,
d, J=5.21 Hz), 8.54 (1
H, s), 9.09 (1 H, s), 10.97 (1 H, s); ESIMS found for C24H25N70S m/z 460.2
(M+1).
-141/
NQJJ
375
180
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0906] 2-(3 -(Dimethylamino)azetidin-1 -y1)-N-(6-(2-
(dimethylamino)thiazol-5 -y1)
isoquinolin-3-yl)isonicotinamide 375.
[0907] Yellow solid (34.6 mg, 0.073 mmol, 27.6% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.13 (6H, s), 3.13 (6H, s), 3.18 - 3.26 (1 H, m), 3.80(2 H, dd,
J=8.51, 5.21 Hz),
4.06 (2 H, t, J=7.68 Hz), 7.03 (1 H, s), 7.15 (1 H, dd, J=5.21, 1.37 Hz), 7.79
(1 H, dd, J=8.51, 1.65
Hz), 7.84 (1 H, s), 7.90 (1 H, s), 8.02 (1 H, d, J=8.51 Hz), 8.20 (1 H, d,
J=5.49 Hz), 8.54 (1 H, s),
9.09 (1 H, s), 10.98 (1 H, br s); ESIMS found for C25H27N70S m/z 474.2 (M+1).
HN/
A4 0
376
[0908] N-(6-(2 -(Methylamino)thiazol-5 -yl)i soquinolin-3 -y1)-2-(4-
methylpiperazin-
1-yl)isonicotinamide 376.
[0909] Yellow solid (59.0 mg, 0.128 mmol, 29.2% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.42 (4 H, br t, J=4.94 Hz), 2.90 (3 H, d,
J=4.67 Hz), 3.56 - 3.63
(4 H, m), 7.15 (1 H, dd, J=5.08, 1.23 Hz), 7.46 (1 H, s), 7.76 -7.80 (2 H, m),
7.81 (1 H, s), 7.95 (1
H, q, J=4.57 Hz), 8.02 (1 H, d, J=8.51 Hz), 8.25 (1 H, d, J=5.21 Hz), 8.55 (1
H, s), 9.10 (1 H, s),
11.03 (1 H, s); ESIMS found for C24H25N70S m/z 460.2 (M+1).
N)I-S
1411HN
0
377
[0910] N-(6-(2 -(Dimethylamino)thiazol-5 -yl)i soquinolin-3 -y1)-2-(4 -
methylpiperazin-l-yl)isonicotinamide 377.
[0911] Yellow solid (25.6 mg, 0.054 mmol, 11.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.20 - 2.27 (3 H, m), 2.39 - 2.47 (4 H, m), 3.09 - 3.20 (6 H,
m), 3.55 - 3.66 (4 H,
m), 7.15 (1 H, dd, J=4.94, 1.10 Hz), 7.46 (1 H, s), 7.80 (1 H, dd, J=8.64,
1.78 Hz), 7.85 (1 H, s),
7.91(1 H, s), 8.03(1 H, d, J=8.51 Hz), 8.25(1 H, d, J=5.21 Hz), 8.56(1 H, s),
9.10(1 H, s), 11.03
(1 H, s); ESIMS found for C25H27N70S m/z 474.2 (M+1).
HN/
141N
A4I 0
378
181
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0912] 2-(4 -Isopropylpiperazin-1 -y1)-N-(6-(2-(methylamino)thiazol-5 -
y1)
isoquinolin-3-yl)isonicotinamide 378.
[0913] Yellow solid (53.8 mg, 0.110 mmol, 35.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.02 (6 H, br d, J=6.04 Hz), 2.56 (4 H, br s), 2.70 (1 H, br
s), 2.90 (3 H, d, J=4.67
Hz), 3.58 (4 H, br s), 7.14 (1 H, d, J=4.67 Hz), 7.44 (1 H, s), 7.75 - 7.81 (2
H, m), 7.81 (1 H, s),
7.95 (1 H, q, J=4.85 Hz), 8.02 (1 H, d, J=8.51 Hz), 8.25 (1 H, d, J=4.94 Hz),
8.55 (1 H, s), 9.10 (1
H, s), 11.03 (1 H, s); ESIMS found for C26H29N70S m/z 488.2 (M+1).
N HrCji
N I
0
379
[0914] 2-(4 -Methylpiperazin-l-y1)-N-(6-(2 -methylthiazol-5 -yl)i
soquinolin-3 -y1)
isonicotinamide 379.
[0915] Off-yellow solid (44.4 mg, 0.100 mmol, 42.6% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.38 -2.46 (4 H, m), 2.73 (3 H, s), 3.55 -3.66
(4 H, m), 7.16 (1 H,
dd, J=5.08, 0.96 Hz), 7.46 (1 H, s), 7.85 (1 H, dd, J=8.51, 1.65 Hz), 8.13 (1
H, d, J=8.51 Hz), 8.17
(1 H, s), 8.26(1 H, d, J=5.21 Hz), 8.29(1 H, s), 8.65(1 H, s), 9.19(1 H, s),
11.05(1 H, s); ESIMS
found for C24H24N60S m/z 444.9 (M+1).
F C
3 )7....s 1.1)
380
[0916] 6-(4 -Methylpiperazin-l-y1)-N-(6-(5 -(trifluoromethyl)-1,3,4-
thiadiazol-2 -y1)
isoquinolin-3-yl)nicotinamide 380.
[0917] White solid (5.2 mg, 0.010 mmol, 6.9% yield). 'H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.40 (4 H, br t, J=4.80 Hz), 3.60 - 3.71 (4 H, m),
6.91 (1 H, d, J=9.06 Hz),
8.21 (2 H, dd, J=8.64, 1.78 Hz), 8.30 (1 H, d, J=8.51 Hz), 8.76 (1 H, s), 8.80
(1 H, s), 8.86 (1 H, d,
J=2.20 Hz), 9.34 (1 H, s), 10.84 (1 H, s); ESIMS found for C23H20F3N70S m/z
500.1 (M+1).
N,Nr,
0
381
[0918] 2-(4 -Methylpiperazin-l-y1)-N-(6-(5 -(trifluoromethyl)-1,3,4-
thiadiazol-2 -y1)
isoquinolin-3-yl)isonicotinamide 381.
182
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0919] White solid (4.0 mg, 0.008 mmol, 3.0% yield). 'FINMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.43 (4 H, br t, J=4.80 Hz), 3.55 -3.65 (4 H, m),
7.17 (1 H, dd, J=5.21,
1.10 Hz), 7.48 (1 H, s), 8.21 - 8.26 (1 H, m), 8.27 (1 H, d, J=5.21 Hz), 8.30 -
8.37 (1 H, m), 8.82
(2 H, d, J=8.51 Hz), 9.37 (1H, s), 11.25 (1 H, s); ESIMS found for
C23H20F3N70S m/z 500.1 (M+1).
,s OTF
o
382
[0920] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-4-
(difluoromethoxy)
benzamide 382.
[0921] White solid (5.0 mg, 0.013 mmol, 6.2% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 7.41 (2 H, t, J=73.70 Hz), 7.32 (2 H, d, J=8.78 Hz), 8.16 - 8.19 (2
H, m), 8.20 - 8.23 (1
H, m), 8.26 - 8.32 (1 H, m), 8.66(1 H, s), 8.79(1 H, s), 9.32(1 H, s), 9.75 (1
H, s), 11.07(1 H, s);
ESIMS found for CI9H12F2N402S m/z 398.8 (M+1).
LA
;
383
[0922] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-3-(4-
methylpiperazin-1-y1)
benzamide 383.
[0923] Yellow solid (9.4 mg, 0.022 mmol, 4.5% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (2 H, s), 2.46 -2.49 (4 H, m), 3.23 - 3.29 (4 H, m), 7.10 -7.21
(1 H, m), 7.36 (1 H,
t, J=7.96 Hz), 7.46 -7.53 (1 H, m), 7.62 - 7.70 (1 H, m), 8.16 - 8.24 (1 H,
m), 8.24 - 8.32 (1 H, m),
8.64 (1 H, d, J=0.82 Hz), 8.79 (1 H, s), 9.31 (1 H, s), 9.74 (1 H, s), 10.96
(1 H, s); ESIMS found
for C23H22N60S m/z 431.9 (M+1).
ON
\ H
o
384
[0924] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-4-(piperidin-4-
yloxy)
benzamide 384.
[0925] White solid (15.7 mg, 0.036 mmol, 69.1% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 1.41 - 1.54(2 H, m), 1.95 (2 H, br dd, J=8.64, 3.16 Hz), 2.56 - 2.66
(2 H, m), 2.96(2 H,
dt, J=12.49, 3.91 Hz), 4.49 -4.60 (1 H, m), 7.01 - 7.10 (2 H, m), 8.01 - 8.14
(2 H, m), 8.14 - 8.23
183
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(1 H, m), 8.23 - 8.32 (1 H, m), 8.63 (1 H, s), 8.78 (1 H, s), 9.30 (1 H, s),
9.74 (1 H, s), 10.80 (1 H,
s); ESIMS found for C23H211\1502S m/z 432.1 (M+1).
0
385
[0926] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-4-((1-
methylpiperidin-4-y1)
oxy)benzamide 385.
[0927] Off-yellow solid (17.7 mg, 0.038 mmol, 40.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.60 - 1.73 (2 H, m), 1.97 (2 H, br dd, J=9.47, 3.98 Hz), 2.16 -
2.24 (2 H, m),
2.18 (3 H, s), 2.57 -2.69 (2 H, m), 4.52 (1 H, tt, J=8.13, 3.95 Hz), 7.07 (2
H, d, J=9.06 Hz), 8.03 -
8.14 (2 H, m), 8.14 - 8.23 (1 H, m), 8.23 - 8.30 (1 H, m), 8.64 (1 H, s), 8.78
(1 H, s), 9.30 (1 H, s),
9.74 (1 H, s), 10.82 (1 H, s); ESIMS found for C24H23N502S m/z 445.9 (M+1).
H 0-
N N
0
0
386
[0928] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-3-((1-
methylpiperidin-4-y1)
oxy)benzamide 386.
[0929] Yellow solid (162.0 mg, 0.345 mmol, 24.0% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 1.63 - 1.76 (2 H, m), 1.93 - 2.03 (2 H, m), 2.18 - 2.25 (2 H,
m), 2.19 (3 H, s),
2.57 -2.68 (2 H, m), 4.53 (1 H, tt, J=7.99, 3.95 Hz), 7.18 (1 H, ddd, J=8.23,
2.47, 1.10 Hz), 7.43
(1 H, t, J=8.10 Hz), 7.62 - 7.70 (2 H, m), 8.16 - 8.24 (1 H, m), 8.24 - 8.32
(1 H, m), 8.65 (1 H, d,
J=0.82 Hz), 8.79 (1 H, s), 9.32 (1 H, s), 9.75 (1 H, s), 10.99 (1 H, s); ESIMS
found for C24H23N502S
m/z 446.2 (M+1).
H
N,Nr,
387
[0930] N5-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-N2-methylpyridine-
2,5-
dicarboxamide 387.
[0931] White solid (5.2 mg, 0.013 mmol, 6.3% yield). 'H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.86 (3 H, d, J=4.94 Hz), 8.16 (1 H, d, J=7.96 Hz), 8.20 - 8.27 (1
H, m), 8.27 - 8.32 (1
H, m), 8.57 (1 H, dd, J=8.23, 2.20 Hz), 8.69 (1 H, s), 8.82 (1 H, s), 8.95 (1
H, q, J=4.57 Hz), 9.23
184
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
(1 H, d, J=1.37 Hz), 9.34(1 H, s), 9.75 (1 H, s), 11.47(1 H, s); ESIMS found
for CI9H14N602S m/z
391.1 (M+1).
NO1
/1--S
A4 0
388
[0932] N-(6-(1,3,4-Thiadiazol-2 -yl)i soquinolin-3 -y1)-6-(4 -
methylpipe razin-l-y1)
nicotinamide 388.
[0933] Brown solid (14.1 mg, 0.033 mmol, 10.7% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.22 (3 H, s), 2.40 (4 H, t, J=5.08 Hz), 3.60 - 3.71 (4 H, m),
6.91 (1 H, d, J=9.06
Hz), 8.14 - 8.23 (2 H, m), 8.23 - 8.30 (1 H, m), 8.62 (1 H, s), 8.76 (1 H, s),
8.86 (1 H, d, J=2.47
Hz), 9.30 (1 H, s), 9.74 (1 H, s), 10.80 (1 H, s); ESIMS found for C22H2N7OS
m/z 431.9 (M+1).
r
N,Nr,
QJJQ
389
[0934] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-1'-methyl-
l',2',3',6'-tetrahydro-
12,4'-bipyridinel-4-carboxamide 389.
[0935] White solid (2.5 mg, 0.006 mmol, 5.7% yield). 1HNMR (499 MHz,
DMSO-
d6) 6 ppm 2.31 (3 H, s), 2.58 -2.63 (2 H, m), 2.64 -2.69 (2 H, m), 3.08 -3.15
(2 H, m), 6.90 (1 H,
t, J=3.43 Hz), 7.79 (1 H, dd, J=4.94, 1.37 Hz), 8.18 (1 H, s), 8.21 - 8.26 (1
H, m), 8.26 - 8.35 (1 H,
m), 8.64 - 8.74 (2 H, m), 8.82 (1 H, s), 9.35 (1 H, s), 9.75 (1 H, s), 11.41
(1 H, br s); ESIMS found
for C23H201\160S m/z 429.1 (M+1).
/r-S
NQQN)HNON
0
390
[0936] N-(6-(1,3,4-Thiadiazol-2 -yl)i soquinolin-3 -y1)-2-(3 -
(dimethylamino)azetidin-
1-yl)i sonicotinamide 390.
[0937] White solid (15.0 mg, 0.035 mmol, 10.1% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.14 (6 H, s), 3.17 -3.26 (1 H, m), 3.81 (2 H, dd, J=8.37, 5.35 Hz),
4.07 (2 H, t, J=7.55
Hz), 7.05 (1 H, s), 7.16 (1 H, dd, J=5.21, 1.10 Hz), 8.18 - 8.25 (2 H, m),
8.25 - 8.33 (1 H, m), 8.66
(1 H, s), 8.78 (1 H, s), 9.33 (1 H, s), 9.75 (1 H, s), 11.15 (1 H, s); ESIMS
found for C22H211\170S
m/z 432.1 (M+1).
185
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
H
N,N,
,N
391
[0938] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-l-y1)
isonicotinamide 391.
[0939] White solid (15.2 mg, 0.035 mmol, 9.6% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.24 (3 H, s), 2.44 (4 H, br d, J=4.12 Hz), 3.61 (4 H, br s), 7.17
(1 H, br d, J=4.94 Hz),
7.47 (1 H, s), 8.18 - 8.25 (1 H, m), 8.25 - 8.33 (2 H, m), 8.65 (1 H, s), 8.78
(1 H, s), 9.32 (1 H, s),
9.69 - 9.78 (1 H, m), 11.15 (1 H, br s); ESIMS found for C22H21N7OS m/z 431.9
(M+1).
NcLQ
H
0
1
392
[0940] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-2-(4-
isopropylpiperazin-1-y1)
isonicotinamide 392.
[0941] Yellow solid (10.1 mg, 0.022 mmol, 16.1% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.02 (6 H, d, J=6.59 Hz), 2.52 - 2.60 (4 H, m), 2.66 -2.76 (1
H, m), 3.53 - 3.64
(4 H, m), 7.16 (1 H, dd, J=5.21, 1.37 Hz), 7.46 (1 H, s), 8.18 - 8.25 (1 H,
m), 8.26 (1 H, d, J=5.21
Hz), 8.27 - 8.32 (1 H, m), 8.67 (1 H, d, J=0.82 Hz), 8.80 (1 H, s), 9.33 (1 H,
s), 9.75 (1 H, s), 11.20
(1 H, s); ESIMS found for C24H25N70S m/z 460.2 (M+1).
/is-s
N,Nr,
N.,46o
393
[0942] N-(6-(1,3,4-Thiadiazol-2-ypisoquinolin-3-y1)-2-
morpholinoisonicotinamide
393.
[0943] Beige solid (10.0 mg, 0.024 mmol, 8.0% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 3.54 -3.60 (4 H, m), 3.69 - 3.76 (4 H, m), 7.22 (1 H, dd, J=5.21,
1.10 Hz), 7.48 (1 H, s),
8.18 - 8.25 (1 H, m), 8.25 - 8.33 (2 H, m), 8.67 (1 H, s), 8.80 (1 H, s), 9.33
(1 H, s), 9.75 (1 H, s),
11.21(1 H, s); ESIMS found for C2IHI8N602S m/z 419.1 (M+1).
N
14/1N
'14
0
406
186
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0944] 2-(3-(Dimethylamino)azetidin-1-y1)-N-(6-(5-methy1-1,3,4-
thiadiazol-2-y1)
isoquinolin-3-yl)isonicotinamide 406.
[0945] Beige solid (20.0 mg, 0.045 mmol, 25.2% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.13 (6 H, s), 2.84 (3 H, s), 3.17 -3.26 (1 H, m), 3.81 (2 H, dd,
J=8.51, 5.49 Hz), 4.07(2
H, t, J=7.55 Hz), 7.05 (1 H, s), 7.16 (1 H, dd, J=5.21, 1.37 Hz), 8.16 (1 H,
dd, J=8.51, 1.65 Hz),
8.22 (1 H, d, J=4.94 Hz), 8.26 (1 H, d, J=8.78 Hz), 8.55 (1 H, s), 8.76 (1 H,
s), 9.31 (1 H, s), 11.14
(1 H, s); ESIMS found for C23H23N70S m/z 446.2 (M+1).
N
N I
Aki 0 N
409
[0946] 1'-Methyl-N-(6-(5-methy1-1,3,4-thiadiazol-2-ypisoquinolin-3-y1)-
11,21,31,6'-
tetrahydro42,4'-bipyridinel-4-carboxamide 409.
[0947] Off-white solid (2.6 g, 5.87 mmol, 56.9% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.31 (3 H, s), 2.56 -2.63 (2 H, m), 2.63 -2.69 (2 H, m), 2.84 (3 H,
s), 3.08 - 3.16 (2 H,
m), 6.89 (1 H, dt, J=3.29, 1.92 Hz), 7.79 (1 H, dd, J=4.94, 1.65 Hz), 8.12 -
8.22 (2 H, m), 8.26 (1
H, d, J=8.78 Hz), 8.57 (1 H, d, J=0.82 Hz), 8.72 (1 H, d, J=4.94 Hz), 8.80 (1
H, s), 9.33 (1 H, s),
11.39(1 H, s); ESIMS found for C24H22N60S m/z 443.2 (M+1).
Nµpr.
N
412
[0948] N-(6-(5-Methy1-1,3,4-thiadiazol-2-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-1-y1)isonicotinamide 412.
[0949] Beige solid (35.0 mg, 0.079 mmol, 38.3% yield). IFINMR (500
MHz, DMSO-
d6) 6 ppm 2.23 (3 H, s), 2.41 - 2.46 (4 H, m), 2.84 (3 H, s), 3.55 - 3.66 (4
H, m), 7.16 (1 H, dd,
J=5.21, 1.10 Hz), 7.48 (1 H, s), 8.16(1 H, dd, J=8.51, 1.65 Hz), 8.20 - 8.30
(2 H, m), 8.55 (1 H, s),
8.78(1 H, s), 9.31(1 H, s), 11.20 (1 H, s); ESIMS found for C23H23N70S m/z
446.2 (M+1).
NL3J
Ikr N
419
[0950] 2-(Methyl(1-methylpiperidin-4-yl)amino)-N-(6-(5-methyl-1,3,4-
thiadiazol-2-
ypisoquinolin-3-y1)isonicotinamide 419.
187
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0951] Beige solid (35.0 mg, 0.074 mmol, 36.0% yield). 'FINMR (500
MHz, DMSO-
d6) 6 ppm 1.49 - 1.61 (2 H, m), 1.80 (2 H, qd, J=12.12, 3.70 Hz), 1.98 -2.08
(2 H, m), 2.19 (3 H,
s), 2.86(2 H, br d, J=11.53 Hz), 2.93 (3 H, s), 4.50(1 H, ddt, J=11.66, 7.89,
3.95, 3.95 Hz), 7.08
(1 H, dd, J=5.21, 1.37 Hz), 7.19(1 H, s), 8.16(1 H, dd, J=8.51, 1.65 Hz),
8.23(1 H, d, J=5.21 Hz),
8.25 (1 H, d, J=8.78 Hz), 8.55 (1 H, s), 8.77 (1 H, s), 9.31 (1 H, s), 11.16
(1 H, s); ESIMS found
for C25H27N70S m/z 474.2 (M+1).
of./NH
o
420
[0952] 2-(Azetidin-3 -yloxy)-N-(6-(5 -methyl-1,3 ,4 soquinolin-3 -
y1)
isonicotinamide 420.
[0953] Beige solid (4.0 mg, 0.010 mmol, 10.1% yield). 1HNMR (500 MHz,
DMSO-
d6) 6 ppm 2.84 (3 H, s), 3.50 -3.59 (2 H, m), 3.72 - 3.81 (2 H, m), 5.35 -5.45
(1 H, m), 7.41 (1 H,
s), 7.55 (1 H, dd, J=5.49, 1.37 Hz), 8.17 (1 H, dd, J=8.51, 1.65 Hz), 8.26 (1
H, d, J=8.51 Hz), 8.31
(1 H, d, J=5.49 Hz), 8.57(1 H, s), 8.77(1 H, s), 9.32 (1 H, s), 11.26(1 H, br
s); ESIMS found for
C2,tli8N602S m/z 419.1 (M+1).
H 0-
NQ
Q)
0
422
[0954] N-(6-(5 -methyl-1,3 ,4-thiadiazol-2 -yl)i soquinolin-3 -y1)-3
-
methylpiperidin-4-yl)oxy)benzamide 422.
[0955] Yellow solid (22.8 mg, 0.047 mmol, 10.7% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.63 - 1.74 (2 H, m), 1.93 - 2.00 (2 H, m), 2.16 - 2.24 (2 H,
m), 2.19 (3 H, s),
2.56 - 2.69 (2 H, m), 2.84 (3 H, s), 4.53 (1 H, tt, J=8.03, 3.91 Hz), 7.18 (1
H, ddd, J=8.16, 2.40,
0.96 Hz), 7.43 (1 H, t, J=8.10 Hz), 7.59 - 7.69 (2 H, m), 8.15 (1 H, dd,
J=8.51, 1.65 Hz), 8.25 (1
H, d, J=8.78 Hz), 8.54 (1 H, d, J=0.82 Hz), 8.77 (1 H, s), 9.30 (1 H, s),
10.98 (1 H, s); ESIMS
found for C25H25N502S m/z 460.2 (M+1).
Hlra ;)1
N \ I s
o
423
[0956] N-(6-(5 -Methyl-1,3,4soquinolin-3 -y1)-2 -
methylpiperidin-4-yl)thio)isonicotinamide 423.
188
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
109571 Light yellow solid (44.0 mg, 0.092 mmol, 33.7% yield). 'FINMR
(499 MHz,
DMSO-d6) 6 ppm 1.60 - 1.72 (2 H, m), 1.98 -2.07 (2 H, m), 2.12 (2 H, br t,
J=10.43 Hz), 2.17 (3
H, s), 2.69(2 H, br d,J=10.98 Hz), 2.84(3 H, s), 3.84 (1H, brt,J=10.15 Hz),
7.64(1 H, dd,J=5.21,
1.37 Hz), 7.82 (1 H, s), 8.17 (1 H, dd, J=8.51, 1.65 Hz), 8.26 (1 H, d, J=8.51
Hz), 8.56 (1 H, s),
8.62 (1 H, d, J=5.21 Hz), 8.76 (1 H, s), 9.31(1 H, s), 11.30 (1 H, s); ESIMS
found for C24H24N60S2
m/z 477.1 (M+1).
427
[0958] N-(7-Fluoro-6-(5-methy1-1,3,4-thiadiazol-2-yl)isoquinolin-3-y1)-
2-(4-
methylpiperazin-1-y1)isonicotinamide 427.
[0959] Off-white solid (15.0 mg, 0.032 mmol, 17.9% yield). "H NMR (499
MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.39 -2.45 (4 H, m), 2.86 (3 H, s), 3.58 -3.64
(4 H, m), 7.16 (1 H,
dd, J=5.21, 1.37 Hz), 7.47(1 H, s), 8.20(1 H, d, J=11.25 Hz), 8.26(1 H, d,
J=4.94 Hz), 8.23 - 8.24
(1 H, m), 8.79 (1 H, s), 8.84 (1 H, d, J=7.14 Hz), 9.30 (1 H, s), 11.20 (1 H,
s); ESIMS found for
C23H22FN70S m/z 464.2 (M+1).
NI4r,
0
428
[0960] N-(6-(5 -(Dimethylamino)-1,3,4-thiadiazol-2-yl)i soquinolin-3 -
y1)-2-(4-
methylpiperazin-1-yl)isonicotinamide 428.
[0961] Yellow solid (14.6 mg, 0.031 mmol, 26.8% yield). 11-1 NMR (499
MHz,
DMSO-d6) 6 ppm 2.32 (3 H, br s), 2.52 - 2.67 (4 H, m), 3.19 (6 H, s), 3.64 (4
H, br s), 7.14 - 7.21
(1 H, m), 7.48(1 H, s), 8.07(1 H, dd, J=8.51, 1.65 Hz), 8.17(1 H, s), 8.24 -
8.29 (2 H, m), 8.70(1
H, s), 9.24 (1 H, s), 11.14 (1 H, s); ESIMS found for C24H26N80S m/z 475.2
(M+1).
Q11A41 NI6
429
[0962] N-(6-(1-Methy1-5-(piperidin-1-ylmethyl)-1H-pyrazol-4-
ypisoquinolin-3-y1)-
2-morpholinoisonicotinamide 429.
189
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[0963] White solid (23.0 mg, 0.045 mmol, 25.0% yield). 11-INMR (499
MHz, DMSO-
d6) 6 ppm 1.32 - 1.44 (2 H, m), 1.45 - 1.55 (4 H, m), 2.38 (4 H, br s), 3.53 -
3.62 (4 H, m), 3.67 (2
H, s), 3.71 - 3.77 (4 H, m), 3.92 (3 H, s), 7.21 (1 H, dd, J=5.21, 1.10 Hz),
7.47 (1 H, s), 7.76 (1 H,
dd, J=8.51, 1.65 Hz), 7.82 (1 H, s), 8.09 (1 H, d, J=8.51 Hz), 8.14 (1 H, s),
8.29 (1 H, d, J=5.21
Hz), 8.61 (1 H, s), 9.17(1 H, s), 11.01 (1 H, s); ESIMS found for C29H33N702
m/z 512.0 (M+1).
NQCLN I N=
430
[0964] N-(6-(5-Amino-1,3,4-thiadiazol-2-ypisoquinolin-3-y1)-2-(4-
methylpiperazin-
1-y1)isonicotinamide 430.
[0965] Yellow solid (3.7 mg, 0.008 mmol, 5.4% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.27 (3 H, br s), 3.62 (4 H, br s), 7.12 - 7.20 (1 H, m), 7.48 (1 H,
s), 7.60 (2 H, s), 8.07
(1 H, dd, J=8.51, 1.65 Hz), 8.16 (1 H, d, J=8.78 Hz), 8.25 (1 H, s), 8.27 (1
H, d, J=4.94 Hz), 8.71
(1 H, s), 9.24(1 H, s), 11.13 (1 H, s); ESIMS found for C22H221\180S m/z 447.2
(M+1).
\N
GQ1CL
µ141 N
NH
431
[0966] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-
(piperazin-1-y1)
isonicotinamide 431.
[0967] Beige solid (76.0 mg, 0.183 mmol, 42.6% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.77 -2.85 (4 H, m), 3.50 -3.58 (4 H, m), 4.15 (3 H, s), 7.14 (1 H,
dd, J=5.21, 1.10 Hz),
7.43 (1 H, s), 8.08 (1 H, dd, J=8.51, 1.37 Hz), 8.18 (1 H, d, J=8.51 Hz), 8.25
(1 H, d, J=5.21 Hz),
8.38 (1 H, s), 8.66(1 H, s), 8.76(1 H, s), 9.21 (1 H, s), 11.09(1 H, s); ESIMS
found for C22H22N80
m/z 415.2 (M+1).
NN0
o
432
[0968] 2-(Azetidin-1-y1)-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-
3 -y1)
isonicotinamide 432.
[0969] Off-white solid (73.7 mg, 0.192 mmol, 66.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.31 -2.41 (2 H, m), 3.85 (3 H, s), 4.03 (4 H, t, J=7.41 Hz),
7.01 (1 H, d, J=0.82
Hz), 7.15 (1 H, dd, J=5.21, 1.65 Hz), 7.33 (1 H, d, J=1.10 Hz), 7.74 (1 H, dd,
J=8.37, 1.78 Hz),
190
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
7.81 (1 H, s), 8.09 (1 H, s), 8.15 (1 H, d, J=8.51 Hz), 8.21 (1 H, d, J=5.21
Hz), 8.68 (1 H, s), 9.22
(1 H, s), 11.04(1 H, s); ESIMS found for C22H20N60 m/z 385.2 (M+1).
/
N\C
A.1 0al
N
OMe
Hy
433
[0970] 2-Methoxy-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-3 -y1)
isonicotinamide 433.
[0971] Off-white solid (28.0 mg, 0.078 mmol, 34.9% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.85 (3 H, s), 3.93 (3 H, s), 7.33 (1 H, s), 7.42 (1 H, d,
J=1.37 Hz), 7.55 (1 H,
dd, J=5.21, 1.37 Hz), 7.75 (1 H, dd, J=8.51, 1.65 Hz), 7.81 (1 H, s), 8.11 (1
H, d, J=0.82 Hz), 8.16
(1 H, d, J=8.51 Hz), 8.35(1 H, d, J=5.21 Hz), 8.69(1 H, s), 9.23(1 H, s),
11.16(1 H, s); ESIMS
found for C201-117N502m/z 360.1 (M+1).
1
N
434
[0972] 2-Methyl-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-3 -yl)i
sonicotinamide
434.
[0973] Off-white solid (32.1 mg, 0.094 mmol, 41.9% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.58 (3 H, s), 3.85 (3 H, s), 7.33 (1 H, d, J=0.82 Hz), 7.71 -
7.78 (2 H, m), 7.81
(1 H, s), 7.86(1 H, s), 8.12(1 H, s), 8.16(1 H, d, J=8.51 Hz), 8.64(1 H, d,
J=4.94 Hz), 8.69(1 H,
s), 9.23 (1 H, s), 11.14 (1 H, s); ESIMS found for C201-117N50 m/z 344.1
(M+1).
Hyal
N
CN
A.1 0
435
[0974] 2-Cyano-N-(6-(1-methy1-1H-imidazol-5 -yl)i soquinolin-3 -yl)i
sonicotinamide
435.
[0975] Off-white solid (36.0 mg, 0.102 mmol, 45.6% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 3.86(3 H, s), 7.34(1 H, d, J=0.82 Hz), 7.77(1 H, dd, J=8.51,
1.65 Hz), 7.81(1
H, s), 8.14(1 H, s), 8.17(1 H, d, J=8.51 Hz), 8.26(1 H, dd, J=4.94, 1.65 Hz),
8.60(1 H, d, J=0.82
Hz), 8.70(1 H, s), 8.93 - 8.99 (1 H, m), 9.24(1 H, s), 11.44(1 H, s); ESIMS
found for C201-114N60
m/z 355.1 (M+1).
191
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Ni\
N
0
436
[0976] 5 -Chloro-N-(6-(1-methy1-1H-pyrazol-4-ypi soquinolin-3 -y1)-2-
(4-
methylpiperazin-1 -yl)isonicotinamide 436.
[0977] Off-white solid (18.7 mg, 0.041 mmol, 67.2% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.21 (3 H, s), 2.39 (4 H, br t, J=4.94 Hz), 3.49 -3.58 (4 H,
m), 3.91 (3 H, s), 7.08
(1 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.05(1 H, d, J=8.78 Hz), 8.11 (1 H,
s), 8.16(1 H, s), 8.19
(1 H, s), 8.38 (1 H, s), 8.55 (1 H, s), 9.08 (1 H, s), 11.15 (1 H, s); ESIMS
found for C24H24C1N70
m/z 462.2 (M+1).
N
437
[0978] 2-(3,3-Difluoroazetidin-l-y1)-N-(6-(1-methy1-1H-imidazol-5-
y1)isoquinolin-
3-y1)isonicotinamide 437.
[0979] White solid (11.5 mg, 0.027 mmol, 9.5% yield). NMR (499 MHz,
DMSO-
d6) 6 ppm 3.85 (3 H, s), 4.49 (4 H, t, J=12.49 Hz), 7.24 (1 H, s), 7.31 (1 H,
dd, J=5.21, 1.37 Hz),
7.33(1 H, s), 7.75(1 H, dd, J=8.64, 1.51 Hz), 7.81(1 H, s), 8.10(1 H, s),
8.16(1 H, d, J=8.51 Hz),
8.31 (1 H, d, J=5.21 Hz), 8.69(1 H, s), 9.23(1 H, s), 11.11 (1 H, s); ESIMS
found for C22H18F2N60
m/z 421.1 (M+1).
\N
141,
N
NONicDD
0
438
[0980] 2-(4,4-Bis(methyl-d3)-44-piperazin-l-y1)-N-(6-(1-methy1-1H-
1,2,3-triazol-
4-ypisoquinolin-3-ypisonicotinamide 438.
[0981] Beige solid (62.0 mg, 0.108 mmol, 74.3% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 3.53 (4 H, t, J=5.21 Hz), 3.94 -4.04 (4 H, m), 4.15 (3 H, s), 7.32
(1 H, dd, J=5.21, 1.10
Hz), 7.61 (1 H, s), 8.08 (1 H, dd, J=8.64, 1.51 Hz), 8.19 (1 H, d, J=8.78 Hz),
8.35 (1 H, d, J=5.21
Hz), 8.40 (1 H, s), 8.68 (1 H, s), 8.76 (1 H, s), 9.23 (1 H, s), 11.13 (1 H,
s); ESIMS found for
C24H21[2H611\180 m/z 449.3 (M+).
192
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
\N
Nix
N I
'141
D
439
[0982] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-(4-
(methyl-d3)
piperazin-l-yl)isonicotinamide 439.
[0983] Beige solid (44.0 mg, 0.102 mmol, 35.5% yield). 1H NMR (499
MHz, DMSO-
d6) 6 ppm 2.43 (4 H, t, J=4.94 Hz), 3.56 -3.63 (4 H, m), 4.15 (3 H, s), 7.17
(1 H, dd, J=5.08, 0.96
Hz), 7.47 (1 H, s), 8.08 (1 H, dd, J=8.37, 1.51 Hz), 8.18 (1 H, d, J=8.51 Hz),
8.26 (1 H, d, J=5.21
Hz), 8.38 (1 H, s), 8.66 (1 H, s), 8.76 (1 H, s), 9.21 (1 H, s), 11.11 (1 H,
s); ESIMS found for
C23H2112H311\180 m/z 432. (M+1).
NyyLN
0 CI N\
440
[0984] 3 -Chloro-N-(6-(1-methy1-1H-pyrazol-4-ypi soquinolin-3 -y1)-2-
(4-
methylpiperazin-1 -yl)isonicotinamide 440.
[0985] Off-white solid (90.7 mg, 0.196 mmol, 29.4% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.24 (3 H, s), 2.49 (4 H, br s), 3.26 - 3.31 (4 H, m), 3.91 (3
H, s), 7.17 (1 H, d,
J=4.67 Hz), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.05 (1 H, d, J=8.51 Hz), 8.11(1
H, s), 8.17 (1 H, s),
8.29 (1 H, d, J=4.67 Hz), 8.38 (1 H, s), 8.55 (1 H, s), 9.07 (1 H, s), 11.21
(1 H, s); ESIMS found
for C24H24C1N70 m/z 462.2 (M+1).
N I
N
441
[0986] 2-(4,4-Difluoropiperidin-l-y1)-N-(6-(1-methy1-1H-imidazol-5-
ypisoquinolin-
3-ypisonicotinamide 441.
[0987] White solid (18.9 mg, 0.042 mmol, 24.4% yield). IFINMR (499
MHz, DMSO-
d6) 6 ppm 1.99 - 2.09 (4 H, m), 3.81 (4 H, br d, J=5.76 Hz), 3.85 (3 H, s),
7.19 (1 H, dd, J=5.21,
1.10 Hz), 7.33 (1 H, d, J=0.82 Hz), 7.58 (1 H, s), 7.74 (1 H, dd, J=8.51, 1.65
Hz), 7.81 (1 H, s),
8.10(1 H, s), 8.16(1 H, d, J=8.51 Hz), 8.29(1 H, d, J=5.21 Hz), 8.70(1 H, s),
9.23(1 H, s), 11.14
(1 H, s); ESIMS found for C24H22F2N60 m/z 449.2 (M+1).
193
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
NI\
0
442
[0988] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-(5-methyl-2,5-
diazabicyclop.2.11heptan-2-yDisonicotinamide 442.
[0989] Off-white solid (74.4 mg, 0.161 mmol, 59.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.77 (1 H, br d, J=9.06 Hz), 1.90 (1 H, br d, J=8.78 Hz), 2.30
(3 H, s), 2.48 (1
H, br s), 2.86 (1 H, dd, J=9.47, 1.78 Hz), 3.34 (1 H, dd, J=9.88, 2.20 Hz),
3.49 (1 H, br s), 3.57 (1
H, br d, J=9.88 Hz), 3.91 (3 H, s), 4.70(1 H, br s), 7.05 (1 H, dd, J=5.21,
1.37 Hz), 7.11 (1 H, s),
7.81 (1 H, dd, J=8.64, 1.51 Hz), 8.07(1 H, d, J=8.51 Hz), 8.09 - 8.16 (2 H,
m), 8.19(1 H, d, J=4.94
Hz), 8.38 (1 H, s), 8.59 (1 H, s), 9.12 (1 H, s), 10.98 (1 H, s); ESIMS found
for C25H25N70 m/z
440.2 (M+1).
/
0
443
[0990] 2-Isopropoxy-N-(6-(1 -methyl-1H-imidazol-5 -yl)i soquinolin-3 -
y1)
isonicotinamide 443.
[0991] Off-white solid (94.6 mg, 0.244 mmol, 54.8% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.33 (6H, d, J=6.31 Hz), 3.85(3 H, s), 5.30(1 H, spt, J=6.17
Hz), 7.30(1 H, s),
7.33 (1 H, d, J=0.82 Hz), 7.50 (1 H, dd, J=5.21, 1.37 Hz), 7.75 (1 H, dd,
J=8.37, 1.78 Hz), 7.81 (1
H, s), 8.11(1 H, s), 8.15(1 H, d, J=8.51 Hz), 8.32(1 H, d, J=5.21 Hz), 8.68(1
H, s), 9.22(1 H, s),
11.11(1 H, s); ESIMS found for C22H2IN502 m/z 388.2 (M+1).
\N
\
NHLN
0 114F1
444
[0992] 2-(2,5-Diazabicyclo[2.2.11heptan-2-y1)-N-(6-(1-methy1-1H-pyrazol-
4-y1)
isoquinolin-3-yl)isonicotinamide 444.
[0993] Off-white solid (145.0 mg, 0.324 mmol, 88.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.71 (1 H, br d, J=9.06 Hz), 1.82 (1 H, br d, J=9.33 Hz), 2.86
(1 H, br d, J=9.61
Hz), 2.96 (1 H, br d, J=8.78 Hz), 3.29 (1 H, br s), 3.52 (1 H, dd, J=9.33,
1.37 Hz), 3.75 (1 H, br s),
3.91 (3 H, s), 4.76(1 H, br s), 7.07(1 H, d, J=4.94 Hz), 7.12(1 H, br s), 7.81
(1 H, dd, J=8.51, 1.65
194
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Hz), 8.07(1 H, d, J=8.51 Hz), 8.11 (1 H, s), 8.13 (1 H, s), 8.19(1 H, d,
J=4.94 Hz), 8.38 (1 H, s),
8.59 (1 H, s), 9.12 (1 H, s), 10.97 (1 H, s); ESIMS found for C24H23N70 m/z
426.2 (M+1).
\N NNJ
0
445
[0994] N-(6-(1-Methy1-1H-1,2,3-triazol-4-ypisoquinolin-3-y1)-2-(2-(4-
methylpiperazin-1-y1)pyridin-4-y1)acetamide 445.
[0995] Beige solid (2.0 mg, 0.005 mmol, 3.1% yield). IFINMR (499 MHz,
DMSO-
d6) 6 ppm 2.22 (3 H, s), 2.40 (4 H, br t, J=4.94 Hz), 3.45 - 3.51(4 H, m),
3.71 (2 H, s), 4.13 (3 H,
s), 6.66 (1 H, d, J=4.67 Hz), 6.83 (1 H, s), 8.01 - 8.06 (2 H, m), 8.12 (1 H,
d, J=8.78 Hz), 8.28 (1
H, s), 8.46 (1 H, s), 8.72 (1 H, s), 9.13 (1 H, s), 10.85 (1 H, s); ESIMS
found for C24H261\180 m/z
443.2 (M+1).
\N
141/\
NyyLN
0 F
454
[0996] 3 -Fluoro-N-(6-(1-methy1-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2
-(4-
methylpiperazin-1 -yl)isonicotinamide 454.
[0997] Off-white solid (85.9 mg, 0.193 mmol, 24.0% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.42 -2.47 (4 H, m), 3.41 - 3.49 (4 H, m), 3.91
(3 H, s), 7.05 (1 H,
t, J=4.39 Hz), 7.82 (1 H, dd, J=8.51, 1.65 Hz), 8.06 (1 H, d, J=8.51 Hz), 8.08
(1 H, d, J=4.94 Hz),
8.11(1 H, s), 8.16(1 H, s), 8.38(1 H, s), 8.55(1 H, s), 9.09(1 H, s), 11.17(1
H, s); ESIMS found
for C24H24FN70 m/z 446.2 (M+1).
\N
Ni\ 1,11 N
0
455
[0998] N-(6-(1-Methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-2-((4-
methylpiperazin-1-
y1)methyl)isonicotinamide 455.
[0999] Off-white solid (12.5 mg, 0.028 mmol, 15.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.17 (3 H, s), 2.36 (4 H, dt, J=3.77, 2.09 Hz), 2.42 -2.49 (4
H, m), 3.68 (2 H, s),
3.91 (3 H, s), 7.83 (1 H, dd, J=13.45, 1.65 Hz), 7.83 (1 H, d, J=1.65 Hz),
7.95 (1 H, s), 8.07 (1 H,
195
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
d, J=8.51 Hz), 8.12 (1 H, s), 8.15 (1 H, s), 8.39 (1 H, s), 8.59 (1 H, s),
8.68 (1 H, d, J=4.94 Hz),
9.13(1 H, s), 11.18(1 H, s); ESIMS found for C25H27N70 m/z 442.2 (M+1).
\ N (0
N 0
456
[01000] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-
(morpholinomethyl)
isonicotinamide 456.
[01001] Off-white solid (13.6 mg, 0.032 mmol, 80.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.47 (4 H, br s), 3.59 - 3.65 (4 H, m), 3.69 (2 H, s), 3.91 (3
H, s), 7.83 (1 H, br
dd, J=16.47, 1.65 Hz), 7.83 - 7.84 (1 H, m), 7.98 (1 H, s), 8.08 (1 H, d,
J=8.51 Hz), 8.12 (1 H, s),
8.15 (1 H, s), 8.39 (1 H, s), 8.59 (1 H, s), 8.69 (1 H, d, J=4.94 Hz), 9.13 (1
H, s), 11.19 (1 H, s);
ESIMS found for C24H24N602 m/z 429.2 (M+1).
11-411 I NI
N 0
457
[01002] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-
(pyrrolidin-1-ylmethyl)
isonicotinamide 457.
[01003] Off-white solid (12.0 mg, 0.029 mmol, 80.7% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 1.74 (4 H, dt, J=6.52, 3.19 Hz), 2.56 (4 H, br s), 3.82 (2 H,
s), 3.91 (3 H, s), 7.81
- 7.84 (2 H, m), 7.96 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 8.12 (1 H, s), 8.15
(1 H, s), 8.39 (1 H, s),
8.59 (1 H, s), 8.67 (1 H, d, J=4.94 Hz), 9.13 (1 H, s), 11.19 (1 H, s); ESIMS
found for C24H24N60
m/z 413.2 (M+1).
N-
N 0 N
458
[01004] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1)-2-(2-(4 -
methylpiperazin-
1-yl)pyridin-4-yl)acetamide 458.
[01005] Beige solid (10.0 mg, 0.023 mmol, 5.3% yield). 1H NMR (499 MHz,
DMSO-
d6) 6 ppm 2.21 (3 H, s), 2.37 - 2.42 (4 H, m), 3.43 - 3.49 (4 H, m), 3.70 (2
H, s), 3.89 (3 H, s), 6.66
(1 H, d, J=4.94 Hz), 6.83 (1 H, s), 7.76 (1 H, dd, J=8.51, 1.65 Hz), 8.01 (1
H, d, J=8.51 Hz), 8.03
196
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
- 8.05 (2 H, m), 8.08 (1 H, s), 8.35 (1 H, s), 8.39 (1 H, s), 9.04 (1 H, s),
10.77 (1 H, s); ESIMS
found for C25H27N70 m/z 442.2 (M+1).
14/\
N1HLN
0
459
[01006] N-(6-(1 -Methyl-1H-pyrazol-4-ypi soquinolin-3 -y1-1 -d)-2-(4-
methylpiperazin-
1-yl)isonicotinamide 459.
[01007] Off-white solid (69.0 mg, 0.179 mmol, 64.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.56 - 3.64 (4 H, m),
3.91 (3 H, s), 7.16
(1 H, dd, J=5.08, 1.24 Hz), 7.46(1 H, s), 7.81(1 H, dd, J=8.64, 1.51 Hz),
8.07(1 H, d, J=8.51 Hz),
8.11 (1 H, s), 8.14 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.38 (1 H, s), 8.59 (1
H, s), 11.04 (1 H, s);
ESIMS found for C24H242H1N70 m/z 429. (M+1).
\N
N I
461
[01008] N-(6-(1 -Methyl-1H-pyrazol-4 -yl)i soquinolin-3 -y1-1 -d)-2-
(pipe razin-1 -y1)
isonicotinamide 461.
[01009] Off-white solid (69.0 mg, 0.179 mmol, 64.5% yield). 11-1 NMR
(499 MHz,
DMSO-d6) 6 ppm 2.77 - 2.84 (4 H, m), 3.48 - 3.57 (4 H, m), 3.91 (3 H, s), 7.13
(1 H, dd, J=5.08,
1.24 Hz), 7.42 (1 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 8.07 (1 H, d, J=8.51
Hz), 8.11 (1 H, s),
8.14(1 H, s), 8.25(1 H, d, J=5.21 Hz), 8.38(1 H, s), 8.59(1 H, s), 11.03(1 H,
s); ESIMS found
for C23H22[21-11N70 m/z 415. (M+1).
N
Hi\ \
0
462
[01010] 1-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-1H-
indazole-5-
carboxamide 462.
197
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[01011] Light yellow solid (32.0 mg, 0.084 mmol, 18.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.92 (3 H, s), 4.11(3 H, s), 7.75 (1 H, d, J=9.06 Hz), 7.80 (1
H, dd, J=8.51, 1.65
Hz), 8.06(1 H, d, J=8.51 Hz), 8.12(1 H, dd, J=8.92, 1.51 Hz), 8.12(1 H, s),
8.14(1 H, s), 8.24(1
H, s), 8.38 (1 H, s), 8.62 (2 H, s), 9.12 (1 H, s), 10.82 (1 H, s); ESIMS
found for C22F1181\160 m/z
383.15 (M+1).
\N
14/\
0
463
[01012] 1-Methyl-N-(6-(1-methy1-1H-pyrazol-4-ypisoquinolin-3-y1)-1H-
benzo[d]
imidazole-5-carboxamide 463.
[01013] Light yellow solid (35.6 mg, 0.093 mmol, 20.8% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 3.90 (3 H, s), 3.92 (3 H, s), 7.70 (1 H, d, J=8.51 Hz), 7.79 (1
H, dd, J=8.51, 1.65
Hz), 8.06 (2 H, d, J=8.51 Hz), 8.11(1 H, s), 8.13 (1 H, s), 8.33 (1 H, s),
8.38 (1 H, s), 8.47(1 H, d,
J=1.65 Hz), 8.62 (1 H, s), 9.12 (1 H, s), 10.78 (1 H, s); ESIMS found for
C22F1181\160 m/z 383.2
(M+1).
NHL/410
0
464
[01014] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-
(pyrrolidin-1-y1)
isonicotinamide 464.
[01015] Off-white solid (51.7 mg, 0.125 mmol, 45.3% yield). NMR
(499 MHz,
DMSO-d6) 6 ppm 1.95 - 2.01 (4 H, m), 2.40(3 H, s), 3.45 - 3.51 (4 H, m),
3.68(3 H, s), 7.06(1 H,
dd, J=5.21, 1.37 Hz), 7.08 (1 H, s), 7.14 (1 H, s), 7.67 (1 H, dd, J=8.51,
1.65 Hz), 8.00 (1 H, s),
8.14(1 H, d, J=8.78 Hz), 8.17 - 8.23 (1 H, m), 8.67(1 H, s), 9.22(1 H, s),
11.03(1 H, s); ESIMS
found for C24H24N60 m/z 413.2 (M+1).
11
y
A4 0
465
[01016] N-(6-(1,2-Dimethy1-1H-imidazol-5-ypisoquinolin-3-y1)-2-
(dimethylamino)
isonicotinamide 465.
198
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[01017] Off-
white solid (69.0 mg, 0.179 mmol, 64.5% yield). 11-1 NMR (499 MHz,
DMSO-d6) 6 ppm 2.40(3 H, s), 3.11 (6 H, s), 3.68(3 H, s), 7.09(1 H, dd,
J=5.21, 1.10 Hz), 7.14
(1 H, s), 7.25(1 H, s), 7.67(1 H, dd, J=8.51, 1.65 Hz), 8.00(1 H, s), 8.14(1
H, d, J=8.51 Hz), 8.23
(1 H, d, J=4.94 Hz), 8.68 (1 H, s), 9.22 (1 H, s), 11.07 (1 H, s); ESIMS found
for C22H22N60 m/z
387.2 (M+1).
Example 4.
[01018] The
screening assay for Wnt activity is described as follows. Reporter cell
lines can be generated by stably transducing cancer cell lines (e.g., colon
cancer) or primary cells
(e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-
responsive promoter
driving expression of the firefly luciferase gene.
[01019] SW480
colon carcinoma cells were transduced with a lentiviral vector
expressing luciferase with a human Sp5 promoter consisting of a sequence of
eight TCF/LEF
binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a
hygromycin
resistance gene were selected by treatment with 150 pg/mL of hygromycin for 7
days. These stably
transduced SW480 cells were expanded in cell culture and used for all further
screening activities.
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare
compound source
plates. Serial dilution (1:3, 10-point dose-response curves starting from 10
I.A.M) and compound
transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-
well white solid
bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a
final DMSO
concentration of 0.1%. For 5p5-Luc reporter gene assays, the cells were plated
at 4,000 cells/well
in 384-well plates with a DMEM medium containing 1% fetal bovine serum, and 1%
Penicillin-
Streptomycin and incubated for 36 to 48 hours at 37 C and 5% CO2. Following
incubation, 15 ill
of BriteLite Plus luminescence reagent (Perkin Elmer) was added to each well
of the 384-well
assay plates. The plates were placed on an orbital shaker for 2 min and then
luminescence was
quantified using the Envision (Perkin Elmer) plate reader. Readings were
normalized to DMSO
only treated cells, and normalized activities were utilized for EC50
calculations using the dose-
response log (inhibitor) vs. response ¨variable slope (four parameters)
nonlinear regression feature
available in GraphPad Prism 5.0 (or Dotmatics). For EC50 of >10 1.1.M, the
percent inhibition at 10
I.A.M is provided.
[01020] Table 2
shows the measured activity for representative compounds of Formula
I as described herein.
199
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
Table 2.
Compound ECso ( M) Compound ECso ( M) Compound ECso ( M) Compound ECso ( M)
1 0.067 90 0.132 219 0.890 339 0.699
2 0.091 91 0.107 220 0.463 340 0.346
3 0.116 92 0.103 221 0.608 359 0.013
4 0.370 93 0.036 222 0.189 373 6.427
0.089 94 0.110 223 0.489 374 0.211
6 0.070 95 >10 (3.5%) 230 0.037 375
>10 (44.7%)
7 0.113 97 0.041 232 0.256 376 0.113
8 0.170 99 0.041 233 0.120 377 5.568
9 0.039 100 8.409 236 0.070 378 0.268
0.046 101 1.041 238 0.036 379 0.100
11 0.116 102 0.979 240 0.035 380
>10(11.2%)
12 0.487 103 2.272 241 0.183 381 3.515
13 0.171 104 0.177 242 0.042 382 0.509
14 0.153 105 0.764 243 0.094 383 0.116
>10 (8.0%) 106 0.307 245 0.038 384 0.162
16 0.062 107 0.912 249 1.223 385 0.211
17 0.058 108 0.193 250 0.055 386 0.106
18 0.200 109 0.312 253 0.054 387
>10 (46.4%)
19 0.066 110 0.320 256 0.117 388 0.139
0.705 111 0.184 257 3.911 389 0.561
21 0.745 112 0.128 258 1.749 390 0.117
22 2.109 113 0.120 261 0.101 391 0.043
23 0.425 114 0.131 265 0.106 392 0.111
24 >10 (0%) 116 0.136 266 0.057 393 0.080
>10 (48.8%) 117 0.375 268 0.104 406 0.116
26 3.785 118 >10 (0%) 271 0.114 409 0.041
27 4.362 119 0.554 273 0.083 412 0.059
28 0.472 120 0.328 275 0.012 419 0.069
29 0.307 122 0.238 276 0.093 420 0.449
37 0.033 123 0.264 277 0.156 422 0.107
40 0.684 126 0.185 278 0.088 423 0.040
45 0.449 127 0.214 285 0.090 427 3.676
47 3.357 130 0.250 286 0.107 428 0.138
49 0.098 131 0.285 289 0.174 429 0.073
52 1.003 132 0.365 290 0.104 430 0.036
53 0.039 133 0.223 291 0.710 431 0.047
54 0.035 134 0.058 292 0.375 432 0.109
55 0.032 135 0.236 293 2.268 433 0.559
56 0.031 136 2.124 294 0.161 434 0.104
57 0.109 137 0.949 296 >10 (14.6%) 435 0.136
59 0.062 138 3.188 301 0.101 436 3.134
60 0.680 139 2.962 306 1.019 437 0.500
61 0.182 140 0.152 309 0.103 438 2.511
62 0.127 141 >10 (8.8%) 310 1.692 439 0.048
63 0.108 142 0.055 313 2.139 440
>10 (48.0%)
64 0.298 143 0.045 317 0.279 441 0.228
65 0.422 144 0.051 318 0.396 442 0.116
66 0.047 145 0.039 319 0.844 443 0.501
67 0.057 146 0.749 325 3.564 444 0.133
71 0.044 147 0.179 326 1.722 445 0.144
72 0.062 148 3.766 328 0.113 454 0.324
74 0.052 149 0.047 329 0.162 455 0.113
76 0.295 151 0.265 330 >10 (15.0%) 456 0.497
78 0.776 168 0.106 331 >10 (28.7%) 457 0.475
80 0.597 172 0.270 332 3.841 458 0.214
84 0.021 182 0.230 333 1.042 459 0.055
85 0.034 183 0.414 334 0.126 461 0.043
86 0.162 184 0.182 335 0.107 462 0.193
87 3.639 185 0.189 336 0.060 463 0.159
88 0.131 186 0.074 337 0.091 464 0.480
89 3.376 204 0.023 338 0.057 465 0.231
200
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Example 5.
[01021]
Representative compounds were screened using the assay procedure for
DYRK1A kinase activity as described below.
[01022] Each
compound was dissolved in DMSO as a 10 mM stock and used to prepare
compound source plates. Serial dilution (1:3, 11-point dose-response curves
from 10 [IM to 0.00016
[IM) and compound transfer was performed using the ECHO 550 (Labcyte,
Sunnyvale, CA) into
1536-well black-walled round bottom plates (Corning).
[01023] The
DYRK1A kinase assay was run using the Ser/Thr 18 peptide Z-lyte assay
kit according to manufacturer's instructions (Life Technologies- a Division of
Thermo-Fisher).
This is a non-radioactive assay using fluorescence resonance energy transfer
(FRET) between
coumarin and fluorescein to detect kinase activity which is represented as a
ratio of coumarin
emission/fluorescein emission.
[01024]
Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were
prepared in 1X Kinase buffer to final concentrations of 0.19 [tg/mL, 30 [IM,
and 4 [IM respectively.
The mixture was allowed to incubate with the representative compounds for one
hour at room
temperature. All reactions were performed in duplicate. Unphosphorylated ("0%
Control") and
phosphorylated ("100% control") forms of Ser/Thr 18 served as control
reactions. Additionally,
an 11-point dose-response curve of Staurosporine (luM top) was run to serve as
a positive
compound control.
[01025] After
incubation, Development Reagent A was diluted in Development Buffer
then added to the reaction and allowed to further incubate for one hour at
room temperature. The
plate was read at Ex 400 Em 455 to detect the coumarin signal and Ex 400 Em
520 to measure the
signal (EnVision Multilabel Plate Reader, PerkinElmer).
[01026] The
Emission ratio (Em) was calculated as a ratio of the coumarin (C) emission
signal (at 445 nm)/Fluorescein (F) emission signal (at 520 nm). The percent
phosphorylation was
then calculated using the following formula: [1 - ((Em ratio X F100%)-C100%)/
((CO%-C100%)
+ (Em ratio X (F100% - F0%)))]. Dose-response curves were generated and
inhibitory
concentration (IC50) values were calculated using non-linear regression curve
fit in the Dotmatics'
Studies Software (Bishops Stortford, UK).
[01027] Table 3
shows the measured activity for representative compounds of Formula
I as described herein.
201
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
Table 3.
Compound ECso ( M) Compound ECso ( M) Compound ECso ( M) Compound ECso ( M)
1 0.0012 90 0.0023 219 0.0027 339 0.0395
2 0.0013 91 0.0067 220 0.0063 340 0.0012
3 0.0009 92 0.0010 221 0.0026 359 0.0037
4 0.0025 93 0.0007 222 0.0014 373 0.0177
0.0012 94 0.0013 223 0.0045 374 0.0038
6 0.0011 95 0.0034 230 0.0019 375 0.0126
7 0.0012 97 0.0013 232 0.0017 376 0.0067
8 0.0009 99 0.0025 233 0.0015 377 0.0093
9 0.0004 100 0.0444 236 0.0012 378 0.0028
0.0010 101 0.0257 238 0.0027 379 0.0025
11 0.0013 102 0.0093 240 0.0018 380 0.8647
12 0.0029 103 0.0055 241 0.0025 381
>10 (48.9%)
13 0.0020 104 0.0077 242 0.0017 382 0.0023
14 0.0009 105 0.0435 243 0.0024 383 0.0021
0.3124 106 0.0034 245 0.0016 384 0.0012
16 0.0011 107 0.0021 249 0.0018 385 0.0009
17 0.0018 108 0.0024 250 0.0022 386 0.0015
18 0.0017 109 0.0022 253 0.0014 387 0.0030
19 0.0015 110 0.0024 256 0.0017 388 0.0008
0.0552 111 0.0017 257 0.0184 389 0.0053
21 0.0632 112 0.0023 258 0.0189 390 0.0014
22 0.0551 113 0.0019 261 0.0016 391 0.0007
23 0.0100 114 0.0022 265 0.0019 392 0.0011
24 0.0673 116 0.0047 266 0.0013 393 0.0012
0.1583 117 0.0056 268 0.0019 406 0.0027
26 0.0412 118 0.0320 271 0.0021 409 0.0025
27 0.0333 119 0.0103 273 0.0011 412 0.0022
28 0.0011 120 0.0127 275 0.0006 419 0.0019
29 0.0012 122 0.0041 276 0.0011 420 0.0071
37 0.0009 123 0.0035 277 0.0008 422 0.0026
40 0.0035 126 0.0038 278 0.0028 423 0.0025
45 0.0018 127 0.0053 285 0.0012 427 0.0137
47 0.0397 130 0.0032 286 0.0008 428 0.0073
49 0.0042 131 4.9972 289 0.0033 429 0.0064
52 0.0031 132 0.0032 290 0.0029 430 0.0023
53 0.0020 133 0.0044 291 0.0116 431 0.0019
54 0.0020 134 0.0016 292 0.0057 432 0.0016
55 0.0011 135 0.0039 293 0.0145 433 0.0068
56 0.0014 136 0.0038 294 0.0105 434 0.0013
57 0.0026 137 0.0062 296 0.0053 435 0.0010
59 0.0013 138 0.0553 301 0.0009 436 0.0212
60 0.0037 139 0.0185 306 0.0023 437 0.0013
61 0.0026 140 0.0042 309 0.0015 438 0.0024
62 0.0023 141 0.3745 310 0.0017 439 0.0024
63 0.0027 142 0.0016 313 0.0021 440 0.0191
64 0.0033 143 0.0015 317 0.0011 441 0.0011
65 0.0030 144 0.0012 318 0.0017 442 0.0017
66 0.0055 145 0.0008 319 0.0014 443 0.0019
67 0.0017 146 0.0374 325 0.0018 444 0.0021
71 0.0019 147 0.0057 326 0.0026 445 0.0023
72 0.0019 148 0.2215 328 0.0036 454 0.0059
74 0.0070 149 0.0020 329 0.0046 455 0.0024
76 0.0028 151 0.0043 330 0.0115 456 0.0030
78 0.0021 168 0.0034 331 0.1220 457 0.0037
80 0.0136 172 0.0015 332 0.3297 458 0.0015
84 0.0029 182 0.0063 333 0.0435 459 0.0014
85 0.0016 183 0.0203 334 0.0010 461 0.0015
86 0.0019 184 0.0311 335 0.0015 462 0.0017
87 0.0039 185 0.0023 336 0.0011 463 0.0014
88 0.0028 186 0.0024 337 0.0017 464 0.0058
89 0.0223 204 0.0021 338 0.0010 465 0.0087
202
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Example 6.
[01028]
Representative compounds were screened using the assay procedure for
GSK3r3 kinase activity as described below.
[01029] Each
compound is dissolved in DMSO as a 10 mM stock and used to prepare
compound source plates. Serial dilution (1:3, 11-point dose-response curves
from 10 uM to 0.0003
uM) and compound transfer was performed using the ECHO 550 (Labcyte,
Sunnyvale, CA) into
1536-well black-walled round bottom plates (Corning).
[01030] The
G5K3I3 kinase assay is run using the Ser/Thr 09 peptide Z-lyte assay kit
according to manufacturer's instructions (Life Technologies- a Division of
Thermo-Fisher). This
is a non-radioactive assay using fluorescence resonance energy transfer (FRET)
between coumarin
and fluorescein to detect kinase activity which is represented as ratio of
coumarin
emission/fluorescein emission.
[01031]
Briefly, recombinant GSK3I3 kinase, ATP and Ser/Thr peptide 09 are prepared
in 1X Kinase buffer to final concentrations of 0.04 ug/mL, 46 uM, and 4 uM
respectively. The
mixture is allowed to incubate with the representative compounds for one hour
at room temperature.
All reactions were performed in duplicate. Unphosphorylated ("0% Control") and
phosphorylated
("100% control") forms of Ser/Thr 18 serve as control reactions.
[01032]
After incubation, diluted Development Buffer is added to the reaction and
allowed to further incubate for one hour at room temperature. The plate is
read at Ex 400 Em 455
to detect the coumarin signal and Ex 400 Em 520 to measure the signal
(EnVision Multilabel Plate
Reader, PerkinElmer).
[01033] The
Emission ratio (Em) is calculated as a ratio of the coumarin (C) emission
signal (at 445 nm)/Fluorescein (F) emission signal (at 520 nm). The percent
phosphorylation is
then calculated using the following formula: [1 - ((Em ratio X F100%)-C100%)/
((CO%-C100%)
+ (Em ratio X (F100% - F0%)))].
[01034] Dose-
response curves are generated and inhibitory concentration (IC50) values
are calculated using non-linear regression curve fit in the Dotmatics' Studies
Software (Bishops
Stortford, UK).
[01035]
Table 4 shows the activity of representative compounds of Formula I as
provided herein.
Table 4.
Compound ECso (AM) Compound ECso (AM) Compound ECso (AM) Compound ECso ( M)
1 3.346 90 3.862 219 0.986 339 8.182
2 3.689 91 9.164 220 4.438 340 2.603
203
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
3 3.726 92 5.321 221 0.343 359 1.833
4 2.066 93 6.272 222 0.780 373 >10
3.250 94 4.553 223 1.914 374 5.461
6 2.931 95 >10 230 0.886 375 >10
7 0.330 97 6.640 232 0.112 376 >10
8 0.668 99 1.566 233 0.100 377 >10
9 3.403 100 >10 236 0.299 378 3.696
1.842 101 >10 238 0.750 379 3.192
11 3.895 102 9.067 240 0.212 380 >10
12 4.032 103 0.040 241 0.514 381 >10
(6.1%)
13 4.265 104 0.012 242 0.361 382 0.367
14 0.479 105 0.009 243 0.809 383 0.829
9.838 106 0.002 245 0.740 384 0.212
16 1.258 107 0.010 249 1.090 385 0.256
17 1.532 108 0.001 250 0.568 386 0.608
18 3.756 109 0.469 253 0.295 387 0.101
19 6.027 110 1.795 256 0.378 388 0.085
9.838 111 2.150 257 >10 389 0.827
21 9.838 112 3.832 258 >10 390 0.955
22 9.838 113 1.713 261 1.884 391 0.595
23 >10 114 2.137 265 3.429 392 1.957
24 >10 116 1.138 266 2.498 393 0.460
>10 117 >10 268 3.128 406 0.142
26 >10 118 >10 271 4.550 409 0.242
27 >10 119 >10 273 2.901 412 0.368
28 0.537 120 >10 275 4.177 419 1.164
29 0.818 122 4.616 276 1.853 420 0.333
37 3.519 123 0.492 277 1.520 422 1.201
40 >10 126 2.097 278 >10 423 0.351
45 1.884 127 2.891 285 0.256 427 >10
47 >10 130 4.464 286 0.938 428 1.412
49 >10 131 >10 (5.2%) 289 6.000 429 1.658
52 4.322 132 >10 290 >10 430 0.610
53 0.859 133 3.207 291 2.176 431 0.563
54 2.421 134 >10 292 1.876 432 4.216
55 1.435 135 7.398 293 3.571 433 7.370
56 3.967 136 >10 294 6.573 434 1.860
57 2.037 137 >10 296 >10 435 2.368
59 3.856 138 0.666 301 8.288 436 >10
60 0.439 139 >10 306 >10 437 3.472
61 2.225 140 >10 309 2.693 438 1.646
62 2.825 141 >10 310 0.584 439 0.453
63 2.701 142 6.388 313 7.538 440 4.544
64 5.842 143 3.270 317 >10 441 4.314
65 1.085 144 1.359 318 2.822 442 7.115
66 2.712 145 3.694 319 7.099 443 5.029
67 3.649 146 >10 325 5.953 444 4.103
71 0.728 147 7.824 326 6.980 445 0.003
72 5.046 148 >10 328 1.410 454 1.350
74 4.124 149 2.941 329 0.811 455 2.892
76 0.937 151 >10 330 >10 456 2.226
78 1.291 168 >10 331 >10 457 >10
80 >10 172 >10 332 5.472 458 0.010
84 1.523 182 1.882 333 >10 459 3.845
85 0.506 183 0.704 334 0.593 461 3.198
86 3.051 184 1.959 335 0.685 462 >10
(41.3%)
87 3.566 185 1.445 336 1.477 463 0.261
88 8.925 186 1.859 337 3.832 464 9.708
89 7.389 204 0.763 338 2.073 465 >10
(51.0%)
Example 7.
[01036]
Representative compounds were screened using the assay procedure to assess
the effect on cell viability as described below.
204
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
[01037]
SW480 colon carcinoma cells were transduced with a lentiviral vector
expressing luciferase with a human Sp5 promoter consisting of a sequence of
eight TCF/LEF
binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a
hygromycin
resistance gene were selected by treatment with 150 [tg/mL of hygromycin for 7
days. These stably
transduced SW480 cells were expanded in cell culture and used for all further
screening activities.
Each compound was dissolved in DMSO as a 10 mM stock and used to prepare
compound source
plates. Serial dilution (1:3, 8-point dose-response curves from 10 [IM to
0.0045 M) and compound
transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-
well white solid
bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a
final DMSO
concentration of 0.1%.
[01038] For
the Cell Viability Assays, the cells were plated at 2,000 cells/well in 384-
well plates with a DMEM medium containing 1% fetal bovine serum, and 1%
Penicillin-
Streptomycin and incubated for four days hours at 37 C and 5% CO2. Eight
replicates of DMSO-
treated cells served as controls and cells treated with compound were
performed in duplicate.
[01039]
After incubation, 10 pi of CellTiter-Glo (Promega) was added to each well
allowed to incubate for approximately 12 minutes. This reagent "results in
cell lysis and generation
of a luminescent signal proportional to the amount of ATP present. The amount
of ATP is directly
proportional to the number of cells present in culture, in agreement with
previous reports. The
CellTiter-Glo0 Assay generates a "glow-type" luminescent signal, produced by
the luciferase
reaction (Promega.com)".
[01040]
After incubation, the plates were read at Ex 560 nm Em 590 nm (Cytation 3,
BioTek). Dose-response curves were generated and EC50 concentration values
were calculated
using non-linear regression curve fit in the GraphPad Prism (San Diego, CA) or
Dotmatics' Studies
Software (Bishops Stortford, UK). For EC50 of >10 M, the percent inhibition
at 10 [tM is provided.
[01041]
Table 5 shows the activity of representative compounds of Formula I as
provided herein.
Table 5.
Compound EC50 (AM) Compound EC50 (AM) Compound EC50 (AM) Compound EC50 ( M)
1 0.165 90 0.165 219 2.255 339 4.763
2 0.091 91 0.415 220 0.645 340 1.050
3 0.105 92 0.323 221 1.413 359 0.045
4 0.390 93 0.126 222 0.371 373 6.837
0.038 94 0.470 223 4.893 374 0.383
6 0.049 95 7.608 230 0.084 375
>10 (23.5%)
7 0.089 97 0.182 232 0.418 376 0.387
8 0.087 99 0.089 233 0.310 377 8.204
9 0.037 100 >10 (34.8%) 236 0.193 378 0.852
0.101 101 3.251 238 0.065 379 0.464
205
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
11 0.222 102 4.969 240 0.066 380 >10
(19.9%)
12 0.632 103 4.344 241 0.446 381 9.050
13 0.159 104 0.037 242 2.437 382 7.854
14 0.269 105 0.694 243 0.214 383 0.276
15 >10 106 0.367 245 0.123 384 0.426
16 0.048 107 0.890 249 2.519 385 4.465
17 0.075 108 0.567 250 0.159 386 0.222
18 0.137 109 0.834 253 0.238 387 >10
(32.4%)
19 0.080 110 0.675 256 0.277 388 0.334
20 0.478 111 0.447 257 3.581 389 0.595
21 0.677 112 0.318 258 2.221 390 0.388
22 0.745 113 0.369 261 0.286 391 0.132
23 0.733 114 0.410 265 0.174 392 0.260
24 9.391 116 0.210 266 0.174 393 0.475
25 >10 117 0.544 268 0.168 406 0.336
26 1.700 118 >10 (10.6%) 271 0.460 409 0.124
27 >10 119 0.649 273 0.106 412 0.218
28 0.547 120 0.058 275 0.012 419 0.273
29 0.368 122 0.301 276 0.503 420 0.542
37 0.060 123 0.400 277 0.569 422 3.151
40 0.826 126 0.105 278 1.583 423 0.113
45 0.187 127 0.149 285 0.690 427 8.055
47 2.900 130 0.360 286 0.297 428 0.403
49 0.430 131 0.406 289 0.405 429 0.464
52 1.454 132 0.359 290 0.234 430 0.058
53 0.072 133 0.258 291 2.771 431 0.089
54 0.060 134 0.242 292 0.491 432 0.273
55 0.076 135 2.292 293 3.024 433 1.091
56 0.094 136 2.127 294 0.469 434 0.245
57 0.476 137 1.542 296 >10 (17.3%) 435 0.429
59 0.213 138 4.142 301 0.682 436 3.641
60 0.886 139 4.949 306 2.492 437 0.782
61 0.406 140 0.308 309 0.310 438 3.528
62 0.455 141 >10 (12.2%) 310 4.996 439 0.108
63 0.225 142 0.099 313 2.796 440 4.307
64 0.413 143 0.114 317 1.730 441 0.535
65 0.427 144 0.100 318 0.799 442 0.283
66 0.111 145 0.080 319 5.486 443 1.052
67 0.139 146 3.190 325 9.738 444 0.272
71 0.044 147 0.318 326 2.651 445 0.470
72 0.107 148 2.174 328 0.334 454 0.578
74 0.266 149 0.073 329 0.512 455 0.112
76 0.564 151 0.343 330 >10 (13.3%) 456 0.765
78 3.556 168 0.121 331 6.588 457 0.449
80 0.869 172 0.486 332 5.109 458 0.208
84 0.059 182 0.464 333 >10 (45.9%) 462 0.443
85 0.234 183 0.586 334 0.275 463 0.381
86 0.402 184 0.325 335 0.266 464 0.481
87 5.293 185 0.236 336 0.246 465 0.413
88 0.228 186 0.115 337 0.400
89 >10 (41.5%) 204 0.058 338 0.328
Example 6.
[01042]
Representative compounds were screened using the assay procedure for tau
phosphorylation activity described below.
[01043] SH-SY5Y
cells (human neuroblastoma) were cultured in DMEM/F-12
medium supplemented with 15% FBS, Non-essential Amino Acid and
Penicillin/Streptomycin.
Two days before treatment, cells were seeded onto 96 well plates at 5 x 104
cells/well.
206
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
[01044] The above synthesized compounds were screened using the cell assay
procedure to assess decrease Tau phosphorylation at Ser396 (pSer396) described
below.
[01045] DMSO-resuspended compounds were dispensed to 8 wells as a serial
titration
from 10 M to 4.6 nM final in medium and cells were exposed overnight (16-18 h)
in a humidified
incubator at 36.6c before harvest. Wells were visually checked for cell death
or change in
morphology and supernatants were tested for cytotoxicity by measurement of
lactate
dehydrogenase release (LDH, CytoToxOne kit, Promega) if necessary. As
controls, commercially
available DYRK1A inhibitors, Harmine and Indy which were shown to have good
DYRK1A
inhibition in the kinase assay with no CDK1 activity (EC50 18 and 53 nM
respectively, 6 1.1.M for
CDK1) but weak EC50 in the Tau assay >10 (A.M.
[01046] Cells were lysed with RIPA buffer complemented with phosphatase and
protease inhibitors then lysates were spun down at 12,000g for 10 min to
remove any cellular debris.
Lysates are then either directly tested for pSer396 by ELISA (Life Technology,
Kit KHB7031) or
loaded on NuPage Bis-Tris gels for western blot analysis. Colorimetric
detection of ELISA signal
is performed by Cytation3 plate reader (Biotek) and the chemiluminescence
signal for HRP-linked
antibodies used in western blotting is detected using a Carestream Image
Station. The same p5er396
antibody is used for detection of pTau in both assays.
[01047] Blot densitometry for p5er396 and 13-actin were analyzed using
ImageJ (NIH)
and p5er396 Tau ELISA signal was used to plot, draw the curve fitting, and
determine each
compounds EC50 in Prism (GraphPad).
[01048] Table 6 shows the activity of representative compounds as provided
herein.
Table 6.
pSer396 pSer396
pSer396 Tau pSer396 Tau
Compound Tau ECso Compound
EC so (AM) Compound
EC CuM) Compound Tau ECso
(11-1,M)
(p,M)
1.390 232 0.095 285 7.600 406 >10
6 >10 233 0.174 382 >10 409 >10
7 1.100 236 >10 384 0.583 412 >10
14 3.900 240 >10 385 0.337 420 >10
60 3.500 242 >10 387 >10 423
5.600
109 >10 253 1.800 388 1.100
221 >10 256 1.200 393 >10
Example 7.
[01049] Representative compounds were screened using primary human
fibroblasts
(derived from IPF patients) treated with TGF-(31 to determine their ability to
inhibit the fibrotic
process.
207
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
1010501 Human
Fibroblast Cell Culture: Primary human fibroblasts derived from IPF
patients (LL29 cells) [lXiaoqiu Liu, etal., "Fibrotic Lung Fibroblasts Show
Blunted Inhibition by
cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation",
Journal of
Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; 2Watts, K.
L., et.al.,
"RhoA signaling modulates cyclin D1 expression in human lung fibroblasts;
implications for
idiopathic pulmonary fibrosis", Respiratory Research (2006), 7(1), 881 were
obtained from
American Type Culture Collection (ATCC) and expanded in F12 medium
supplemented with 15%
Fetal Bovine Serum and 1% Penicillin/Streptomycin.
[01051]
Compound Screening: Each compound was dissolved in DMSO as a 10 mM
stock and used to prepare compound source plates. Serial dilution (1:2, 11-
point dose-response
curves from 10 aM to 0.94 nM) and compound transfer was performed using the
ECHO 550
(Labcyte, Sunnyvale, CA) into 384-well clear bottom assay plates (Greiner Bio-
One) with
appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells
were plated at
1,500 cells/well in 70 aL/well F12 medium supplemented with 1% Fetal Bovine
Serum. TGF-I31
(Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2
above). Wells treated
with TGF-01 and containing DMSO were used as positive control, and cells with
only DMSO were
negative control. Cells were incubated at 37 C and 5% CO2 for 4 days.
Following incubation for 4
days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher
Scientific]) was added
to the wells at a final concentration of 1 aM and incubated at room
temperature for 30 min. Cells
were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3
times with PBS
followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA;
Sigma) and
0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody
specific to a-smooth
muscle actin (aSMA; Abcam) (ref 1 and 2 above) in 3% Bovine Serum Albumin
(BSA; Sigma)
and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4 C. Cells
were then washed 3
times with PBS, followed by incubation with Alexa Flor-647 conjugated
secondary antibody (Life
Technologies [Thermo Fisher Scientific]) and DAPI in 3% Bovine Serum Albumin
(BSA; Sigma)
and 0.3% Triton X-100 (Sigma) in PBS at room temperature for 1 hour. Cells
were then washed 3
times with PBS and plates were sealed for imaging. aSMA staining was imaged by
excitation at
630 nm and emission at 665 nm and quantified using the Compartmental Analysis
program on the
CellInsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded
from analysis based
on positive SYTOX green staining. % of total cells positive for aSMA were
counted in each well
and normalized to the average of 11 wells treated with TGF-01 on the same
plate using Dotmatics'
Studies Software. The normalized averages (fold change over untreated) of 3
replicate wells for
each compound concentration were used to create dose-responses curves and EC50
values were
208
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
calculated using non-linear regression curve fit in the Dotmatics' Studies
Software. For EC50 of
>10 p.M, the percent inhibition at 10 M is provided.
[01052]
Table 7 shows the activity of representative compounds of Formula I as
provided herein.
Table 7.
Compound ECso ( M) Compound ECso ( M) Compound ECso ( M) Compound ECso ( M)
1 0.079 72 0.135 185 0.300 325 0.863
2 1.162 74 6.836 186 0.585 326 0.611
3 0.158 78 >10 (0.5%) 204 0.143 328 0.159
4 0.239 84 0.094 219 >10(25.1%) 329 0.339
0.179 85 1.244 220 0.276 330 >10 (6.0%)
6 0.195 86 0.433 221 0.978 331 2.196
7 2.563 87 >10 (48.7%) 222 0.190 332 2.230
8 0.196 91 0.204 223 >10 (13.5%) 333
>10 (15.8%)
9 0.083 92 0.708 230 0.181 334 0.090
0.085 93 0.270 232 0.612 335 0.196
11 0.071 94 0.678 233 0.144 336 0.254
12 1.058 95 >10 (3.0%) 236 >10 (39.7%) 337 1.589
13 0.194 97 0.117 238 0.145 338 0.335
14 0.061 99 0.079 240 0.120 339 3.846
>10 (36.3%) 100 0.829 241 0.499 340 0.299
16 1.000 101 5.193 242 0.197 359 0.087
17 0.937 102 0.820 245 2.152 373 1.270
18 0.152 109 0.601 249 3.022 374 1.382
19 0.083 110 0.187 250 0.127 375 2.654
3.881 111 0.167 253 0.360 376 1.043
21 2.370 112 0.181 256 0.752 377 2.701
22 3.826 113 0.217 257 1.202 378 1.292
23 0.769 114 0.186 258 0.329 379 0.379
24 >10 (24.3%) 116 0.298 261 1.246 380 4.899
1.656 122 1.296 265 0.293 381 >10 (38.4%)
26 1.200 123 0.262 266 0.353 382 0.624
27 1.677 127 0.207 268 0.324 383 0.438
28 0.207 130 0.273 271 0.133 384 0.406
29 0.302 131 0.154 273 0.253 385 1.948
37 0.142 132 >10 (37.6%) 275 0.292 386 0.437
40 2.006 133 0.151 276 0.147 387
>10 (37.7%)
45 0.992 134 0.244 277 0.869 388 0.807
47 1.099 135 0.653 278 5.494 389 4.200
49 1.249 136 0.312 285 1.391 390 0.538
52 3.894 137 0.333 286 0.665 391 2.764
53 0.553 138 1.525 289 0.329 392 0.297
54 0.120 139 2.120 290 0.562 393 0.350
55 0.081 140 0.317 291 6.396 406 1.280
56 >10 (30.2%) 143 0.094 292 1.264 409 0.281
57 0.133 145 0.092 293 5.338 412 0.245
59 0.013 146 1.847 294 0.544 419 1.005
60 >10 (24.6%) 147 0.128 296 0.198 420 2.467
61 0.694 148 1.251 301 0.501 422 0.202
62 0.167 149 0.149 306 0.820 423 0.307
63 0.263 151 0.859 309 0.392 427 4.578
64 >10 (40.9%) 168 0.466 310 0.920 428
>10 (12.5%)
65 1.991 172 0.463 313 0.306 429 0.411
66 0.603 182 0.509 317 1.139 430 0.139
67 0.030 183 0.644 318 1.480
71 1.915 184 0.194 319 4.728
209
CA 03022002 2018-10-23
WO 2017/189829
PCT/US2017/029805
Example 8.
[01053]
Representative compounds were screened using the following assay procedure
to determine their ability to inhibit IL-6 and therefore demonstrate their
anti-inflammatory
properties.
[01054] Human
Peripheral Blood Mononuclear Cells: Fresh Normal PB MNC
(Catalog # PB001, AllCells, Alameda, CA) were shipped overnight at 4 C and
resuspended in
Roswell Park Memorial Institute (RPMI) 1640 Medium, with GlutaMAX Supplement
(Catalog
#61870127, ThermoFisher Scientific, Waltham, MA) supplemented with 1%
Penicillin-
Streptomycin (Catalog# 15140163. ThermoFisher Scientific, Waltham, MA) and 1%
fetal bovine
serum (FBS) ( Catalog # 16140089, ThermoFisher Scientific, Waltham, MA) assay
media.
[01055]
Compound Screening: Fresh normal human peripheral blood mononuclear
cells (huPBMCs) were resuspended in 1% FBS-RPMI assay media with 1% Penicillin-
Streptomycin 1% to a cell concentration of 1 x 10e6 cells/mL. Each compound
was dissolved in
DMSO (Catalog # D8418-100m1, Sigma-Aldrich, St. Louis, MO) as a 10 mM stock
and used to
prepare compound source plates. Serial dilution (1:3, 10-point dose-response
curves starting from
uM) and compound transfer was performed using the ECHO 550 (Labcyte,
Sunnyvale, CA) into
384-well white Proxiplate-Plus assay plates (Catalog #6008289, PerkinElmer,
Shelton, CT) with
appropriate DMSO backfill for a final DMSO concentration of 0.25%. huPBMCs
were plated at
5000 cells/well in the 384-well Proxiplate-Plus assay plates and incubated at
37 C-5% CO2 for 2
hours. 50 ng/mL of Lipopolysaccharides from Escherichia coli 0111:B4 (Catalog
#L5293-2ML,
Sigma-Aldrich, St. Louis, MO) was added after 2 hours and cells were incubated
for another 22
hours at 37 C-5% CO2 . After 22 hour incubation, a mixture of anti-IL6 XL665
and anti-IL-6
Cryptate diluted in reconstitution buffer (Catalog #62IL6PEC, Cisbio Inc.,
Bedford, MA) was
added to each well. Following incubation for 3 hours at room temperature,
Homogeneous Time-
Resolved Fluorescence (HTRF) was measured using the Envision (Perkin Elmer,
Shelton, CT) at
665 nm and 620 nM. The ratio of fluorescence at 665 nm to 620 nm was used as a
readout for IL-
6 quantification. All samples were processed in duplicate. Readings were
normalized to DMSO
treated cells and normalized activities were utilized for EC50 calculations.
EC50 was determined
using software generated by Dotmatics Limited (Windhill Bishops Stortford
Herts, UK) using the
Levenberg-Marquardt 4 parameter fitting procedure with finite different
gradients. For EC50 of
>10 uM, the percent inhibition at 10 uM is provided.
[01056] Table 8
shows the activity of representative compounds of Formula I as
provided herein.
210
CA 03022002 2018-10-23
WO 2017/189829 PCT/US2017/029805
Table 8.
Compound ECso ( M) Compound ECso ( M) Compound ECso ( M) Compound ECso ( M)
1 0.389 89 >10 (4.0%) 186 0.216 336 1.579
2 0.270 90 1.081 204 2.637 337
>10 (4.0%)
3 0.287 91 1.858 219 7.679 338 3.821
4 1.714 92 0.671 220 3.292 339
>10 (6.3%)
0.143 93 1.811 221 3.773 340 2.114
6 0.173 94 2.007 222 1.486 359 3.396
7 0.307 95 1.653 223 >10 (12.7%) 373
>10 (8.0%)
8 1.541 97 0.823 230 0.216 374
>10(12.1%)
9 0.166 99 0.791 232 7.768 375
>10 (4.3%)
0.428 100 >10 (1.3%) 233 0.566 376 >10 (11.9%)
11 0.215 101 >10 (18.2%) 236 2.136 377
>10 (4.8%)
12 2.621 102 >10 (12.2%) 238 0.325 378
>10 (27.0%)
13 0.489 103 1.081 240 0.237 379 1.594
14 0.584 104 1.125 241 1.118 380
>10(3.1%)
>10 (2.8%) 105 0.362 242 0.349 381 >10 (26.4%)
16 0.805 106 0.369 243 2.657 382
>10 (11.8%)
17 1.028 107 0.426 245 1.211 383 1.048
18 0.376 108 0.361 249 3.976 384 1.060
19 0.194 109 1.699 250 1.503 385
>10 (23.4%)
1.178 110 0.942 253 1.274 386 5.074
21 1.323 111 1.048 256 0.744 387
>10(6.1%)
22 1.209 112 4.463 257 >10 (3.9%) 388 1.140
23 2.474 113 0.791 258 >10 (12.9%) 389
>10 (27.6%)
24 >10 (5.5%) 114 1.386 261 2.599 390 7.186
>10 (41.8%) 116 2.346 265 0.936 391 0.867
26 4.477 117 3.252 266 0.371 392 8.722
27 4.510 118 >10 (14.3%) 268 2.838 393 1.119
28 0.834 119 >10 (17.4%) 271 1.610 406
>10(15.1%)
29 0.669 120 1.383 273 0.829 409
>10 (32.5%)
37 0.379 122 >10 (41.7%) 275 0.292 412 1.180
40 3.648 123 1.187 276 3.078 419
>10 (43.6%)
45 1.499 126 >10 (6.0%) 277 0.819 420
>10 (11.7%)
47 1.301 127 >10 (26.1%) 278 3.352 422 0.452
49 0.614 130 >10 (18.3%) 285 3.009 423 4.204
52 >10 (31.2%) 131 >10 (16.4%) 286 1.123
427 >10 (15.6%)
53 1.156 132 >10 (8.3%) 289 0.828 428
>10 (36.4%)
54 0.208 133 >10 (35.2%) 290 1.410 429 1.806
55 0.308 134 >10 (46.7%) 291 >10(47.1%) 430 0.388
56 0.172 135 7.724 292 9.705 431 0.499
57 0.364 136 2.355 293 >10 (32.2%) 432 1.157
59 0.339 137 3.928 294 >10 (48.9%) 433
>10 (12.5%)
60 >10 (9.6%) 138 >10 (4.5%) 296 >10 (4.4%) 434 3.259
61 2.625 139 >10 (1.2%) 301 >10 (33.0%) 435
>10 (7.2%)
62 0.725 140 3.093 306 3.107 436
>10 (11.3%)
63 0.455 141 >10 (4.6%) 309 5.244 437 2.718
64 1.329 142 0.666 310 >10 (17.3%) 438
>10 (30.9%)
65 2.815 143 0.232 313 8.611 439 0.747
66 0.259 144 0.375 317 >10 (11.4%) 440
>10 (4.7%)
67 0.293 145 0.293 318 5.272 441 0.819
71 0.477 146 >10 (22.4%) 319 >10 (3.7%) 442 1.286
72 0.196 147 0.650 325 >10 (9.7%) 443
>10 (47.2%)
74 0.485 148 >10 (5.2%) 326 8.423 444 0.921
76 3.190 149 0.307 328 9.285 445 0.992
78 >10 (6.0%) 151 1.042 329 3.206 454 1.217
80 >10 (31.3%) 168 1.161 330 >10 (6.8%) 455 0.749
84 0.187 172 0.890 331 5.799 456 2.203
85 1.049 182 0.613 332 7.290 457 1.852
86 >10 (36.2%) 183 0.733 333 >10 (18.2%) 458 0.170
87 >10 (13.4%) 184 4.005 334 3.891
88 1.562 185 0.865 335 3.535
211
